compound_name,cas_number,smiles,primary_category,secondary_category,tertiary_category,primary_action,biological_description,Mol Weight
(-)-Quinpirole hydrochloride,[85798-08-9],Cl.[H][C@]12CCCN(CCC)[C@]1([H])CC1=CNN=C1C2,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,Selective D2-like agonist,"Selective dopamine D2 receptor agonist (Ki values are 4.8, ~24, ~30 and 1900 nM at D2, D3, D4 and D1 receptors respectively).",255.79
(-)-U-50488 hydrochloride,[114528-79-9],O=C(CC3=CC(Cl)=C(Cl)C=C3)N([C@@H]1[C@@H](N2CCCC2)CCCC1)C.Cl,7-TM Receptors,Opioid Receptors,Kappa Opioid Receptors,Selective kappa agonist; more active enantiomer of (+/-)-U-50488 (Cat. No. 0495),More active enantiomer of (+/-)-U-50488. Racemate and (+)-enantiomer also available.,405.79
(+)-JQ1,[1268524-70-4],O=C(OC(C)(C)C)C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C,Epigenetics,Bromodomains,,Potent and selective BET bromodomain inhibitor; cell permeable,"Potent, high affinity, selective BET bromodomain inhibitor (IC50 values are 17.7, 32.6, 76.9 and 12942 nM for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP respectively; Kd values are 49, 59.5, 82, 90.1, 128 and 190 nM for BRD4 (N), BRD3 (N), BRD3 (C), BRD4 (C), BRD2 (N) and BRDT (N) respectively). Induces squamous differentiation in NUT midline carcinoma (NMC) cell lines; inhibits tumor growth in NMC xenograft models in vivo. Exhibits reversible contraceptive effects in germ cells from male mice. Inactive Analog also available. Carboxylic acid-functionalized (Cat. No. 6588) and click-activated (alkyne) (Cat. No. 6589) versions for PROTAC development also available.",456.99
(+)-MK 801 maleate,[77086-22-7],O=C(O)/C=C\C(O)=O.C[C@]1(N4)C3=C(C=CC=C3)C[C@@H]4C2=C1C=CC=C2,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Non-competitive NMDA antagonist; acts at ion channel site,"A potent, selective and non-competitive NMDA receptor antagonist. Acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca2+ flux. An effective anti-ischemic agent in several animal models. Available as part of the Mixed NMDA Receptor Tocriset™. (-)-enantiomer also available.",337.37
(+/-)-5'-Chloro-5'-deoxy-ENBA,[103626-26-2],O[C@@H]1[C@H](O)[C@@H](CCl)O[C@H]1N(C=N3)C2=C3C(NC4C5CCC(C5)C4)=NC=N2,7-TM Receptors,Adenosine Receptors,Adenosine A1 Receptors,Highly selective A1 agonist,"Highly selective adenosine A1 receptor agonist (Ki values are 0.51, 1290, 1340 and 2740 nM at A1, A3, A2A and A2B receptors respectively). Reverses formaline-induced nocifensive behavior in mice; antinociceptive.",379.84
(+/-)-AC 7954 hydrochloride,[477313-09-0],Cl.CN(C)CCC1(CC2=CC=CC=C2C(=O)O1)C1=CC=C(Cl)C=C1,7-TM Receptors,Peptide Receptors,Urotensin-II Receptors,Non-peptide UT receptor agonist,"Highly selective, non-peptide urotensin-II (UT) receptor agonist that displays potent activity at human and rat UT receptors (pEC50 values are 6.5 and 6.7 respectively).",366.28
(+/-)-AMG 487,[947536-03-0],CCOC(C=C3)=CC=C3N2C(C1=CC=CN=C1N=C2C(N(CC4=CC=CN=C4)C(CC5=CC=C(OC(F)(F)F)C=C5)=O)C)=O,7-TM Receptors,Chemokine Receptors,Chemokine CXC Receptors,CXCR3 antagonist; inhibits cell migration and metastasis,"Antagonist of CXCR3; inhibits binding of 125I-IP-10 and 125I-ITAC to CXCR3 (IC50 values are 8.0 and 8.2 nM respectively). Inhibits CXCR3-mediated cell migration by the chemokines IP-10, ITAC and MiG in vitro (IC50 values are 8, 15 and 36 nM respectively). Also shown to inhibit lung metastasis in a mouse model of metastatic breast cancer. This product is racemic. ",603.59
(+/-)-CPSI 1306,[1309793-47-2],FC(C=C2F)=CC=C2C1=NOC(CC(N3CCOCC3)=O)C1,Signal Transduction,Cytokine and NF-kB Signaling,Cytokines,Reported macrophage migration inhibitory factor (MIF) inhibitor,Reported to be a macrophage inhibitory factor (MIF) inhibitor. This product is racemic. ,310.3
(+/-)-NBI 74330,[473722-68-8],CCOC(C=C3)=CC=C3N2C(C1=CC=CN=C1N=C2C(N(CC4=CC=CN=C4)C(CC5=CC(C(F)(F)F)=C(F)C=C5)=O)C)=O,7-TM Receptors,Chemokine Receptors,Chemokine CXC Receptors,Potent and selective CXCR3 antagonist,Potent and selective CXCR3 antagonist; potently inhibits 125I-CXCL10 binding to CXCR3 (pKi = 8.13). Inhibits calcium mobilization in response to CXCL11 and CXCL10 in RBL cells. Exhibits no significant effect on chemotaxis induced by CXCR4 or CCR7. Displays a five-fold greater affinity for CXCR3 than (+/-)-AMG 487. This product is racemic. ,605.58
(+/-)-SLV 319,[362519-49-1],ClC(C=C4)=CC=C4C1=NN(/C(NS(C3=CC=C(Cl)C=C3)(=O)=O)=N\C)CC1C2=CC=CC=C2,7-TM Receptors,Cannabinoid Receptors,CB1 Receptors,High affinity and selective CB1 antagonist,"High affinity and selective CB1 receptor antagonist (Ki = 7.8 nM). Exhibits 1000-fold selectivity for CB1 over CB2 receptors. Inhibits CP 55,940-induced hypotension and WIN 55,212-2-induced hypothermia in vivo. Orally active.",487.4
(+/-)-Vesamicol hydrochloride,[120447-62-3],O[C@@H]1CCCC[C@H]1N(CC3)CCC3C2=CC=CC=C2.Cl,Transporters,Neurotransmitter Transporters,Acetylcholine Transporters,Inhibits ACh transport,Inhibitor of acetylcholine transport (Ki = 2 nM). Centrally active following systemic administration in vivo.,295.85
(R)-(-)-Rolipram,[85416-75-7],O=C1NC[C@@H](C2=CC(OC3CCCC3)=C(OC)C=C2)C1,Enzymes,Phosphodiesterases,,PDE4 inhibitor. More active enantiomer of rolipram (Cat. No. 0905),More active enantiomer of the PDE4 inhibitor rolipram; 2-10-fold more potent than the S-(+) enantiomer. Available as part of the Phosphodiesterase Inhibitor Tocriset™. Racemate and S-enantiomer also available.,275.35
(R)-CR8,[1786438-30-9],CC(C)N2C1=NC(N[C@H](CC)CO)=NC(NCC3=CC=C(C4=NC=CC=C4)C=C3)=C1N=C2.Cl.Cl.Cl,Enzymes,Kinases,Cyclin-dependent Kinase,Cdk inhibitor; potently inhibits cdk1 and cdk2; also inhibits CK1,"Cyclin dependent kinase (cdk) inhibitor (reported IC50 values are 0.036 - 0.07, 0.09 - 0.8, 0.13 - 0.68, 0.18 - 1 and >1 muM for cdk2, cdk1, cdk5, cdk9 and cdk7, respectively). Also inhibits casein kinase 1 (CK1; IC50 = 0.6 muM).",540.92
(R)-DRF053 dihydrochloride,[1241675-76-2],CC(C)N2C1=NC(N[C@H](CC)CO)=NC(NC3=CC(C4=NC=CC=C4)=CC=C3)=C1N=C2.Cl.Cl,Enzymes,Kinases,Casein Kinase 1,Potent CK1 inhibitor; also inhibits cyclin-dependent kinases,"Potent casein kinase 1 (CK1) inhibitor (IC50 = 14 nM). Also an ATP-competitive cyclin-dependent kinase (cdk) inhibitor (IC50 values are 0.093 - 0.29, 0.21 and 0.82 muM for cdk2, cdk5 and cdk7, respectively). Shown to inhibit amyloid-beta production in N2A-APP695 cells.",490.43
(RS)-(+/-)-Sulpiride,[15676-16-1],CCN1CCCC1CNC(=O)C1=C(OC)C=CC(=C1)S(N)(=O)=O,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,Standard selective D2-like antagonist,Standard D2-like dopamine receptor antagonist. S-enantiomer also available.,341.42
(S)-(-)-Sulpiride,[23672-07-3],NS(C1=CC(C(NC[C@]2([H])CCCN2CC)=O)=C(OC)C=C1)(=O)=O,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,Standard selective D2-like antagonist,"Active enantiomer. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively). Racemate also available.",341.42
(S)-(+)-Ibuprofen,[51146-56-6],CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Cyclooxygenase inhibitor (COX-1 > COX-2),Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase 1 and cyclooxygenase 2 (IC50 values are 12 and 80 muM respectively). Active isomer of ibuprofen.,206.28
(S)-(+)-Niguldipine hydrochloride,[113145-69-0],O=C(OC)C1=C(C)NC(C)=C(C(OCCCN3CCC(C4=CC=CC=C4)(C5=CC=CC=C5)CC3)=O)[C@H]1[C@]2=CC=CC([N+]([O-])=O)=C2.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,"alpha1 antagonist, L-type Ca2+ channel blocker",L-type Ca2+ channel blocker and alpha1A-adrenoceptor antagonist; more active enantiomer. R-enantiomer also available.,646.18
(S)-Duloxetine hydrochloride,[136434-34-9],CNCC[C@@H](C3=CC=CS3)OC2=CC=CC1=CC=CC=C12.Cl,Transporters,Neurotransmitter Transporters,5-HT Transporters,Potent 5-HT and NA reuptake inhibitor (SNRI); also blocks dopamine reuptake,"High affinity, competitive 5-HT and noradrenaline (NA) re-uptake inhibitor (Ki values are 8.5 and 45 nM for 5-HT and NA reuptake respectively in cortical synaptosomes; IC50 values are 28 and 46 nM for 5-HT and NA reuptake respectively in rat hippocampal slices). Also blocks dopamine reuptake (Ki = 300 nM in striatal synaptosomes). Exhibits antidepressant and anxiolytic effects. Orally bioavailable.",333.88
1-EBIO,[10045-45-1],CCN1C(=O)NC2=C1C=CC=C2,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Activator of epithelial KCa channels,"Activator of epithelial KCa channels, stimulates a large and sustained trans-epithelial Cl- secretory response across T84 monolayers. Induces hyperpolarization to the same magnitude as ACh in aortic value endothelial cells. Promotes embryonic stem cell (ESC) differentiation into cardiomyocytes.",162.19
1-Naphthyl PP1,[221243-82-9],NC1=NC=NC2=C1C(C3=C4C(C=CC=C4)=CC=C3)=NN2C(C)(C)C,Enzymes,Kinases,Src Kinases,Src family kinase inhibitor; also inhibits c-Abl,"Selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl. (IC50 values are 1.0, 0.6, 0.6, 18 and 22 muM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). Preferentially inhibits mutant over wild-type kinases (IC50 values are 1.5 vs 1000 nM for I338G v-src and v-src respectively).",317.39
10-DEBC hydrochloride,[925681-41-0],Cl.CCN(CC)CCCCN1C2=CC=CC=C2OC2=C1C=C(Cl)C=C2,Enzymes,Kinases,Akt (Protein Kinase B),Selective Akt/PKB inhibitor,"Selective inhibitor of Akt/PKB. Inhibits IGF-1-stimulated phosphorylation and activation of Akt (complete inhibition at 2.5 muM), suppressing downstream activation of mTOR, p70 S6 kinase and S6 ribosomal protein. Shows no activity at PDK1, SGK1 or PI 3-kinase. Inhibits cell growth (IC50 ~ 2-6 muM) and induces apoptosis in rhabdomyosarcoma cells.",381.34
10058-F4,[403811-55-2],O=C(NC(S2)=S)/C2=C\C1=CC=C(CC)C=C1,Signal Transduction,MAPK Signaling,Myc,Inhibits c-Myc-Max dimerization,"Cell permeable c-Myc-Max dimerization inhibitor. Inhibits proliferation, induces apoptosis and arrests cells in G0/G1 in rat1a-c-Myc cells. Also reduces tumor growth in vivo.",249.35
2-Chloro-N6-cyclopentyladenosine,[37739-05-2],O[C@@H]1[C@@H](CO)O[C@@H](N(C=N4)C2=C4C(NC3CCCC3)=NC(Cl)=N2)[C@@H]1O,7-TM Receptors,Adenosine Receptors,Adenosine A1 Receptors,"Potent, selective A1 agonist","Potent and selective adenosine A1 receptor agonist (Ki values are 0.8, 2300 and 42 nM for human A1, A2A and A3 receptors respectively; EC50 = 18800 nM for hA2B). Centrally active following systemic administration in vivo.",369.81
2-Chloroadenosine,[146-77-0],O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC(Cl)=NC(N)=C2N=C3)[C@@H]1O,7-TM Receptors,Adenosine Receptors,Non-selective Adenosine,Adenosine receptor agonist,"Metabolically stable analog of adenosine that behaves as an adenosine receptor agonist (Ki values are 300, 80 and 1900 nM for A1, A2A and A3 receptors respectively). Anticonvulsive in vivo.",301.69
2-Methoxyestradiol,[362-07-2],OC1=C(OC)C=C2C(CC[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@H]4O)=C1,Regulated Cell Death,Apoptosis,Apoptosis Inducers,Apoptotic and antiangiogenic agent,"Apoptotic, antiproliferative and antiangiogenic agent, in vitro and in vivo; acts via an estrogen receptor-independent mechanism. Induces p53-induced apoptosis via two pathways: activation of p38 and NF-kappaB; and activation of JNK and AP-1 leading to Bcl-2 phosphorylation. Also upregulates death receptor 5 and binds to tubulin, inhibiting its assembly.",302.41
2-Phenylmelatonin,[151889-03-1],COC1=CC=C2NC(=C(CCNC(C)=O)C2=C1)C1=CC=CC=C1,7-TM Receptors,Melatonin (MT) Receptors,,Potent melatonin agonist,Highly potent melatonin agonist; displays higher affinity and greater potency than melatonin itself. The EC50 values for G protein activation in MT1 and MT2-transfected cells are 65 and 58 pM respectively.,308.38
2-Pyridylethylamine dihydrochloride,[3343-39-3],Cl.Cl.NCCC1=NC=CC=C1,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,H1 agonist,Histamine H1 receptor agonist that produces vasoconstriction in vivo.,195.09
2'-MeCCPA,[205171-12-6],O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC3=C2N=C(Cl)N=C3NC4CCCC4)[C@@](C)1O,7-TM Receptors,Adenosine Receptors,Adenosine A1 Receptors,Very selective and potent A1 receptor agonist,"Potent and highly selective agonist at A1 adenosine receptors (Ki values are 3.3, 9580, 37600 and 1150 nM for human recombinant A1, A2A, A2B and A3 receptors respectively). Acts as a full agonist; inhibits forskolin-stimulated adenylyl cyclase activity in rat cortical membranes with an IC50 value of 13.1 nM.",383.83
3-Bromo-7-nitroindazole,[74209-34-0],[O-][N+](=O)C1=C2NN=C(Br)C2=CC=C1,Enzymes,Synthases/Synthetases,NO Synthases,Selective nNOS inhibitor,Potent inhibitor of rat cerebellar nitric oxide synthase; more potent than 7-nitroindazole (Cat. No. 0602).,242.03
3'-Fluorobenzylspiperone maleate,[1135278-61-3],OC(=O)\C=C/C(O)=O.FC1=CC=C(C=C1)C(=O)CCCN1CCC2(CC1)N(CN(CC1=CC=CC(F)=C1)C2=O)C1=CC=CC=C1,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,D2-like receptor ligand,"A very potent and selective ligand for the D2 receptor (Ki = 0.023 nM). Compared with spiperone, displays a 2.5-fold greater affinity at D2 and a 12-fold lower affinity at 5-HT2 receptors.",619.67
4-CMTB,[300851-67-6],ClC1=CC=C(C(C(C)C)C(NC2=NC=CS2)=O)C=C1,7-TM Receptors,Free Fatty Acid Receptors,,FFA2 agonist; also exhibits positive allosteric modulatory activity,Free fatty acid receptor FFA2 agonist (pEC50 = 6.38) and positive allosteric modulator. Binds at a site distinct from the orthosteric site; modulates the activity of short-chain fatty acids at FFA2 via the FFA2 second extracellular loop (ECL2).,294.8
4-P-PDOT,[620170-78-7],CCC(=O)NC1CC(C2=CC=CC=C2)C2=C(C1)C=CC=C2,7-TM Receptors,Melatonin (MT) Receptors,,MT2 antagonist,"Melatonin receptor antagonist, >300-fold selective for the MT2 (vs MT1) subtype.",279.38
4-PPBP maleate,[201216-39-9],OC(=O)\C=C/C(O)=O.C(CCC1=CC=CC=C1)CN1CCC(CC1)C1=CC=CC=C1,Other Pharmacology,Sigma Receptors,Sigma-Related,"Specific sigma ligand, NMDA antagonist",sigma ligand and selective non-competitive antagonist at recombinant NR1a/2B NMDA receptors expressed in Xenopus oocytes.,409.52
4BP-TQS,[360791-49-7],BrC1=CC=C(C2NC(C=CC(S(=O)(N)=O)=C4)=C4C3C2CC=C3)C=C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,alpha7 nAChR agonist; acts at an allosteric site,"Allosteric agonist at alpha7 nAChR. Binds at a separate site and exhibits more efficacious receptor agonism compared to acetylcholine (Cat. No. 2809), displays 8-fold lower EC50 value and 45-fold larger maximal response.",405.31
4E1RCat,[328998-25-0],O=C1N(C3=CC=C(C(O)=O)C=C3)C(C4=CC=CC=C4)=C/C1=C\C2=CC=C(C5=CC=C([N+]([O-])=O)C=C5)O2,Enzymes,GTPases,Protein-synthesizing GTPases,Inhibits eIF4F subunit interaction; inhibits protein translation,Inhibitor of protein translation; blocks eIF4E:eIF4G and eIF4E:4E-BP1 interaction. Prevents assembly of the eIF4F complex and inhibits cap-dependent translation (IC50 ~4 muM). Exhibits chemosensitizing properties.,478.45
4F 4PP oxalate,[144734-36-1],OC(=O)C(O)=O.FC1=CC=C(C=C1)C(=O)C1CCN(CCCCC2=CC=CC=C2)CC1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Selective 5-HT2A antagonist,A selective 5-HT2A antagonist with almost as high affinity (Ki = 5.3 nM) as ketanserin but with a much lower affinity for 5-HT2C sites (Ki = 620 nM).,429.49
5-Azacytidine,[320-67-2],O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N2C(N=C(N)N=C2)=O,Enzymes,Transferases,DNA Methyltransferases,DNA methyltransferase inhibitor,"DNA methyltransferase inhibitor. Incorporates into DNA forming covalent adducts with cellular DNMT1, depleting enzyme activity. Induces demethylation and reactivation of silenced genes. Improves the efficiency of reprogramming of stem cells; induces differentiation of mesenchymal stem cells into cardiomyocytes.",244.2
5-BDBD,[768404-03-1],BrC1=CC(C(C3=C4C2=C(O3)C=CC=C2)=NCC(N4)=O)=CC=C1,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Potent and selective P2X4 antagonist,Potent and selective P2X4 receptor antagonist. Blocks P2X4-mediated currents in Chinese hamster ovary cells (IC50 = 0.50 muM). Exhibits no significant antagonist effects at other P2X receptors. Reduces long-term potentiation (LTP) in rat hippocampal slices.,355.19
6-Chloromelatonin,[63762-74-3],COC1=C(Cl)C=C2NC=C(CCNC(C)=O)C2=C1,7-TM Receptors,Melatonin (MT) Receptors,,Melatonin agonist,Potent melatonin agonist (pKi values are 9.10 and 9.77 for human recombinant MT1 and MT2 receptors respectively). Displays higher affinity for binding to hamster brain membrane and chicken retina than melatonin.,266.73
7-Chlorokynurenic acid,[18000-24-3],OC(=O)C1=CC(O)=C2C=CC(Cl)=CC2=N1,Transporters,Neurotransmitter Transporters,Glutamate Transporters,Potent competitive inhibitor of L-glutamate uptake,NMDA receptor antagonist acting at the glycine site. Potent competitive inhibitor of L-glutamate transport into synaptic vesicles. Available as part of the NMDA Receptor - Glycine Site Tocriset™. Sodium Salt also available.,223.62
7-Hydroxy-DPAT hydrobromide,[76135-30-3],Br.CCCN(CCC)C1CCC2=CC=C(O)C=C2C1,7-TM Receptors,Dopamine Receptors,D3 Receptors,Dopamine agonist (D3 greater than or equal to D2 < > D4),"D3 dopamine receptor agonist (Ki values are ~ 1, 10, 650 and ~ 5000 nM for D3, D2, D4 and D1 receptors respectively). 8-Hydroxy Isomer also available.",328.28
7-Nitroindazole,[2942-42-9],[O-][N+](=O)C1=C2NN=CC2=CC=C1,Enzymes,Synthases/Synthetases,NO Synthases,Non-selective NOS inhibitor,"Reversible, competitive and non-selective NOS inhibitor. Monosodium Salt also available.",163.14
8-M-PDOT,[134865-70-6],CCC(=O)NC1CCC2=C(C1)C(OC)=CC=C2,7-TM Receptors,Melatonin (MT) Receptors,,Melatonin agonist,"Melatonin receptor agonist, 20-fold selective for the MT2 (vs MT1) subtype. At human recombinant MT1 and MT2 receptors, displays pKi values of 8.23 and 8.95 respectively.",233.31
A 1070722,[1384424-80-9],O=C(NC3=NC(C(F)(F)F)=CC=C3)NC2=CC=NC1=CC(OC)=CC=C12,Enzymes,Kinases,Glycogen Synthase Kinase 3,"Highly potent, selective GSK-3 inhibitor","Potent glycogen synthase kinase-3 (GSK-3) inhibitor (Ki = 0.6 nM for GSK-3alpha and GSK-3beta). Displays high selectivity (> 50-fold) for GSK-3 over a panel of other kinases tested, including CDK family members. Decreases phosphorylation of microtubule-associated protein Tau in vitro; protects rat primary cortical neurons against beta amyloid and glutamate challenge. Brain penetrant.",362.31
A 1120,[1152782-19-8],O=C(NC3=C(C(O)=O)C=CC=C3)N1CCC(C2=C(C(F)(F)F)C=CC=C2)CC1,Other Pharmacology,Miscellaneous Compounds,,High affinity retinol-binding protein 4 (RBP4) ligand,High affinity retinol-binding protein 4 (RBP4) ligand (Ki = 8.3 nM); non-retinoid. Selective against a range of different cellular targets. As efficacious as fenretinide (Cat. No. 1396) in the reduction of serum RBP4 and retinol. Displaces transthyretin (TTR) from RBP4-TTR complexes.,392.37
A 205804,[251992-66-2],CC1=CC=C(SC2=C3C=C(SC3=CN=C2)C(N)=O)C=C1,Enzyme-Linked Receptors,Integrins,,Selective inhibitor of E-selectin and ICAM-1 expression,"Selective inhibitor of E-selectin and ICAM-1 expression (IC50 values are 20, 25 and > 1000 nM for TNF-alpha-induced E-selectin, ICAM-1 and VCAM-1 expression respectively). Effective inhibitor of cell-cell adhesion in an in vitro flow experiment.",300.39
A 366,[1527503-11-2],COC1=C(OCCCN4CCCC4)C=C(N=C(N)C32CCC3)C2=C1,Enzymes,Transferases,Lysine Methyltransferases,Potent and selective G9a/GLP inhibitor,Potent and selective G9a/GLP histone lysine methyltransferase inhibitor (IC50 = 3.3 nM). Exhibits >1000-fold selectivity for G9a/GLP over 21 other methyltransferases. Decreases levels of lysine 9 dimethylation on histone H3 (H3K9Me2) in PC3 cells.,329.44
A 412997 dihydrochloride,[1347744-96-0],O=C(CN2CCC(C3=CC=CC=N3)CC2)NC1=CC=CC(C)=C1.Cl.Cl,7-TM Receptors,Dopamine Receptors,D4 Receptors,Selective D4 agonist,Selective agonist for the dopamine D4 receptor (Ki values are 7.9 and 12.1 nM for human D4 and rat D4 receptors). Displays no affinity (<1000 nM) for other dopamine receptors. Shows efficacy in rat models of ADHD and short-term memory.,382.33
A 425619,[581809-67-8],O=C(NCC1=CC=C(C(F)(F)F)C=C1)NC2=CC=CC3=CN=CC=C32,Ion Channels,Transient Receptor Potential Channels,TRPV,Potent TRPV1 antagonist,"Potent TRPV1 antagonist (IC50 = 3-9 nM). Blocks capsaicin-evoked currents in rat DRG neurons and inhibits TRPV1-activation by anandamide (Cat. No. 1339) and N-arachidonoyl-dopamine. Reduces pain in inflammatory, postoperative and osteoarthritic in vivo pain models.",345.32
A 438079 hydrochloride,[899431-18-6],ClC1=C(C2=NN=NN2CC3=CN=CC=C3)C=CC=C1Cl.Cl,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Competitive P2X7 antagonist,Competitive P2X7 receptor antagonist (pIC50 = 6.9 for the inhibition of Ca2+ influx in the human recombinant P2X7 cell line). Devoid of activity at other P2 receptors (IC50 >> 10 muM). Possesses antinociceptive activity in models of neuropathic pain in vivo. Inhibits methamphetamine-induced microglial migration and phagocytosis in vitro.,342.61
A 582941,[848591-90-2],[H][C@@]12[C@@](CN(C3=CC=C(C4=CC=CC=C4)N=N3)C2)([H])CN(C)C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,alpha7 nAChR partial agonist,Selective alpha7 nAChR partial agonist; exhibits high affinity for both rat and human alpha7 receptors (Ki values are 10.8 and 16.7 nM respectively). Displays ~15-fold selectivity for alpha7 over 5-HT3 receptors (Ki = 150 nM for 5-HT3).,280.37
A 740003,[861393-28-4],CC(C)(C)C(NC(CC3=CC(OC)=C(OC)C=C3)=O)N/C(NC2=CC=CC1=NC=CC=C12)=N/C#N,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Potent and selective P2X7 antagonist,Potent and selective P2X7 receptor antagonist (IC50 values are 18 and 40 nM for rat and human receptors respectively). Displays selectivity over a variety of P2X and P2Y receptors up to a concentration of 100 muM. Reduces nociception in animal models of persistent neuropathic and inflammatory pain. Also reduces neuroblastoma tumor growth in mice.,474.55
A 784168,[824982-41-4],O=C(NC3=CC=C(S(=O)(C(F)(F)F)=O)C=C3)C(CC2)=CCN2C1=C(C(F)(F)F)C=CC=N1,Ion Channels,Transient Receptor Potential Channels,TRPV,Potent and selective TRPV1 antagonist,"Potent TRPV1 antagonist (IC50 = 25 nM for inhibition of TRPV1 activation by 50 nM capsaicin). Displays no activity against a range of receptors, including TRPA1, GABA, opioid, and purinergic receptors.",479.4
A 803467,[944261-79-4],ClC(C=C2)=CC=C2C1=CC=C(C(NC3=CC(OC)=CC(OC)=C3)=O)O1,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Selective NaV1.8 channel blocker,"Selective blocker of NaV1.8 channels (IC50 values are 8, 2450, 6740, 7340 and 7380 nM for hNaV1.8, hNaV1.3, hNaV1.7, hNaV1.5 and hNaV1.2 channels respectively). Shows no significant activity against TRPV1, P2X2/3, CaV2.2 and KCNQ2/3 channels. Antinociceptive; potently attenuates mechanical allodynia in two models of neuropathic pain following i.p. administration.",357.79
A 804598,[1125758-85-1],C[C@@H](C3=CC=CC=C3)NC(NC2=CC=CC1=NC=CC=C12)=NC#N,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Potent and selective P2X7 antagonist,"Potent, competitive P2X7 receptor antagonist (IC50 values are 8.9, 9.9 and 10.9 nM for mouse, rat and human P2X7 receptors respectively). Selective for P2X7 receptors (IC50 > 5-10 muM for a wide array of cell surface receptors and ion channels). Binds with high affinity (Ki app = 2.4 nM for rat P2X7 receptors).",315.37
A 839977,[870061-27-1],ClC(C(Cl)=CC=C4)=C4N1N=NN=C1NCC2=CC=CC=C2OC3=NC=CC=C3,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Potent P2X7 antagonist,"Potent P2X7 antagonist; blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20, 42 and 150 nM respectively). Displays antinociceptive effects in rat and mice models of inflammatory pain. CNS penetrant.",413.26
A 867744,[1000279-69-5],O=C(CC)C1=C(C)N(C3=CC=C(S(N)(=O)=O)C=C3)C(C2=CC=C(Cl)C=C2)=C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Positive allosteric modulator of alpha7 nAChRs,"Positive allosteric modulator of alpha7 nAChRs (IC50 values are 0.98 and 1.12 muM for human and rat alpha7 receptor ACh-evoked currents respectively, in X. laevis oocytes). Displays no activity at 5-HT3A, alpha3beta4 or alpha4beta2 nAChRs. Brain penetrant.",402.89
A 887826,[1266212-81-0],ClC1=C(OCCCC)C=CC(C2=CN=CC(C(NCC3=CC=CN=C3N4CCOCC4)=O)=C2)=C1,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Potent voltage-dependent NaV1.8 channel blocker,Potent voltage-dependent NaV1.8 channel blocker (IC50 = 11 nM in recombinant human NaV1.8 channels). Reduces tactile allodynia in neuropathic rat models. 3- and 28-fold more potent at NaV1.8 channels compared to NaV1.2 and NaV1.7 channels respectively.,480.99
A 922500,[959122-11-3],O=[C@]([C@@H]3CCC[C@H]3[C@@](O)=O)C(C=C2)=CC=C2C1=CC=C(NC(NC4=CC=CC=C4)=O)C=C1,Enzymes,Transferases,Diacylglycerol O-Acyltransferase,Potent DGAT-1 inhibitor,"Diacylglycerol acyltransferase 1 (DGAT-1) inhibitor (IC50 values are 7 and 24 nM at human and mouse DGAT-1 respectively) that is devoid of activity at DGAT-2, ACAT1 or ACAT2. Induces significant weight loss without altering food intake, and decreases liver and plasma triglyceride levels in vivo. Orally active.",428.48
A 939572,[1032229-33-6],O=C(NC3=CC(C(NC)=O)=CC=C3)N1CCC(OC2=C(Cl)C=CC=C2)CC1,Enzymes,Oxygenases/Oxidases,Stearoyl-CoA 9-desaturase,Potent SCD-1 inhibitor,Potent stearoyl-CoA desaturase 1 (SCD1) inhibitor (IC50 = 0.4 nM). Selective for SCD1 over a range of kinases and hERG channels. Inhibits proliferation of squamous cell carcinoma FaDu cells in vitro. Also induces cell death of undifferentiated human embryonic stem cells (ESCs). Orally bioavailable.,387.86
A 967079,[1170613-55-4],FC1=CC=C(/C=C(C)/C(CC)=N/O)C=C1,Ion Channels,Transient Receptor Potential Channels,TRPA1,Selective TRPA1 channel blocker,"Selective TRPA1 channel blocker (IC50 values are 67 and 289 nM at human and rat TRPA1 receptors respectively). Displays 1000-fold selectivity for TRPA1 over other TRP channels, and is >150-fold selective over 75 other ion channels, enzymes and G-protein-coupled receptors. Exhibits analgesic effects in a rat osteoarthritic pain model.",207.24
A 987306,[1082954-71-9],NC3=NC1=C(C(N4CCNCC4)=N3)CCC2=C1[C@@](CCCC5)([H])[C@@]5([H])O2,7-TM Receptors,Histamine Receptors,Histamine H4 Receptors,Potent and selective H4 antagonist,"Potent histamine H4 receptor antagonist (pKi values are 8.24 and 8.47 in human and rat H4 receptors respectively). Displays 162-fold, 620-fold, and > 1600-fold selectivity over human H3, H1 and H2 receptors. Blocks zymosan-induced neutrophil reflux and attenuates thermal hypersensitivity in vivo (ED50 = 42 mumol/kg, ip).",327.42
A-7 hydrochloride,[79127-24-5],Cl.NCCCCCCCCCCNS(=O)(=O)C1=C2C=CC=C(Cl)C2=CC=C1,Signal Transduction,Calcium Signaling,Calcium Binding Protein,Calmodulin antagonist,Potent calmodulin antagonist (inhibits calmodulin-activated PDE activity with an IC50 of 3 muM).,433.44
A12B4C3,[1005129-80-5],O=C2N(C4=CC=CC=C4)C(C1C=CC(C(O)CCCCCCCCCC)N(NC3=CC=C([N+]([O-])=O)C=C3)C12)=O,Enzymes,Kinases,Other Kinases,Potent and selective polynucleotide kinase/phosphatase (PNKP) inhibitor,"Potent and selective polynucleotide kinase/phosphatase (PNKP) inhibitor (IC50 = 60 nM). Displays no effect on calcineurin, protein PP-1 or APTX. Interrupts DNA repair and enhances radiosensitivity of human A549 lung carcinoma and MDA-MB-231 cells.",534.65
A66,[1166227-08-2],CC(C)(C)C1=NC(C2=C(C)N=C(NC(N3[C@H](C(N)=O)CCC3)=O)S2)=CS1,Enzymes,Kinases,PI 3-Kinase,Potent and selective PI 3-kinase p110alpha inhibitor,Potent and selective PI 3-kinase p110alpha inhibitor (IC50 = 32 nM). Exhibits >100-fold selectivity for p110alpha over other PI 3-kinase isoforms. Inhibits Akt signaling and tumor growth in SK-OV-3 xenografts in mice.,393.53
AA 29504,[945828-50-2],NC1=C(NC(OCC)=O)C=CC(NCC2=C(C)C=C(C)C=C2C)=C1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Positive allosteric modulator of GABAA receptors,"Positive allosteric modulator of GABAA receptors. Modulates both alpha4beta3delta-containing extrasynaptic receptors and alpha1beta3gamma2S-containing receptors in Xenopus oocytes, displaying a stronger modulatory effect at the former. Reduces motor coordination and exhibits anxiolytic effects in vivo.",327.42
Abacavir hemisulfate,[188062-50-2],OS(O)(=O)=O.NC1=NC(NC2CC2)=C2N=CN(C3C[C@H](CO)C=C3)C2=N1.NC1=NC(NC2CC2)=C2N=CN(C3C[C@H](CO)C=C3)C2=N1,Enzymes,Polymerases,RNA/DNA Polymerase,Reverse transcriptase inhibitor; antiretroviral,Competitive reverse transcriptase inhibitor; inhibits HIV replication. Orally active and brain penetrant. Antiretroviral agent.,335.37
ABT 751,[141430-65-1],OC(C=C2)=CC=C2NC1=NC=CC=C1NS(C3=CC=C(OC)C=C3)(=O)=O,Cytoskeleton and Motor Proteins,Microtubules,,Inhibitor of microtubule polymerization; antimitotic and antitumor,"Antimitotic agent, inhibits microtubule polymerization. Binds to beta-tubulin on the colchine site; blocks cell cycle at G2M phase and induces apoptosis. Exhibits antitumor activity. Also displays activity in cell lines resistant to vincristine, doxorubicin and cisplatin. Orally bioavailable.",371.41
AC 186,[1421854-16-1],FC1(F)CCC(C2=C(F)C=CC=C2)(C3=CC=C(O)C=C3)CC1,Nuclear Receptors,Estrogen and Related Receptors,,Potent and selective ERbeta agonist; neuroprotective,Potent and selective ERbeta agonist (EC50 values are 6 and 5000 nM for ERbeta and ERalpha respectively). Exhibits gender selective neuroprotective effects in a male rat model of Parkinson's disease. Decreases Abeta levels in combination with ACP-105 in a rat model of Alzheimer's disease.,306.32
AC 261066,[870773-76-5],CC1=C(OCCOCCCC)N=C(C2=CC=C(C(O)=O)C(F)=C2)S1,Nuclear Receptors,Retinoic Acid Receptors,,RARbeta2 agonist,"Potent RARbeta2 agonist (pEC50 = 8.1). Selective over RARbeta1, RARalpha and RARgamma (pEC50 values are 6.4, 6.2 and 6.3 respectively). More potent and orally available than AC 55649 (Cat. No. 2436).",353.41
AC 264613,[1051487-82-1],O=C1[C@@H]([C@](N/N=C(C)/C3=CC=CC(Br)=C3)=O)[C@H]([C@]2=CC=CC=C2)CN1,7-TM Receptors,Peptide Receptors,Protease-Activated Receptors,PAR2 receptor agonist,"Potent and selective protease-activated receptor 2 (PAR2) agonist (pEC50 = 7.5). Displays no activity at other PAR subtypes and exhibits no significant activity at over 30 other receptors implicated in nociception and inflammation. Stimulates PI hydrolysis, Ca2+ mobilization and cellular proliferation in vitro (pEC50 values are 6.9, 7.0 and 7.5 respectively).",400.27
AC 5216,[226954-04-7],O=C(N1C)N(CC(N(CC)CC2=CC=CC=C2)=O)C3=C1C=NC(C4=CC=CC=C4)=N3,Other Pharmacology,Translocator Protein,,Selective TSPO ligand,"Ligand of translocator protein (TSPO, peripheral benzodiazepine receptor). Exhibits high affinity for TSPO in rat whole brain (Ki = 0.297 nM), and high potency against human and rat glial TSPO (IC50 values are 2.73 and 3.04 nM respectively). Displays no noticeable binding to a number of other receptors, transporters or ion channels. Also displays anxiolytic and antidepressant effects in rodent models, without inducing benzodiazepine-like adverse effects.",401.46
AC 55649,[59662-49-6],CCCCCCCCC1=CC=C(C=C1)C1=CC=C(C=C1)C(O)=O,Nuclear Receptors,Retinoic Acid Receptors,,Selective RARbeta2 agonist,"Potent, isoform-selective RARbeta2 receptor agonist (pEC50 values are 6.9, 5.7 and 5.6 at RARbeta2, RARbeta1 and RARalpha respectively) that displays 100-fold selectivity versus other retinoid receptors. Inhibits proliferation of the breast cancer cell line MCF-7.",310.44
AC 710,[1351522-04-7],CC(C2)(C)N(CC)C(C)(C)CC2OC1=CC=C(C(NC3=CC=C(NC(NC4=NOC(C(C)(C)C)=C4)=O)C=C3)=O)N=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),PDGFR,Potent and selective PDGFR family inhibitor,"Potent PDGFR family inhibitor (IC50 values are 1.2, 2, 7.7 and 10.5 nM for KIT, FLT3, PDGFRbeta and CSF1R respectively; Kd = 1.3 nM for PDGFRalpha). Exhibits >30-fold selectivity over a panel of other kinases and exhibits no activity against cytochrome P450. Causes tumor regression of leukemia cell xenografts in mice. Also reduces joint swelling and inflammation in a mouse model of collagen-induced arthritis. Orally active.",562.7
Acarbose,[56180-94-0],C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Enzymes,Glycosylases,,Glucosidase alpha inhibitor (intestinal),Inhibitor of intestinal alpha-glucosidase (IC50 = 11 nM). Antidiabetic; inhibits the hydrolysis of complex carbohydrates.,645.25
Acetaminophen,[103-90-2],CC(=O)NC1=CC=C(O)C=C1,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Cyclooxygenase inhibitor; may be selective for COX-3,"Cyclooxygenase inhibitor; may be selective for COX-3 (IC50 values are 460, > 1000 and > 1000 muM for canine COX-3, and murine COX-1 and COX-2 respectively). Widely used analgesic and antipyretic agent.",151.16
Acifran,[72420-38-3],CC1(OC(=CC1=O)C(O)=O)C1=CC=CC=C1,7-TM Receptors,Hydroxycarboxylic Acid Receptors,,Hypolipidemic agent; agonist for the GPR109A (HM74A) and GPR109B receptors,"Hypolipidemic agent. Exhibits higher potency than nicotinic acid and clofibrate. Full and potent agonist at the human orphan GPCR HM74A/GPR109A and GPR109B (EC50 values are 1.3 and 4.2 muM respectively). Reduces serum triglycerides and circulating LDL-cholesterol in vivo, without affecting liver weight or liver enzymes.",218.21
Acipimox,[51037-30-0],CC1=CN=C(C(O)=O)C=[N+]1[O-],Cell Metabolism,Lipid Metabolism,Other Lipid Metabolism,Antilipolytic agent,"Antilipolytic agent; lowers plasma free fatty acid (FFA), triglyceride (TG), glucose and insulin levels and increases leptin levels.",154.12
ACT 462206,[1361321-96-1],CC1=CC(NC([C@@H]2CCCN2S(C3=CC=C(OC)C=C3)(=O)=O)=O)=CC(C)=C1,7-TM Receptors,Peptide Receptors,Orexin Receptors,"Potent, dual orexin receptor antagonist","Potent, dual orexin receptor antagonist (IC50 values are 11 and 60 nM for OX2 and OX1 receptors respectively). Exhibits anxiolytic-like properties in vivo. Brain penetrant.",388.48
Acyclovir,[59277-89-3],NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,Enzymes,Polymerases,RNA/DNA Polymerase,Inhibits viral DNA polymerase; antiherpetic agent,"Antiviral agent, active against herpes simplex viruses HSV-1 and HSV-2 (EC50 values are 0.85 and 0.86 muM respectively). Interferes with viral DNA polymerization through competitive inhibition with guanosine triphosphate. Induces apoptosis in cells transfected with HSV-TK (suicidal gene therapy).",225.21
Adapalene,[106685-40-9],COC1=CC=C(C3=CC=C(C=C(C(O)=O)C=C4)C4=C3)C=C1C25CC(C6)CC(CC6C5)C2,Nuclear Receptors,Retinoic Acid Receptors,,RARbeta and RARgamma agonist,"Retinoic acid analog that is a RARbeta and RARgamma agonist (AC50 values are 2.2, 9.3, 22 and > 1000 nM for RARbeta, RARgamma, RARalpha and RXRalpha receptors respectively). Inhibits proliferation and induces apoptosis in colorectal cancer cell in vitro. Displays comedolytic activity.",412.52
AdipoRon hydrochloride,[1781835-20-8],O=C(C2=CC=C(OCC(NC3CCN(CC4=CC=CC=C4)CC3)=O)C=C2)C1=CC=CC=C1.Cl,7-TM Receptors,Peptide Receptors,Other Peptide Receptors,Orally active AdipoR1 and AdipoR2 agonist; antidiabetic,"Agonist of adiponectin receptors AdipoR1 and AdipoR2 (Kd values are 1.8 and 3.1 muM respectively). Activates AMPK and PPARalpha signaling; ameliorates insulin resistance, dyslipidemia and glucose intolerance in db/db mice. Orally active antidiabetic agent.",464.98
ADX 10059 hydrochloride,[757949-98-7],CC1=CC(C)=NC(C#CC2=CC=CC(F)=C2)=C1N.Cl,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Negative allosteric modulator of mGlu5 receptors,Reported to be a negative allosteric modulator at the mGlu5 receptor. Analog of MPEP (Cat. No. 1212).,276.74
AEE 788,[497839-62-0],C[C@@H](NC2=C(C=C(C4=CC=C(CN5CCN(CC)CC5)C=C4)N3)C3=NC=N2)C1=CC=CC=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,Potent EGFR and VEGFR inhibitor,"Potent EGFR and VEGFR inhibitor (IC50 values are 2, 6, 59, 77, 160 and 330 nM for EGFR, ErbB2, VEGFR-1, VEGFR-2, ErbB4 and VEGFR-3 respectively). Also inhibits c-Abl, c-Fms and c-Src (IC50 values are 52, 60 and 61 nM respectively). Inhibits proliferation of EGFR and ErbB2 overexpressing cancer cell lines in vitro. Inhibits tumor xenograft growth and VEGF-induced angiogenesis in mice. Orally active.",440.58
AEG 3482,[63735-71-7],NS(=O)(=O)C1=NN2C=C(N=C2S1)C1=CC=CC=C1,Enzymes,Kinases,MAPK Family,Inhibitor of JNK signaling,"Inhibitor of c-jun N-terminal kinase (JNK) signaling. Binds Hsp90 and facilitates HSF1 release, induces expression of Hsp70, which in turn blocks JNK activation and JNK-dependent apoptosis. Antiapoptotic; inhibits NGF withdrawal-induced death in SCG neurons (EC50 = 20 muM).",280.33
AH 6809,[33458-93-4],CC(C)OC1=CC=C2C(OC3=C(C=C(C=C3)C(O)=O)C2=O)=C1,7-TM Receptors,Prostanoid Receptors,,EP1 and EP2 receptor antagonist,Antagonist at prostaglandin EP1 (pA2 = 6.8) and EP2 (Ki = 350 nM) receptors. Also weakly inhibits DP receptors (pA2 = 4.45).,298.3
AH 7614,[6326-06-3],CC(C=C4)=CC=C4S(NC2C3=C(C=CC=C3)OC1=CC=CC=C12)(=O)=O,7-TM Receptors,Free Fatty Acid Receptors,,Selective FFA4 (GPR120) antagonist,Selective free fatty acid receptor 4 (FFA4/GPR120) antagonist (pIC50 values are 7.1 and <4.6 for human FFA4 and FFA1 receptors respectively). Inhibits linoleic acid and GSK 137647A-induced intracellular calcium accumulation in U2OS osteosarcoma cells expressing the FFA4 receptor.,351.42
AICAR,[2627-69-2],O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(C(N)=O)=C2N)[C@@H]1O,Enzymes,Kinases,AMPK,AMPK activator,"Cell-permeable, allosteric activator of AMP-activated protein kinase (AMPK). Augments proliferation, differentiation and mineralization of osteoblastic MC3T3-EI cells and attenuates psychosine-induced expression of proinflammatory cytokines and iNOS in astrocytes. Promotes osteogenic differentiation of hAMSCs and BM-MSCs in vitro.",258.23
AIM 100,[873305-35-2],C1(C(C4=CC=CC=C4)=C(C5=CC=CC=C5)O3)=C3N=CN=C1NC[C@H]2OCCC2,Enzymes,Kinases,Ack1,Potent and selective Ack1 (TNK2) inhibitor,"Potent Ack1 (TNK2) inhibitor (IC50 = 22 nM). Exhibits selectivity for Ack1 over ABL1, BTK, Lck and LYN; exhibits no inhibition of 25 other kinases. Suppresses phosphorylation of Tyr267 of the androgen receptor in prostate cancer cells. Also suppresses growth of radioresistant castration-resistant prostate cancer in xenograft tumors in mice. Also promotes DAT endocytosis and oligomerization.",371.43
AK 7,[420831-40-9],O=C(NC2=CC(Br)=CC=C2)C1=CC(S(N3CCCCCC3)(=O)=O)=CC=C1,Enzymes,Histone Deacetylases,Class III HDACs (Sirtuins),Selective SIRT2 inhibitor; brain penetrant,Selective SIRT2 inhibitor (IC50 = 15.5 muM); displays no effect on SIRT1 or SIRT3. Decreases neuronal cholesterol levels; improves motor function and ameliorates brain atrophy in a mouse model of Huntington's disease. Brain penetrant.,437.35
AL 8697,[1057394-06-5],CC1=C(F)C=C(C(NC4CC4)=O)C=C1C3=C(F)C2=NN=C(C(C)(C)C)N2C=C3F,Enzymes,Kinases,MAPK Family,Potent and selective p38alpha inhibitor,Potent and selective p38alpha inhibitor (IC50 = 6 nM). Exhibits 14-fold greater inhibition of p38alpha compared to p38beta; also displays 300-fold selectivity for p38alpha compared to a panel of 91 kinases. Exhibits anti-inflammatory properties.,402.41
Alantolactone,[546-43-0],O=C3C([C@@]2([H])C=C1[C@@H](C)CCC[C@@](C)1C[C@]([H])2O3)=C,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),BMP and Other Activin Receptors,Antiproliferative; induces activin/Smad3 signaling,Sesquiterpene lactone. Induces activin/SMAD3 signaling and disrupts Cripto-1/activin receptor type II A interaction. Displays antiproliferative activity in human colon adenocarcinoma HCT-8 cells.,232.32
Alda 1,[349438-38-6],O=C(C3=C(Cl)C=CC=C3Cl)NCC1=CC(OCO2)=C2C=C1,Enzymes,Dehydrogenases,Aldehyde Dehydrogenase,ALDH2 activator; cardioprotective,Activator of aldehyde dehydrogenase 2 (ALDH2). Increases activity of wild-type ALDH2*1 and variant ALDH2*2 (by ~2-fold and 11-fold respectively). Capable of partly restoring mutant ALDH2*2 activity; protective against cardiac ischemia.,324.16
Aliskiren hemifumarate,[173334-58-2],COC1=C(OCCCOC)C=C(C[C@H]([C@@H](C)C)C[C@@H]([C@@H](O)C[C@@H]([C@@H](C)C)C(NCC(C)(C)C(N)=O)=O)N)C=C1.COC2=C(OCCCOC)C=C(C[C@H]([C@@H](C)C)C[C@@H]([C@@H](O)C[C@@H]([C@@H](C)C)C(NCC(C)(C)C(N)=O)=O)N)C=C2.O=C(/C=C/C(O)=O)O,Enzymes,Proteases,Other Proteases,Potent renin inhibitor; antihypertensive,Potent renin inhibitor (IC50 = 0.6 and 80 nM for human and rat respectively). Exhibits selectivity for renin over a range of other aspartic proteinases (>5000 nM). Lowers blood pressure in a hypertensive rodent model. Orally active.,609.83
Allopregnanolone,[516-54-1],C[C@@]12[C@](CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4C(C)=O)([H])C[C@H](O)CC1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Positive allosteric modulator of GABAA receptors,GABAA receptor positive allosteric modulator. Neuroactive steroid. Deuterated analog also available. ,318.49
Altanserin hydrochloride,[1135280-78-2],Cl.FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=S)NC3=CC=CC=C3C2=O)CC1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2A receptor antagonist,"Potent and selective 5-HT2A receptor antagonist (Ki values are 0.13, 4.55, 40, 62 and 1570 nM at 5-HT2A, alpha1, 5-HT2C, D2 and 5-HT1A respectively). Centrally active following systemic administration in vivo.",447.95
ALX 5407 hydrochloride,[200006-08-2],FC(C=C2)=CC=C2[C@@H](CCN(CC(O)=O)C)OC1=CC=C(C3=CC=CC=C3)C=C1.Cl,Transporters,Neurotransmitter Transporters,Glycine Transporters,Selective non-transportable GlyT1 inhibitor,"Selective non-transportable inhibitor of the glycine transporter GlyT1 (IC50 values are 3 nM and > 100 muM for human GlyT1c and GlyT2 respectively). Does not recognize other glycine sites, including the glycine site on the NMDA receptor (IC50 > 100 muM). Racemate also available.",429.92
AM 92016 hydrochloride,[133229-11-5],Cl.CN(CCC1=CC(Cl)=C(Cl)C=C1)CC(O)COC1=CC=C(NS(C)(=O)=O)C=C1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV channel blocker,"A specific blocker of the time dependent delayed rectifier potassium current, devoid of any beta-adrenoceptor blocking activity. Exhibits proarrhythmic and prohypertensive activity in vivo.",483.84
Ambroxol hydrochloride,[23828-92-4],NC1=C(Br)C=C(Br)C=C1CN[C@H]2CC[C@H](O)CC2.Cl,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Na+ channel blocker,"Sodium channel blocker and mucolytic agent with antioxidant, anti-viral and anti-inflammatory properties. Inhibits tetrodotoxin (TTX)-resistant channels more potently than TTX-sensitive subtypes (IC50 values for tonic block are 35.2 and 111.5 muM respectively). Inhibits release of histamine, leukotrienes and cytokines from human leukocytes and mast cells.",414.57
AMD 3465 hexahydrobromide,[185991-07-5],C1(CN3CCCNCCNCCCNCC3)=CC=C(CNCC2=NC=CC=C2)C=C1.Br.Br.Br.Br.Br.Br,7-TM Receptors,Chemokine Receptors,Chemokine CXC Receptors,Potent and selective CXCR4 antagonist,"Potent, selective CXCR4 antagonist; exhibits 8-fold higher affinity than AMD 3100 (Cat.No. 3299). Inhibits SDF-1alpha-ligand binding (Ki = 41.7 nM). Potently inhibits HIV cell entry in vitro; causes leukocytosis and mobilizes haematopoietic stem cells in vivo.",896.07
AMG 548,[864249-60-5],O=C1N(C)C(NC[C@@H](N)CC5=CC=CC=C5)=NC(C4=CC=NC=C4)=C1C3=CC2=C(C=C3)C=CC=C2,Enzymes,Kinases,MAPK Family,Potent and selective p38alpha inhibitor,"Potent and selective inhibitor of p38alpha (Ki values are 0.5, 3.6, 2600 and 4100 nM for p38alpha, p38beta, p38gamma and p38delta respectively). Displays >1000-fold selectivity against 36 other kinases; inhibits whole blood LPS-stimulated TNFalpha (IC50 = 3 nM). Efficacious in acute and chronic models of arthritis.",461.56
AMG 9810,[545395-94-6],CC(C)(C)C1=CC=C(C=C1)\C=C\C(=O)NC1=CC=C2OCCOC2=C1,Ion Channels,Transient Receptor Potential Channels,TRPV,"Potent and selective, competitive antagonist of TRPV1","Potent and selective, competitive vanilloid TRPV1 receptor antagonist (IC50 = 17 nM). Inhibits capsaicin-, proton-, heat- and endogenous ligand-induced activation of human and rat recombinant TRPV1 receptors. Displays antihyperalgesic properties in a rat model of inflammatory pain.",337.42
AMG PERK 44,,CC2=NC1=CC=C(C3=C(N)C(C(C4=C(C5=CC=CC=C5)N(C)N(C6=CC=CC=C6)C4=O)=O)=CC=C3C)C=C1C=C2.Cl,Enzymes,Kinases,PERK,Potent and selective PERK inhibitor; orally bioavailable,"Potent and selective PERK inhibitor (IC50 = 6 nM). Exhibits >160-fold selectivity for PERK over B-Raf and GCN2, as well as a panel of 387 other kinases. Orally bioavailable.",561.07
Aminopurvalanol A,[220792-57-4],ClC1=CC(N)=CC(NC2=C3C(N(C(C)C)C=N3)=NC(N[C@H]([C@@H](C)C)CO)=N2)=C1,Enzymes,Kinases,Cyclin-dependent Kinase,"Selective cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5","Cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 20 - 35 nM for cdk1, cdk2 and cdk5). Also inhibits ERK1 (IC50 = 12.0 muM) and ERK2 (IC50 = 3.1 muM) and is 3000-fold selective over a range of other protein kinases (IC50 >100 muM). Arrests cell cycle at G2/M boundary (IC50 = 1.25 muM), and induces apoptosis at concentrations >10 muM. Cell permeable.",403.91
Amlexanox,[68302-57-8],CC(C)C1=CC=C2C(C(C(C=C(C(O)=O)C(N)=N3)=C3O2)=O)=C1,Enzymes,Kinases,TANK binding kinase (TBK),Selective inhibitor of TBK,"Selective inhibitor of TANK-binding kinase 1 (TBK1) and IKKepsilon (IC50 values are ~1-2 muM). Displays no effect on IKKalpha or IKKbeta at these concentrations. Reversibly lowers weight, increases insulin sensitivity, and reduces inflammation and steatosis in three mouse models of obesity. Exhibits antiallergic activity; inhibits the release of histamine from rat mast cells. Also binds to Hsp90 and inhibits C-terminal chaperone activity in vitro.",298.29
Amlodipine besylate,[111470-99-6],OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV1.x blocker,L-type calcium channel blocker that displays antihypertensive properties. Inhibits Ca2+-induced contractions in depolarized rat aorta (IC50 = 1.9 nM) and displays vasoprotective effects in cardiovascular disease. Inhibits proliferation of human vascular smooth muscle cells and epidermoid carcinoma A431 cells (IC50 = 25 muM).,567.05
AMN 082 dihydrochloride,[97075-46-2],Cl.Cl.C(CNC(C1=CC=CC=C1)C1=CC=CC=C1)NC(C1=CC=CC=C1)C1=CC=CC=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group III Receptors,Selective mGlu7 agonist,The first selective mGlu7 agonist. Potently inhibits cAMP accumulation and stimulates GTPgammaS binding in recombinant cells and on membranes expressing mGlu7 (EC50 = 64 - 290 nM). Selective over other mGluR subtypes and selected ionotropic glutamate receptors up to 10 muM. Acts via a novel allosteric site and is orally active and brain penetrant. Reduces haloperidol-induced catalepsy in rats. View important information regarding the usage of AMN 082 dihydrochloride.,465.45
ANA 12,[219766-25-3],O=C(NC4C(NCCCC4)=O)C1=C(NC(C2=CC3=C(C=CC=C3)S2)=O)C=CC=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Trk Receptors,TrkB receptor antagonist,"TrkB receptor antagonist. Demonstrates a 2-site mode of action, preventing activation by BDNF non-competitively (IC50 values are 45.6 nM and 41.1 muM for the high and low affinity sites respectively). Displays no effect on TrkA and TrkC in an assay of neurite outgrowth. Demonstrates antidepressant properties. Also exhibits anti-seizure effects in an ischemia-induced neonatal seizure model by blocking down-regulation of KCC2.",407.49
Anastrozole,[120511-73-1],CC(C)(C#N)C1=CC(CN2C=NC=N2)=CC(C(C)(C)C#N)=C1,Enzymes,Cytochrome P450,,Potent aromatase (CYP19) inhibitor,Potent and highly selective aromatase (CYP19) inhibitor (IC50 = 15 nM) that has no discernible effect on adrenocorticoid hormone synthesis. Reduces plasma estrogen levels and exhibits antitumor activity in vivo. Orally active.,293.37
Aniracetam,[72432-10-1],COC1=CC=C(C=C1)C(=O)N1CCCC1=O,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Inhibits desensitization; AMPA > kainate,"Nootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration.",219.24
Anpirtoline hydrochloride,[99201-87-3],Cl.ClC1=NC(SC2CCNCC2)=CC=C1,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Highly potent 5-HT1B agonist; also 5-HT3 antagonist,"Highly potent 5-HT1B receptor agonist (Ki values are 28, 150 and 1490 nM at 5-HT1B, 5-HT1A and 5-HT2 receptors respectively). Decreases central serotonin synthesis and attenuates aggressive behavior in vivo. Also acts as an antagonist at 5-HT3 receptors (Ki = 29.5 nM) and is brain penetrant.",265.2
ANR 94,[634924-89-3],CCN2C1=NC=NC(N)=C1N=C2OCC,7-TM Receptors,Adenosine Receptors,Adenosine A2A Receptors,Adenosine A2A antagonist,Adenosine A2A receptor (AA2AR) antagonist (Ki values are 643 and 46 nM for rat and human AA2ARs respectively). Most active AA2AR antagonist for human receptors. Displays activity in the treatment of Parkinson's disease in vivo; improves parkinsonian motor deficits and tremors. Exhibits neuroprotective and anti-inflammatory effects.,207.23
Antalarmin hydrochloride,[220953-69-5],CC1=C(C)N(C3=C(C)C=C(C)C=C3C)C2=C1C(N(CC)CCCC)=NC(C)=N2.Cl,7-TM Receptors,Peptide Receptors,CRF Receptors,CRF1 antagonist,Non-peptide corticotropin-releasing hormone receptor 1 (CRF1) antagonist (Ki = 1 nM). Suppresses CRF-induced ACTH secretion. Blocks CRF- and novelty-induced anxiety-like behavior in animal models of anxiety.,415.01
AP 18,[55224-94-7],ClC1=CC=C(/C=C(C)/C(C)=N/O)C=C1,Ion Channels,Transient Receptor Potential Channels,TRPA1,Reversible TRPA1 channel blocker,Reversible TRPA1 channel blocker (IC50 values are 3.1 and 4.5 muM at human and mouse TRPA1 respectively). Blocks cinnameldehyde-induced but not capsaicin-induced nociception and reverses mechanical hyperalgesia in vivo. Also blocks TRPA1 pore dilation (IC50 = 10.3 muM for the inhibition of Yo-Pro uptake).,209.67
APcK 110,[1001083-74-4],FC(C=C3)=CC=C3C1=NNC2=C1C=CC(C4=CC(OC)=CC(OC)=C4)=N2,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Other RTKs,KIT inhibitor,"KIT inhibitor; inhibits phosphorylation of KIT, STAT3, STAT5 and Akt. Suppresses proliferation of OCI/AML3 cells (IC50 = 175 nM). Caspase-dependant apoptosis inducer.",349.36
API-1,[36707-00-3],O[C@@H]1[C@@H](CO)O[C@@H](N2C(N=CN=C3N)=C3C(C(C(N)=O)=C2)=O)[C@@H]1O,Enzymes,Kinases,Akt (Protein Kinase B),Selective Akt/PKB inhibitor. Antitumor,"Akt/protein kinase B (PKB) inhibitor. Binds the pleckstrin homology domain of Akt and blocks Akt membrane translocation. Inhibits EGF-induced kinase activity of Akt1, Akt2 and Akt3. Induces cell growth arrest and apoptosis in human cancer cells expressing constitutively active Akt. Displays antitumor activity in vitro and in vivo.",337.29
API-2,[35943-35-2],O[C@@H]1[C@@H](CO)O[C@@H](N2C3=C(C4=NC=N3)C(C(N)=NN4C)=C2)[C@@H]1O,Enzymes,Kinases,Akt (Protein Kinase B),Selective inhibitor of Akt/PKB signaling. Antitumor and antiviral,"Selective inhibitor of Akt (protein kinase B) signaling; displays minimal inhibition of PKC, PKA, SGK and p38 pathways. Inhibits phosphorylation and activation of downstream targets of Akt including Bad, GSK-3beta and AFX. Induces apoptosis and growth arrest in vitro, preferentially in human cancer cells with elevated levels of Akt. Potently and selectively inhibits growth of Akt-overexpressing tumors in mice. Inhibits DNA synthesis and displays antiviral activity against HIV-1 and -2.",320.31
Apoptosis Activator 2,[79183-19-0],ClC1=CC=C(CN2C(=O)C(=O)C3=CC=CC=C23)C=C1Cl,Enzymes,Proteases,Caspases,Promotes apoptosome formation and activates caspase-9/caspase-3 pathway. Selectively induces tumor cell apoptosis,"Apoptosis activator; promotes the cytochrome c-dependent oligomerization of Apaf-1 into the mature apoptosome. Increases procaspase-9 processing and subsequent caspase-3 activation. Induces apoptosis in tumor cells (IC50 = 4 - 9 muM for leukemia cells) with weak or no effect on normal cell lines or those defective/deficient in Apaf-1, caspase-9 or caspase-3 activity (IC50 > 40 muM).",306.14
APY 29,[1216665-49-4],C1(NC2=CC(NC=N3)=C3C=C2)=NC=CC(NC4=CC(C5CC5)=NN4)=N1,Enzymes,Esterases,IRE1,Inhibits IRE1alpha autophosphorylation; activates IRE1alpha endoribonuclease activity,Allosteric modulator of IRE1alpha. Inhibits IRE1alpha autophosphorylation (IC50 = 280 nM) and activates IRE1alpha ribonuclease activity.,332.36
AQ-RA 741,[123548-16-3],CCN(CC)CCCCC1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1,7-TM Receptors,Acetylcholine Muscarinic Receptors,M2 Receptors,High affinity and selective M2 antagonist,"High affinity, selective muscarinic M2 receptor antagonist (pKi values are 8.3, 7.7 and 6.82 for M2, M1 and M3 receptors, respectively). Displays cardioselectivity in vivo, over intestinal, tracheal and bladder muscarinic receptors; inhibits vagally and agonist-induced bradycardia.",463.62
AR-A 014418,[487021-52-3],O=C(NCC2=CC=C(OC)C=C2)NC1=NC=C([N+]([O-])=O)S1,Enzymes,Kinases,Glycogen Synthase Kinase 3,Selective GSK-3 inhibitor,Selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 104 nM). Exhibits specificity for GSK-3 over cdk2 and cdk5 (IC50 values are > 100 muM) and over 26 other kinases. Inhibits beta-amyloid-mediated neurodegeneration in hippocampal slices.,308.31
Arctigenin,[7770-78-7],OC(C=C3)=C(OC)C=C3C[C@@H](C(OC2)=O)[C@H]2CC1=CC(OC)=C(OC)C=C1,Enzymes,Kinases,MEK,Potent MEK1 inhibitor. Also inhibits IkappaBalpha phosphorylation,"Antioxidant, anti-inflammatory, antiproliferative and antiviral agent. Inhibits LPS-induced iNOS expression via inhibition of IkappaBalpha phosphorylation and p65 nuclear translocation (IC50 = 10 nM). Inhibits HIV-1 replication in vitro. Also potently inhibits MKK1 (MEK1) (IC50 = 0.5 nM) and provides neuroprotection by binding to kainate receptors.",372.42
Arcyriaflavin A,[118458-54-1],O=C1NC(=O)C2=C1C1=C(NC3=CC=CC=C13)C1=C2C2=C(N1)C=CC=C2,Enzymes,Kinases,Cyclin-dependent Kinase,Potent cdk4 inhibitor; also potently inhibits CaM kinase II; antiviral,Potent cyclin-dependent kinase 4 (cdk4) inhibitor (IC50 value reported between 60 and 190 nM). Displays activity at other cdks in the sub-micromolar range. Also potently inhibits CaM kinase II (IC50 = 25 nM). Inhibits human cytomegalovirus (HCMV) replication in vitro.,325.32
Argatroban,[74863-84-6],O=C(N1[C@@H]([C@@](O)=O)C[C@H](C)CC1)[C@@H](NS(C2=CC=CC3=C2NCC(C)C3)(=O)=O)CCCNC(N)=N,Enzymes,Proteases,Other Proteases,Potent thrombin inhibitor,Potent inhibitor of thrombin mediated fibrinogen cleavage (Ki = 19 nM). Competitive inhibitor of thrombin-induced platelet activation and clotting. Shown to exhibit antithrombotic activity in animal models. This compound is a mixture of 2 diastereomers (approximate ratio 65/35).,508.63
Aripiprazole,[129722-12-9],O=C2CCC1=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C1N2,7-TM Receptors,Dopamine Receptors,D2 Receptors,High affinity D2 and 5-HT1A receptor partial agonist; also 5-HT2A antagonist,High affinity dopamine D2 and 5-HT1A receptor partial agonist (Ki values are ~1.64 and 5.59 nM respectively). Also 5-HT2A antagonist (Ki = 8.7 nM). Suppresses morphine-induced emesis in vivo. Atypical antipsychotic.,448.39
Artemisinin,[63968-64-9],O=C1O[C@]([H])(O[C@@](OO4)(C)CC3)[C@]24[C@](CC[C@@H](C)[C@]32[H])([H])[C@H]1C,Enzymes,ATPases,Ca2+-ATPase,Antimalarial; inhibits P-type ATPase (PfATP6) of P.falciparum,"Antimalarial agent; interacts with heme to produce carbon-centred free radicals, causes protein alkylation and damages parasite microorganelles and membranes. Also selectively inhibits the P-type ATPase (PfATP6) of Plasmodium falciparum (Ki ~ 150 nM). Displays antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies.",282.33
AS 1269574,[330981-72-1],BrC(C=C2)=CC=C2C1=NC(NCCO)=CC(C)=N1,7-TM Receptors,GPR119,,GPR119 receptor agonist,GPR119 receptor agonist (EC50 = 2.5 muM in HEK293 cells expressing human GPR119). Enhances insulin secretion stimulated by glucose in vivo. Stimulates proglucagon gene promoter actvity. Orally available.,308.17
AS 1892802,[928320-12-1],O=C(N[C@H](CO)C3=CC=CC=C3)NC(C=C2)=CC=C2C1=CC=NC=C1,Enzymes,Kinases,Rho-kinases,Potent ROCK inhibitor; orally bioavailable,"Potent, ATP-competitive ROCK inhibitor (IC50 values are 52, 57 and 122 nM for human ROCK2, rat ROCK2 and human ROCK1 respectively by ELISA); also inhibits PKAC-alpha and PRKX (IC50 values are 200 and 325 nM respectively). Exhibits analgesic effects in rat models of inflammatory (AIA) and noninflammatory (MIA) arthritic pain. Orally bioavailable.",333.38
AS 1949490,[1203680-76-5],ClC(C=C2)=CC=C2COC1=C(C(N[C@@H](C)C3=CC=CC=C3)=O)SC=C1,Enzymes,Phosphatases,Inositol Phosphatases,SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2) inhibitor,Selective SHIP2 (SH2 domain-containing inositol 5'-phosphatase 2) inhibitor (IC50 values are 0.34 muM and 0.62 muM for mouse and human respectively); displays approximately 30-fold affinity for SHIP2 over SHIP1. Increases insulin-induced phosphorylation of Akt in L6 myotubules. Stimulates activation of glucose metabolism; regulates gluconeogenesis in vitro and in vivo and exhibits antidiabetic effects. Also promotes increased BDNF mRNA levels in cultured cortical neurons and has memory enhancing and antidepressant effects in vivo.,371.88
AS 2034178,[1030846-42-4],FC1=C(CCC(O)=O)C=CC(NCC2=C(CCCN3CCOC4=CC=CC=C4)C3=CC=C2)=C1,7-TM Receptors,Free Fatty Acid Receptors,,Selective FFA1 (GPR40) agonist,"Selective free fatty acid receptor 1 (FFA1/GPR40) agonist. Exhibits selectivity for GPR40 over GPR41, GPR43, GPR119, GPR120 and PPARgamma. Induces glucose-dependent insulin secretion in pancreatic MIN6 cells and in vivo. Enhances insulin sensitivity in a type 2 diabetes model in vivo. Orally available.",448.53
AS 2444697,[1287665-60-4],O=C(N)C2=NN(C=C2NC(C3=COC(C4=CC=NC(C)=C4)=N3)=O)C1CCOCC1.Cl,Enzymes,Kinases,IRAK,Potent and selective IRAK4 inhibitor,Potent and selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor (IC50 = 21 nM). Displays 30-fold selectivity for IRAK4 over IRAK1. Inhibits LPS-induced TNF-alpha and IL-6 production in PBMCs in vitro. Renoprotective and anti-inflammatory in a rodent model of chronic kidney disease.,432.86
Asenapine maleate,[85650-56-2],CN2C[C@]1([H])C3=C(C=CC=C3)OC4=C(C=C(Cl)C=C4)[C@]([H])1C2.CN6C[C@@]5([H])C7=C(C=CC=C7)OC8=C(C=C(Cl)C=C8)[C@@]([H])5C6,7-TM Receptors,5-HT Receptors,Non-selective 5-HT,"Non-selective 5-HT, dopamine, adrenalin and histamine receptor antagonist; antipsychotic agent","Novel psychopharmacologic agent. Displays antagonist activity at 5-HT, dopamine, noradrenalin and histamine receptor subtypes (pKi values are 8.60, 8.40, 10.15, 9.75, 10.46, 8.84, 9.60, 9.94, 8.85, 8.90, 8.84, 9.38, 8.95, 8.93, 8.9, 9.49, 8.91, 9.00 and 8.21 for 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, 5-HT7, D1, D2L, D2S, D3, D4, alpha1A, alpha2A, alpha2B, alpha2C, H1 and H2 receptors respectively). Displays no appreciable affinity for muscarinic receptors. Exhibits potent activity in animal models predictive of antipsychotic efficacy.",401.84
ASP 2535,[374886-51-8],CC(C)C1=NN=C(C4=CN=C(C5=CC=CC=C5)C=C4)N1C3=CC=CC2=NON=C23,Transporters,Neurotransmitter Transporters,Glycine Transporters,Potent and selective GlyT1 inhibitor,Potent and selective GlyT1 inhibitor (IC50 = 92 nM). Exhibits 50-fold selectivity over GlyT2. Attenuates MK 801-induced working memory deficits and PCP-induced visual learning deficits in mice. Orally available and brain penetrant.,382.42
Aspirin,[50-78-2],CC(OC1=C(C(O)=O)C=CC=C1)=O,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Cyclooxygenase inhibitor; NSAID,Inhibitor of cyclooxygenase (COX)-1. Blocks the production of prostaglandins and thromboxanes. Exhibits antiplatelet and antithrombotic activities. Displays anticancer effects in some solid tumors. One of the first described NSAID drugs.,180.16
Astemizole,[68844-77-9],FC(C=C5)=CC=C5CN2C1=CC=CC=C1N=C2NC3CCN(CCC4=CC=C(OC)C=C4)CC3,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,"Orally active, potent H1 antagonist; also KV11.1 (hERG) channel blocker","Orally active, potent histamine H1 antagonist (IC50 = 4 nM) that displays 20-fold, > 250-fold and > 250-fold selectivity over 5-HT, dopamine and muscarinic acetylcholine receptors respectively. Exhibits antimalarial activity in multidrug resistant strains in vitro (IC50 = 227 - 734 nM). Also potent KV11.1 (hERG) channel blocker (IC50 = 0.9 nM) that displays cardiotoxicity in vivo.",458.57
AT 101,[90141-22-3],OC1=[C@]([C@]2=C(O)C(C(C=O)=C(O)C(O)=C3C(C)C)=C3C=C2C)C(C)=CC4=C1C(C=O)=C(O)C(O)=C4C(C)C,Regulated Cell Death,Apoptosis,Bcl-2 Family,Downregulates Bcl-2 and Mcl-1; pro-apoptotic,"R-(-)-enantiomer of gossypol (Cat. No. 1964). Mimics the BH3 domains of Bcl-2, Bcl-XL and Mcl-1. Disrupts heterodimerization of Bcl-2 with proapoptotic family members. Induces apoptosis in vitro through activation of caspase-9; cytotoxic to multiple myeloma and drug-resistant cell lines. Delays onset of androgen-independent growth of VCaP prostate cancer xenografts in vivo.",518.56
AT 1015,[190508-50-0],O=C(C5CCN(C=O)CC5)NCCN(CC3)CC/C3=C1C(C=CC=C4)=C4C=CC2=C\1C=CC=C2.Cl,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Long-acting 5-HT2A antagonist,Long-acting 5-HT2A receptor antagonist; inhibits vasoconstriction and blocks platelet aggregation. Prolongs clotting time in a rat model of thrombus formation; ameliorates laurate-induced peripheral vascular lesions in rodents.,492.05
Atipamezole hydrochloride,[104075-48-1],CCC2(C3=CN=CN3)CC1=CC=CC=C1C2.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,Selective alpha2 antagonist,"Selective alpha2-adrenergic receptor antagonist (Ki values are 1.1, 1.0, 0.89, 1300 and 6500 nM for alpha2A, alpha2B, alpha2C, alpha1A and alpha1B receptors respectively). Brain penetrant.",248.75
Atorvastatin hemicalcium salt,[134523-03-8],[Ca++].CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1)C1=CC=CC=C1.CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC([O-])=O)C1=CC=C(F)C=C1)C1=CC=CC=C1,Enzymes,Reductases,HMG-CoA Reductase,Potent HMG-CoA reductase inhibitor,Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model.,577.67
Axitinib,[319460-85-0],O=C(NC)C1=C(SC2=CC=C(C(/C=C/C4=CC=CC=N4)=NN3)C3=C2)C=CC=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,"Potent VEGFR-1, -2 and -3 inhibitor","Potent inhibitor of VEGFR-2, -3, and -1 (IC50 values are 0.2, 0.1-0.3, and 1.2 nM respectively). Exhibits minimal activity against a panel of ~100 protein kinase. Inhibits angiogenesis and vascular permeability. Also a high affinity BCR-ABL1 (T315I) inhibitor (Ki = 149 pM for autophosphorylated ABL1 (T315I)). Blocks proliferation of Ba/F3 cells expressing BCR-ABL1 (T315I). Orally available.",386.47
AZ 10397767,[333742-63-5],C[C@@H](NC1=C2SC(NC2=NC(SCC3=C(C(Cl)=CC=C3)F)=N1)=O)CO,7-TM Receptors,Chemokine Receptors,Chemokine CXC Receptors,Potent CXCR2 antagonist,"Potent CXCR2 antagonist (IC50 = 1 nM); attenuates oxaliplatin-induced NF-kappaB activation, increases oxaliplatin cytotoxicity, and potentiates oxaliplatin-induced apoptosis in AIPC cells. Reduces the numbers of neutrophils infiltrating into tumors in both in vitro and in vivo models and delayed tumor growth. Orally bioavailable.",400.88
AZ 10417808,[331645-84-2],[O-][N+](=O)C1=CC2=C(N=C(NC3=CC(Cl)=C(Cl)C=C3)NC2=O)C(=C1)C(=O)NCC=C,Enzymes,Proteases,Caspases,Selective non-peptide caspase-3 inhibitor,"Selective non-peptide inhibitor of caspase-3 (Ki = 247 nM); displays > 40-fold selectivity over caspases 1, 2, 6, 7 and 8 (Ki > 10 muM). Completely blocks staurosporine-induced intracellular DEVDase activity in SH-SY5Y cells (IC50 = 14.9 muM).",434.23
AZ 10606120 dihydrochloride,[607378-18-7],O=C(NC4=C(C=CC(NCCNCCO)=N5)C5=CC=C4)CC1(C3)CC2CC(CC3C2)C1.Cl.Cl,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Potent P2X7 receptor antagonist,"Potent P2X7 receptor antagonist (KD values are 1.4 and 19 nM at human and rat P2X7 receptors respectively). Binds in a positive cooperative manner to sites distinct from, but coupled to, the ATP binding site and acts as a negative allosteric modulator. Inhibits tumor growth and displays antiangiogenic effects in mice.",495.48
AZ 12080282 dihydrochloride,,CC1=CC=C(C2=NC=CN2)C=C1NC(C3=CC=C(OCC4=CC=CC=N4)C=C3)=O.Cl.Cl,Signal Transduction,Hedgehog Signaling,,Inhibitor of Hedgehog (Hh) signaling,Inhibitor of Hedgehog (Hh) signaling (IC50 <0.012 muM in a firefly reporter assay against the Hh pathway). Shown to displace cyclopamine in HeLa cells expressing Smoothened. Exhibits selectivity against p38alpha. Orally bioavailable.,457.35
AZ 191,[1594092-37-1],CN2C=C(C3=CC=NC(NC4=C(OC)C=C(N5CCN(C)CC5)C=C4)=N3)C1=CC=NC=C12,Enzymes,Kinases,DYRK,Potent DYRK1B inhibitor,"Potent DYRK1B inhibitor (IC50 values are 17, 88 and 1890 nM for DYRK1B, DYRK1A and DYRK2 respectively). Inhibits DYRK1B-induced Gi phase cell cycle arrest in Panc-1 cells in vitro.",429.52
AZ 20,[1233339-22-4],CS(C4(CC4)C1=CC(N5[C@H](C)COCC5)=NC(C2=CC=CC3=C2C=CN3)=N1)(=O)=O,Enzymes,Kinases,ATM & ATR Kinase,Potent and selective ATR kinase inhibitor; antitumor,"Potent and selective ATR kinase inhibitor (IC50 = 5 nM). Exhibits 7.6-fold selectivity over mTOR and selectivity over a panel of 442 kinases, including ATM kinase, PI3-K isoforms, and DNA-PK. Inhibits cell growth in cell lines with high baseline levels of replication stress. Displays antitumor effects in vivo.",412.51
AZ 3146,[1124329-14-1],CN(C1=CN=C(NC4=CC=C(OC5CCN(C)CC5)C=C4OC)N=C1N2C3CCCC3)C2=O,Enzymes,Kinases,Monopolar Spindle 1 Kinase,Potent and selective Mps1 kinase inhibitor,"Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM). Displays selectivity over 46 other kinases including Cdk1 and aurora kinase B. Interferes with chromosome alignment and overrides spindle assembly checkpoint. Inhibits the recruitment of Mad1, Mad2 and centromere protein E (CENP-E) to kinetochores.",452.55
AZ 6102,[1645286-75-4],CC1=CC(N2C[C@H](C)N[C@H](C)C2)=NC=C1C3=CC=C(C(N4)=NC5=C(C=CN5C)C4=O)C=C3,Enzymes,Polymerases,Tankyrase,Potent TNKS1/2 inhibitor,"Potent TNKS2 and TNKS1 inhibitor (IC50 values are 1 and 3 nM, respectively). Exhibits >100-fold selectivity for TNKS1/2 over PARP-1, PARP-2 and PARP-6. Inhibits Wnt signaling in DLD-1 cells (IC50 = 5 nM). Exhibits moderate oral bioavailability.",428.53
AZ 628,[878739-06-1],CC(C)(C#N)C1=CC=CC(C(NC2=CC(NC3=CC(C(N(C)C=N4)=O)=C4C=C3)=C(C)C=C2)=O)=C1,Enzymes,Kinases,Raf Kinase,Potent Raf kinase inhibitor,"Potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM for c-Raf1, B-RafV600E and wild-type B-Raf, respectively). Displays selectivity for Raf kinases over a panel of 150 other kinases; inhibits activation of tyrosine protein kinases such as VEGFR2, Lyn, Flt1 and Fms. Also inhibits growth, and induces cell cycle arrest and apoptosis in colon and melanoma cell lines with the B-RafV600E mutation.",451.52
Azathioprine,[446-86-6],CN1C=NC([N+]([O-])=O)=C1SC2=C3C(N=CN3)=NC=N2,Cell Metabolism,"DNA, RNA and Protein Synthesis",,Purine analog; prodrug of 6-mercaptopurine (Cat. No. 4103),Purine analog. Blocks DNA replication and the de novo pathway of purine synthesis. Immunosuppressive and anti-inflammatory drug; induces apoptosis in human T-lymphocytes. Prodrug of 6-mercaptopurine (Cat. No. 4103).,277.26
AZD 1480,[935666-88-9],C[C@@H](C1=NC=C(F)C=N1)NC2=NC=C(Cl)C(NC3=NNC(C)=C3)=N2,Enzymes,Kinases,JAK Kinase,Potent and selective JAK2 inhibitor; antiangiogenic,"Potent and selective JAK2 inhibitor (IC50 < 3 nM). Exhibits >50-fold selectivity for JAK2 over JAK3. Exhibits antitumor effects and inhibits formation of lung metastases in a mouse renal cancer model. Also inhibits STAT3 signaling, tumor angiogenesis and myeloid cell migration in vivo.",348.77
AZD 3147,[1101810-02-9],OCCNC(NC(C=C1)=CC=C1C2=NC(C3(CC3)S(C4CC4)(=O)=O)=CC(N5[C@@H](C)COCC5)=N2)=S,Enzymes,Kinases,mTOR,Potent and selective dual mTORC1 and 2 inhibitor; orally bioavailable,Potent and selective dual mTORC1 and 2 inhibitor (IC50 = 1.5 nM). Exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. Orally bioavailable.,517.66
AZD 3988,[892489-52-0],O=C(NC3=CC=[C@@]([C@H]4CC[C@H](CC(O)=O)CC4)C=C3)C1=NN=C(NC2=CC(F)=C(F)C=C2)O1,Enzymes,Transferases,Diacylglycerol O-Acyltransferase,Potent and selective DGAT-1 inhibitor,"Potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM). Exhibits selectivity for DGAT-1 over DGAT-2, Kv11.1 (hERG) and cytochrome P450 enzymes. Suppresses triacylglyceride (TAG) plasma excursion and adipose tissue TAG synthesis in rats. Reduces body weight of diet-induced obese rats. Cell permeable and orally bioavailable.",456.44
AZD 5438,[602306-29-6],CS(C(C=C3)=CC=C3NC1=NC(C2=CN=C(C)N2C(C)C)=CC=N1)(=O)=O,Enzymes,Kinases,Cyclin-dependent Kinase,"Cdk inhibitor; potently inhibits cdk1, 2, 5 and 9","Potent inhibitor of cyclin dependent kinases (cdks; reported IC50 values are 6 - 45, 14, 16 and 20 nM for cdk2, cdk5, cdk1 and cdk9 respectively). Also inhibits cdk4 and cdk7 in the sub micromolar range. Exhibits antiproliferative activity in human tumor cell lines. Blocks cell cycling at G2-M, S and G1 phases; reduces the proportion of actively cycling cells in vivo.",371.46
AZD 6482,[1173900-33-8],OC(C1=C(N[C@@H](C2=CC(C)=CN3C2=NC(N4CCOCC4)=CC3=O)C)C=CC=C1)=O,Enzymes,Kinases,PI 3-Kinase,Potent and selective PI 3-Kbeta inhibitor,"Potent and selective inhibitor of PI 3-kinase beta (PI 3-Kbeta) (IC50 values are 0.69, 13.6, 47.8 and 136 nM for PI 3-Kbeta, PI 3-Kdelta, PI 3-Kgamma and PI 3-Kalpha, respectively). Selectively inhibits in vivo growth of the PTEN-deficient tumor xenografts HCC70 and PC3. Also exhibits antithrombotic activity.",408.45
AZD 7762 hydrochloride,[1246094-78-9],FC1=CC=CC(C2=CC(NC(N)=O)=C(C(N[C@@H]3CNCCC3)=O)S2)=C1.Cl,Enzymes,Kinases,Checkpoint Kinases,Potent and selective ATP-competitive inhibitor of Chk1 and Chk2; also enhances CRISPR-Cpf1-mediated genome editing,Potent and selective ATP-competitive inhibitor of Chk1 and Chk2 (IC50 vales are 5 nM for both kinases); displays at least >10 fold selectivity over a panel of 164 kinases. Potentiates cytotoxicity of DNA-damaging agents. Active in vivo. Also improves efficiency of CRISPR-Cpf1-mediated genome editing in hPSC lines (2.7-fold at 1 muM).,398.88
AZD 9272,[327056-26-8],FC1=CC=C(C2=NOC(C3=CC(F)=CC(C#N)=C3)=N2)N=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Potent and selective mGlu5 antagonist; brain penetrant,"Potent and selective mGlu5 antagonist (IC50 values are 2.6 and 7.6 nM for rat and human receptors, respectively). Exhibits >3900-fold selectivity for mGlu5 over other mGlu receptors. Also selective over a panel of other targets. Displays discriminative effects in rats. Orally bioavailable and brain penetrant.",284.22
Azilsartan,[147403-03-0],O=C1NC(C2=CC=CC=C2C(C=C5)=CC=C5CN4C3=C(C(O)=O)C=CC=C3N=C4OCC)=NO1,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,Potent AT1 inverse agonist; antihypertensive,Potent angiotensin II type 1 (AT1) receptor inverse agonist (IC50 = 2.6 nM at the human AT1 receptor). Inhibits angiotensin II-induced IP1 accumulation in COS-7 cells; decreases maximal contraction of rabbit aortic strips in a concentration-dependent manner (pD'2 = 9.9). Antihypertensive; prevents vascular cell proliferation and expression of PAI-1.,456.45
Azithromycin,[83905-01-5],[H][C@@]1(O[C@@H]([C@H](C)[C@@H](O[C@@]3([H])[C@H](O)[C@@H](N(C)C)C[C@@H](C)O3)[C@](C)(O)C[C@@H](C)C2)[C@@H](C)C(O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)N2C)=O)O[C@@H](C)[C@H](O)[C@](C)(OC)C1,Cell Metabolism,"DNA, RNA and Protein Synthesis",,Antibiotic; inhibits 50S ribosomal subunit formation and elongation at transpeptidation,Macrolide antibiotic. Inhibits 50S ribosomal subunit formation and elongation at transpeptidation step in gram-positive and gram-negative organisms. Orally active with improved pharmacokinetics over erythromycin in mouse models. Inhibits autophagy.,748.98
AZM 475271,[476159-98-5],ClC1=CC=C(OC)C=C1NC3=NC=NC2=CC(OCC4CCN(C)CC4)=C(OC)C=C23,Enzymes,Kinases,Src Kinases,Src tyrosine kinase inhibitor,"Src tyrosine kinase inhibitor. Reduces tumor size, vascularity and metastasis, and increases apoptosis in human pancreatic cells grown in nude mice. Also exhibits antiangiogenic activity in vitro and in vivo. Sensitizes tumor cells to the cytotoxic effects of gemcitabine (Cat. No. 3259).",442.94
BAG 956,[853910-02-8],CC3=NC1=C(N3C4=CC=C(C(C)(C#N)C)C=C4)C2=C(C=CC(C#CC5=CN=CC=C5)=C2)N=C1,Enzymes,Kinases,PI 3-Kinase,Dual PI 3-kinase and PDPK1 (PDK1) inhibitor,"Dual PDPK1 (PDK1) and class I PI 3-K inhibitor (IC50 values are 245, 56, 446, 35 and 117 nM for PDPK1 and PI 3-K p110 -alpha, -beta, -delta, and -gamma respectively). Inhibits cellular AKT phosphorylation at Thr308. Blocks cell proliferation, causing arrest in G1 phase of the cell cycle. Slows tumor progression in mouse xenograft models.",427.5
Balicatib,[354813-19-7],O=C(NC1(CCCCC1)C(NCC#N)=O)C(C=C2)=CC=C2N3CCN(CCC)CC3,Enzymes,Proteases,Cathepsin,Potent and selective cathepsin K inhibitor,"Potent and selective cathepsin K inhibitor (IC50 values are 1.4, 56 and 480 nM for human, rat and mouse cathepsin K, respectively). Exhibits >300-fold selectivity for cathepsin K over cathepsins L, B and S. Long term supratherapeutic dosing increases tissue levels of cathepsins L and B in rats.",411.54
BAN ORL 24,[1401463-54-4],O=[C@@]([C@H]2CCCN2CC3=CC=CC=C3)NCCCN1CCC4(OCC5=C4C=CC=C5)CC1.Cl.Cl,7-TM Receptors,Opioid Receptors,NOP Receptors,Potent and selective NOP antagonist,"Potent and selective NOP receptor antagonist (IC50 values are 0.27, 2500, 6700 and > 10000 nM for NOP, kappa-, mu- and delta-receptors respectively). Inhibits nociceptin-induced stimulation of [35S]-GTPgammaS binding and Ca2+ mobilization in CHO cells in vitro and antagonizes NOP agonist-induced reduction in locomotor activity in vivo. Brain penetrant.",506.51
Bax channel blocker,[329349-20-4],Cl.Cl.OC(CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2)CN1CCNCC1,Regulated Cell Death,Apoptosis,Bcl-2 Family,Allosteric inhibitor of Bax channel activation,Allosteric inhibitor of Bax channel activation. Binds inactive Bax at allosteric site and inhibits tBID-mediated Bax activation (IC50 = 3.3 muM). Selectively inhibits Bax-dependent apoptosis. Potent inhibitor of Bax-mediated mitochondrial cytochrome c release (IC50 = 0.52 muM).,540.12
BAY 41-2272,[256376-24-6],FC(C=CC=C3)=C3CN2N=C(C4=NC=C(C5CC5)C(N)=N4)C1=CC=CN=C12,Enzymes,Cyclases,Guanylyl Cyclase,Soluble guanylyl cyclase (sGC) activator,Activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC alpha1 subunit. Inhibits platelet aggregation (IC50 = 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC50 = 0.30 muM). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.,360.39
BAY 58-2667 hydrochloride,[646995-35-9],OC(CCCCN(CC1=CC=C(C(O)=O)C=C1)CCC2=C(C=CC=C2)OCC3=CC=C(C=C3)CCC4=CC=CC=C4)=O.Cl,Enzymes,Cyclases,Guanylyl Cyclase,Potent soluble guanylyl cyclase (sGC) activator,Potent soluble guanylyl cyclase (sGC) activator (EC50 = 6.4 nM). Binds heme-free sGC. Exhibits antihypertensive effects in vivo.,602.16
BAY 60-6583,[910487-58-0],NC1=NC(SCC(N)=O)=C(C#N)C(C2=CC=C(OCC3CC3)C=C2)=C1C#N,7-TM Receptors,Adenosine Receptors,Adenosine A2B Receptors,Potent A2B agonist; cardioprotective,"Potent adenosine A2B receptor agonist (EC50 = 2.83 nM for murine A2B receptor). Displays selectivity for A2B over A1, A2A and A3 receptors. Decreases fMLP-induced superoxide production in neutrophils at low concentrations (1-10 nM). Cardioprotective; attenuates infarct size in a mouse model of myocardial ischemia. Exhibits ERK1/2-biased agonism.",379.44
BAZ2-ICR,,CN(N=C4)C=C4CCN1C=NC(C3=CN(C)N=C3)=C1C2=CC=C(C#N)C=C2,Epigenetics,Bromodomains,,Selective BAZ2 inhibitor,Selective BAZ2 bromodomain inhibitor (IC50 values are 130 and 180 nM for BAZ2A and BAZ2B respectively). Exhibits 15-fold selectivity for the BAZ2 bromodomain over the CERC2 bromodomain and >100-fold selectivity over a range of other bromodomains. Accelerates FRAP recovery in a BAZ2A FRAP assay.,357.41
Bazedoxifene acetate,[198481-33-3],CC2=C(C3=CC=C(O)C=C3)N(CC4=CC=C(OCCN5CCCCCC5)C=C4)C1=CC=C(O)C=C12.OC(C)=O,Nuclear Receptors,Estrogen and Related Receptors,,Potent and selective estrogen receptor modulator (SERM),Potent selective estrogen receptor modulator (SERM) (IC50 values are 26 and 99 nM for ERalpha and ERbeta respectively). Inhibits 17beta-estradiol-induced proliferation in MCF-7 cells. Co-treatment with Raloxifene (Cat No. 2280) completely abolishes raloxifene-induced stimulation of luminal epithelial cells and myometrium.,530.65
BC 11 hydrobromide,[443776-49-6],NC(SCC1=CC=C(B(O)O)C=C1)=N.Br,Enzymes,Proteases,Urokinase,Selective urokinase (uPA) inhibitor,Selective urokinase (uPA) inhibitor (IC50 = 8.2 muM). Exhibits no activity at 8 other related enzymes. Inhibits clot lysis with no effect on clot formation. Also decreases viability of MDA-MB231 breast cancer cells in vitro.,290.97
BCTC,[393514-24-4],ClC1=CC=CN=C1N2CCN(C(NC3=CC=C(C(C)(C)C)C=C3)=O)CC2,Ion Channels,Transient Receptor Potential Channels,TRPV,TRPV1 antagonist,Orally effective vanilloid receptor 1 (TRPV1 receptor) antagonist. Inhibits acid- and capsaicin-induced activation of rat TRPV1 receptors (IC50 values are 6.0 and 35 nM respectively). Displays analgesic properties in rat models of inflammatory and neuropathic pain. CNS penetrant.,372.89
BD 1047 dihydrobromide,[138356-21-5],Br.Br.CN(C)CCN(C)CCC1=CC=C(Cl)C(Cl)=C1,Other Pharmacology,Sigma Receptors,Sigma1 Receptors,sigma1 selective antagonist,"sigma1 receptor antagonist, exhibiting a similar binding profile to that of BD 1063 (Cat. No. 0883) but with higher affinity (approximately 10-fold) at both sigma1 and sigma2 sites.",437.04
Begacestat,[769169-27-9],ClC1=CC=C(S(N[C@H](CO)C(C(F)(F)F)C(F)(F)F)(=O)=O)S1,Enzymes,Proteases,Gamma-Secretase,gamma-secretase inhibitor; lowers Abeta40 and Abeta42 levels,gamma-secretase inhibitor; selectively inhibits cleavage of amyloid precursor protein (APP) over Notch. Lowers levels of Abeta42 and Abeta40 (EC50 values are 12.4 and 14.8 nM respectively in cells expressing human recombinant APP). Orally active.,391.74
Benazepril hydrochloride,[86541-74-4],O=[C@@](OCC)[C@H](CCC3=CC=CC=C3)N[C@H]1CCC2=C(C=CC=C2)N(CC(O)=O)C1=O.Cl,Enzymes,Proteases,Angiotensin-Converting Enzyme,Angiotensin-converting enzyme (ACE) inhibitor,Non-peptide angiotensin-converting enzyme (ACE) inhibitor. Reduces blood pressure and myocardial hypertrophy in spontaneous hypertensive rats.,460.96
Benzamil,[161804-20-2],NC1=C(Cl)N=C(C(NC(NCC2=CC=CC=C2)=N)=O)C(N)=N1.Cl,Transporters,Ion Pumps/Transporters,Na+/Ca2+ Exchanger,"NCX inhibitor, Deg/ENaC channel blocker; amiloride (Cat. No. 0890) derivative",Na+/Ca2+ exhanger (NCX) inhibitor (IC50 ~ 100 nM); TRPP3 channel blocker (IC50 = 1.1 muM for inhibition of Ca2+-activated TRPP3 channel activity). Also non-selective Deg/ENaC family blocker; reduces mechanosensitivity of colonic afferents. More potent derivative of amiloride (Cat. No. 0890).,356.21
Bepridil hydrochloride,[68099-86-5],CC(C)COCC(N3CCCC3)CN(C2=CC=CC=C2)CC1=CC=CC=C1.Cl,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,Non-selective Ca2+ channel blocker; also NCX inhibitor,"Calcium channel blocker. Also inhibits Na+/Ca2+ exchange (NCX), sodium channels and cardiac sarcolemmal KATP channels; opens mitochondrial KATP channels. Antiarrhythmic and antihypertensive; acts as a calcium sensitizer.",403
BETP,[1371569-69-5],CCS(C1=NC(C2=CC=CC(OCC3=CC=CC=C3)=C2)=CC(C(F)(F)F)=N1)=O,7-TM Receptors,Peptide Receptors,Glucagon and Related Peptide Receptors,Positive allosteric modulator of GLP-1 receptors,"Selective positive allosteric modulator and partial agonist of the glucagon-like peptide 1 (GLP-1) receptor. Increases binding affinity of oxyntomodulin for the GLP-1 receptor. Potentiates oxyntomodulin-mediated GLP-1 receptor signaling in vitro and insulin secretion in vivo. Has no effect on GLP-2, GIP, PTH or glucagon receptors.",406.42
Betulinic acid,[472-15-1],O[C@H]1CC[C@@]2(C)[C@](CC[C@]3(C)[C@@]([H])2CC[C@@]4([H])[C@](C)3CC[C@]5([C@](O)=O)[C@@]([H])4[C@H]([C@@](C)=C)CC5)([H])C(C)1C,Regulated Cell Death,Apoptosis,Apoptosis Inducers,Antitumor and anti-HIV agent; activates NF-kappaB. Also TGR5 agonist,"Natural triterpenoid that displays anti-HIV and antitumor activity. Induces the production of reactive oxygen species (ROS) and activates NF-kappaB. Also a GPBA receptor partial agonist (EC50 = 1.04 muM, efficacy 83%).",456.7
BF 2649 hydrochloride,[903576-44-3],ClC1=CC=C(CCCOCCCN2CCCCC2)C=C1.Cl,7-TM Receptors,Histamine Receptors,Histamine H3 Receptors,Potent and selective H3 inverse agonist,"Potent and selective histamine H3 receptor inverse agonist (EC50 = 1.5 nM, Ki = 0.16 nM). Exhibits nootropic effects in cognitive disorders; reduces locomotor hyperactivity induced by methamphetamine. Brain penetrant.",332.31
BI 78D3,[883065-90-5],O=C1NN=C(SC3=NC=C([N+]([O-])=O)S3)N1C2=CC=C4C(OCCO4)=C2,Enzymes,Kinases,MAPK Family,"Selective, competitive JNK inhibitor",Competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) that displays > 100 fold selectivity over p38alpha and no activity at mTOR and PI-3K. Inhibits JNK interacting protein 1 (JIP1)-JNK binding (IC50 = 500 nM) and prevents JNK substrate phosphorylation. Blocks JNK-dependent Con A-induced liver damage and restores insulin sensitivity in a mouse model of type II diabetes.,379.37
BIBO 3304 trifluoroacetate,[2310085-85-7],OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.NC(=N)NCCC[C@@H](NC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)NCC1=CC=C(CNC(N)=O)C=C1,7-TM Receptors,Peptide Receptors,NPY Receptors,Highly selective NPY Y1 receptor antagonist,"High affinity NPY Y1 receptor antagonist (IC50 values are 0.38 and 0.72 nM at human and rat receptors respectively) that displays > 2600-fold selectivity over Y2, Y4 and Y5 receptors. Inhibits NPY- and fasting-induced feeding in vivo following central administration. Also antagonizes anxiolytic-like effects of NPY.",757.69
BIBR 1532,[321674-73-1],C/C(C2=CC1=CC=CC=C1C=C2)=C\C(NC3=C(C(O)=O)C=CC=C3)=O,Enzymes,Polymerases,Telomerase,Selective telomerase inhibitor,"Selective telomerase inhibitor (IC50 values are 93, > 100000 and > 100000 nM for human telomerase, human RNA polymerase I and human RNA polymerase II + III respectively). Causes telomere shortening in exponentially growing NCI-H460 lung carcinoma cells and eventual growth arrest.",331.36
BIBU 1361 dihydrochloride,[1643609-75-9],Cl.Cl.CCN(CC)CC1CCN(CC1)C1=NC=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=N1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,Selective inhibitor of EGFR-kinase,Potent inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM). Displays ~ 100-fold lower potency against ErbB2 (IC50 = 290 nM) and is selective over a range of other related tyrosine kinases (IC50 > 10 muM). Blocks downstream EGFR signaling events such as MAPKK/MAPK activation. Oral administration inhibits growth of established human xenografts in athymic mice.,516.87
BIBX 1382 dihydrochloride,[1216920-18-1],Cl.Cl.CN1CCC(CC1)NC1=NC=C2N=CN=C(NC3=CC(Cl)=C(F)C=C3)C2=N1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,Highly selective EGFR-kinase inhibitor,"Potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM). Displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 muM) and a range of other related tyrosine kinases (IC50 > 10 muM). Oral administration inhibits growth of established human xenografts in athymic mice.",460.77
Bicalutamide,[90357-06-5],O=C(C(O)(C)CS(C2=CC=C(F)C=C2)(=O)=O)NC1=CC(C(F)(F)F)=C(C#N)C=C1,Nuclear Receptors,Androgen Receptor,,Non-steroidal androgen receptor antagonist,Orally active non-steroidal androgen receptor antagonist (IC50 = 190 nM). Displays peripheral selectivity and does not effect serum levels of LH and testosterone. Exhibits potent anticancer activity in vivo.,430.37
Bicifadine hydrochloride,[66504-75-4],CC(C=C3)=CC=C3C12CNCC1C2.Cl,Transporters,Neurotransmitter Transporters,Adrenergic Transporters,"Noradrenalin, 5-HT and dopamine re-uptake inhibitor","Potent antagonist of the noradrenalin transporter (IC50 = 55 nM); also displays antagonist activity at the 5-HT and dopamine transporters (IC50 values are 117 nM and 910 nM respectively). Orally active. Exhibits antinociceptive and antiallodynic activity in rodent models of acute, persistent, and chronic pain.",209.72
Bifemelane hydrochloride,[62232-46-6],Cl.CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1,Enzymes,Oxygenases/Oxidases,Monoamine Oxidase,Non-selective MAO inhibitor,Antidepressant MAO inhibitor. Reverses catalepsy induced by tetrabenazine in mice and increases locomotor activity in MPTP-treated marmosets.,305.84
BIIB 021,[848695-25-0],ClC1=C2C(N(CC3=NC=C(C)C(OC)=C3C)C=N2)=NC(N)=N1,Signal Transduction,Heat Shock Proteins,Hsp90,Selective Hsp90 inhibitor,"Selective, Hsp90 competitive inhibitor (Ki = 1.7 nM). Displays no significant activity at a range of ATP-binding kinases or Na+K+ ATPase. Induces degradation of HER-2 in vitro (EC50 = 38 nM in MCF-7 cells). Inhibits growth and promotes cell death in a variety of human tumor cells. Orally bioavailable.",318.76
BIMU 8,[134296-40-5],[H][C@]12CC[C@](CC(NC(N3C(C=CC=C4)=C4N(C(C)C)C3=O)=O)C2)([H])N1C.Cl,7-TM Receptors,5-HT Receptors,5-HT4 Receptors,Potent 5-HT4 agonist,Potent 5-HT4 receptor full agonist (KD = 77 nM and EC50 = 18 nM for wild type 5-HT4 receptors). Binds to receptors in a mechanism different to that of the endogenous ligand 5-HT.,378.9
BINA,[866823-73-6],CC1=C(C)C(C(C(C5CCCC5)C4)=O)=C4C=C1OCC2=CC(C3=CC=C(C(O)=O)C=C3)=CC=C2,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group II Receptors,Selective positive allosteric modulator of mGlu2 receptors,Selective positive allosteric modulator of mGlu2 (EC50 = 33.2 nM in CHO cells expressing human mGlu2). Displays no effect on glutamate-induced activation of other mGlu receptor subtypes. Exhibits antipsychotic and anxiolytic properties in mice.,454.56
BIO 5192,[327613-57-0],O=C(NC2=CC=C(CC(N(C)[C@@H](CC(C)C)C(NCC[C@@H]([C@@](O)=O)N[C@]([C@H]3N(S(C4=CC(Cl)=CC(Cl)=C4)(=O)=O)CCC3)=O)=O)=O)C=C2)NC1=CC=CC=C1C,Enzyme-Linked Receptors,Integrins,,Highly potent and selective inhibitor of integrin alpha4beta1 (VLA-4),"Highly selective and potent inhibitor of integrin alpha4beta1 (Very Late Antigen-4; VLA-4) (Kd < 10 pM). Selectively binds alpha4beta1 over a range of other integrins (IC50 values are 1.8, 138, 1053, > 500 and > 10,000 nM for alpha4beta1, alpha9beta1, alpha2beta1, alpha4beta7 and alphaIIbbeta3, respectively). Induces a 30-fold increase in mobilization of murine hematopoietic stem and progenitor cells; displays a 3-fold additive effect with AMD 3100 (Cat. No. 3299). Decreases oxidative damage and improves neurological function following spinal cord injury in rats.",817.78
BIRT 377,[213211-10-0],CN([C@@](CC3=CC=C(Br)C=C3)(C)C(N1C2=CC(Cl)=CC(Cl)=C2)=O)C1=O,Enzyme-Linked Receptors,Integrins,,Potent negative allosteric modulator of LFA-1,Potent negative allosteric modulator of LFA-1 (lymphocyte function-associated antigen-1) (Kd = 26 nM). Binds to the I-domain of LFA-1. Reversibly inhibits LFA-1 mediated binding of SKW3 leukemia cells to ICAM-1. Inhibits superantigen (SEB)-induced IL-2 production from lymphocytes in vitro and attenuates the SEB-induced increase in IL-2 plasma levels in a mouse model in vivo. Orally available.,442.13
BIX 01294,[1392399-03-9],CN(CCC3)CCN3C2=NC1=CC(OC)=C(OC)C=C1C(NC4CCN(CC5=CC=CC=C5)CC4)=N2.Cl.Cl.Cl,Enzymes,Transferases,Lysine Methyltransferases,GLP and G9a inhibitor,"GLP and G9a histone lysine methyltransferase inhibitor (IC50 values are 0.7 and 1.7 muM respectively) that displays no activity at other histone methyltransferases up to 37 muM. Modulates H3K9me2 levels in mammalian cells and potentiates induction of pluripotent stem cells from somatic cells in vitro. Also inhibits H3K36 methylation by oncoproteins NSD1, NSD2 and NSD3 (IC50 values are 40 - 112 muM).",600.02
BIX 02189,[1265916-41-3],O=C2NC1=CC(C(N(C)C)=O)=CC=C1/C2=C(C4=CC=CC=C4)/NC3=CC(CN(C)C)=CC=C3,Enzymes,Kinases,MEK,Selective MEK5 and ERK5 inhibitor,"Selective MEK5 and ERK5 inhibitor (IC50 values are 1.5 and 59 nM respectively). Inhibits sorbitol-induced ERK5 phosphorylation in HeLa cells. Selective for MEK5 and ERK5 over MEK1/2, ERK1/2 and a panel of 87 kinases. Induces apoptosis in acute myeloid leukemia tumor cells.",440.54
BMS 182874 hydrochloride,[1215703-04-0],Cl.CN(C)C1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NC1=C(C)C(C)=NO1,7-TM Receptors,Peptide Receptors,Endothelin Receptors,"Highly selective, orally active non-peptide ETA antagonist","Potent, selective and competitive non-peptide endothelin ETA receptor antagonist (Ki = 48 nM). Displays > 1000-fold selectivity over ETB receptors. Inhibits ET-1-induced pressor response following oral or intravenous administration in vivo. Inhibits ET-1-induced longitudinal muscle contraction in the mouse colon in vitro.",381.88
BMS 191011,[202821-81-6],OC1=CC=C(Cl)C=C1CN1N=C(OC1=O)C1=CC=C(C=C1)C(F)(F)F,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Potent BKCa (KCa1.1) channel opener,"Potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1). Neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke).",370.71
BMS 309403,[300657-03-8],CCC1=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=NN1C2=CC=CC=C2C3=CC=CC(OCC(O)=O)=C3,Cell Metabolism,Lipid Metabolism,Other Lipid Metabolism,Potent and selective FABP4 inhibitor,"Potent and selective fatty acid binding protein 4, adipocyte (FABP4) inhibitor (Ki values are <2, 250 and 350 nM for FABP4, FABP3 and FABP5 respectively). Decreases fatty acid uptake in adipocytes in vitro and reduces atherosclerotic lesion area in a mouse model of atherosclerosis. Reduces blood glucose levels and increases insulin sensitivity in a mouse model of obesity. Orally active.",474.55
BMS 345541,[547757-23-3],NCCNC1=NC3=C(C=C(C)C=C3)N2C1=NC=C2C.Cl,Enzymes,Kinases,IkB Kinase,Selective allosteric inhibitor of IKK; anti-inflammatory,Selective allosteric inhibitor of IKK (IC50 values are 0.3 and 4.0 muM for IKKbeta and IKKalpha respectively). Exhibits no effect against a panel of 15 other kinases. Attenuates LPS-induced cytokine production in vitro and blocks NFkappaB dependent transcription in mice. Also suppresses joint destruction in a mouse model of arthritis.,291.78
BMS 470539 dihydrochloride,[2341796-82-3],O=C(N2CCC(C(CCC)=O)(C4=CC=CC=C4)CC2)[C@H](NC([C@@H](N)CC3=CN=CN3C)=O)CC1=CC=C(OC)C=C1.Cl.Cl,7-TM Receptors,Peptide Receptors,Melanocortin Receptors,"Potent, selective MC1 receptor agonist","Potent, selective melanocortin MC1 receptor agonist (IC50 = 120 nM). Exhibits anti-inflammatory properties following ischemia-reperfusion in the vasculature. Inhibits leukocyte trafficking.",632.62
BMS 536924,[468740-43-4],O=C1NC=CC(NC[C@H](C5=CC=CC(Cl)=C5)O)=C1C3=NC2=CC(N4CCOCC4)=CC(C)=C2N3,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Insulin and insulin-like Receptors,Dual IR/IGF1R inhibitor,Dual inhibitor of the insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) (IC50 values are 73 and 100 nM respectively). Inhibits receptor autophosphorylation and downstream MEK1/2 and Akt signaling. Induces G1 arrest and apoptosis in ML-1 cells; also inhibits cell proliferation in multiple tumor types. Reverses EMT through the attenuation of Snail mRNA expression in MCF10A cell over expressing IGF1R.,479.96
BMS 566419,[566161-24-8],O=C2C3=C(C=C(C(NC(C)(C)C4=CC=C(N5CCN(CC)CC5)N=C4)=O)C(F)=C3)NC1=CC=CC=C12,Enzymes,Dehydrogenases,Other Dehydrogenases,Inosine monophosphatase dehydrogenase (IMPDH) inhibitor,Potent inosine monophosphate dehydrogenase (IMPDH) inhibitor (IC50 = 17 nM). Inhibits proliferation of human T-lymphoblasts and PBMCs in vitro. Reduces paw swelling in a rat adjuvant arthritis model. Orally available.,487.57
BMS 599626 dihydrochloride,,FC1=CC(CN2N=CC3=C2C=CC(NC4=NC=NN5C4=C(C)C(NC(OC[C@@H]6COCCN6)=O)=C5)=C3)=CC=C1.Cl.Cl,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,"Potent, selective EGFR and ErbB2 inhibitor",Potent and selective EGFR and ErbB2 inhibitor (IC50 values are 22 nM and 32 nM respectively). Also inhibits HER4 (IC50 = 190 nM). Inhibits EGFR and ErbB2 with 100-fold greater potency than MEK and Lck. Antiproliferative agent in vitro and anti-tumorigenic agent in vivo. Orally bioavailable.,603.48
BMS 986187,[684238-37-7],CC(C=CC=C1)=C1COC2=CC=C(C=C2)C3C4=C(CC(C)(C)CC4=O)OC5=C3C(CC(C)(C)C5)=O,7-TM Receptors,Opioid Receptors,Delta Opioid Receptors,Potent positive allosteric modulator of delta receptors,"Potent delta-opioid receptor positive allosteric modulator (EC50 = 30 nM). Exhibits 100-fold selectivity for delta over mu-opioid receptor. Enhances affinity of [Leu5]-Enkephalin (Cat.No. 1889), SNC 80 (Cat.No. 0764) and TAN 67 (Cat.No. 0921) for the delta-opioid receptor.",470.61
BMS CCR2 22,[445479-97-0],O=C(N[C@@H]2CCCC[C@@H]2NC(CNC(C3=C(NC(NC(C)C)=O)C=CC(C(F)(F)F)=C3)=O)=O)C1=CC=C(SC)C=C1,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,"High affinity, potent CCR2 antagonist","High affinity CCR2 chemokine receptor antagonist (IC50 = 5.1 nM). Displays potent functional antagonism, IC50 values are 1 and 18 nM for chemotaxis and antagonism of calcium flux respectively. Selective over CCR3.",593.66
BNTX maleate,[864461-31-4],OC(=O)\C=C/C(O)=O.OC1=C(O7)C([C@]([C@@H]7C(/C(C4)=C/C3=CC=CC=C3)=O)5[C@]4(O)C(N(CC6CC6)CC5)C2)=C2C=C1,7-TM Receptors,Opioid Receptors,Delta Opioid Receptors,Standard delta1 selective antagonist,Standard selective delta1 opioid receptor antagonist. Also inhibits neurogenic ion transport mediated by a putative novel opioid receptor in porcine ileal mucosa.,545.59
Bosentan,[147536-97-8],COC1=C(C=CC=C1)OC2=C(N=C(C3=NC=CC=N3)N=C2NS(=O)(C4=CC=C(C(C)(C)C)C=C4)=O)OCCO,7-TM Receptors,Peptide Receptors,Endothelin Receptors,High affinity dual ETA and ETB receptor antagonist;orally bioavailable,"High affinity dual ETA and ETB receptor antagonist (Ki values are 4.7 and 95 nM for ETA and ETB, respectively). Inhibits ET-1 induced contraction of isolated rat aorta and sarafotoxin S6C-induced contraction of rat trachea in vitro. Orally bioavailable.",551.61
Bosutinib,[380843-75-4],ClC1=CC(Cl)=C(OC)C=C1NC3=C(C#N)C=NC2=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23,Enzymes,Kinases,Src Kinases,Dual Src-Abl inhibitor; antiproliferative,"Dual inhibitor of Abl and Src kinases (IC50 = 1.2 nM for Src in an enzymatic assay). Displays antiproliferative activity against chronic myelogenous leukemia (CML) cells and decreases the motility and invasion of breast cancer cell lines. Also exhibits potent antiproliferative activity in anchorage-independent, Src-transformed rat fibroblasts (IC50 = 100 nM). Displays selectivity for Src over non-Src family kinases such as growth factor receptor tyrosine kinases.",530.45
BP 554 maleate,[1221401-95-1],OC(=O)\C=C/C(O)=O.C(COC1=CC=C2OCOC2=C1)CN1CCN(CC1)C1=CC=CC=C1,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Selective 5-HT1A agonist,Selective 5-HT1A agonist.,456.48
BRD 7389,[376382-11-5],O=C(C3=C2C(N4)=CC=C3)C1=CC=CC=C1C2=C(NCCC5=CC=CC=C5)C4=O,Enzymes,Kinases,RSK,Ribosomal S6 kinase inhibitor,"Ribosomal S6 kinase (RSK) inhibitor (IC50 values are 1.2, 1.5 and 2.4 muM for RSK3, RSK1 and RSK2 respectively). Upregulates insulin expression in terminally differentiated pancreatic alpha-cells.",366.41
BRD 9876,[32703-82-5],CC(C)(C)C2=CC1=CC(C#N)=C(C#N)C=C1C=C2,Enzymes,ATPases,Kinesin,ATP non-competitive kinesin Eg5 inhibitor,ATP non-competitive kinesin Eg5 inhibitor. Selectively inhibits microtubule-bound Eg5. Inhibits multiple myeloma cell growth (IC50 = 2.2 muM).,234.3
Brefeldin A,[20350-15-6],[H][C@]1(C)CCC\C=C\C2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1,Signal Transduction,"Translocation, Exocytosis & Endocytosis",,Disrupts protein translocation to Golgi,"Reversible inhibitor of protein translocation from the endoplasmic reticulum (ER) to the Golgi apparatus. Blocks binding of ADP-ribosylation factor to the Golgi apparatus and inhibits GDP-GTP exchange. Can be used to induce autophagy in mammalian cells. Also enhances CRISPR-mediated homology-directed repair (HDR) efficiency ~2-fold when applied at 100 nM, in human induced pluripotent stem cells (iPSCs).",280.36
Bretazenil,[84379-13-5],O=C(N4[C@]([H])3CCC4)C1=C(Br)C=CC=C1N2C3=C(C(OC(C)(C)C)=O)N=C2,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Benzodiazepine partial agonist,Partial agonist at the GABAA benzodiazepine site (EC50 = 10 nM at alpha1beta1gamma2 receptors). Displays anticonvulsive activity in vivo.,418.28
Bromocriptine mesylate,[22260-51-1],[H][C@]4([C@@](N[C@]([C@H](C)C)5C(N([C@@]([H])(CC(C)C)C(N(CCC7)[C@@]76[H])=O)[C@@]6(O)O5)=O)=O)CN([C@](C3=C4)([H])CC1=C(Br)NC2=C1C3=CC=C2)C.CS(=O)(O)=O,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,D2-like agonist (D2>D3>D4),"Selective D2-like dopamine receptor agonist (Ki values are ~ 8, ~ 5, ~ 290, ~ 440 and ~ 450 nM for D2, D3, D4, D1 and D5 receptors respectively).",750.7
Bromosporine,[1619994-69-2],CC1=C(NS(=O)(C)=O)C=C(C3=NN2C(C(NC(OCC)=O)=C3)=NN=C2C)C=C1,Epigenetics,Bromodomains,,Broad spectrum bromodomain inhibitor,Broad spectrum bromodomain inhibitor. Accelerates FRAP recovery of BRD4 and CREBBP in cells at a concentration of 1 muM.,404.44
BS 181 dihydrochloride,,CC(C)C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1.Cl.Cl,Enzymes,Kinases,Cyclin-dependent Kinase,Selective cdk7 inhibitor,Selective cdk7 inhibitor (IC50 = 21 nM). Displays >40-fold selectivity for cdk7 over others cdks. Promotes cell cycle arrest and apoptosis in a range of cancer cells in vitro and inhibits MCF-7 tumor xenograft growth in mice.,453.45
BTB1,[86030-08-2],ClC1=CC([N+]([O-])=O)=C(S(C2=CC=CC=C2)(=O)=O)C=C1,Enzymes,ATPases,Kinesin,Selective and ATP-competitive Kif18A inhibitor,Selective and ATP-competitive mitotic kinesin Kif18A inhibitor (IC50 = 1.7 muM); reversibly inhibits microtubule-stimulated Kif18A ATPase activity. Displays selectivity against a panel of other mitotic kinesins.,297.71
BTS,[1576-37-0],CC1=CC=C(C=C1)S(=O)(=O)NCC1=CC=CC=C1,Enzymes,ATPases,Myosin,Selective inhibitor of skeletal muscle myosin II ATPase activity,Selective inhibitor of the ATPase activity of skeletal muscle myosin II subfragment 1 (S1) (IC50 ~ 5 mM). Reversibly blocks gliding motility and suppresses force and twitch production in fast skeletal muscle.,261.34
BTS 54-505 hydrochloride,[84484-78-6],Cl.CC(C)CC(N)C1(CCC1)C1=CC=C(Cl)C=C1,Transporters,Neurotransmitter Transporters,5-HT Transporters,Potent 5-HT and NA reuptake inhibitor (SNRI); active metabolite of sibutramine (Cat. No. 2290),"Potently active primary amine metabolite of sibutramine (Cat. No. 2290), exhibits a similar pharmacological profile to the parent compound. Inhibits serotonin and noradrenalin reuptake more potently than sibutramine in vitro. Reduces food intake in rodents following i.c.v. administration and increases energy expenditure via thermogenesis in vivo.",288.26
BTT 3033,[1259028-99-3],FC1=CC=C(N2N=CC(S(N(C3=CC=C(NC(NC4=CC=CC=C4)=O)C=C3)C)(=O)=O)=C2)C=C1,Enzyme-Linked Receptors,Integrins,,Selective inhibitor of integrin alpha2beta1,"Selective inhibitor of integrin alpha2beta1 (EC50 = 130 nM for alpha2beta1 binding to collagen I). Binds to the alpha2I domain. Exhibits selectivity for alpha2beta1 over integrins alpha3beta1, alpha4beta1, alpha5beta1 and alphav. Inhibits platelet aggregation to collagen I coated capillaries under flow. Also inhibits binding of alpha2-expressing CHO cells to collagen I under shear stress conditions.",465.5
Budesonide,[51333-22-3],O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H]5[C@](C(CO)=O)4OC(CCC)O5)=C1,Nuclear Receptors,Glucocorticoid Receptor,,Synthetic glucocorticoid; anti-inflammatory and chemopreventive,Synthetic anti-inflammatory glucocorticoid that displays chemopreventive activity. Prevents formation of lung adenomas and adenocarcinomas in mice following inhalation or oral administration. Reverses DNA hypomethylation and modulates expression of cancer related genes.,430.53
Bumetanide,[28395-03-1],CCCCNC1=CC(C(O)=O)=CC(S(=O)(N)=O)=C1OC2=CC=CC=C2,Transporters,Ion Pumps/Transporters,Na+/K+/Cl- Symporter,Na+/2Cl-/K+ (NKCC) symporter inhibitor,Loop diuretic that inhibits the Na+/2Cl-/K+ (NKCC) cotransporter. More potent than furosemide (Cat. No. 3109).,364.42
BVT 948,[39674-97-0],CC1(C)C(=O)N=C2C1=C(O)C(=O)C1=CC=CC=C21,Enzymes,Phosphatases,Protein Tyrosine Phosphatases,Non-competitive protein tyrosine phosphatase inhibitor,"Non-competitive, cell-permeable inhibitor of protein tyrosine phosphatases (PTPs) (IC50 = 0.09 - 1.7 muM); displays irreversible inhibition through catalysis of the hydrogen peroxide-dependent oxidation of PTP. Enhances insulin signaling in vitro and insulin tolerance in ob/ob mice in vivo. Also inhibits several cytochrome P450 isoforms (IC50 <10 muM).",241.25
BX 471,[217645-70-0],FC1=CC=C(CN2C[C@@H](C)N(C(COC3=CC=C(Cl)C=C3NC(N)=O)=O)CC2)C=C1,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,"Potent, selective CCR1 antagonist","Potent, selective non-peptide CCR1 antagonist (Ki = 1 nM for human CCR1). Exhibits 250-fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. Inhibits MIP-alpha/CCL3-induced intracellular Ca2+ mobilization. Orally active; effectively reduces disease severity in a rat model of multiple sclerosis. Decreases renal fibrosis in a mouse model of obstructive nephropathy.",434.89
BYK 204165,[1104546-89-5],O=C(NC3=O)C1=CC=CC=C1/C3=C/C2=CC=CN2C,Enzymes,Polymerases,Poly(ADP-ribose) Polymerase,Selective PARP-1 inhibitor,Potent and selective poly(ADP-ribose) polymerase (PARP)-1 inhibitor (pIC50 values are 5.38 and 7.35 for PARP-2 and PARP-1 respectively).,252.27
C 021 dihydrochloride,[1784252-84-1],COC1=C(OC)C=C(N=C(N4CCC(N5CCCCC5)CC4)N=C2NC3CCCCCC3)C2=C1.Cl.Cl,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,Potent CCR4 antagonist,Potent CCR4 chemokine receptor antagonist (IC50 values are 0.14 and 0.039 muM for inhibition of chemotaxis in human and mouse respectively).,540.57
C-1,[84468-24-6],O=S(=O)(N1CCNCC1)C1=C2C=CN=CC2=CC=C1,Enzymes,Kinases,Broad Spectrum Protein Kinase Inhibitors,"Inhibits PKG, PKA and PKC","Protein kinase inhibitor. Inhibits PKG, PKA and PKC (IC50 values are 4, 8 and 12 µM, respectively). Widely used as a ROCK inhibitor. Increases efficiency of human fibroblast reprogramming with PD 0325901 (Cat.No 4192), CHIR 99021 (Cat.No 4432), A 83-01 (Cat.No 2939) and hLIF. Improves survival of human pluripotent stem cells in culture.",277.34
C34,[40592-88-9],CC(OC[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](NC(C)=O)[C@@H](OC(C)C)O1)=O,Enzyme-Linked Receptors,Toll-like Receptors,,TLR4 inhibitor,"TLR4 inhibitor; attenuates TLR4 signaling in enterocytes and macrophages in vitro, and reduces systemic inflammation in mouse models of endotoxemia and necrotizing enterocolitis (NEC). Also suppresses LPS signaling in human ileum displaying NEC ex-vivo. Displays no significant effects on signaling via TLR2 or TLR9.",389.4
Cabergoline,[81409-90-7],CC2=C(C(C[C@]3([H])[C@@]([H])2C[C@@H]([C@@](N(C(NCC)=O)CCCN(C)C)=O)CN3CC=C)=CN1)/C/1=C,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,D2-like agonist (D2>D3>D4),"Selective D2-like dopamine receptor agonist (Ki values are 0.7, 1.5, 9.0 and 165 nM for D2, D3, D4 and D5 receptors respectively) that also displays high affinity for several serotonin receptor subtypes (Ki = 1.2 - 20.0 nM for 5-HT1A, 5-HT1D, 5-HT2A and 5-HT2B). Inhibits secretion of prolactin and growth hormone and reverses levodopa-induced dyskinesias in Parkinsonian monkeys.",451.6
CaCCinh-A01,[407587-33-1],CC(C)(C)C1CCC2=C(SC(NC(C3=CC=CO3)=O)=C2C(O)=O)C1,Ion Channels,Chloride Channels,Ca2+-Activated Chloride Channels,Calcium-activated chloride channel (CaCC) inhibitor,"Calcium-activated chloride channel (CaCC) inhibitor (IC50 ~ 10 muM). Inhibits CaCC currents in human bronchial and intestinal cells. Also inhibits TMEM16A channels (IC50 = 2.1 muM, in TMEM16A-expressing FRT cells).",347.43
Calhex 231 hydrochloride,,O=C(C4=CC=C(Cl)C=C4)N[C@@H](CCCC3)[C@H]3N[C@H](C)C1=C2C(C=CC=C2)=CC=C1.Cl,7-TM Receptors,Calcium-Sensing Receptor,,Negative allosteric modulator of calcium-sensing receptor (CaSR),Negative allosteric modulator of the calcium sensing receptor (CaSR). Blocks increases in [3H]inositol phosphate levels elicited by wild-type hCasR activation (IC50= 0.39 muM in transiently transfected HEK293 cells).,443.41
Calpeptin,[117591-20-5],O=C(OCC1=CC=CC=C1)N[C@H](C(N[C@H](C([H])=O)CCCC)=O)CC(C)C,Signal Transduction,Calcium Signaling,Calcium-Sensitive Proteases,Calpain and cathepsin L inhibitor,"Potent, cell-permeable inhibitor of the Ca2+-dependent protease, calpain. Prevents collagen- and thrombin-induced platelet aggregation, probably by blocking calpain induced phospholipase C and thromboxane synthase activation. Potent cathepsin L inhibitor. Recently shown to preferentially inhibit a subset of protein-tyrosine phosphatases.",362.47
Camostat mesylate,[59721-29-8],O=C(C2=CC=C(NC(N)=N)C=C2)OC1=CC=C(CC(OCC(N(C)C)=O)=O)C=C1.CS(=O)(O)=O,Enzymes,Proteases,Other Proteases,Orally active protease inhibitor,"Orally active protease inhibitor. Known to inhibit trypsin and various inflammatory proteases including plasmin, kallikrein and thrombin. Suppresses pancreatitis-induced pain in rats following oral administration.",494.52
Candesartan,[139481-59-7],CCOC1=NC(C=CC=C5C(O)=O)=C5N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,AT1 antagonist,"Angiotensin II receptor 1 (AT1) antagonist (IC50 values are 1.12 and 2.86 nM in bovine adrenal cortex and rabbit aorta, respectively). Exhibits antihypertensive effects in animal models. Also available as a prodrug, candesartan cilexetil (Cat. No. 4792).",440.45
Capecitabine,[154361-50-9],C[C@H]1O[C@@H](N2C=C(F)C(NC(OCCCCC)=O)=NC2=O)[C@H](O)[C@@H]1O,Cell Metabolism,"DNA, RNA and Protein Synthesis",,Prodrug of 5-Fluorouracil (Cat. No. 3257). Inhibits DNA synthesis,Prodrug of 5-Fluorouracil (5-FU) (Cat. No. 3257). Selectively activated in tumor cells by thymidine phosphorylase; inhibits DNA synthesis upon conversion to 5-FU. Orally available.,359.35
Capsazepine,[138977-28-3],OC1=C(O)C=C2CN(CCCC2=C1)C(=S)NCCC1=CC=C(Cl)C=C1,Ion Channels,Transient Receptor Potential Channels,TRPV,Vanilloid receptor antagonist; also activator of ENaCdelta,Selective vanilloid receptor antagonist (Ki = 3.2 muM). Inhibits carrageenan inflammation-induced hyperalgesic responses in the rat. Also activates amiloride-sensitive epithelial Na+ channel ENaCdelta. Also available as part of the Vanilloid TRPV1 Receptor Tocriset™.,376.9
Carbamazepine,[298-46-4],NC(N1C3=C(C=CC=C3)C=CC2=C1C=CC=C2)=O,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Inhibitor of neuronal NaV channels; anticonvulsant,"Inhibitor of neuronal voltage-gated Na+ channels. Exhibits anticonvulsant activity. Potentiates GABA-induced Cl- currents in HEK 293 cells expressing the GABAA receptor alpha1beta2gamma2 subtype combination. Can induce autophagy by inhibiting inositol synthesis. Also delays disease onset and prolongs survival in a mouse amyotrophic lateral sclerosis (ALS) model, as well as reducing motor neuron loss and altered muscle morphology.",236.27
Cardiogenol C hydrochloride,[1049741-55-0],OCCNC1=CC=NC(NC2=CC=C(OC)C=C2)=N1.Cl,Stem Cells,Stem Cell Differentiation,ESCs and iPSC,Induces cardiomyocyte differentiation in ESCs,Induces differentiation of mouse embryonic stem cells (ESCs) into cardiomyocytes (EC50 = 100 nM).,296.75
Cardionogen 1,[577696-37-8],C12=NN=C(C3=CC=CO3)N1N=C(C4CCCCC4)S2,Signal Transduction,Wnt Signaling,Beta-catenin,Inhibitor of Wnt/beta-catenin signaling,Wnt signaling modulator. Potently inhibits Wnt/beta-catenin-dependent transcription in murine ES cells (EC50 = 23 nM) and zebrafish embryos. Enlarges heart size via cardiomyocyte hyperplasia; induces ES cell cardiac differentiation.,274.34
Carvedilol,[72956-09-3],COC1=C(OCCNCC(O)COC2=CC=CC3=C2C2=C(N3)C=CC=C2)C=CC=C1,7-TM Receptors,Adrenergic Receptors,Non-selective Adrenergic Beta Receptors,Potent and non-selective beta antagonist; also potent alpha1 antagonist,"Potent beta-adrenoceptor and alpha1-adrenoceptor antagonist (Ki values are 0.81, 0.96 and 2.2 nM for beta1-, beta2- and alpha1-adrenoceptors respectively) that displays antihypertensive and peripheral vasodilatory activity. Blocks cardiac inward-rectifier K+ (KIR) channels, voltage-dependent Ca2+ channels and exhibits antioxidant properties at higher concentrations.",406.47
CASIN,[425399-05-9],OCCNC1C2=C(C(C=C(C4=CC=CC=C4)C=C3)=C3N2)CCC1,Enzymes,GTPases,Small Monomeric GTPases,Cdc42 inhibitor,Cdc42 GTPase inhibitor (IC50 = 2 muM). Reduces active levels of Cdc42 in aged hematopoietic stem cells (HSCs) to that in young HSCs. Reverses the aging-related and polarity phenotype of aged HSCs to that of young HSCs in vivo. Increases histone H4K16 acetylation in aged HSCs.,306.4
Castanospermine,[79831-76-8],[H][C@]12[C@@H](O)CCN1C[C@H](O)[C@@H](O)[C@@H]2O,Enzymes,Glycosylases,,Glucosidases alpha and beta inhibitor,"Potent inhibitor of alpha- and beta-glucosidases, especially glucosidase l (required for glucoprotein processing by transfer of mannose and glucose from asparagine-linked lipids). Inhibits HIV syncytium formation and replication.",189.21
CBiPES hydrochloride,[856702-40-4],O=S(N(CC2=CC=CN=C2)C1=CC(C3=CC=C(C#N)C=C3)=CC=C1)(CC)=O.Cl,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group II Receptors,Positive allosteric modulator of mGlu2 receptors,Selective positive allosteric modulator of the mGlu2 receptor (IC50 = 98.2 nM). Mimics the action of LY 379268 (Cat. No. 2453); attenuates ketamine-evoked histamine release in vivo.,413.92
CC4,[492-02-4],O=C1N2C([C@@](C3)([H])CN(CCN5C[C@](C6)([H])C(N4C[C@]6([H])C5)=CC=CC4=O)C[C@@]3([H])C2)=CC=C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,High affinity and subtype-selective alpha6beta2 and alpha4beta2 nAChR partial agonist,High affinity and subtype selective alpha6beta2 and alpha4beta2 partial agonist (Ki values are 12 and 26nM for rat alpha6beta2 and alpha4beta2 receptors respectively). Has low affinity for alpha3beta4 and alpha7 receptors (Ki values are 4.8 and 13 muM for human alpha3beta4 and rat alpha7 receptors respectively). Stimulates dopamine release from striatal slices in vitro. Attenuates nicotine-induced self-administration and conditional place preference in rats.,406.52
CCG 1423,[285986-88-1],O=C(NOC(C)C(NC2=CC=C(Cl)C=C2)=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1,Enzymes,GTPases,Small Monomeric GTPases,Rho/SRF pathway inhibitor; induces intermediate mesoderm differentiation from ESCs,"Rho/SRF pathway inhibitor; stimulates apoptosis of a melanoma cell line overexpressing RhoC (A375M2). Suppresses Rho-dependent invasion of PC-3 prostate cancer cells in vitro and inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells. When used in combination with Retinoic acid, LY 294002 and Pyridone 6, it induces intermediate mesoderm differentiation from ESCs.",454.75
CCG 50014,[883050-24-6],FC(C=C3)=CC=C3CN(C(N(C2=CC=C(C)C=C2)S1)=O)C1=O,Enzymes,GTPases,Heterotrimeric G-protein GTPases,Potent and selective inhibitor of regulator of G-protein signaling 4 (RGS4) protein,Potent and selective inhibitor of regulator of G-protein signaling 4 (RGS4) protein (IC50 values are 30.1 nM and 11.0 muM for RGS4 and RGS8 respectively). Exhibits >20-fold selectivity for RGS4 over other RGS proteins.,316.35
CCMI,[917837-54-8],CC1=NOC(=C1)C(=CNC1=CC=C(Cl)C=C1)C(=O)NC1=CC=C(Cl)C=C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Positive allosteric modulator of alpha7 nAChRs,Positive allosteric modulator of alpha7 neuronal nicotinic acetylcholine receptors (nAChR). Evokes positive modulation of acetylcholine (ACh)-induced EC5 currents (EC50 = 0.7 muM). Exhibits cognitive-enhancing properties in rodent models; displays no cytotoxic effects in PC12 cells or rat primary cortical neurons.,388.25
CCT 018159,[171009-07-7],CCC1=C(O)C=C(O)C(=C1)C1=NNC(C)=C1C1=CC2=C(OCCO2)C=C1,Signal Transduction,Heat Shock Proteins,Hsp90,Hsp90 inhibitor,Novel inhibitor of heat shock protein 90 (Hsp90) ATPase activity (IC50 = 5.7 muM) that displays selectivity over human Hsp72 and topoisomerase II. Inhibits proliferation of HCT116 human colon tumor cells and produces upregulation of Hsp70 and downregulation of c-Raf and cdk4. More soluble than 17-AAG (Cat. No. 1515) and is independent of NQO1/DT-diaphorase and P-glycoprotein expression.,352.39
CCT 031374 hydrobromide,[1219184-91-4],O=C(C4=CC=C(C5=CC=CC=C5)C=C4)CN1C3=C(C=CC=C3)N2C1=NCC2.Br,Signal Transduction,Wnt Signaling,Beta-catenin,Inhibits TCF-dependent transcription; lowers beta-catenin levels,Inhibitor of TCF-dependent transcription. Blocks BIO-induced beta-catenin stabilization; reduces nuclear and cytosolic beta-catenin levels in mouse L-cells. Inhibits growth and reduces TCF-dependent transcription in SW480 colon carcinoma cells.,434.33
CCT 137690,[1095382-05-0],CN(CC4)CCN4C(C=C3)=CC=C3C2=NC1=C(N5CCN(CC6=NOC(C)=C6)CC5)C(Br)=CN=C1N2,Enzymes,Kinases,Aurora Kinases,Potent pan-Aurora kinase inhibitor,"Potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 muM at Aurora A, Aurora C and Aurora B respectively). Displays antiproliferative activity in a range of human tumor cell lines. Orally bioavailable.",551.48
CD 3254,[196961-43-0],CC1(C)C2=C(C=C(C3=C(O)C=CC(/C=C/C(O)=O)=C3)C(C)=C2)C(C)(C)CC1,Nuclear Receptors,Retinoid X Receptor,,Potent and selective RXRalpha agonist,"Selective RXRalpha agonist; exhibits no activity at RARalpha, RARbeta or RARgamma receptors.",364.48
CD 437,[125316-60-1],OC(=O)C1=CC=C2C=C(C=CC2=C1)C1=CC=C(O)C(=C1)C12CC3CC(CC(C3)C1)C2,Nuclear Receptors,Retinoic Acid Receptors,,RARgamma-selective agonist,Synthetic retinoid that is an RARgamma-selective agonist. Displays RARgamma-dependent and -independent effects on differentiation and apoptosis.,398.5
CDPPB,[781652-57-1],O=C(C4=CC(C#N)=CC=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Positive allosteric modulator of mGlu5 receptors,"Brain penetrant, selective positive allosteric modulator at the mGlu5 receptor (EC50 values are 10 and 20 nM for human and rat receptors respectively). Antipsychotic; reverses amphetamine-induced locomotor activity and amphetamine-induced deficits in prepulse inhibition in rats.",364.4
CE3F4,[143703-25-7],BrC1=C(F)C(Br)=C(CCC(C)N2C=O)C2=C1,Enzymes,GTPases,Small Monomeric GTPases,Noncompetitive Epac1 inhibitor,Noncompetitive Epac1 inhibitor. Blocks Epac-induced Rap activation and prevents isoprenaline-induced autophagy flux in cardiomyocytes. Has no effect on PKA activity in the presence of cAMP.,351.01
Celecoxib,[169590-42-5],CC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(N)=O)C=C2,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Selective cyclooxygenase-2 (COX-2) inhibitor,Selective cyclooxygenase-2 (COX-2) inhibitor (IC50 values are 15 and 0.04 muM for COX-1 and COX-2 respectively). Anti-inflammatory with shorter plasma half-life in vivo than SC 58121 (Cat. No. 2895). Displays chemopreventive activity in in vivo tumor models.,381.37
Cerestat,[137160-11-3],N=C(N(C)C3=CC=CC(CC)=C3)NC1=C2C(C=CC=C2)=CC=C1.Cl,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Potent and noncompetitive NMDA antagonist,Potent and noncompetitive NMDA receptor antagonist (IC50 = 36 nM). Exhibits >70-fold selectivity for NMDA receptor over sigma receptor. Neuroprotective in a rat model of focal ischemia.,339.86
CFTRinh 172,[307510-92-5],O=C(N(C3=CC=CC(C(F)(F)F)=C3)C(S2)=S)\C2=C/C1=CC=C(C(O)=O)C=C1,Ion Channels,Chloride Channels,CFTR,"Voltage-independent, selective CFTR chloride channel blocker","Voltage-independent, selective CFTR chloride channel blocker (Ki = 300 nM) that alters channel gating. Blocks intestinal fluid secretion induced by cholera toxin and Escherichia coli and suppresses cyst growth in animal models of polycystic kidney disease. Orally active. Inhibits mitochondrial respiration and increases reactive oxygen species (ROS) production independently of CFTR in several cell lines.",409.4
CGK 733,[905973-89-9],[O-][N+](=O)C1=CC(NC(=S)NC(NC(=O)C(C2=CC=CC=C2)C2=CC=CC=C2)C(Cl)(Cl)Cl)=CC=C1F,Regulated Cell Death,Apoptosis,Other Apoptosis,Induces apoptosis in prematurely senescent cells,Originally defined as a selective inhibitor of ATR and ATM kinases. Induces cell death in prematurely senescent breast cancer cells. Decreases p21CIP1 levels in premature senescent MCF-7 and HCT-116 cells; also exhibits antiproliferative activity in a range of cancer cell lines. Blocks camptothecin-induced p53 phosphorylation and protects cells from camptothecin-induced apoptosis.,555.84
CGP 37157,[75450-34-9],ClC1=CC=C2NC(=O)CSC(C3=CC=CC=C3Cl)C2=C1,Transporters,Ion Pumps/Transporters,Na+/Ca2+ Exchanger,Antagonist of mitochondrial Na+/Ca2+ exchange,Selective antagonist of the mitochondrial Na+-Ca2+ exchanger (IC50 = 0.4 muM).,324.22
CGP 52411,[145915-58-8],O=C2NC(C1=CC(NC4=CC=CC=C4)=C(NC3=CC=CC=C3)C=C12)=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,EGFR inhibitor. Also inhibits Abeta42 fibril formation,Selective inhibitor of the epidermal growth factor receptor (EGFR) (IC50 = 0.3 muM in vitro). Also inhibits and reverses the formation of Abeta42 fibers associated with Alzheimer's disease. Eliminates calcium influx potential when coincubated with amyloid beta-peptide (1-42) (Cat.No. 1428); reduces neurotoxicity by blocking Ca2+ influx into neuronal cells.,329.35
CGP 53353,[145915-60-2],FC1=CC=C(NC2=CC3=C(C=C2NC2=CC=C(F)C=C2)C(=O)NC3=O)C=C1,Enzymes,Kinases,Protein Kinase C,Selective inhibitor of PKCbetaII,Selective inhibitor of PKCbetaII (IC50 values are 0.41 and 3.8 muM for PKCbetaII and PKCbetaI respectively). Also inhibits prionogenic Sup35 fibrillization (IC50 ~ 3.4 muM) and inhibits de novo Abeta42 assembly in vitro.,365.34
CGP 54626 hydrochloride,[149184-21-4],OP(CC1CCCCC1)(C[C@@H](O)CN[C@@H](C)C2=CC(Cl)=C(Cl)C=C2)=O.Cl,7-TM Receptors,GABAB Receptors,,Potent and selective GABAB antagonist,"A potent, selective GABAB receptor antagonist (IC50 = 4 nM).",444.76
CGP 55845 hydrochloride,[149184-22-5],Cl.C[C@H](NC[C@H](O)CP(O)(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C(Cl)=C1,7-TM Receptors,GABAB Receptors,,Potent and selective GABAB antagonist,"Potent, selective GABAB receptor antagonist (IC50 = 5 nM) that prevents agonist binding (pKi = 8.35) and inhibits GABA and glutamate release (pEC50 values are 8.08 and 7.85 respectively). Inhibits GABAB responses to baclofen (IC50 = 130 nM in an isoproterenol assay) and potentiates the hypoglycemic response to glucose in vitro.",438.71
CGP 57380,[522629-08-9],NC1=C2C(NC3=CC=C(F)C=C3)=NNC2=NC=N1,Enzymes,Kinases,Mnk,Selective inhibitor of Mnk1,"Inhibitor of MAP-kinase interacting kinase-1 (Mnk1, MKNK1) (IC50 = 2.2 muM) that displays selectivity over p38, JNK1, ERK1, ERK2, PKC and c-src family kinases. Blocks phosphorylation of eIF4E in cellular assays (IC50 = 3 muM) and inhibits LPS-induced TNFalpha expression in macrophages.",244.23
CGP 60474,[164658-13-3],OCCCNC1=NC=CC(C2=NC(NC3=CC(Cl)=CC=C3)=NC=C2)=C1,Enzymes,Kinases,Cyclin-dependent Kinase,Potent cdk inhibitor,"Potent cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 3 - 80, 9.5, 13, 17 - 60, 200 and 220 nM for cdk2, cdk5, cdk9, cdk1, cdk4 and cdk7, respectively). Also inhibits PKCalpha in the low micromolar range. Displays reversible G1/S cell cycle arrest in U2-OS cells.",355.82
CGP 71683 hydrochloride,[192322-50-2],NC1=NC(NC[C@H]3CC[C@H](CNS(=O)(C4=CC=CC5=C4C=CC=C5)=O)CC3)=NC2=C1C=CC=C2.Cl,7-TM Receptors,Peptide Receptors,NPY Receptors,Highly selective and potent non-peptide NPY Y5 receptor antagonist,"Extremely selective, non-peptide NPY Y5 receptor antagonist. Displays > 1000-fold selectivity over Y1, Y2 and Y4 receptors; IC50 values are 1.4, 2765, 7187 and 5637 nM at cloned rat Y5, Y1, Y2 and Y4 receptors respectively. Potently inhibits NPY-induced food intake following i.p. administration in diabetic, free-feeding and fasted rats.",512.07
CGP 74514 dihydrochloride,,CCN2C1=NC(N[C@@H]4CCCC[C@@H]4N)=NC(NC3=CC(Cl)=CC=C3)=C1N=C2.Cl.Cl,Enzymes,Kinases,Cyclin-dependent Kinase,Potent cdk1 inhibitor,Potent cdk1 inhibitor (IC50 = 25 nM). Reduces Akt phosphorylation and increases mitochondrial damage in leukemia cells in vitro in combination with LY 294002.,458.82
CGP 7930,[57717-80-3],CC(C)(CO)CC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C,7-TM Receptors,GABAB Receptors,,Positive allosteric modulator of GABAB receptors,Positive allosteric modulator of GABAB receptors. Increases the potency and efficacy of GABA at both native and recombinant GABAB receptors (EC50 values are 5.37 and 4.60muM respectively) and enhances the inhibitory effect of the agonist L-baclofen in cultured cortical neurons. Reduces operant self-administration of ethanol in alcohol-preferring rats following i.p. administration.,292.46
CGS 20625,[111205-55-1],COC1=CC=C(C=C1)N1N=C2C(=CNC3=C2CCCCC3)C1=O,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Selective benzodiazepine partial agonist,"Selective, partial agonist for the benzodiazepine binding site of the GABAA receptor. Potently inhibits [3H]-flunitrazepam binding to central benzodiazepine receptors (IC50 = 1.3 nM) and displays weak affinity for peripheral benzodiazepine (IC50 = 0.68 - 2.25 muM) and GABA binding sites (IC50 > 10000 muM). Displays anxiolytic activity in vivo following oral administration. .",309.36
CGS 9343B,[109826-27-9],OC(=O)\C=C/C(O)=O.CC1(CN2CCC(CC2)N2C(=O)NC3=C2C=CC=C3)OCC2=C(C=CC=C2)N2C=CC=C12,Signal Transduction,Calcium Signaling,Calcium Binding Protein,Calmodulin antagonist,"Calmodulin antagonist; inhibits calmodulin-stimulated cAMP phosphodiesterase activity with an IC50 of 3.3 nM. Also prevents estrogen-induced transcription activation by ER, reversibly blocks voltage-activated Na+, Ca2+ and K+ currents in PC12 cells and inhibits nAChR.",544.61
Ch 55,[110368-33-7],CC(C)(C)C1=CC(=CC(=C1)C(=O)\C=C\C1=CC=C(C=C1)C(O)=O)C(C)(C)C,Nuclear Receptors,Retinoic Acid Receptors,,Potent RAR agonist,Highly potent synthetic retinoid that has high affinity for RAR-alpha and RAR-beta receptors and low affinity for cellular retinoic acid binding protein (CRABP). Inhibits rabbit tracheal epithelial cell differentiation by inhibiting transglutaminase and increasing cholesterol sulfate (EC50 values are 0.02 and 0.03 nM respectively). Induces differentiation of embryonic carcinoma F9 and melanoma S91 cells (EC50 values are 0.26 and 0.5 nM respectively) and inhibits the induction of ornithine decarboxylase activity in 3T6 fibroblasts (EC50 = 1 nM).,364.47
CHC,[28166-41-8],OC1=CC=C(/C=C(C#N)/C(O)=O)C=C1,Transporters,Ion Pumps/Transporters,Monocarboxylate Transporters,MCT inhibitor; decreases glycoloysis,"Monocarboxylic acid transport (MCT) inhibitor. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo; decreases glycolytic metabolism, migration, and invasion in U251 cells. Enhances the effect of antitumor agent temozolomide (Cat No. 2706). Blocks lactate efflux from glioma cells and sensitizes cells to irradiation.",189.17
CHIR 99021,[252917-06-9],ClC(C=C1Cl)=CC=C1C2=NC(NCCNC3=CC=C(C#N)C=N3)=NC=C2C4=NC=C(C)N4,Enzymes,Kinases,Glycogen Synthase Kinase 3,Highly selective GSK-3 inhibitor,"Potent and highly selective inhibitor of glycogen synthase kinase 3 (GSK-3) (IC50 values are 6.7 and 10 nM for GSK-3beta and GSK-3alpha respectively). Exhibits >500-fold selectivity for GSK-3 over closely related kinases; also displays >800-fold selectivity against 45 additional enzymes and receptors. In combination with tranylcypromine (Cat. No. 3852), enables reprogramming of mouse embryonic fibroblasts, transduced by Oct4 and Klf4 only, into iPSCs. Enhances mouse and human ESC self-renewal when used in combination with PD 0325901 (Cat. No. 4192). Allows formation of extended pluripotent stem (EPS) cells in combination with (S)-(+)-Dimethindene maleate (Cat.No. 1425), minocycline hydrochloride (Cat.No. 3268) and human leukemia inhibitory factor. CHIR 99021 synthesized to cGMP guidelines also available.",465.34
CHR 6494 trifluoroacetate,[1458630-17-5],CCCNC2=NN1C(C3=CC(C=NN4)=C4C=C3)=CN=C1C=C2.OC(C(F)(F)F)=O,Enzymes,Kinases,Haspin,Potent and selective haspin inhibitor,"Potent and selective haspin kinase inhibitor (IC50 = 2 nM). Selective over 27 other protein kinases including Aurora B kinase. Induces cell cycle arrest at G2/M, inhibits cell proliferation and promotes apoptosis in multiple cancer cell lines. Inhibits angiogenesis ex vivo and attenuates tumor growth of HCT-116 xenografts in rats.",406.36
CI 966 hydrochloride,[110283-66-4],Cl.OC(=O)C1=CCCN(CCOC(C2=CC=C(C=C2)C(F)(F)F)C2=CC=C(C=C2)C(F)(F)F)C1,Transporters,Neurotransmitter Transporters,GABA Transporters,Selective inhibitor of GAT-1,Selective inhibitor of the GABA transporter GAT-1 (IC50 values are 0.26 and 1.2 muM at cloned human and rat GAT-1 respectively). Displays over 200-fold selectivity over GAT-2 and GAT-3. Centrally active upon systemic administration in vivo. Anticonvulsive and neuroprotective.,509.87
CI 976,[114289-47-3],CCCCCCCCCCC(C)(C)C(=O)NC1=C(OC)C=C(OC)C=C1OC,Enzymes,Transferases,Acyl-CoA:Cholesterol Acyltransferase,Selective ACAT inhibitor,Selective acyl-coenzyme A:cholesterol acyltransferase (ACAT) inhibitor (IC50 = 0.073 muM). Lowers non-high density lipoprotein (HDL)-cholesterol and increases HDL-cholesterol concentrations in rats with pre-established dyslipidemia. Orally active. Also inhibits Golgi-associated LPL acyltransferase (LPAT) activity (IC50 = 15 muM).,393.57
CI 994,[112522-64-2],O=C(NC2=C(N)C=CC=C2)C1=CC=C(NC(C)=O)C=C1,Enzymes,Histone Deacetylases,Class I HDACs,Class I histone deacetylase inhibitor; orally active,"Orally active class I histone deacetylase (HDAC) inhibitor (Ki values are 0.41, 0.75, >100 and >100 muM for HDAC1, HDAC3, HDAC6 and HDAC8 respectively). Mediates G1 cell cycle arrest, inhibits proliferation and induces apoptosis in vitro and in vivo. Increases neuroplasticity during memory extinction. Also increases efficiency of hepatic differentiation of hPSCs",269.3
CID 16020046,[834903-43-4],O=C1N(C5=CC=C(C(O)=O)C=C5)C(C4=CC=CC(O)=C4)C2=C1NN=C2C3=CC=C(C)C=C3,7-TM Receptors,GPR55,,Selective GPR55 antagonist,"Selective GPR55 antagonist. Inhibits LPI-induced Ca2+ signaling (IC50 = 0.21 muM in HEK-GPR55 cells), ERK1/2 phosphorylation and GPR55-mediated transcription factor activation. Displays weak inhibition of acetylcholinesterase, mu-opioid receptor, KCNH2 and hERG. Decreases LPI-induced GPR55 internalization. Reduces experimental intestinal inflammation in mice.",425.44
CID 2011756,[638156-11-3],O=C(NC3=CC=C(CN4CCOCC4)C=C3)C1=CC=C(C2=CC=CC(Cl)=C2)O1,Enzymes,Kinases,Protein Kinase D,Pan protein kinase D (PKD) inhibitor; cell permeable,"Protein kinase D (PKD) inhibitor (IC50 values are 0.6, 0.7 and 3.2 muM for PKD2, PKD3 and PKD1 respectively). Cell permeable (EC50 = 10 muM for PKD1 inhibition). ATP-competitive.",396.87
CID 2745687,[264233-05-8],FC1=CC(F)=CC=C1N2C(/C=N/NC(NC(C)(C)C)=S)=C(C(OC)=O)C=N2,7-TM Receptors,GPR35,,GPR35 antagonist,"Competitive, reversible antagonist of the orphan receptor GPR35 (Ki = 12.8 nM). Blocks the GPR35-mediated increase in ERK1/2 phosphorylation and beta-arrestin recruitment induced by pamoic acid (Cat. No. 4298).",395.43
Cilnidipine,[132203-70-4],COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OCC=CC1=CC=CC=C1,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,Dual CaV1.x and CaV2.x blocker,"Dual L- and N-type calcium channel blocker that displays antihypertensive, sympatholytic and neuroprotective activity. Lowers mean blood pressure and reduces the size of cerebral infarction in the rat model of focal brain ischemia.",492.52
Cilostamide,[68550-75-4],CN(C1CCCCC1)C(=O)CCCOC1=CC=C2NC(=O)C=CC2=C1,Enzymes,Phosphodiesterases,,PDE3 inhibitor,Selective inhibitor of type III phosphodiesterase (PDE3). Displays moderate selectivity for PDE3A isozyme vs. PDE3B (IC50 values are 0.027 and 0.050 muM for PDE3A and PDE3B respectively). Inhibits ADP-induced platelet aggregation (IC50 = 16.8 muM); antithrombotic. Also available as part of the Phosphodiesterase Inhibitor Tocriset™.,342.44
Cilostazol,[73963-72-1],O=C1CCC2=CC(OCCCCC3=NN=NN3C3CCCCC3)=CC=C2N1,Enzymes,Phosphodiesterases,,PDE3A inhibitor. Also adenosine uptake inhibitor,"Potent phosphodiesterase III A (PDE3A) inhibitor (IC50 = 0.2 muM) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo.",369.47
CIM 0216,[1031496-06-6],O=C(NC1=NOC(C)=C1)C(C2=CC=CC=C2)N(CCC3)C4=C3C=CC=C4,Ion Channels,Transient Receptor Potential Channels,TRPM,Selective TRPM3 agonist,"Selective TRPM3 agonist. Exhibits selectivity for TRPM3 over TRPM1, TRPM2 and TRPM4-8. Stimulates insulin release from pancreatic islet cells in vitro. Evokes nocifensive behavior in mice.",347.41
Cimetidine,[51481-61-9],CN\C(NCCSCC1=C(C)NC=N1)=N\C#N,7-TM Receptors,Histamine Receptors,Histamine H2 Receptors,"H2 antagonist, I1 agonist",Widely used H2 histamine antagonist which has more recently been described as an inverse agonist. Also a potent I1 imidazoline binding site ligand.,252.34
Cinalukast,[128312-51-6],CCC(CC)(CC(=O)NC1=CC(\C=C\C2=NC(=CS2)C2CCC2)=CC=C1)C(O)=O,7-TM Receptors,Leukotriene and Related Receptors,,"Potent, selective CysLT1 (LTD4) antagonist; orally active","Potent, selective CysLT1 (LTD4) leukotriene receptor antagonist (IC50 = 6.4 nM). Inhibits LTD4-induced bronchoconstriction in guinea pigs when administered intravenously, orally or by aerosol.",412.55
CINPA 1,[102636-74-8],O=C(CN(CC)CC)N1C2=C(C=CC=C2)CCC3=C1C=C(NC(OCC)=O)C=C3,Nuclear Receptors,Constitutive Androstane Receptor,,Potent CAR antagonist,"Potent CAR antagonist (IC50 = 70 nM). Exhibits >90-fold selectivity for CAR over pregnane X receptor (PXR). Also selective over a panel of other nuclear receptors including FXR, LXR, PPARgamma and RXR.",395.49
CIQ,[486427-17-2],O=C(C3=CC(Cl)=CC=C3)N2C(COC4=CC=C(OC)C=C4)C1=CC(OC)=C(OC)C=C1CC2,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Potentiator of NMDA receptors containing GluN2C/GluN2D,Subunit-selective potentiator of NMDA receptors containing the GluN2C (formally NR2C) or GluN2D (formally NR2D) subunit. Increases channel opening efficiency and enhances NMDA receptor responses. Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.,467.94
Cirazoline hydrochloride,[40600-13-3],Cl.C(OC1=C(C=CC=C1)C1CC1)C1=NCCN1,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,Selective alpha1 agonist,Selective alpha1 agonist. Also available as part of the alpha1-Adrenoceptor Tocriset™ and Mixed Adrenergic Tocriset™.,252.74
Cisapride,[81098-60-4],CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=C(OC)C=C(N)C(Cl)=C1,7-TM Receptors,5-HT Receptors,5-HT4 Receptors,5-HT4 agonist; stimulates intestinal ACh release,"5-HT4 receptor agonist and gastrokinetic agent. Stimulates intestinal acetylcholine release, possibly via 5-HT4 receptor-dependent and -independent mechanisms, leading to increased intestinal motility.",465.95
CJ 033466,[519148-48-2],ClC2=C(N)N1C(C(C(NCC3CCN(CC(C)C)CC3)=O)=C2)=NC(C)=C1,7-TM Receptors,5-HT Receptors,5-HT4 Receptors,Selective 5-HT4 partial agonist,Potent and selective 5-HT4 partial agonist (EC50= 0.927 nM). Displays > 1000-fold selectivity for 5-HT4 over other 5-HT and D2 receptors. Exhibits gastroprokinetic effects in vivo following oral administration. Weakly blocks hERG (IC50 = 2.6 muM).,377.91
CKI 7 dihydrochloride,[1177141-67-1],ClC2=CC=C(S(NCCN)(=O)=O)C1=CN=CC=C12.Cl.Cl,Enzymes,Kinases,Casein Kinase 1,CK1 inhibitor,"Casein kinase 1 (CK1) inhibitor. Also inhibits SGK, S6K1 and MSK1. Induces retinal cell differentiation from human ESCs and iPSCs in combination with SB 431542 (Cat. No. 1614) and Y-27632 (Cat. No. 1254).",358.67
Clemastine fumarate,[14976-57-9],[H]OC(=O)\C=C\C(=O)O[H].CN1CCC[C@@H]1CCO[C@](C)(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,H1 antagonist,H1-receptor antagonist. Enhances differentiation of oligodendrocyte progenitor cells into myelin basic protein-positive oligodendrocytes in vitro and promotes remyelination in vivo. Also displays antimuscarinic properties. Clinically-used antihistamine.,459.97
Clofarabine,[123318-82-1],O[C@@H]1[C@@H](CO)O[C@@H](N(C=N3)C2=C3C(N)=NC(Cl)=N2)[C@H]1F,Enzymes,Kinases,Other Kinases,Deoxycytidine kinase (dCK) substrate,"Deoxycytidine kinase (dCK) substrate. Phosphorylated to form clofarabine triphosphate, which competes with dATP for DNA polymerase-alpha and -epsilon and potently inhibits ribonucleotide reductase (IC50 = 65 nM). Induces apoptosis by directly altering mitochondrial transmembrane potential. Demonstrates growth inhibition and cytotoxic activity in a variety of leukemias and solid tumors.",303.68
Clotrimazole,[23593-75-1],ClC1=CC=CC=C1C(C3=CC=CC=C3)(C4=CC=CC=C4)N2C=CN=C2,Enzymes,Cytochrome P450,,Cytochrome P450 inhibitor; antifungal,Imidazole antimycotic and cytochrome P450 inhibitor. Inhibits Ca2+-activated K+ current (IC50 = 3 muM) and L-type Ca2+ current; increases the firing rate of action potentials. Exhibits antiproliferative activity in vitro and in vivo. Also an inverse agonist of the human constitutive androstane receptor (hCAR).,344.84
CMPD-1,[41179-33-3],OC1=CC=C(NC(=O)CCCC2=CC=C(C=C2)C2=CC=CC=C2F)C=C1,Enzymes,Kinases,MAPK Family,Selective inhibitor of p38alpha-mediated MK2a phosphorylation; also tubulin polymerization inhibitor,"Non-ATP-competitive, selective inhibitor of p38alpha-mediated MK2a (mitogen-activated protein kinase-2a) phosphorylation (apparent Ki = 330 nM). Does not inhibit p38alpha-mediated phosphorylation of MBP and ATF-2. Also tubulin polymerization inhibitor. Cytotoxic in glioblastoma cells at concentrations that do not affect the MK2 pathway.",349.4
Co 101244 hydrochloride,[193356-17-1],Cl.CC1=CC=C(CC2(O)CCN(CCOC3=CC=C(O)C=C3)CC2)C=C1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,GluN2B-selective NMDA antagonist,"Novel, potent and selective antagonist of GluN2B (formally NR2B)-containing NMDA receptors (IC50 values are 0.043, > 100 and > 100 muM for GluN1A/2B (NR1A/2B), GluN1A/2A (NR1A/2A) and GluN1A/2C (NR1A/2C) subunit combinations respectively). Displays neuroprotective effects in vivo and in vitro. Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.",377.91
COR 170,[1048039-15-1],O=C(C4=CN(CCCCC)C5=C(C=C(C6=CC=CC=C6)C=C5)C4=O)NC12CC(C3)CC(CC3C2)C1,7-TM Receptors,Cannabinoid Receptors,CB2 Receptors,Selective CB2 receptor inverse agonist,"Selective inverse agonist of CB2 receptors (Ki values are 3.8 and >10,000 nM for CB2 and CB1, respectively).",468.63
Cordycepin,[73-03-0],NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)C[C@H]3O,Cell Metabolism,"DNA, RNA and Protein Synthesis",,RNA synthesis inhibitor,"Nucleoside analog that acts as an anticancer and antifungal agent. Can be converted to 3'-deoxyadenosine triphosphate (3'-dATP), which inhibits ATP-dependent DNA synthesis. Inhibits growth of various tumor cells in vitro.",251.24
Corticosterone,[50-22-6],[H][C@@]23CCC1=CC(CC[C@@](C)1[C@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@@H]4[C@@](CO)=O)=O,Nuclear Receptors,Glucocorticoid Receptor,,Endogenous glucocorticoid,Endogenous glucocorticoid that acts as an agonist at glucocorticoid and mineralocorticoid receptors.,346.46
CP 316819,[186392-43-8],O=C(N[C@@H](CC3=CC=CC=C3)[C@H](C(N(OC)C)=O)O)C2=CC1=CC(Cl)=CC=C1N2,Enzymes,Transferases,Phosphorylases,Selective glycogen phosphorylase inhibitor,Selective glycogen phosphorylase inhibitor [IC50 values are 0.017 and 0.034 muM against human skeletal muscle glycogen phosphorylase a (huSMGPa) and liver glycogen phosphorylase a (huLGPa) respectively]. Antihyperglycemic agent.,415.87
CP 376395 hydrochloride,[1013933-37-3],CC1=CC(NC(CC)CC)=C(C)C(OC2=C(C)C=C(C)C=C2C)=N1.Cl,7-TM Receptors,Peptide Receptors,CRF Receptors,Potent and selective CRF1 antagonist; binds at an allosteric site,Potent and selective CRF1 receptor antagonist (Ki values are 12 and >10000 nM for CRF1 and CRF2 receptors respectively). Binds at an allosteric site. Attenuates CRF-induced activation of the HPA axis in vivo following i.v. administration. Orally active.,362.94
CP 471474,[210755-45-6],FC1=CC=C(OC2=CC=C(S(NC(C)(C)C(NO)=O)(=O)=O)C=C2)C=C1,Enzymes,Proteases,Matrix Metalloprotease,Broad spectrum MMP inhibitor,"Broad spectrum MMP inhibitor (IC50 values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice.",368.38
CP 690550 citrate,[540737-29-9],C[C@H]1[C@@H](N(C2=NC=NC3=C2C=CN3)C)CN(C(CC#N)=O)CC1.OC(CC(O)=O)(C(O)=O)CC(O)=O,Enzymes,Kinases,JAK Kinase,Potent JAK inhibitor,"Potent JAK inhibitor (IC50 values are 1, 20, and 112 nM for JAK3, JAK2 and JAK1 respectively). Orally active immunosuppressant; exhibits efficacy in rodent rheumatoid arthritis models.",504.49
CP 775146,[702680-17-9],O=C(CC3=CC=C(C(C)C)C=C3)N(C2)CCC[C@H]2[C@@]1=CC(OC(C)(C)C(O)=O)=CC=C1,Nuclear Receptors,PPARs,PPARalpha Receptors,"Selective, high affinity PPARalpha agonist","Selective, high affinity PPARalpha agonist (Ki values are 24.5 nM for PPARalpha and >10 muM for PPARbeta and PPARgamma in vitro). Exhibits hypolipidemic activity in vivo.",423.54
CP 94253 hydrochloride,[845861-39-4],Cl.CCCOC1=CC=C2NC=C(C2=N1)C1=CCNCC1,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Potent and selective 5-HT1B agonist,"Potent, selective 5-HT1B agonist (Ki values are 89, 2, 860, 49 and 1,600 nM for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D and 5-HT2 receptors respectively). Centrally active upon systemic administration in vivo.",293.8
CP 99994 dihydrochloride,[145148-39-6],COC(C=CC=C3)=C3CN[C@@H]1[C@H]([C@]2=CC=CC=C2)NCCC1.Cl.Cl,7-TM Receptors,Peptide Receptors,Tachykinin Receptors,High affinity NK1 antagonist,High affinity NK1 antagonist (Ki = 0.145 nM in vitro). Also displays high ex vivo binding potency in gerbil striatum (IC50 = 36.8 nM). Attenuates endothelium-dependent contraction induced by substance P.,369.33
CPCCOEt,[179067-99-3],O=C(OCC)C3(C2C3)OC1=CC=CC=C1/C2=N/O,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Selective non-competitive mGlu1 antagonist,"hmGlu1 subtype-selective non-competitive antagonist (IC50 = 6.5 muM). Has no agonist or antagonist activity at hmGlu2, 4a, 5a, 7b, 8a or ionotropic receptors at concentrations of up to 100 muM.",247.25
CPI 203,[1446144-04-2],NC(C[C@@H]1N=C(C4=CC=C(Cl)C=C4)C3=C(SC(C)=C3C)N2C1=NN=C2C)=O,Epigenetics,Bromodomains,,BET bromodomain inhibitor; arrests cell cycle at G1 phase,"BET bromodomain inhibitor. Downregulates Myc expression, causes G1 cell cycle arrest and attenuates cell proliferation in human pancreatic neuroendocrine tumors. Arrests the growth of T cell acute lymphoblastic leukemia cells in vitro (EC50 = 91.2 nM). Also enhances the antitumor effect of rapamycin (Cat. No. 1292) in vitro and attenuates rapamycin induced Akt activation. Orally bioavailable.",399.9
CPT 11,[100286-90-6],CCC2=C4C(C(N3C4)=CC([C@](CC)(O)C(OC5)=O)=C5C3=O)=NC1=CC=C(OC(N6CCC(N7CCCCC7)CC6)=O)C=C12.Cl,Enzymes,Isomerases,DNA Topoisomerase,DNA topoisomerase I inhibitor; antitumor,"Inhibitor of DNA topoisomerase I that displays antitumor activity against a range of tumor types. Active metabolite available (SN 38, Cat. No. 2684).",623.14
CU CPT 4a,[1279713-77-7],O=C(N[C@H](CC3=CC=CC=C3)[C@@](O)=O)C2=C(Cl)C1=CC=C(F)C=C1S2,Enzyme-Linked Receptors,Toll-like Receptors,,Selective TLR3 inhibitor,"Selective TLR3 inhibitor (IC50 = 3.44 muM in RAW 264.7 cells); suppresses downstream signaling pathways mediated by the TLR3/dsRNA complex, inhibiting TNF-alpha and IL-1beta production in whole cells. Reduces death of crypt cells and improves gastrointestinal syndrome in mice.",377.82
CU-T12-9,,CNC1=CC=C([N+]([O-])=O)C=C1N2C=C(C3=CC=C(C(F)(F)F)C=C3)N=C2,Enzyme-Linked Receptors,Toll-like Receptors,,Potent TLR1/2 agonist,Potent TLR1/2 agonist (EC50 = 52.9 nM). Activates the NF-kappaB pathway and upregulates proinflammatory cytokines in vitro. Also enhances TLR1 and TLR2 dimerization.,362.31
CVT 10216,[1005334-57-5],O=C2C1=CC=C(OCC4=CC(C(O)=O)=CC=C4)C=C1OC=C2C3=CC=C(NS(=O)(C)=O)C=C3,Enzymes,Dehydrogenases,Aldehyde Dehydrogenase,Potent and selective ALDH2 inhibitor,"Potent and selective, reversible inhibitor of aldehyde dehydrogenase 2 (ALDH2) (IC50 values are 29 and 1300 nM for ALDH2 and ALDH1, respectively). Exhibits anxiolytic effects in rat models.",465.48
CW 008,[1134613-19-6],O=C(C1=CC=C(F)C=C1)NC2=NNC3=NC(C4=C5N(C=CC(OC)=C5)N=C4)=C(F)C=C32,Enzymes,Kinases,Protein Kinase A,PKA signaling activator; promotes osteogenesis from hMSCs,cAMP/PKA/CREB pathway activator. Promotes osteogenic differentiation of human bone marrow-derived MSCs in vitro. Increases bone mass and bone volume density in ovariectomized mice.,420.37
Cyclic Pifithrin-alpha hydrobromide,[511296-88-1],CC(C=C4)=CC=C4C1=CN(C2=C(S3)CCCC2)C3=N1.Br,Cell Cycle,p53,,p53 inhibitor,"Cyclic analog of pifithrin-alpha (Cat. No. 1267), a small molecule inhibitor of p53. Prevents dexamethasone-induced cell death in murine thymocytes (EC50 = 2.01 muM). Sensitizes p53-deficient tumors to radiotherapy and chemotherapy; increases apoptosis in target cells when used in combination with antimicrotubule agents.",349.29
Cyclothiazide,[2259-96-3],NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Positive allosteric modulator of AMPA receptors; inhibits AMPA desensitization,Positive allosteric modulator of AMPA receptors that potently inhibits AMPA receptor desensitization. Selective for the flip variant of each of the four receptor subunits.,389.87
CYM 50260,[1355026-60-6],ClC1=CC(Cl)=C(OCCOC2=CC=C(CF)N=C2Cl)C=C1,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Potent and selective S1P4 agonist,Potent sphingosine-1-phosphate receptor 4 (S1P4) agonist (EC50 = 45 nM). Displays no activity at other S1P receptor subtypes (S1P1-3 and S1P5) at concentrations up to 25 muM.,350.6
CYM 50358 hydrochloride,[1781750-72-8],O=C(NC3=C(C)C=C(CN)C=C3C)C1=CC=C(C2=C(Cl)C=CC(Cl)=C2)O1.Cl,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Potent and selective S1P4 antagonist,"Potent S1P4 antagonist (IC50 = 25 nM). Displays selectivity for S1P4 against S1P1, S1P2, S1P3 and S1P5 receptors.",425.74
CYM 50769,[1421365-63-0],ClC(C=N4)=C(OC5=CC=C(OC)C=C5)C(N4C2C3=C(C=CC=C3)C1=CC=CC=C12)=O,7-TM Receptors,Peptide Receptors,Other Peptide Receptors,Novel non-peptide NPBWR1 antagonist,"Novel non-peptide antagonist of neuropeptide W/B receptor 1 (NPBWR1, GPR7) (IC50 = 0.12 muM).",416.86
CYM 5541,[945128-26-7],O=C(N(C3CCCCC3)C2CCCCC2)C1=NOC(C4CC4)=C1,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Selective S1P3 receptor allosteric agonist,"Selective sphingosine-1-phosphate receptor 3 (S1P3) allosteric agonist (EC50 = 72-132 nM). Occupies a different space within the ligand binding pocket of S1P3 than S1P. Displays no activity at S1P1, S1P2, S1P4 and S1P5 receptors at concentrations up to 10 muM. Shows no significant activities in a profiling panel of 55 GPCRs, ion channels and transporters.",316.44
CZC 24832,[1159824-67-5],NC2=NN1C=C(C3=CN=CC(S(NC(C)(C)C)(=O)=O)=C3)C=C(F)C1=N2,Enzymes,Kinases,PI 3-Kinase,Selective inhibitor of PI 3-kinase gamma,Selective inhibitor of PI 3-kinase gamma (IC50 = 1.0 muM in a PI 3-Kgamma-dependent fMLP-induced neutrophil migration assay). Exhibits limited off-target effects in kinome profiling of 154 identified lipid and protein kinases and 922 other proteins. Orally effective in a rodent model of inflammatory disease.,364.4
CZC 54252 hydrochloride,[1784253-05-9],ClC1=C(NC3=CC=CC=C3NS(C)(=O)=O)N=C(NC2=C(OC)C=C(N4CCOCC4)C=C2)N=C1.Cl,Enzymes,Kinases,RIP kinase family,Potent LRRK2 inhibitor; neuroprotective,Potent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively). Attenuates neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM).,541.45
D 4476,[301836-43-1],O=C(N)C4=CC=C(C=C4)C1=NC(C2=CC(OCCO5)=C5C=C2)=C(C3=NC=CC=C3)N1,Enzymes,Kinases,Casein Kinase 1,Selective CK1 inhibitor. Also inhibits TGF-betaRI,Selective inhibitor of casein kinase 1 (CK1) and TGF-beta type-I receptor (ALK5) that displays > 20-fold selectivity over SAPK2/p38 and a much greater selectivity over all other protein kinases tested. Suppresses site-specific phosphorylation and nuclear exclusion of FOXO1a.,398.41
Daidzein,[486-66-8],OC1=CC=C(C=C1)C1=COC2=CC(O)=CC=C2C1=O,Cell Cycle,Cell Cycle Inhibitors,,Arrests cell cycle in G1 phase,Analog of the phytoestrogen genistein (Cat. No. 1110). Blocks G1 phase cell cycle progression. Agonist at estrogen receptors.,254.24
Daminozide,[1596-84-5],O=C(NN(C)C)CCC(O)=O,Enzymes,Demethylases,Histone Demethylases,Selective KDM2/7 inhibitor,"Histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.55, 1.5 and 2.1 muM for PHF8, KDM2A and KDM7A respectively). Exhibits greater than or equal to 60-fold selectivity for KDM2/7 demethylases over other histone demethylases and 2-oxoglurate oxygenases (IC50 > 100 muM).",160.17
DAPT,[208255-80-5],CC(C)(C)OC([C@H]([C@]2=CC=CC=C2)NC([C@H](C)NC(CC1=CC(F)=CC(F)=C1)=O)=O)=O,Stem Cells,Stem Cell Differentiation,Neural Stem Cells,gamma-secretase inhibitor; induces neuronal differentiation,"Inhibitor of gamma-secretase; causes a reduction in Abeta40 and Abeta42 levels in human primary neuronal cultures (IC50 values are 115 and 200 nM for total Abeta and Abeta42 respectively) and in brain extract, cerebrospinal fluid and plasma in vivo. Does not affect APPalpha and APPbeta levels. Blocks Notch signaling in hybrid human-mouse fetal thymus organ culture (FTOC). Activity causes ESCs to commit to neuronal differentiation. DAPT synthesized to cGMP guidelines also available.",432.46
DAU 5884 hydrochloride,[131780-48-8],Cl.CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)N1CC2=C(NC1=O)C=CC=C2,7-TM Receptors,Acetylcholine Muscarinic Receptors,M3 Receptors,M3 receptor antagonist,"Selective muscarinic M3 receptor antagonist. In bovine tracheal smooth muscle, inhibits methacholine-dependent effects on cell proliferation and muscle contractility.",351.83
DBeQ,[177355-84-9],C12=CC=CC=C1N=C(NCC4=CC=CC=C4)N=C2NCC3=CC=CC=C3,Enzymes,ATPases,p97 ATPase,Selective and reversible p97 ATPase inhibitor,"Selective and reversible inhibitor of p97 ATPase (VCP, IC50 = 1.5 muM). Induces executioner caspases (caspase-3 and caspase-7) rapidly. Blocks the degradation of endoplasmic reticulum-associated degradation (ERAD) reporters; also blocks autophagosome maturation and promotes accumulation of LC3-II.",340.42
DBZ,[209984-56-5],CN1C2=C(C=CC=C2)C3=C(C=CC=C3)[C@H](NC([C@@H](NC(CC4=CC(F)=CC(F)=C4)=O)C)=O)C1=O,Enzymes,Proteases,Gamma-Secretase,gamma-secretase inhibitor; inhibits Notch pathway,Inhibitor of gamma-secretase. Blocks Notch cleavage (IC50< 2 nM) in a cell-based assay; inhibits the Notch pathway. Stimulates the formation of human iPSCs from human keratinocytes.,463.48
DC 260126,[346692-04-4],CCCCC(C=C2)=CC=C2NS(C1=CC=C(F)C=C1)(=O)=O,7-TM Receptors,Free Fatty Acid Receptors,,FFA1 (GPR40) antagonist,"Free fatty acid receptor 1 (FFA1/GPR40) antagonist. Inhibits FFA-induced increases in intracellular Ca2+ levels and suppresses palmitic acid potentiated glucose-stimulated insulin secretion in Min6 pancreatic beta cells in vitro. Decreases serum insulin levels, improves insulin sensitivity and reduces the number of apoptotic pancreatic beta cells in obese diabetic (db/db) rats.",307.38
DDR1-IN-1 dihydrochloride,[1780303-76-5],CC1=C(OC4=CC(CC(N5)=O)=C5C=C4)C=C(NC(C2=CC=C(CN3CCN(CC)CC3)C(C(F)(F)F)=C2)=O)C=C1.Cl.Cl,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Other RTKs,Selective DDR1 inhibitor,Selective discoidin domain receptor 1 (DDR1) tyrosine kinase inhibitor (IC50 values are 105 and 413 nM for DDR1 and DDR2 respectively). Inhibits integrin-induced DDR1 autophosphorylation in an osteosarcoma cell line.,625.51
Decitabine,[2353-33-5],O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(N)=NC2=O)C1,Enzymes,Transferases,DNA Methyltransferases,DNA methyltransferase inhibitor,Cytosine analog that once incorporated into DNA acts as a suicide substrate for DNA methyltransferase. Inhibits DNA methyltransferase and results in DNA hypomethylation and activation of silent genes. Chemotherapeutic agent; suppresses growth of human tumor cell lines. Demethylates differentiation-related genes; reverses embryonic stem cell differentiation.,228.21
Delavirdine mesylate,[147221-93-0],O=C(N3CCN(C4=NC=CC=C4NC(C)C)CC3)C2=CC1=CC(NS(=O)(C)=O)=CC=C1N2.CS(O)(=O)=O,Enzymes,Polymerases,RNA/DNA Polymerase,Non-nucleoside reverse transcriptase inhibitor,"Non-nucleoside reverse transcriptase inhibitor (NNRTI). Selectively inhibits HIV-1 reverse transcriptase (RNA-dependent DNA polymerase) over other cellular polymerases (IC50 values are 0.26, 440 and >550 muM for HIV-1 reverse transcriptase, DNA polymerase alpha and DNA polymerase delta). Prevents HIV-1 spread in vivo and blocks viral replication in peripheral blood lymphocytes. Orally active.",552.67
Deltarasin,[1440898-82-7],C12=CC=CC=C1N=C(C4=CC=C(OC[C@H]([C@H]8CCNCC8)N5C(C7=CC=CC=C7)=NC6=C5C=CC=C6)C=C4)N2CC3=CC=CC=C3.Cl.Cl.Cl,Enzymes,GTPases,Small Monomeric GTPases,High affinity PDEdelta-KRas interaction inhibitor; binds to PDEdelta,High affinity PDEdelta-KRAS interaction inhibitor (Kd = 41 nM); binds to PDEdelta. Reduces proliferation and induces cell death of KRAS-dependent Panc-Tu-1 and Capan-1 pancreatic cancer cells. Attenuates tumor growth of Panc-Tu-1 xenografts in mice.,713.14
Dexamethasone,[50-02-2],O=C1C=CC2(C)C(CC[C@]3([H])[C@@](F)2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H](C)[C@@](O)4C(CO)=O)=C1,Nuclear Receptors,Glucocorticoid Receptor,,Anti-inflammatory glucocorticoid,Glucocorticoid; anti-inflammatory. Reduces levels of activated NF-kappaB in immature dendritic cells (DCs) and inhibits differentiation into mature DCs. Induces differentiation of human mesenchymal stem cells (MSCs). Also induces autophagy in acute lymphoblastic leukemia (ALL) cell lines.,392.47
Dexmedetomidine hydrochloride,[145108-58-3],C[C@H](C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,"Potent, highly selective alpha2 agonist. Active isomer of medetomidine (Cat. No. 5160)","Active isomer of medetomidine, a potent, highly selective alpha2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for alpha2- and alpha1-adrenoceptors respectively). Displays greater selectivity over alpha1-adrenoceptors than clonidine and UK 14,304 (1620-, 220- and 300-fold respectively). Active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects. Racemate also available.",236.74
DG 172 dihydrochloride,[1361504-77-9],BrC(C=CC=C1)=C1/C(C#N)=C/C2=CC=C(N3CCN(C)CC3)C=C2.Cl.Cl,Nuclear Receptors,PPARs,Non-selective PPAR,Potent PPARbeta/delta inverse agonist; promotes BMC differentiation,Potent PPARbeta/delta inverse agonist (IC50 = 26.9 nM). Inhibits Angptl4 gene expression in mouse myoblasts (IC50 = 9.5 nM) in vitro. Also augments GM-CSF/IL-4-induced differentiation of mature dendritic cells from bone marrow cells in culture. Orally available.,455.22
Diazoxide,[364-98-7],CC1=NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Inhibits AMPA desensitization,"Antihypertensive, activates ATP-dependent K+ channels (Kir6). Induces activation of PKCepsilon, an intermediate in the opening of mitoKATP channels, results in cardioprotection against hypoxia-induced death. Blocks desensitization of AMPA receptors.",230.67
"Dibutyryl-cAMP, sodium salt",[16980-89-5],[Na+].[H][C@@]12COP([O-])(=O)O[C@@]1([H])[C@@H](OC(=O)CCC)[C@@H](O2)N1C=NC2=C1N=CN=C2NC(=O)CCC,Signal Transduction,Inositol and cAMP Signaling,cAMP,Cell-permeable cAMP analog,Cell-permeable analog of cAMP; activates cAMP-dependent protein kinases. Promotes differentiation of dopaminergic neurons (iDA) from hPSCs in combination with other reagents.,491.37
Dihydroergocristine mesylate,[24730-10-7],CS(=O)(O)=O.[H][C@]4([C@@]([H])3C[C@@H]([C@@](N[C@@]5([C@H](C)C)C(N([C@@]([H])(CC8=CC=CC=C8)C(N7[C@]([H])6CCC7)=O)[C@@]6(O)O5)=O)=O)CN4C)CC1=CNC2=C1C3=CC=C2,7-TM Receptors,Adrenergic Receptors,Non-selective Adrenergic Alpha Receptors,alpha partial agonist,5-HT receptor antagonist; partial agonist at adrenergic and dopaminergic receptors.,707.84
Dihydroergotamine mesylate,[6190-39-2],CS(=O)(O)=O.[H][C@]4([C@@]([H])3C[C@@H]([C@@](N[C@@]5(C)C(N([C@@]([H])(CC8=CC=CC=C8)C(N7[C@]([H])6CCC7)=O)[C@@]6(O)O5)=O)=O)CN4C)CC1=CNC2=C1C3=CC=C2,7-TM Receptors,Adrenergic Receptors,Non-selective Adrenergic Alpha Receptors,alpha partial agonist; also D2-like partial agonist and 5-HT antagonist,Partial alpha-adrenergic agonist. Partial D2 dopaminergic receptor agonist. Competitive 5-HT antagonist.,679.79
Diltiazem hydrochloride,[33286-22-5],[H][C@]2(C3=CC=C(OC)C=C3)[C@@]([H])(OC(C)=O)C(N(CCN(C)C)C1=CC=CC=C1S2)=O.Cl,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV1.x blocker,Antihypertensive and cardioprotective agent; an inhibitor of L-type Ca2+ channels.,450.98
Dimebon dihydrochloride,[97657-92-6],CC(N=C4)=CC=C4CCN2C1=CC=C(C)C=C1C3=C2CCN(C)C3.Cl.Cl,Cell Metabolism,Amyloid Beta Peptides,,Neuroprotectant; protects against beta-amyloid neurotoxicity,"Non-selective antihistamine that displays cognitive enhancing abilities. Also displays high affinity for 5-HT (particularly 5-HT6 and 5-HT7), alpha-adrenergic, dopaminergic, AMPA and NMDA receptors, and L-type calcium channels. Does not inhibit acetylcholinesterase activity. Exhibits neuroprotective activity in cellular models of Alzheimer's and Huntington's disease and preserves cognitive function following administration to AF64A lesioned rats. Protects neurons against the neurotoxic action of beta-amyloid fragment; shown to enhance autophagy in yeast and reduce intracellular Abeta42 levels.",392.37
Dipyridamole,[58-32-2],OCCN(CCO)C1=NC(N2CCCCC2)=C2N=C(N=C(N3CCCCC3)C2=N1)N(CCO)CCO,Transporters,Neurotransmitter Transporters,Nucleoside Transporters,Adenosine transport inhibitor,"Coronary vasodilator; adenosine transport inhibitor. Phosphodiesterase inhibitor (IC50 values are 0.37, 0.38, 0.45, 0.9 and 4.5 muM for PDE11, 6, 10, 5 and 8 respectively). Inhibits ENT1 and ENT2 (IC50 = 144.8 nM and Ki = 8.18 nM for ENT1).",504.63
DL-TBOA,[205309-81-5],[H][C@@](OCC1=CC=CC=C1)(C(O)=O)[C@@]([H])(C(O)=O)N.[H][C@](OCC2=CC=CC=C2)(C(O)=O)[C@]([H])(C(O)=O)N,Transporters,Neurotransmitter Transporters,Glutamate Transporters,Selective non-transportable inhibitor of EAATs,"A competitive, non-transportable blocker of excitatory amino acid transporters (IC50 values are 70, 6, and 6 muM for EAAT1, EAAT2 and EAAT3 respectively). Also inhibits EAAT4 and EAAT5 (Ki values are 4.4 and 3.2 muM respectively). Displays high selectivity for EAATs over ionotropic and metabotropic glutamate receptors. Also available as part of the Excitatory Amino Acid Transporter Inhibitor Tocriset™.",239.23
DMAB-anabaseine dihydrochloride,[154149-38-9],CN(C)C1=CC=C(/C=C2/C(C3=CN=CC=C3)=NCCC2)C=C1.Cl.Cl,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Partial agonist at alpha7 nAChR; also alpha4beta2 antagonist,Partial agonist at alpha7-containing neuronal nicotinic receptors and antagonist at alpha4beta2 and other nicotinic receptors. Displays specific cognition-enhancing effects; improves long-term memory in rats.,364.32
DMH-1,[1206711-16-1],CC(C)OC(C=C3)=CC=C3C(C=N2)=CN1C2=C(C4=CC=NC5=C4C=CC=C5)C=N1,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),BMP and Other Activin Receptors,Selective ALK2 inhibitor,"Selective inhibitor of bone morphogenic protein (BMP) type-I receptor activin receptor-like kinase 2 (ALK2) receptor (IC50 = 108 nM [Hao et al., 2010] or 12.6 nM [Mohedas et al., 2013] in in vitro kinase assays). Exhibits 6- and 19-fold selectivity for ALK-2 over ALK-1 and ALK-3, respectively, and no significant inhibition of AMPK, ALK5, KDR (VEGFR-2) or PDGFRbeta receptors. Blocks BMP4-induced phosphorylation of Smads 1, 5 and 8 in HEK293 cells. Promotes neurogenesis in human induced pluripotent stem cells (iPSCs) when used in combination with SB 431542 (Cat. No. 1614).",380.44
DMH4,[515880-75-8],C(C=N2)(C4=CC=C(OCCN5CCOCC5)C=C4)=CN1C2=C(C3=CC=CC=C3)C=N1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,Selective VEGFR-2 inhibitor,"Selective VEGFR-2 inhibitor (IC50 values are 161, 3558, 8038 and > 30000 nM for VEGFR-2, BMPR-I, AMPK and TGFbetaR-I respectively). Displays antiangiogenic activity in vitro and in vivo.",400.47
DMP 543,[160588-45-4],FC1=CC(CC2(CC3=CC(F)=NC=C3)C3=CC=CC=C3C(=O)C3=C2C=CC=C3)=CC=N1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,"Potent, orally active ACh release enhancer","Acetylcholine release stimulator. Potently enhances K+-stimulated [3H]-ACh release from rat hippocampal slices (EC50 = 700 nM), and increases release of dopamine and glutamate (EC50 values are 0.25 and 0.22 muM, respectively). Orally active in vivo; increases ACh levels in rats (with a minimum effective dose of 1 mg/kg) and exerts a long duration of action. More potent than linopirdine (Cat. No. 1999) both in vitro and in vivo. Also K+ channel blocker.",412.44
DNQX,[2379-57-9],[O-][N+](=O)C1=C(C=C2NC(=O)C(=O)NC2=C1)[N+]([O-])=O,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Selective non-NMDA iGluR antagonist,Selective non-NMDA receptor antagonist. Water-soluble Salt also available.,252.14
Dobutamine hydrochloride,[49745-95-1],Cl.CC(CCC1=CC=C(O)C=C1)NCCC1=CC=C(O)C(O)=C1,7-TM Receptors,Adrenergic Receptors,Non-selective Adrenergic Beta Receptors,"alpha1, beta1 and beta2 agonist",beta1- and beta2-adrenoceptor agonist with some action at the alpha1-adrenoceptor.,337.85
Dofetilide,[115256-11-6],CN(CCC2=CC=C(NS(=O)(C)=O)C=C2)CCOC1=CC=C(NS(=O)(C)=O)C=C1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV11.1 (hERG) channel blocker; inhibits rapid delayed rectifier K+ current (IKr),Selective potassium channel blocker. Blocks KV11.1 (hERG) channels; inhibits the rapid delayed-rectifier K+ current (IKr). Displays class III antiarrhythmic properties.,441.56
Dolasetron mesylate,[115956-13-3],O=C(O[C@@H]3C[C@H](C5)N(CC(C5C4)=O)[C@@]4([H])C3)C2=CNC1=CC=CC=C12.CS(=O)(O)=O,Ion Channels,Ligand-gated Ion Channels,5-HT3 Receptors,Potent and selective 5-HT3 antagonist,"Potent and selective 5-HT3 receptor antagonist (pIC50 = 7.55). Exhibits 200-fold selectivity for 5-HT3 over 5-HT1A, 5-HT1B and 5-HT2 receptors, and a range of other GPCRs. Blocks the 5-HT-elicited von Bezold-Jarisch reflex in rats and suppresses cisplatin-induced vomiting in ferrets.",420.48
Dorsomorphin dihydrochloride,[1219168-18-9],C(C=N2)(C4=CC=C(OCCN5CCCCC5)C=C4)=CN1C2=C(C3=CC=NC=C3)C=N1.Cl.Cl,Enzymes,Kinases,AMPK,Potent AMPK inhibitor; also BMP type I receptor inhibitor,"Potent inhibitor of AMP-activated protein kinase (AMPK) (Ki = 109 nM). Displays no significant activity on several structurally related kinases including ZAPK, SYK, PKCtheta, PKA and JAK3. Inhibits AMPK activation induced by AICAR (Cat. No. 2840) and metformin (Cat. No. 2864). Also inhibits bone morphogenetic protein (BMP) type I receptors (ALK2, ALK3 and ALK6). Promotes cardiomyogenesis in mouse embryonic stem cells (ESCs) in vitro. Shown to induce autophagy in cancer cell lines via a mechanism independent of AMPK inhibition.",472.41
Doxazosin mesylate,[77883-43-3],NC2=NC(N3CCN(C(C4COC(C=CC=C5)=C5O4)=O)CC3)=NC1=CC(OC)=C(OC)C=C12.CS(=O)(O)=O,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,alpha1 antagonist,"Selective alpha1-adrenoceptor antagonist (pKi values are 9.0, 8.5 and 8.4 for human alpha1B, alpha1A and alpha1D receptors respectively). Displays antihypertensive activity.",547.58
Doxorubicin hydrochloride,[25316-40-9],OC1=C(C[C@]([C@](CO)=O)(O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C(O)C3=C1C(C2=CC=CC(OC)=C2C3=O)=O.Cl,Enzymes,Isomerases,DNA Topoisomerase,Antitumor antibiotic agent. Inhibits DNA topoisomerase II,Antitumor antibiotic agent that inhibits DNA topoisomerase II. DNA intercalator that inhibits nucleic acid synthesis and induces apoptosis. Reduces intracellular tau levels.,579.99
DR 4485 hydrochloride,[402942-53-4],ClC1=C2C(C3(CCCCN4CCC(C5=CC=C(Cl)C=C5)=CC4)CCC2)=C(NC3=O)C=C1.Cl,7-TM Receptors,5-HT Receptors,5-HT7 Receptors,High affinity and selective 5-HT7 antagonist; orally bioavailable,High affinity and selective 5-HT7 antagonist (pKi = 8.14). Exhibits selectivity for 5-HT7 over other 5-HT receptors. Inhibits 5-HT-induced cAMP accumulation in HEK-293 cells expressing the 5-HT7 receptor. Orally bioavailable.,491.88
DSR 6434,[1059070-10-8],O=C2N(CC3=CC=C(OCCN(C)C)N=C3)C1=NC(NCCCC)=NC(N)=C1N2,Enzyme-Linked Receptors,Toll-like Receptors,,Potent TLR7 agonist,Potent TLR7 agonist (EC50 = 7.2 nM). Activates several immune effector cells in vitro. Suppresses metastasis in vivo and enhances efficacy of radiation therapy in a model of colorectal carcinoma.,400.48
DuP 697,[88149-94-4],CS(=O)(=O)C1=CC=C(C=C1)C1=C(SC(Br)=C1)C1=CC=C(F)C=C1,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Cyclooxygenase-2 (COX-2) inhibitor,Potent and selective inhibitor of cyclooxygenase-2 (IC50 values are 10 and 800 nM for COX-2 and COX-1 respectively). Inhibits prostaglandin synthesis and is anti-inflammatory in vivo. Orally active.,411.3
DY131,[95167-41-2],CCN(CC)C1=CC=C(C=C1)\C=N\NC(=O)C1=CC=C(O)C=C1,Nuclear Receptors,Estrogen and Related Receptors,,Agonist selective for estrogen-related receptors ERRbeta and ERRgamma,"Novel selective agonist at estrogen-related receptors ERRbeta and ERRgamma. Displays minimal activity at ERRalpha, ERalpha and ERbeta at concentrations up to 30 muM.",311.38
Dynole 34-2,[1128165-88-7],CN(C)CCCN2C1=CC=CC=C1C(/C=C(C(NCCCCCCCC)=O)\C#N)=C2,Enzymes,GTPases,Dynamin,Dynamin I inhibitor,Dynamin I inhibitor (IC50 = 1.3 muM). Inhibits receptor-mediated endocytosis (RME) (IC50 = 5.0 muM).,408.58
E-4031 dihydrochloride,[113559-13-0],Cl.Cl.CC1=CC=CC(CCN2CCC(CC2)C(=O)C2=CC=C(NS(C)(=O)=O)C=C2)=N1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV11.1 (hERG) channel blocker; inhibits rapid delayed rectifier K+ current (IKr),"Selective blocker of KV11.1 (hERG) channels; inhibits the rapid delayed-rectifier K+ current (IKr). Reversibly prolongs action potential duration in guinea pig papillary muscle and isolated ventricular myocytes, without affecting Na+ or Ca2+ inward currents. Class III antiarrhythmic agent.",474.44
Eact,[461000-66-8],O=C(C3=CC(OC)=C(OC)C(OC)=C3)N(CCOC)C1=NC(C2=CC=CC=C2)=CS1,Ion Channels,Chloride Channels,Ca2+-Activated Chloride Channels,Activator of Ca2+-activated Cl- channel transmembrane protein 16A (TMEM16A),TMEM16A (ANO1) calcium-activated chloride channel (CaCC) activator (EC50 = 3 muM). Also transient receptor potential vanilloid 1 (TRPV1) channel activator (EC50 = 11.6 muM). Ca2+-independent. Displays no effect on CFTR Cl- or ENaC Na+ conductance. Stimulates submucosal gland secretion in human bronchi.,428.5
EB 47,[1190332-25-2],O=C(NC2=CC=CC3=C2CNC3=O)CN(CC1)CCN1[C@]([C@@H]4O[C@H](N5C=NC6=C5N=CN=C6N)[C@@H](O)[C@H]4O)=O.Cl.Cl,Enzymes,Polymerases,Poly(ADP-ribose) Polymerase,Potent PARP-1 inhibitor,Potent inhibitor of PARP-1 (IC50 = 45 nM). Reduces infarct volume in both a rat transient middle cerebral arterial occlusion model and a cardiac reperfusion model.,610.45
EC 144,[911397-80-3],ClC1=C2C(N(CC3=C(C)C(OC)=C(C)C=N3)C=C2C#CCC(C)(C)O)=NC(N)=N1,Signal Transduction,Heat Shock Proteins,Hsp90,"High affinity, potent and selective Hsp90 inhibitor","High affinity, potent and selective Hsp90 inhibitor (Ki = 0.2 nM and IC50 = 1.1 nM). Exhibits selectivity for Hsp90 over Grp94 and TRAP1 (Ki values are 61 and 255 nM respectively) and has no effect (IC50 >10 muM) against a panel of 285 kinases. Degrades Her-2 in MCF-7 breast cancer cells (EC50 = 14 nM). Blocks tumor growth and induces partial tumor regression in an N87 gastric tumor mouse model. Also inhibits LPS-induced TNFalpha release in an LPS shock mouse model and suppresses disease development in a rat model of collagen-induced arthritis. Exhibits <20-fold efficacy over BIIB 021 (Cat. No. 4608) in mice. Orally available and brain penetrant.",413.9
EC 23,[104561-41-3],CC1(C)C2=C(C=CC(C#CC3=CC=C(C(O)=O)C=C3)=C2)C(C)(C)CC1,Nuclear Receptors,Retinoic Acid Receptors,,Synthetic retinoid; induces differentiation of stem cells,Photostable synthetic retinoid; analog of ATRA (Cat. No. 0695). Displays similar activity to ATRA when tested on the embryonal carcinoma stem cell model TERA2.cl.SP12. Potently induces neural differentiation in human pluripotent embryonic stem cells.,332.44
eCF 309,[2001571-40-8],CCOC(OCC)CN1N=C(C2=CC(N=C(N)O3)=C3C=C2)C4=C1N=CN=C4N,Enzymes,Kinases,mTOR,Potent mTOR inhibitor,Potent mTOR inhibitor (IC50 = 15 nM). Exhibits >60-fold selectivity for mTOR over PI 3-kinases and is inactive against a panel of other kinases. Inhibits growth of ER-positive MCF7 breast cancer cells in vitro (EC50 = 8.5 nM). Cell permeable.,383.41
Edaglitazone,[213411-83-7],CC(OC(C5=CC=CC=C5)=N4)=C4CCOC(C3=C2SC=C3)=CC=C2CC1C(NC(S1)=O)=O,Nuclear Receptors,PPARs,PPARgamma Receptors,Potent and selective PPARgamma agonist; antidiabetic,"Potent and selective PPARgamma agonist (EC50 values are 35.6 and 1053 nM for PPARgamma and PPARalpha cofactor recruitment respectively. Enhances insulin sensitivity in obese, but not lean, rats. Antidiabetic and orally bioavailable.",464.56
Efonidipine hydrochloride monoethanolate,[111011-76-8],CC1=C(P4(OCC(C)(C)CO4)=O)C(C3=CC([N+]([O-])=O)=CC=C3)C(C(OCCN(CC5=CC=CC=C5)C2=CC=CC=C2)=O)=C(C)N1.CCO.Cl,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV1.x and CaV3.x blocker,Selective blocker of L-type and T-type Ca2+ channels. Displays minimal inhibition of N- and P/Q-type channels and no inhibition of R-type channels. R(-) and S(+)-enantiomers display different channel selectivity; S(+)-Efonidipine blocks L-type and T-type channels whereas R(-)-Efonidipine displays selectivity for T-type channels. Exhibits antihypertensive activity.,714.18
EG 00229,[1018927-63-3],O=S(C1=CC=CC2=NSN=C12)(NC3=C(C(N[C@H](C(O)=O)CCCNC(N)=N)=O)SC=C3)=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,Neuropilin 1 (NRP1) receptor antagonist; inhibits VEGFA binding to NRP1,Neuropilin 1 (NRP1) receptor antagonist; inhibits VEGFA binding to the NRP1 b1 domain. Has no effect on VEGFA binding to VEGFR-1 and VEGFR-2. Reduces VEGFA-induced VEGFR-2 tyrosine phosphorylation in HUVECs. Also attenuates VEGFA-induced HUVEC cell migration and reduces A549 lung carcinoma cell viability in vitro. Increases chemo-sensitivity of A549 cells in combination with Taxol (Cat. No. 1097). Blocks pro-tumorigenic M2 polarization in glioma-associated microglia and macrophages and reduces tumor growth and vascularization in NSG mice.,497.57
EIPA,[1154-25-2],ClC1=C(N(C(C)C)CC)N=C(N)C(C(NC(N)=N)=O)=N1,Ion Channels,Transient Receptor Potential Channels,TRPP,Inhibits TRPP3-mediated currents; also inhibits the Na+/H+ exchanger (NHE),TRPP3 channel inhibitor (IC50 = 10.5 muM). Inhibits the Na+/H+ exchanger (NHE). Derivative of amiloride (Cat. No. 0890).,299.76
Eletriptan hydrobromide,[177834-92-3],CN1[C@@H](CC3=CNC2=CC=C(CCS(=O)(C4=CC=CC=C4)=O)C=C23)CCC1.Br,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,5-HT1B and 5-HT1D agonist; orally active,"Orally active, selective 5-HT1B/1D receptor agonist. Produces a dose-dependent reduction in carotid artery blood flow in vivo. Displays antimigraine activity.",463.43
Elinogrel,[936500-94-6],O=C(NS(C4=CC=C(Cl)S4)(=O)=O)NC(C=C3)=CC=C3N2C(C1=CC(F)=C(NC)C=C1NC2=O)=O,7-TM Receptors,Purinergic P2Y Receptors,,P2Y12 antagonist,P2Y12 antagonist; exhibits antiplatelet activity.,523.95
EMD 281014 hydrochloride,[443144-27-2],O=C(N3CCN(CCC4=CC=C(F)C=C4)CC3)C1=C2C(C(C#N)=CN2)=CC=C1.Cl,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Selective 5-HT2A antagonist,"Selective 5-HT2A antagonist; displays high affinity for human 5-HT2A over 5-HT2C receptors (Ki values are 0.87 and 557 nM respectively). Exhibits low off-target activity (Ki values are >1000 and 1268 nM for human D2 receptors and IKr channels, respectively).",412.89
EMD 386088 hydrochloride,[1171123-46-8],Cl.CC1=C(C2=CC(Cl)=CC=C2N1)C1=CCNCC1,7-TM Receptors,5-HT Receptors,5-HT6 Receptors,Potent 5-HT6 agonist,"Potent 5-HT6 receptor agonist (EC50 = 1.0 nM) that displays selectivity over other 5-HT receptors (IC50 values are 7.4, 110, 180, 240, 450, 620, 660 and 3000 nM for 5-HT6, 5-HT1D, 5-HT1B, 5-HT2A, 5-HT2C, 5-HT4, 5-HT1A and 5-HT7 receptors respectively). Shows moderate affinity at 5-HT3 receptors (IC50 = 34 nM).",283.2
EMD 66684,[1216884-39-7],Cl.CCCCC1=NC2=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(=O)N(CC(=O)N(C)C)C=C2,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,Potent and selective non-peptide AT1 antagonist,Highly potent and very selective non-peptide angiotensin AT1 receptor antagonist (IC50 values are 0.7 and > 10000 nM for AT1 and AT2 receptors respectively). Potently inhibits angiotensin II-induced contractions in isolated rabbit aorta (IC50 = 0.2 nM) and reduces blood pressure in hypertensive rats.,547.05
endo-IWR 1,[1127442-82-3],[H][C@]13[C@](C(N(C4=CC=C(C(NC5=CC=CC6=C5N=CC=C6)=O)C=C4)C3=O)=O)([H])[C@H]2C=C[C@@H]1C2.[H][C@@]79[C@@](C(N(C%10=CC=C(C(NC%11=CC=CC%12=C%11N=CC=C%12)=O)C=C%10)C9=O)=O)([H])[C@@H]8C=C[C@H]7C8,Signal Transduction,Wnt Signaling,Beta-catenin,Wnt/beta-catenin signaling inhibitor; axin stabilizer,Inhibitor of Wnt signaling. Induces an increase in Axin2 protein levels; promotes beta-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes. Negative Control also available.,409.44
EO 1428,[321351-00-2],CC1=CC=CC=C1C(C2=CC=C(NC3=C(N)C=C(Br)C=C3)C=C2Cl)=O,Enzymes,Kinases,MAPK Family,Selective inhibitor of p38alpha and p38beta2,"Selective inhibitor of p38alpha and p38beta2 that displays no activity at p38gamma, p38delta, ERK1/2 and JNK1. Inhibits production of inflammatory cytokines including IL-8, TNF-alpha, IL-6, IL-1beta and IL-10 (IC50 values are 4, 5, 17, 30 and 74 nM respectively). Displays anti-inflammatory activity in murine models of acute and chronic dermatitis.",415.71
EPPTB,[1110781-88-8],O=C(NC3=CC(OCC)=CC=C3)C1=CC(C(F)(F)F)=C(N2CCCC2)C=C1,7-TM Receptors,Trace Amine 1 Receptor,,Trace amine 1 (TA1) receptor antagonist/inverse agonist,"Trace amine 1 (TA1) receptor antagonist/inverse agonist; exhibits a higher potency at the mouse TA1 receptor than the rat and human TA1 receptors (IC50 values are 27.5, 4539 and 7487 nM, respectively). Blocks the TA1 receptor-mediated activation of an inwardly rectifying K+ current, which increases the firing frequency of dopamine (DA) neurons in the ventral tegmental area. Increases DA potency at the D2 receptor. Also displays inverse agonism, reducing basal cAMP levels in vitro (IC50 = 19 nM).",378.39
ER 27319 maleate,[1204480-26-1],OC(=O)\C=C/C(O)=O.CC1=C(C)C2=C(C=C1)C(=O)C1=CC=CC=C1N2CCCN,Enzymes,Kinases,Syk Kinase,Selective Syk kinase inhibitor,"Selective inhibitor of Syk kinase. Inhibits tyrosine phosphorylation of Syk initiated by the engagement of FcepsilonRI in rat and human mast cells. Results in the abrogation of degranulation, TNF-alpha production (IC50 = 10 muM) and other related signaling events.",396.17
ER 50891,[187400-85-7],CC(C)C1=C2C(C(C3=CC=CC=C3)=CC(C4=CC=C(C5=CC=C(C(O)=O)C=C5)N4)=N2)=CC=C1,Nuclear Receptors,Retinoic Acid Receptors,,Selective RARalpha antagonist,"Antagonist of RARalpha receptors (IC50 = 31.2 nM). Displays selective affinity for RARalpha (relative IC50 values are 1.8, 432 and 535 nM for RARalpha, RARgamma and RARbeta respectively).",432.51
ERK5-IN-1,[1435488-37-1],O=C2N(C)C3=C(N=C(NC5=CC=C(C(N6CCC(N7CCN(C)CC7)CC6)=O)C=C5OCC)N=C3)N(C4CCCC4)C1=CC=CC=C12,Enzymes,Kinases,MAPK Family,Potent and selective ERK5 inhibitor,Potent and selective ERK5 inhibitor; inhibits EGFR-induced ERK5 autophosphorylation (EC50 = 90 nM) and ERK5 enzymatic activity (IC50 = 162 nM). Exhibits at least 30-fold selectivity for ERK5 over LRRK2 in a cell based assay. Also selective for ERK5 over a panel of other kinases. Orally bioavailable.,638.8
Escitalopram oxalate,[219861-08-2],FC(C=C3)=CC=C3[C@]1(CCCN(C)C)OCC2=C1C=CC(C#N)=C2.OC(C(O)=O)=O,Transporters,Neurotransmitter Transporters,5-HT Transporters,Selective serotonin reuptake inhibitor (SSRI),"Selective 5-HT reuptake inhibitor (Ki values are 0.89, 8150, and 10500 nM for serotonin, noradrenalin, and dopamine transporters respectively). Is a S-enantiomer and eutomer of citalopram (Cat. No. 1427).",414.43
ESI 09,[263707-16-0],CC(C)(C)C1=CC(C(/C(C#N)=N/NC2=CC=CC(Cl)=C2)=O)=NO1,Enzymes,GTPases,Small Monomeric GTPases,Epac inhibitor,EPAC inhibitor. Inhibits EPAC-mediated insulin releases from pancreatic beta cells. Selective for EPAC over PKA. Decreases migration and invasion of AsPc-1 and PANC-1 pancreatic cancer cells in vitro.,330.77
Etoposide,[33419-42-0],OC(C(OC)=C3)=C(OC)C=[C@@]3[C@@H]2C1=CC6=C(OCO6)C=C1[C@@H](O[C@]4([H])O[C@@](CO[C@@H](C)O7)([H])[C@]7([H])[C@H](O)[C@H]4O)[C@@H]5[C@@H]2[C@](OC5)=O,Enzymes,Isomerases,DNA Topoisomerase,Topoisomerase II inhibitor,Topoisomerase II inhibitor (IC50 = 59.2 muM).,588.56
ETP 45658,[1198357-79-7],CN2C1=NC(C3=CC(O)=CC=C3)=NC(N4CCOCC4)=C1C=N2,Enzymes,Kinases,PI 3-Kinase,Potent PI 3-kinase inhibitor; also inhibits DNA-PK and mTOR,"PI 3-kinase inhibitor (IC50 values are 22, 30, 129 and 710 nM for PI 3-Kalpha, PI 3-Kdelta, PI 3-Kbeta and PI 3-Kgamma respectively). Also inhibits DNA-PK and mTOR (IC50 values are 70.6 and 152 nM respectively). Inhibits proliferation of multiple cancer cell lines in vitro and reduces Akt phosphorylation levels in vivo.",311.34
Ex 26,[1233332-37-0],CC(C1=CC(C)=C(C=C1)Cl)NC2=CC=C(C(C3=CC(C)=C(C(C)=C3)C(NC4(C(O)=O)CC4)=O)=C2)F,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Potent and selective S1P1 receptor antagonist,"Potent and selective S1P1 receptor antagonist (IC50 = 0.93 nM). Exhibits > 3,000-fold selectivity for S1P1 over S1P2, S1P3, S1P4 and S1P5. Induces lymphocyte sequestration in peripheral lymph nodes and upregulates S1P1 receptor expression. Reduces disease severity in mice with EAE. Increases IFN-alpha production in stimulated dendritic cells in vivo.",494.98
Exemestane,[107868-30-4],C[C@@]12C(C(C[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CCC4=O)=C)=CC(C=C1)=O,Enzymes,Cytochrome P450,,Steroidal aromatase (CYP19) inhibitor,Irreversible steroidal aromatase inhibitor (IC50 = 20 nM). Destabilizes aromatase and lowers estrogen levels; orally active.,296.4
exo-IWR 1,[1127442-87-8],O=C(NC5=CC=CC6=C5N=CC=C6)C(C=C4)=CC=C4N2C([C@@]1([H])[C@@H](C3)C=C[C@@H]3[C@]([H])1C2=O)=O,Signal Transduction,Wnt Signaling,Beta-catenin,Negative control for endo-IWR 1 (Cat. No. 3532),Negative control for endo-IWR 1 25-fold less active than endo-IWR 1; exhibits decreased activity against the Wnt/beta-catenin pathway. Active Analog also available.,409.44
Exo1,[461681-88-9],COC(=O)C1=CC=CC=C1NC(=O)C1=CC=C(F)C=C1,Signal Transduction,"Translocation, Exocytosis & Endocytosis",,Inhibits Golgi-ER traffic; blocks exocytosis,"Reversible inhibitor of vesicular trafficking between endoplasmic reticulum and Golgi apparatus. Modifies Golgi ADP-ribosylation factor (ARF)1 GTPase activity and inhibits exocytosis (IC50 ~ 20 mM). Has similar, but not identical, action to brefeldin A (Cat. No. 1231).",273.26
Fasudil hydrochloride,[105628-07-7],Cl.O=S(=O)(N1CCCNCC1)C1=C2C=CN=CC2=CC=C1,Enzymes,Kinases,Rho-kinases,Inhibitor of cyclic nucleotide dependent- and Rho-kinases,Cyclic nucleotide-dependent protein kinase inhibitor and Rho-associated kinase inhibitor (IC50 = 10.7 muM). Suppress MMP-2 expression and induce apoptosis in glioblastoma cells in vivo. Ca2+ antagonist and vasodilator. Also inhibits proliferation of vascular smooth muscle cells.,327.83
Febuxostat,[144060-53-7],CC1=C(C(O)=O)SC(C2=CC(C#N)=C(OCC(C)C)C=C2)=N1,Enzymes,Oxygenases/Oxidases,Other Oxygenases/Oxidases,Xanthine oxidase inhibitor,Non-purine inhibitor of xanthine oxidase (Ki = 1.2 nM). Binds to a channel leading to the enzyme active site; obstructs substrate binding.,316.37
Felbamate,[25451-15-4],NC(=O)OCC(COC(N)=O)C1=CC=CC=C1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,NMDA antagonist; acts glycine site,"Anticonvulsant, acting as an antagonist at the NMDA-associated glycine binding site.",238.24
Felodipine,[72509-76-3],ClC1=C(Cl)C(C2C(C(OC)=O)=C(C)NC(C)=C2C(OCC)=O)=CC=C1,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV1.x blocker,"L-type Ca2+ channel blocker that is selective over N-, R-, P/Q- and T-type channels. Displays high vascular selectivity; lowers arterial blood pressure without altering cardiac contractility. Antihypertensive.",384.25
Fenobam,[57653-26-6],CN1CC(=O)N=C1NC(=O)NC1=CC(Cl)=CC=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Potent and selective mGlu5 negative allosteric modulator (NAM),Potent and selective non-competitive mGlu5 negative allosteric modulator (NAM) that also displays inverse agonist properties; blocks mGlu5 constitutive activity in vitro (IC50 = 87 nM). Acts at an allosteric modulatory site shared with MPEP and binds the mGlu5 receptor with Kd values of 54 and 31 nM for rat and human receptors respectively. Displays anxiolytic activity following oral administration in vivo; also exhibits analgesic properties.,266.69
Fenofibrate,[49562-28-9],CC(C)OC(C(C)(C)OC(C=C2)=CC=C2C(C1=CC=C(Cl)C=C1)=O)=O,Nuclear Receptors,PPARs,PPARalpha Receptors,PPARalpha agonist,PPARalpha agonist; hypolipidemic. Attenuates insulin resistance and increases high-density lipoprotein-cholesterol in db/db mice.,360.83
FERb 033,[1111084-78-6],OC1=C(/C=N/O)C=CC(C2=CC=C(O)C(F)=C2)=C1Cl,Nuclear Receptors,Estrogen and Related Receptors,,Potent and selective ERbeta agonist,"Potent and selective ERbeta receptor agonist (Ki = 7.1 nM, EC50 = 4.8 nM). Displays 62-fold selectivity over ERalpha.",281.67
Ferrostatin 1,[347174-05-4],O=C(OCC)C1=CC(N)=C(NC2CCCCC2)C=C1,Regulated Cell Death,Ferroptosis,,Selective inhibitor of erastin induced ferroptosis,"Selective inhibitor of erastin induced ferroptosis (EC50 = 60 nM). Specifically inhibits Ras selective lethal compound -induced death, but not cell death induced by other oxidative lethal compounds and apoptosis-inducing agents. Inhibits ferroptosis in cancer cells; also inhibits glutamate-induced cell death in organotypic rat brain slices. Prevents erastin induced accumulation of cytosolic and lipid reactive oxygen species.",262.35
Fexaramine,[574013-66-4],O=C(C3CCCCC3)N(CC2=CC=C(C4=CC=C(N(C)C)C=C4)C=C2)C1=CC(/C=C/C(OC)=O)=CC=C1,Nuclear Receptors,LXR-like Receptors,,"Potent, selective farnesoid X receptor (FXR) agonist","Potent, selective farnesoid X receptor agonist (EC50 = 25 nM). Displays no activity at hRXRalpha, hPPARalpha, hPPARgamma, hPPARdelta, mPXR, hPXR, hLXRalpha, hTRbeta, hRARbeta, mCAR, mERRgamma and hVDR receptors.",496.64
Fexofenadine hydrochloride,[153439-40-8],Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,H1 receptor antagonist; non-sedating antiallergic agent,Selective histamine H1 receptor antagonist (pKi = 8.1). Active metabolite of terfenadine that displays non-sedating antiallergic effects.,538.12
FG 7142,[78538-74-6],CNC(=O)C1=CC2=C(NC3=C2C=CC=C3)C=N1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Benzodiazepine inverse agonist,Inverse agonist and anxiogenic agent. Increases tyrosine hydroxylation and causes upregulation of beta-adrenoceptors in mouse cerebral cortex.,225.25
FGIN-1-27,[142720-24-9],O=C(N(CCCCCC)CCCCCC)CC2=C(C3=CC=C(F)C=C3)NC1=CC=CC=C12,Other Pharmacology,Translocator Protein,,"Potent, specific ligand for mitochondrial DBI receptor","Binds specifically and with high affinity to the peptide DBI receptor (benzodiazepine receptor) on mitochondrial membranes, inducing production of neurosteroids, which modulate GABA receptors (EC50 = 3 nM for increase in production of pregnenolone in glial cells). Thus it reduces anxiety without causing sedation.",436.61
FGIN-1-43,[145040-29-5],O=C(N(CCCCCC)CCCCCC)CC2=C(C3=CC=C(Cl)C=C3)NC1=CC=C(Cl)C=C12,Other Pharmacology,Translocator Protein,,"Potent, specific ligand for mitochondrial DBI receptor",Most active of the 2-aryl-3-indoleacetamides; a new class of potent and specific ligands as probes for the mitochondial DBI receptor (peripheral benzodiazepine receptor).,487.51
FH 1,[2719-05-3],CC(NC1=CC=C(CC2=CC=C(NC(C)=O)C=C2)C=C1)=O,Stem Cells,Stem Cell Differentiation,ESCs and iPSC,Enhances iPSC-derived hepatocyte differentiation and maturation,Enhances differentiation of induced pluripotent stem cells (iPSCs) to hepatocytes; also promotes the maturation of iPSC-derived hepatocytes.,282.34
FH 535,[108409-83-2],ClC1=CC(S(NC2=C(C)C=C([N+]([O-])=O)C=C2)(=O)=O)=C(Cl)C=C1,Signal Transduction,Wnt Signaling,Beta-catenin,Inhibitor of Wnt/beta-catenin signaling,"Inhibitor of Wnt/beta-catenin signaling and dual antagonist of PPARgamma/delta activity. Suppresses beta-catenin/Tcf-mediated transcription; inhibits beta-catenin and GRIP1 recruitment to PPARgamma and delta. Exhibits antiproliferative effects in transformed colon, lung and liver cancer cell lines.",361.2
FIPI,[1781834-93-2],O=C(N2)N(C3CCN(CCNC(C4=CC5=C(C=CC(F)=C5)N4)=O)CC3)C1=C2C=CC=C1.Cl,Enzymes,Esterases,Phospholipases,Phospholipase D inhibitor,Potent phosholipase D (PLD) inhibitor (IC50 values are 20 and 25 nM for PLD2 and PLD1 respectively). Ameliorates PLD2-driven suppression of membrane ruffling and cell spreading. Orally available.,457.93
Flavopiridol hydrochloride,[131740-09-5],CN(CC3)C[C@@H](O)[C@H]3[C@]1=C(OC(C4=CC=CC=C4Cl)=CC2=O)C2=C(O)C=C1O.Cl,Enzymes,Kinases,Cyclin-dependent Kinase,Cdk inhibitor; potently inhibits cdk2 and cdk9,"Cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 6 - 25 nM and 84 - 200 nM for cdk9 and cdk2, respectively, and <0.85 muM for cdk1, cdk4, cdk5 and cdk7). Induces cell cycle arrest at G1 and G2 phase. Potently inhibits the growth of breast and lung cancer cell lines (IC50 = 25 - 160 nM) in vitro.",438.3
Flecainide acetate,[54143-56-5],CC(O)=O.FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(=C1)C(=O)NCC1CCCCN1,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Cardiac Na+ channel blocker. Antiarrhythmic,Open Na+ channel blocker that inhibits fast Na+ current in cardiac muscle in a use- and concentration-dependent manner. Orally-active class Ic antiarrhythmic agent.,474.4
FLI 06,[313967-18-9],O=C(OC3CCCCC3)C1=C(C)NC(CC(C)(C)CC4=O)=C4C1C2=CC=C([N+]([O-])=O)C=C2,Signal Transduction,"Translocation, Exocytosis & Endocytosis",,Inhibitor of Notch signaling,Inhibitor of Notch signaling (EC50 = 2.3 muM). Disrupts Notch trafficking and processing. Reduces amyloid beta secretion. Changes the maturation and abolishes shredding of APP. Inhibits ER exporting and converts tubular ER to sheets.,438.52
Fludarabine,[21679-14-1],O[C@@H]1[C@@H](CO)O[C@@H](N3C2=NC(F)=NC(N)=C2N=C3)[C@H]1O,Cell Metabolism,"DNA, RNA and Protein Synthesis",,Purine analog; inhibits DNA synthesis,"Purine analog that inhibits DNA synthesis. Exhibits antiproliferative activity (IC50 = 1.54 muM in RPMI cells) and triggers apoptosis through increasing Bax and decreasing Bid, XIAP and survivin expression. Inhibits cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in lymphocytes. Also displays anticancer activity against hematological malignancies in vivo.",285.23
Flumazenil,[78755-81-4],CCOC(=O)C1=C2CN(C)C(=O)C3=CC(F)=CC=C3N2C=N1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Benzodiazepine antagonist,"Benzodiazepine antagonist, non-selective for alpha1, alpha2, alpha3 or alpha5-containing GABAA receptors. Centrally active upon systemic administration in vivo. Also inhibits repressor element-1 silencing transcription factor (REST) by targeting degradation.",303.29
Flunarizine dihydrochloride,[30484-77-6],Cl[H].Cl[H].FC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Dual Na+/Ca2+ channel (T-type) blocker,Dual Na+/Ca2+ channel blocker; a cerebral and peripheral vasodilator. Neuroprotective.,477.42
Fluoxetine hydrochloride,[56296-78-7],Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Transporters,Neurotransmitter Transporters,5-HT Transporters,5-HT reuptake inhibitor,"Selective serotonin reuptake inhibitor. Binds to the human 5-HT transporter with a Ki of 0.9 nmol/l and is between 150- and 900- fold selective over 5-HT1A, 5-HT2A, H1, alpha1, alpha2-adrenergic, and muscarinic receptors. Antidepressant. Induces differentiation of neuronal precursors, enhancing neuronal characteristics. Deuterated analog also available.",345.78
Flupirtine maleate,[75507-68-5],OC(=O)\C=C/C(O)=O.NC1=C(NC(OCC)=O)C=CC(NCC2=CC=C(F)C=C2)=N1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV7 channel activator; also GABAA modulator and indirect NMDA antagonist,"Non-opioid analgesic with muscle relaxant properties. Activates KV7 potassium channels, indirectly antagonizes NMDA receptors and modulates GABAA receptors. Exhibits neuroprotective actions in a model of cerebral ischemia in mice and reduces apoptosis and necrosis induced by noxious stimuli. Deuterated analog also available.",420.4
Flurizan,[51543-40-9],FC1=C(C2=CC=CC=C2)C=CC([C@@H](C)C(O)=O)=C1,Enzymes,Proteases,Gamma-Secretase,gamma-secretase inhibitor; lowers Abeta42 levels in vitro,Nonsteroidal anti-inflammatory drug (NSAID) that inhibits gamma-secretase activity. Selectively lowers Abeta42 levels in human neuroglioma cells; displays no effect on Abeta40 levels at a concentration of 100 muM.,244.26
Flurofamide,[70788-28-2],NP(N)(=O)NC(=O)C1=CC=C(F)C=C1,Enzymes,Hydrolases,Other Hydrolases,Urease inhibitor,Urease inhibitor.,217.14
Flutamide,[13311-84-7],CC(C)C(NC1=CC(C(F)(F)F)=C([N+]([O-])=O)C=C1)=O,Nuclear Receptors,Androgen Receptor,,Non-steroidal androgen receptor antagonist,Non-steroidal antiandrogen; competitive antagonist of the androgen receptor. Blocks the biological activity of testosterone (Cat. No. 2822) in vivo.,276.21
Fluticasone propionate,[80474-14-2],O=C1C=C[C@@]2(C)C([C@@H](F)C[C@]3([H])[C@@](F)2[C@@H](O)C[C@@]4(C)[C@]([H])3C[C@@H](C)[C@](C(SCF)=O)4OC(CC)=O)=C1,Nuclear Receptors,Glucocorticoid Receptor,,Selective high affinity glucocorticoid receptor agonist,"High affinity, selective glucocorticoid receptor agonist (Kd = 0.5 nM). Potently stimulates glucocorticoid receptor-mediated transactivation of gene expression and enhances human eosinophil apoptosis (EC50 = 3.7 nM) in vitro. Inhibits mast cell accumulation in nasal mucosa following topical administration. Lipophilic anti-inflammatory agent with low oral bioavailability. Also potentiates KV1 channels (EC50 = 37 nM).",500.57
Fluvastatin sodium,[93957-55-2],[Na+].[Na+].CC(C)N1C(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)=C(C2=CC=C(F)C=C2)C2=C1C=CC=C2.CC(C)N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C2=CC=C(F)C=C2)C2=C1C=CC=C2,Enzymes,Reductases,HMG-CoA Reductase,Potent HMG-CoA reductase inhibitor,"Orally active, potent and competitive HMG-CoA reductase inhibitor (IC50 = 40 -100 nM at human liver microsomes). Inhibits vascular smooth muscle proliferation in vitro (IC50 = 70 nM) and exhibits antihypercholesterolemic and antioxidant activity in vivo.",433.45
Formoterol hemifumarate,[43229-80-7],[H]OC(=O)\C=C\C(=O)O[H].COC1=CC=C(C=C1)C[C@H](C)NC[C@@H](O)C1=CC(NC([H])=O)=C(O)C=C1.COC1=CC=C(C=C1)C[C@H](C)NC[C@@H](O)C1=CC(NC([H])=O)=C(O)C=C1,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-2 Receptors,Potent and selective beta2 agonist,"Potent, selective and long-acting beta2-adrenoceptor agonist. Displays 330-fold selectivity for beta2 over beta1 receptors (pKd values are 8.12 and 5.58 respectively). Potently relaxes guinea pig trachea (pD2 = 9.29), and is longer-acting and 100-fold more potent than salbutamol.",402.45
Forskolin,[66575-29-9],C=C[C@](C3)(C)O[C@]2(C)[C@@H](OC(C)=O)[C@@H](O)[C@@]1([H])C(C)(C)CC[C@H](O)[C@@](C)1[C@](O)2C3=O,Enzymes,Cyclases,Adenylyl Cyclase,Adenylyl cyclase activator,"Cell-permeable activator of adenylyl cyclase. Hypotensive and vasodilatory agent. Induces neuronal differentiation in stem cells and in several neuroblastoma. Used to reprogram mouse embryonic fibroblasts to induced pluripotent stem cells in combination with three other small molecules (Cat. Nos. 3742, 4423 and 4703). Available as part of the PKA Tocriset™. Negative Control also available.",410.51
FR 139317,[142375-60-8],O=C([C@H](CC(C)C)NC(N1CCCCCC1)=O)N[C@@H]([C@@](N[C@H](CC2=NC=CC=C2)C(O)=O)=O)CC(C3=CC=CC=C34)=CN4C,7-TM Receptors,Peptide Receptors,Endothelin Receptors,"Highly potent, selective ETA antagonist",A highly potent and selective ETA endothelin receptor antagonist (Ki values are 1 nM and 7.3 muM at ETA and ETB subtypes respectively). Active in vivo.,604.75
FR 180204,[865362-74-9],NC1=NNC2=C1C=C(C3=C(C=CC=C5)N5N=C3C4=CC=CC=C4)N=N2,Enzymes,Kinases,MAPK Family,Selective ERK inhibitor,"Selective ERK inhibitor (IC50 values are 0.14 and 0.31 muM for ERK2 and ERK1 respectively). Displays 30-fold selectivity for ERK over p38alpha (IC50 = 10 muM); displays no activity against human recombinant MEK1, MKK4, IKKalpha, PKCalpha, Src, Syc and PDGFalpha at concentrations less than 30 muM. Also inhibits TGFbeta-induced AP-1 activation in Mv1Lu cells (IC50 = 3.1 muM).",327.34
FRAX 486,[1232030-35-1],FC1=CC(NC3=NC(N(CC)C(C(C5=CC=C(Cl)C=C5Cl)=C4)=O)=C4C=N3)=CC=C1N2CCNCC2,Enzymes,Kinases,P21-activated Kinases,Potent PAK inhibitor; brain penetrant and orally bioavailable,"Potent p21-activated kinase (PAK) inhibitor (IC50 values are 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively). Blocks and reverses the DISC1 knockdown-induced reduction in dendritic spine size in cortical neurons. Attenuates dendritic spine elimination and enhances spine generation in DISC1 knockdown mice. Ameliorates autism-like behavioral symptoms in fragile X mental retardation 1 (Fmr1) knockout mice. Brain penetrant and orally bioavailable.",513.39
FTY 720,[162359-56-0],CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Potent S1P receptor agonist; also immunosuppressant,"S1P receptor agonist; undergoes phosphorylation by sphingosine kinase 2, which then binds S1P1,3,4 and 5 receptors (EC50 values are 0.3 - 0.6 nM for S1P1, 4 and 5 and ~3 nM for S1P3). Immunosuppresant; sequesters lymphocytes in lymph nodes, reducing autoimmune response. Suppresses the development of EAE (an in vivo model of MS). Orally bioavailable and blood-brain barrier permeable.",343.93
Furamidine dihydrochloride,[55368-40-6],NC(C(C=C3)=CC=C3C1=CC=C(C2=CC=C(C(N)=N)C=C2)O1)=N.Cl.Cl,Enzymes,Transferases,Protein Arginine Methyltransferases,Selective PRMT1 inhibitor,"Selective protein arginine methyltransferase 1 (PRMT1) inhibitor (IC50 = 9.4 muM). Exhibits selectivity over PRMT5, PRMT6 and CARM1 (IC50 values are 166, 283 and >400 muM respectively). Inhibits cell proliferation in leukemia cell lines. Cell-permeable.",377.27
Furosemide,[54-31-9],ClC1=CC(NCC2=CC=CO2)=C(C(O)=O)C=C1S(=O)(N)=O,Transporters,Ion Pumps/Transporters,Na+/K+/Cl- Symporter,Na+/2Cl-/K+ (NKCC) symporter inhibitor; also GABAA antagonist,Loop diuretic that inhibits the Na+/2Cl-/K+ (NKCC) symporter. Also acts as a non-competitive antagonist at GABAA receptors with ~ 100-fold greater selectivity for alpha6-containing receptors than alpha1-containing receptors.,330.74
GANT 58,[64048-12-0],C1(C5=CC=NC=C5)=C(C3=CC=NC=C3)C(C2=CC=NC=C2)=C(C4=CC=NC=C4)S1,Signal Transduction,Hedgehog Signaling,,GLI1 antagonist; inhibits Hedgehog (Hh) signaling,GLI antagonist that inhibits GLI1-induced transcription (IC50 = 5 muM). Inhibits the hedgehog (Hh) signaling pathway downstream of SMO and SUFU causing GLI1 nuclear accumulation. Displays antiproliferative and antitumor activity in vivo.,392.48
GANT 61,[500579-04-4],CN(C1=CC=CC=C1CN2CCCN(CC4=C(N(C)C)C=CC=C4)C2C3=CC=NC=C3)C,Signal Transduction,Hedgehog Signaling,,GLI antagonist; inhibits Hedgehog (Hh) signaling,"GLI antagonist that inhibits GLI1 and GLI2-induced transcription (IC50 ~ 5 muM). Inhibits the hedgehog (Hh) signaling pathway downstream of SMO and SUFU causing GLI1 nuclear accumulation. Displays antiproliferative and antitumor activity in vivo. Inhibits the pluripotency factors Oct4, Sox-2, Nanog and c-Myc in pancreatic cancer stem cells.",429.61
Gavestinel,[153436-38-5],[Na+].[O-]C(=O)C1=C(\C=C\C(=O)NC2=CC=CC=C2)C2=C(N1)C=C(Cl)C=C2Cl,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Potent and selective NMDA antagonist; acts at the glycine site,"Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites. Orally bioavailable and active in vivo.",397.19
GBR 12909 dihydrochloride,[67469-78-7],Cl.Cl.FC1=CC=C(C=C1)C(OCCN1CCN(CCCC2=CC=CC=C2)CC1)C1=CC=C(F)C=C1,Transporters,Neurotransmitter Transporters,Dopamine Transporters,Selective DA uptake inhibitor; also sigma ligand,"Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.",523.49
GC 1,[211110-63-3],CC1=CC(OCC(O)=O)=CC(C)=C1CC2=CC(C(C)C)=C(O)C=C2,Nuclear Receptors,Other Nuclear Receptors,,High affinity thyroid receptor alpha (TRalpha) and TRbeta agonist; thyromimetic,Thyromimetic; high affinity agonist at thyroid hormone receptor (TR) beta and TRalpha receptors (KD values are 67 and 440 pM respectively). Displays 5- and 100-fold greater potency than the endogenous agonist T3 in vitro at TRalpha1 and TRbeta1 receptors respectively. Promotes reverse cholesterol transport in chow- and fat-fed mice. Induces proliferation of hepatocytes and pancreatic acinar cells in rats independent of prior tissue injury.,328.4
GDC 0879,[905281-76-7],OCCN1N=C(C3=CC=NC=C3)C(C2=CC=C(/C(CC4)=N/O)C4=C2)=C1,Enzymes,Kinases,Raf Kinase,Potent B-Raf inhibitor,Potent and selective B-Raf inhibitor (IC50 = 0.13 nM against purified B-Raf V600E). Activity reduces phospho-ERK (pERK) levels (IC50 = 63 nM in the Malme-3M cell line). Inhibits the Raf/MEK/ERK signaling pathway in V600E B-Raf mutant cell lines. Does not activate apoptotic pathways in A375 or Colo205 cell lines. Orally bioavailable.,334.37
Gemcitabine hydrochloride,[122111-03-9],OC[C@@H]1[C@@H](O)C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O1.Cl,Cell Metabolism,"DNA, RNA and Protein Synthesis",,DNA synthesis inhibitor,Deoxycytidine analog that inhibits DNA synthesis. Metabolized to form gemcitabine triphosphate (dFdCTP) and gemcitabine diphosphate (dFdCDP). dFdCTD inhibits ribonucleotide reductase causing a reduction in cellular nucleotides. dFdCTP is incorporated in DNA resulting in DNA strand termination. Displays antitumor activity in vitro and in vivo.,299.66
Genistein,[446-72-0],OC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,EGFR kinase inhibitor. Also estrogen and PPARgamma ligand,Phytoestrogen with a wide range of biological actions. Inhibits protein tyrosine kinases including epidermal growth factor receptor kinase. Binds to PPARgamma and estrogen receptors and acts as an agonist at GPER. Inhibits aggregation and fibrilization of Abeta42 and amylin37 (hiAPP). Available as part of the MAPK Cascade Inhibitor Tocriset™.,270.24
GF 109203X,[133052-90-1],CN(C)CCCN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CNC2=CC=CC=C12,Enzymes,Kinases,Protein Kinase C,Protein kinase C inhibitor,"Very potent and selective inhibitor of protein kinase C, selective for the alpha and beta1 isoforms (IC50 values are 0.0084, 0.0180, 0.210, 0.132, and 5.8 muM for alpha, beta1, delta, epsilon and zeta isoforms respectively). Selective over MLCK, PKG and PKA (IC50 values are 0.6, 4.6, and 33 muM respectively). Potent antagonist at the 5-HT3 receptor (Ki = 29.5 nM). Anti-inflammatory in vivo.",412.49
Ginkgolide B,[15291-77-7],O=C1[C@@H](C)[C@@]2(O)[C@@]([C@H](O)C34[C@]52O[C@@]6([H])[C@]([C@@H](O)C(O6)=O)3[C@H]([C@](C)(C)C)C[C@H]4O[C@]5=O)([H])O1,7-TM Receptors,Platelet-activating Factor (PAF) Receptors,,PAF receptor antagonist,Platelet-activating factor (PAF) receptor antagonist (Ki = 1.3 muM). Inhibits neutrophil degranulation and superoxide production in vitro and inhibits bronchoconstriction and is neuroprotective following oral administration in vivo.,424.4
GKA 50,[851884-87-2],O=C(NC3=NC=C(C(O)=O)C=C3)C1=CC(O[C@@H](C)COC)=CC(O[C@@H](C)CC2=CC=CC=C2)=C1,Enzymes,Kinases,Hexokinases,Glucokinase activator,Potent glucokinase activator (EC50 = 33 nM). Significantly reduces plasma glucose levels in diabetic rats; stimulates insulin release from mouse islets of Langerhans.,464.51
Glibenclamide,[10238-21-8],COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1,Ion Channels,Potassium Channels,Inward rectifier Potassium Channels,Kir6 (KATP) channel blocker,"ATP-dependent K+ channel (Kir6, KATP) and CFTR Cl- channel blocker. Inhibits Kir6 currents in the pancreas, causing an increase in intracellular Ca2+ and insulin secretion. Inhibits recombinant CFTR Cl- channels with an IC50 of 20 muM.",494
GNF 2,[778270-11-4],NC(C1=CC(C2=NC=NC(NC3=CC=C(OC(F)(F)F)C=C3)=C2)=CC=C1)=O,Enzymes,Kinases,Abl Kinase,Selective allosteric inhibitor of Bcr-Abl tyrosine kinase activity,"Allosteric inhibitor of Bcr-Abl tyrosine kinase activity (IC50 = 267 nM); inhibits proliferation and induces apoptosis in Bcr-Abl-expressing cells. Selective for Bcr-Abl over a panel of serine, threonine and tyrosine kinases. Non-ATP-competitive.",374.32
GNF 5,[778277-15-9],O=C(NCCO)C1=CC(C2=NC=NC(NC3=CC=C(OC(F)(F)F)C=C3)=C2)=CC=C1,Enzymes,Kinases,Abl Kinase,Selective allosteric inhibitor of Bcr-Abl; analog of GNF 2 (Cat. No. 4399),"Selective, non-ATP competitive allosteric inhibitor of Bcr-Abl (IC50 = 220 nM for wild-type Abl). Binds the myristate-binding site of Abl. Acts in combination with nilotinib to inhibit T315I Bcr-Abl in vitro and in vivo. Analog of GNF 2 (Cat. No. 4399).",418.37
GNF 5837,[1033769-28-6],O=C2NC1=CC(NC4=C(C)C=CC(NC(NC5=C(F)C=CC(C(F)(F)F)=C5)=O)=C4)=CC=C1/C2=C/C3=CC=CN3,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Trk Receptors,"Potent Trk inhibitor; inhibits TrkA, TrkB and TrkC","Potent pan-Trk inhibitor. Displays antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively). Exhibits selectivity for Trk receptors over a range of kinases, with some activity at PDGFR and c-Kit (IC50 values are 0.87 and 0.91 muM respectively). Orally bioavailable.",535.49
GNF 7,[839706-07-9],CC1=NC=C(NC2=NC=C(CN(C3=C(C)C=CC(NC(C4=CC(C(F)(F)F)=CC=C4)=O)=C3)C(N5C)=O)C5=N2)C=C1,Enzymes,GTPases,Small Monomeric GTPases,Ras signaling inhibitor; inhibits Ack1 and GCK,"Ras signaling inhibitor; inhibits Ack1 and germinal center kinase (GCK). Suppresses proliferation, and induces cell cycle arrest and apoptosis in leukemia cells harboring NRAS mutations. Prolongs survival in a leukemia cell xenotransplantation model in mice.",547.53
Golgicide A,[1139889-93-2],FC4=CC([C@]3([H])[C@]([H])2CC=C3)=C(C(F)=C4)NC2C1=CN=CC=C1,Enzymes,GTPases,Small Monomeric GTPases,"Potent, selective and reversible inhibitor of GBF1 ArfGEF","Potent, specific and reversible inhibitor of Golgi BFA resistance factor 1 (GBF1), an ArfGEF, that decreases Arf1 activation in vivo. Arrests secretion of soluble and membrane-associated proteins at the endoplasmic reticulum-Golgi intermediate compartment. Causes disassembly and dispersal of the Golgi and trans-Golgi network.",284.3
GPBAR-A,[877052-79-4],O=C(CO3)N(CC4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)CC1=C3N=CC=C1C2=C(F)C=CC=C2,7-TM Receptors,GPBA Receptors,,GPBA receptor (TGR5) agonist,GPBA receptor agonist. Upregulates GLP-1 secretion from intestinal cultures. Increases MQAE-fluorescence suggesting a decrease in intracellular chloride concentration in gallbladder epithelial cells.,484.37
GPi 688,[918902-32-6],OC[C@H](O)CN(C1=CC=CC=C1CC2NC(C3=CC4=C(SC(Cl)=C4)N3)=O)C2=O,Enzymes,Transferases,Phosphorylases,Allosteric glycogen phosphorylase inhibitor,Allosteric glycogen phosphorylase inhibitor; acts at the indole site of glycogen phosphorylase. Inhibits glucagon-mediated hyperglycemia in vivo in the rat.,419.88
GPP 78 hydrochloride,,O=C(NC3=C(C4=CC=CC=C4)C=CC=C3)CCCCCCCN1N=NC(C2=CC=CN=C2)=C1.Cl,Enzymes,Transferases,NAMPT,NAMPT inhibitor; also induces autophagy,Inhibitor of nicotinamide phosphoribosyltransferase (NAMPT); potently depletes NAD levels and exhibits cytotoxicity in vitro (IC50 values are 3.0 and 3.8 nM respectively). Also shown to induce autophagy in neuroblastoma cells.,476.01
GR 46611,[185259-85-2],O=C(/C=C/C2=CC=C(NC=C3CCN(C)C)C3=C2)NCC1=CC=C(OC)C=C1,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,5-HT1D agonist,5-HT1D receptor agonist. Blockade of GR 46611-induced hypothermia in the guinea pig provides a useful model with which to study the potency and duration of action of centrally acting 5-HT1D receptor ligands.,377.49
GR 89696 fumarate,[126766-32-3],[H]OC(=O)\C=C\C(=O)O[H].COC(=O)N1CCN(C(CN2CCCC2)C1)C(=O)CC1=CC=C(Cl)C(Cl)=C1,7-TM Receptors,Opioid Receptors,Kappa Opioid Receptors,Subtype-selective kappa agonist,Highly potent and selective kappa-opioid agonist (IC50 = 0.04 nM) that may be selective for the putative kappa2 receptor. Anti-nociceptive and neuroprotective in vivo.,530.4
GS 143,[916232-21-8],FC1=CC=CC=C1C2=CC=C(/C=C3C(CC4=CC=CC=C4)=NN(C5=CC=C(C(O)=O)C=C5)C\3=O)O2,Enzymes,Ligases,Ubiquitin E3 Ligases,beta-TrCP1 ligase inhibitor,"beta-TrCP1 ligase inhibitor. Inhibits IkappaBalpha ubiquitination (IC50 = 5.2 muM) without affecting proteasome activity. Blocks LPS-induced expression of inflammatory cytokines in human myelomonocytic cells. Suppresses antigen-induced NFkappaB expression, inflammation and mucus production in airways of OVA-sensitized mice.",466.46
GSK 0660,[1014691-61-2],O=S(NC1=C(OC)C=C(NC3=CC=CC=C3)C=C1)(C2=C(C(OC)=O)SC=C2)=O,Nuclear Receptors,PPARs,PPARdelta Receptors,Selective PPARdelta antagonist,"Selective PPARdelta antagonist (IC50 values are 0.155, > 10 and greater than or equal to 10 muM at PPARdelta, PPARalpha and PPARgamma respectively). Exhibits inverse agonist effects when administered by itself.",418.49
GSK 137647,[349085-82-1],CC1=CC(C)=CC(C)=C1NS(C2=CC=C(OC)C=C2)(=O)=O,7-TM Receptors,Free Fatty Acid Receptors,,Potent and selective FFA4 (GPR120) agonist,"Potent and selective FFA4 (GPR120) agonist (pEC50 values are 6.3, 6.2 and 6.1 at the human, mouse and rat receptor, respectively). Exhibits greater than or equal to100-fold selectivity against a panel of 61 targets including FFA1, FFA2 and FFA3. Enhances glucose-stimulated insulin secretion in MIN6 cells. Induces intracellular calcium accumulation in U2OS cells; this activity is inhibited by AH 7614 (Cat. No. 5256).",305.39
GSK 1562590 hydrochloride,[1003878-07-6],NC(C1=CC=CC(C2=CC=[C@@]([C@@H](N(C(CN4C(C=C(Cl)C(Cl)=C5)=C5OCC4=O)=O)C)CN3CCCC3)C=C2)=C1)=O.Cl,7-TM Receptors,Peptide Receptors,Urotensin-II Receptors,"High affinity, selective urotensin II (UT) receptor antagonist","High affinity and selective urotensin II (UT) receptor antagonist (pKi values are 9.14, 9.28, 9.34, 9.64 and 9.66 at monkey, human, mouse, cat and rat recombinant receptors respectively). Exhibits selectivity for UT receptors over a range of GPCRs, ion channels, enzymes and neurotransmitter transporters. Supresses human urotensin-II (hU-II)-induced contraction of isolated rat aorta in vitro and ex vivo. Inhibits the hU-II-induced increase in mean blood pressure in vivo. Orally active.",617.95
GSK 1838705,[1116235-97-2],O=C(CN(C)C)N4CCC(C4=C5)=CC(OC)=C5NC1=NC(NC3=C(C(NC)=O)C(F)=CC=C3)=C2C(NC=C2)=N1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Insulin and insulin-like Receptors,Potent IR and IGF1R inhibitor; also inhibits anaplastic lymphoma kinase (ALK),"Potent insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) inhibitor (IC50 values are 1.6 and 2 nM, respectively). Also inhibits anaplastic lymphoma kinase (ALK) (IC50 = 0.5 nM). Displays > 800-fold selectivity for IR, IGFR1 and ALK over a panel of 44 kinases including JNK. Blocks proliferation of cancer cell lines in vitro, and causes complete regression of ALK-dependent tumors in vivo. Orally bioavailable.",532.57
GSK 2193874,[1336960-13-4],O=C(NC6(CC6)C5=CC=CC=C5)C2=C(CN4CCC(N7CCCCC7)CC4)C(C3=CC(C(F)(F)F)=CC=C3)=NC1=CC(Br)=CC=C12,Ion Channels,Transient Receptor Potential Channels,TRPV,Potent and selective TRPV4 antagonist; orally active,"Potent and selective TRPV4 antagonist (IC50 values are 2 and 40 nM for rat and human receptors, respectively); inhibits Ca2+ influx through TRPV4 channels. Prevents and reverses pulmonary edema after myocardial infarction in vivo models. Selective over a panel of ~200 human receptors, channels and enzymes. Orally active.",691.62
GSK 2194069,[1332331-08-4],O=C1NN=C(C[C@@H]2CCN(C(C3CC3)=O)C2)N1C4=CC=C(C5=CC=C(OC=C6)C6=C5)C=C4,Enzymes,Transferases,Fatty Acid Synthase,Potent human fatty acid synthase (hFASN) inhibitor,Potent human fatty acid synthase (hFASN) inhibitor (IC50 = 7.7 nM); inhibits hFAS beta-ketoacyl reductase activity. Inhibits lipid synthesis and attenuates proliferation of A549 non-small-cell lung cancer cells (EC50 = 15 nM) in vitro.,428.48
GSK 2334470,[1227911-45-6],C[C@H]1N(C3=NC(NC)=NC(C4=CC(NN=C5N)=C5C=C4)=C3)C[C@@H]([C@](NC2CCCCC2)=O)CC1,Enzymes,Kinases,Phosphoinositide-dependent Kinase 1,"Highly potent, selective PDPK1 (PDK1) inhibitor","Potent 3-phosphoinositide-dependent protein kinase (PDPK1) inhibitor (IC50 ~ 10 nM). Exhibits no effect on other kinases including Aurora, ROCK, p38 MAPK and PI 3-K. Suppresses T-loop phosphorylation and subsequent activation of PDK1 substrates S6K1, SGK and RSK in vitro; exhibits limited inhibitory effect on Akt activation. Delays melanomagenesis and metastasis in BrafV600E::Pten(-/-) mice.",462.59
GSK 2606414,[1337531-36-8],NC1=NC=NC2=C1C(C3=CC(CCN4C(CC5=CC=CC(C(F)(F)F)=C5)=O)=C4C=C3)=CN2C,Enzymes,Kinases,PERK,Potent and selective PERK inhibitor; orally bioavailable,Potent and selective protein kinase R-like ER kinase (PERK) inhibitor (IC50 = 0.4 nM). Exhibits >1000-fold selectivity for PERK over HR1 and PKR. Inhibits thapsigargin-induced PERK phosphorylation in lung carcinoma A549 cells. Attenuates subcutaneous pancreatic human tumor xenograft growth in mice. Orally bioavailable.,451.44
GSK 269962,[850664-21-0],CCN(C(C4=NON=C4N)=N3)C1=C3C=NC(OC2=CC(NC(C5=CC=C(OCCN6CCOCC6)C=C5)=O)=CC=C2)=C1,Enzymes,Kinases,Rho-kinases,Potent and selective ROCK inhibitor,Potent Rho kinase (ROCK) inhibitor (IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively). Displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM); lowers blood pressure in a rat model of hypertension.,570.6
GSK 2830371,[1404456-53-6],ClC1=CC(NCC2=CC=C(C(N[C@H]([C@@](NC4CC4)=O)CC3CCCC3)=O)S2)=C(C)N=C1,Enzymes,Phosphatases,Protein Ser/Thr Phosphatases,Potent and selective allosteric inhibitor of Wip1 phosphatase,"Potent and selective allosteric inhibitor of Wip1 phosphatase (IC50 = 6 nM). Exhibits selectivity for Wip1 over 21 other phosphatases. Increases phosphorylation of Wip1 substrates, including p53, Chk2, H2AX and ATM. Attenuates tumor cell growth in a variety of lymphoid cell lines. Also inhibits lymphoma xenograft growth in vivo. Potentiates growth inhibitory effects of MDM2 inhibition in cancer cell lines in a p53-dependent manner. Orally bioavailable.",461.02
GSK 2837808A,[1445879-21-9],O=S(C2=C(NC3=CC(OC5=CC(F)=CC(F)=C5)=CC(C(O)=O)=C3)C1=CC=C(C6=CN=C(OC)N=C6OC)C=C1N=C2)(NC4CC4)=O,Enzymes,Dehydrogenases,Lactate Dehydrogenase A,"Potent, selective LDHA inhibitor","Potent, selective lactate dehydrogenase A (LDHA) inhibitor (IC50 values are 1.9 and 14 nM for LDHA and LDHB respectively). Inhibits lactate production in selected cancer cell lines. Reduces glucose uptake and enhances mitochondrial oxygen consumption in Snu398 hepatocellular carcinoma cells. Inhibits proliferation and induces apoptosis in Snu398 cells. Inhibits transcription of histone 2B (H2B) gene in HCT116 and NCM460 cells. Cell permeable.",649.62
GSK 3787,[188591-46-0],O=C(C2=CC=C(Cl)C=C2)NCCS(C1=CC=C(C(F)(F)F)C=N1)(=O)=O,Nuclear Receptors,PPARs,PPARdelta Receptors,Potent and selective PPARdelta antagonist,Potent and selective peroxisome proliferator-activated receptor delta (PPARdelta) antagonist (pIC50 = 6.6). Displays no measurable affinity for PPARalpha or PPARgamma in vitro (pIC50< 5).,392.78
GSK 429286,[864082-47-3],O=C1CC(C2=CC=C(C(F)(F)F)C=C2)C(C(NC3=C(F)C=C(NN=C4)C4=C3)=O)=C(C)N1,Enzymes,Kinases,Rho-kinases,Selective Rho-kinase (ROCK) inhibitor,"Selective Rho-kinase inhibitor (IC50 values are 14, 780 and 1940 nM for ROCK1, RSK and p70S6K respectively). Reverses adrenalin-induced contraction of the rat aortic ring (IC50 = 190 nM) and causes a dose-dependent decrease in mean arterial blood pressure in spontaneous hypertensive rats. Orally active.",432.37
GSK 650394,[890842-28-1],O=C(C(C(C5CCCC5)=C4)=CC=C4C2=CNC1=NC=C(C3=CC=CC=C3)C=C12)O,Enzymes,Kinases,Other Kinases,Serum- and glucocorticoid-regulated kinase (SGK) inhibitor,"Serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibitor (IC50 values are 62 and 103 nM for SGK1 and SGK2 respectively). Displays >30-fold selectivity over Akt and other related kinases. Inhibits androgen-stimulated growth of LNCaP cells, a human prostate carcinoma cell line (IC50 ~ 1 muM).",382.45
GSK 690693,[937174-76-0],NC1=NON=C1C(N3CC)=NC2=C3C(CO[C@@H]4CNCCC4)=CN=C2C#CC(C)(C)O,Enzymes,Kinases,Akt (Protein Kinase B),Akt kinase inhibitor. Antitumor,"ATP-competitive pan-Akt kinase inhibitor (IC50 values are 2, 13 and 9 nM of Akt1, 2 and 3 respectively). Also exhibits some inhibition for AMPK, PKA and PAK and PKC isoforms (IC50 < 100 nM). Displays antiproliferative and apoptotic effects in tumor cell lines.",425.48
GSK 9027,[1229096-88-1],FC(C=C3)=CC=C3N2C1=CC=C(C4=C(C(F)(F)F)C=C(NS(CC5=CC=CC=C5)(=O)=O)C=C4)C=C1C=N2,Nuclear Receptors,Glucocorticoid Receptor,,Glucocorticoid receptor agonist,Glucocorticoid receptor agonist (pIC50 = 8). Inhibits production of the proinflammatory mediator IL-6 in vivo.,525.52
GSK J1,[1373422-53-7],O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)O,Enzymes,Demethylases,Histone Demethylases,Potent JMJD3/UTX inhibitor,"Potent inhibitor of the H3K27 histone demethylases JMJD3 (KDM6B) and UTX (KDM6A) (IC50 values are 28 and 53 nM respectively). Also inhibits KDM5B, KDM5C and KDM5A (IC50 values are 170, 550 and 6,800 nM respectively). Exhibits no activity against a panel of other histone demethylases (IC50 >20 muM), and displays no significant inhibitory activity against 100 protein kinases at a concentration of 30 muM. Ethyl ester derivative and Negative Control also available.",389.45
GSK J2,[1394854-52-4],O=C(CCNC1=NC(C2=CC=CN=C2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)O,Enzymes,Demethylases,Histone Demethylases,Inactive isomer of GSK J1 (Cat. No. 4593),"Inactive control of GSK J1 (IC50 > 100 muM for inhibition of JMJD3/UTX). Cell permeable ester derivative, GSK J5 and Active Analog also available.",389.45
GSK J4,[1373423-53-0],O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC,Enzymes,Demethylases,Histone Demethylases,Histone KDM inhibitor; cell permeable,Histone lysine demethylase (KDM) inhibitor; blocks demethylation of histone H3K27. Attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC50 = 9 muM for the inhibition of TNFalpha release). Cell permeable. Ethyl ester derivative of GSK J1. Negative Control also available.,417.5
GSK J5,[1394854-51-3],O=C(CCNC1=NC(C2=CC=CN=C2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC,Enzymes,Demethylases,Histone Demethylases,Inactive isomer of GSK J4 (Cat. No. 4594); cell permeable,"Inactive isomer of GSK J4; also cell permeable ester derivative of the inactive control, GSK J2. Active Analog also available.",417.5
GSK LSD 1 dihydrochloride,,C1(N[C@@H]2C[C@H]2[C@]3=CC=CC=C3)CCNCC1.Cl.Cl,Enzymes,Demethylases,Histone Demethylases,Potent and selective LSD1 inhibitor,"Potent and selective lysine specific demethylase 1 (LSD1) inhibitor (IC50 = 16 nM). Exhibits >1000-fold selectivity for LSD1 over closely related enzymes including LSD2, MAO-1 and MAO-B. Inhibits cancer cell line growth in vitro.",289.24
GSK2578215A,[1285515-21-0],FC1=NC=CC(C2=CC=C(OCC3=CC=CC=C3)C(C(NC4=CC=CN=C4)=O)=C2)=C1,Enzymes,Kinases,RIP kinase family,"Potent, selective LRRK2 inhibitor; brain penetrant",Potent LRRK2 inhibitor (IC50 values are 8.9 and 10.1 nM for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 over a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant.,399.42
GTP 14564,[34823-86-4],N1N=C(C2=C1C1=C(O2)C=CC=C1)C1=CC=CC=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Other RTKs,Class III receptor tyrosine kinase (RTK) inhibitor,"Potent, selective inhibitor of class III receptor tyrosine kinases (IC50 values are 0.3 muM for c-Fms, c-Kit, FLT3 and ITD-FLT3 and 1 muM for PDGFRbeta). Displays no activity against ERK1, ERK2, EGFR, MEK1, HER2, Src, Abl, PKC, PKA and Akt (IC50 > 10 muM). Inhibits FL-dependent proliferation in BaF/ITD-FLT3 cells more potently than BaF/wt-FLT3 cells; anti-leukemic.",234.26
Gue 1654,[397290-30-1],O=C(C(C5=CC=CC=C5)C4=CC=CC=C4)NC(S3)=NC1=C3C(SC(SC)=N2)=C2C=C1,Enzymes,GTPases,Heterotrimeric G-protein GTPases,Selective inhibitor of OXE-R Gbetagamma signaling,Oxoeicosanoid receptor 1 (OXE-R) modulator. Selectively inhibits Gbetagamma but not Galphai signaling upon activation of the Galphai-betagamma heterotrimer by OXE-R. Inhibits Gbetagamma-mediated opening of GIRK1/2 channels in HEK293 cells.,447.6
GW 0742,[317318-84-6],CC1=C(CSC2=CC(C)=C(OCC(O)=O)C=C2)SC(=N1)C1=CC(F)=C(C=C1)C(F)(F)F,Nuclear Receptors,PPARs,PPARdelta Receptors,"Highly selective, potent PPARdelta agonist","Potent and highly selective PPARdelta agonist. EC50 values are 0.001, 1.1 and 2 muM for transactivation of human PPARdelta, -alpha, and -gamma receptors respectively. Neuroprotective in rat cerebellar granule neuronal cultures after brief (12-hour) exposure but exhibits inherent toxicity after prolonged (48-hour) incubation. Increases rate of fatty acid oxidation and protects against ischemia/reperfusion injury in neonatal and adult cardiomyocytes.",471.49
GW 3965 hydrochloride,[405911-17-3],Cl.OC(=O)CC1=CC=CC(OCCCN(CC(C2=CC=CC=C2)C2=CC=CC=C2)CC2=C(Cl)C(=CC=C2)C(F)(F)F)=C1,Nuclear Receptors,LXR-like Receptors,,Orally active liver X receptor (LXR) agonist,"Selective, orally active non-steroidal agonist for the liver X receptor (LXR). In cell-based reporter gene assays, acts as a full agonist of hLXRalpha and hLXRbeta (EC50 values are 190 and 30 nM respectively). Reduces angiotensin II-mediated increases in blood pressure; up-regulates ABCA1 gene expression and raises circulating HDL levels. Displays potent antiatherogenic activity in mouse models of atherosclerosis.",618.51
GW 542573X,[660846-41-3],O=C(OC(C)(C)C)N1CCC(COC(NC2=CC=CC=C2OC)=O)CC1,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Selective activator of KCa2.1 channels,Activator of small-conductance Ca2+-activated K+ channels (KCa2); selective for KCa2.1 (EC50 = 8.2 muM in HEK293 cells expressing hKCa2.1) with the profile hKCa2.1 > hKCa2.2 = hKCa2.3 > hKCa3.1 (IK).,364.44
GW 583340 dihydrochloride,[1173023-85-2],Cl.Cl.CS(=O)(=O)CCNCC1=NC(=CS1)C1=CC=C2N=CN=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,Potent dual EGFR/ErbB2 inhibitor; orally active,"Potent dual EGFR/ErbB2 tyrosine kinase inhibitor (IC50 values are 0.01 and 0.014 muM respectively). Selectively inhibits growth of human tumor cells overexpressing EGFR and ErbB2 (IC50 values are 0.11 muM for inhibition of HN5, N87 and BT474 tumor cell lines vs. > 30 muM for inhibition of non-tumor cell line HFF). Inhibits tumor growth in vivo by ~ 80% in a murine xenograft model following oral administration.",671.03
GW 627368,[439288-66-1],O=C(NS(C5=CC=CC=C5)(=O)=O)CC(C=C4)=CC=C4N3CC2=C(OCC)C1=CC=CC=C1C(OCC)=C2C3=O,7-TM Receptors,Prostanoid Receptors,,Selective EP4 receptor competitive antagonist,Selective prostanoid EP4 receptor competitive antagonist with additional affinity at TP receptors (pKi values are 7.0 and 6.8 in competition radioligand bioassays). Affinity for all other prostanoid receptors is < 5.3. Inhibits U-46619 induced human platelet aggregation.,544.62
GW 6471,[880635-03-0],CC2=C(N=C(C4=CC=CC=C4)O2)CCOC(C=C1)=CC=C1C[C@@H](CNC(CC)=O)N/C(C)=C\C(C3=CC=C(C(F)(F)F)C=C3)=O,Nuclear Receptors,PPARs,PPARalpha Receptors,PPARalpha antagonist,PPARalpha antagonist (IC50 = 0.24 muM). Enhances the binding affinity of the PPARalpha ligand-binding domain to the co-repressor proteins SMRT and NCoR.,619.67
GW 7647,[265129-71-3],CC(C)(SC1=CC=C(CCN(CCCCC2CCCCC2)C(=O)NC2CCCCC2)C=C1)C(O)=O,Nuclear Receptors,PPARs,PPARalpha Receptors,"Highly selective, potent PPARalpha agonist. Orally active","Potent and highly selective PPARalpha agonist (EC50 values are 6, 1100 and 6200 nM for human PPARalpha, PPARgamma and PPARdelta receptors respectively). Modulates oleate metabolism and mitochondrial enzyme gene expression in mature myotubules in vitro. Has lipid-lowering effects following oral administration in vivo. Reduces NO production in macrophages; exhibits anti-inflammatory properties.",502.75
GW 788388,[452342-67-5],O=C(NC5CCOCC5)C(C=C4)=CC=C4C1=CC(C2=CNN=C2C3=CC=CC=N3)=CC=N1,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Potent and selective inhibitor of TGF-betaRI,Potent inhibitor of transforming growth factor-beta type I receptor (ALK5) (IC50 values are 18 and 93 nM for ALK5 binding and for TGF-beta cellular assay respectively). Inhibits esophageal squamous cell carcinoma (ESCC)-induced neoangiogenesis. Orally active.,425.48
GW 843682X,[660868-91-7],O=C(N)C(S3)=C(OCC4=CC=CC=C4C(F)(F)F)C=C3N2C1=CC(OC)=C(OC)C=C1N=C2,Enzymes,Kinases,Polo-like Kinase,Selective inhibitor of PLK1 and PLK3,Selective inhibitor of polo-like kinase 1 (PLK1) and polo-like kinase 3 (PLK3) (IC50 values are 2.2 and 9.1 nM respectively). Displays > 100-fold selectivity over ~30 other kinases tested including cdk1 and cdk2. Inhibits proliferation of most tumor cells in vitro and is selective over normal diploid fibroblasts.,477.46
GW 9508,[885101-89-3],OC(=O)CCC1=CC=C(NCC2=CC=CC(OC3=CC=CC=C3)=C2)C=C1,7-TM Receptors,Free Fatty Acid Receptors,,Potent and selective FFA1 (GPR40) agonist,"Potent and selective agonist for the free fatty acid receptor FFA1 (GPR40) (pEC50 values are 7.32, < 4.3 and < 4.3 for FFA1, FFA2 and FFA3 receptors respectively). Inactive against a range of other GPCRs, kinases, proteases, integrins and PPARs. Potentiates glucose-stimulated insulin secretion in MIN6 cells (pEC50 = 6.14).",347.41
GYKI 52466 dihydrochloride,[2319722-40-0],Cl.Cl.CC1=NN=C(C2=CC=C(N)C=C2)C2=C(C1)C=C1OCOC1=C2,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Selective non-competitive AMPA antagonist,"Selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 muM for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant. Has anti-proliferative effects in transformed cells. Also available as part of the Kainate Receptor Tocriset™.",366.24
H 89 dihydrochloride,[130964-39-5],O=S(C2=CC=CC1=CN=CC=C12)(NCCNC/C=C/C3=CC=C(Br)C=C3)=O.Cl.Cl,Enzymes,Kinases,Protein Kinase A,Protein kinase A inhibitor,"Protein kinase A inhibitor that also inhibits several other kinases (IC50 values are 80, 120, 135, 270, 2600 and 2800 nM for S6K1, MSK1, PKA, ROCKII, PKBalpha and MAPKAP-K1b). Exhibits antinociceptive activity. Enhances survival and clonogenicity of dissociated human ESCs through ROCK inhibition. Also available as part of the PKA TocrisetTM.",519.28
H2L 5765834,[420841-84-5],O=C2N(C3=CC=CC(OC4=CC=C([N+]([O-])=O)C=C4)=C3)C(C1=CC(C(O)=O)=CC=C12)=O,7-TM Receptors,Lysophosphatidic Acid Receptors,,"LPA1,3,5 antagonist","Antagonist of the lysophosphatidic acid receptors LPA1, LPA5 and LPA3 (IC50 values are 94, 463 and 752 nM respectively). Exhibits no effect at LPA2 or LPA4 receptors.",404.33
HA 130,[1229652-21-4],FC1=CC=C(CN3C(/C(SC3=O)=C/C2=CC=C(OCC4=CC(B(O)O)=CC=C4)C=C2)=O)C=C1,Enzymes,Esterases,Autotaxin,Potent and selective autotaxin inhibitor,"Potent and selective autotaxin inhibitor (IC50 = 28 nM). Binds and inhibits autotaxin reversibly. Displays no activity against the proteasome, recombinant NPP1 or alkaline phosphatase. Inhibits ATX-mediated cell migration in an A2058 melanoma cell assay.",463.29
Heclin,[890605-54-6],CC(C1=CC=C(NC(/C=C/C2=CC=C(CC)O2)=O)C=C1)=O,Enzymes,Ligases,Ubiquitin E3 Ligases,HECT E3 ubiquitin ligase inhibitor,"HECT E3 ubiquitin ligase inhibitor; inhibits Nedd4, Smurf2 and WWP1 (IC50 values are 6.3, 6.8 and 6.9 muM respectively). Selective for HECT-mediated over RING-mediated ubiquitination.",283.32
HEMADO,[403842-38-6],O[C@@H]1[C@@H](CO)O[C@@H](N(C=N3)C2=C3C(NC)=NC(C#CCCCC)=N2)[C@@H]1O,7-TM Receptors,Adenosine Receptors,Adenosine A3 Receptors,High affinity selective A3 agonist,"High affinity and selective adenosine A3 receptor agonist (Ki values are 1.1, 327, 1230 and > 30,000 nM for human A3, A1, A2A and A2B receptors respectively).",361.4
Hesperadin hydrochloride,,O=C3/C(C2=CC(NS(CC)(=O)=O)=CC=C2N3)=C(C4=CC=CC=C4)\NC1=CC=C(CN5CCCCC5)C=C1.Cl,Enzymes,Kinases,Aurora Kinases,Potent Aurora kinase B inhibitor,ATP-competitive inhibitor of Aurora B kinase (IC50 = 250 nM). Prevents chromosome alignment and segregation; also induces polyploidy and prevents histone H3-Ser10 phosphorylation. Overrides the spindle assembly checkpoint and induces mitotic exit in monastrol- and taxol-treated HeLa cells.,553.12
HFI 142,[332164-34-8],OC1=CC(OC(N)=C(C(OCC)=O)C2C3=CN=CC=C3)=C2C=C1,Enzymes,Proteases,Aminopeptidases,Insulin-regulated aminopeptidase (IRAP) inhibitor,Insulin-regulated aminopeptidase (IRAP) inhibitor (Ki = 2.01 muM). Improves memory in control and memory-deficient mice models.,312.32
Histamine dihydrochloride,[56-92-8],NCCC1=CNC=N1.Cl.Cl,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,Endogenous histamine receptor agonist,"Endogenous agonist at histamine receptors (H1-4). Released from mast cells and basophils and exhibits inflammatory, vasodilatory and bronchoconstrictory activity. Stimulates gastric acid secretion and acts as a neurotransmitter in vivo.",184.07
HJC 0350,[885434-70-8],CC1=CC(C)=C(S(N2C(C)=CC(C)=C2)(=O)=O)C(C)=C1,Enzymes,GTPases,Small Monomeric GTPases,Selective Epac2 inhibitor,Selective Epac2 inhibitor (IC50 = 0.3 muM). Displays no effect on Epac1. Blocks stimulation of the Epac2-FL FRET sensor in HEK293 cells.,277.38
HKI 357,[848133-17-5],O=C(/C=C/CN(C)C)NC1=C(OCC)C=C(N=CC(C#N)=C2NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,Dual irreversible inhibitor of ErbB2 and EGFR,"Potent, irreversible inhibitor of ErbB2 (HER2) and EGFR (IC50 values are 33 and 34 nM respectively). Suppresses ligand-induced EGFR autophosphorylation and cell proliferation in NCI-H1975 cells containing L858R and T790M mutations. Circumvents mechanisms of resistance to Iressa (Cat. No. 3000) in non-small-cell lung cancer cells.",574.05
HTH 01-015,[1613724-42-7],O=C1N(C)C2=C(N=C(NC3=CN(C4CCNCC4)N=C3)N=C2C)N(C)C5=CC6=CC=CC=C6C=C51,Enzymes,Kinases,NUAK,Potent and selective NUAK1 inhibitor,"Potent and selective NUAK1 inhibitor (IC50 = 100 nM). Exhibits no significant inhibition against a panel of 139 kinases, including ten AMPK family members. Inhibits NUAK1-mediated MYPT1 phosphorylation. Also inhibits cell proliferation in U2OS cells in vitro, to a similar extent as NUAK1 knockdown models.",468.55
Hydrocortisone,[50-23-7],O=C1CC[C@@]2(C)C(CC[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@@](O)4[C@@](CO)=O)=C1,Nuclear Receptors,Glucocorticoid Receptor,,Adrenal glucocorticoid; immunosuppressant,Adrenal glucocorticoid released in the stress response. Increases glucose production by gluconeogenesis. Immunosuppressant and antidiuretic hormone.,362.46
I-BET 151 dihydrochloride,[1883545-47-8],O=C(N3[C@H](C)C4=NC=CC=C4)NC2=C3C1=CC(OC)=C(C5=C(C)ON=C5C)C=C1N=C2.Cl.Cl,Epigenetics,Bromodomains,,BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes,"BET bromodomain inhibitor; blocks recruitment of BET to chromatin. Induces apoptosis and G0/G1 cell cycle arrest in MLL-fusion leukemic cell lines in vitro (IC50 values are 15, 26, 120 and 192 nM for NOMO1, MV4;11, MOLM13 and RS4;11 cell lines respectively); reduces BCL2 expression in NOMO1 cells. Improves survival in two rodent models of MLL-fusion leukemia in vivo. Enhances differentiation of human iPSC into megakaryocytes.",488.37
I-BRD9,[1714146-59-4],O=C1C2=C(SC(C(NC3CCS(CC3)(=O)=O)=N)=C2)C(C4=CC=CC(C(F)(F)F)=C4)=CN1CC,Epigenetics,Bromodomains,,Potent and selective BRD9 inhibitor,"Potent and selective BRD9 inhibitor (pIC50 = 7.3). Exhibits >70-fold selectivity for BRD9 over a panel of 34 other bromodomains and >700-fold selectivity over the BET family. Downregulates CLEC1, DUSP6, FES and SAMSN1 genes in Kasumi-1 cells.",497.55
I-CBP 112,[1640282-31-0],COC(C(OC)=C1)=CC=C1C2=CC(OC[C@H]3CCCN(C)C3)=C(OCCN(C(CC)=O)C4)C4=C2,Epigenetics,Bromodomains,,Selective CBP/p300 BRD inhibitor,"CBP/p300 bromodomain inhibitor (IC50 values are 0.142-0.17 and 0.625 muM for CBP and p300 respectively). Selective for CBP and p300 over ATAD2, BAZ2B, BRD2(2), BRD4(1), PB1(5), PCAF, PHIP(2) and TIF1alpha bromodomains in a BLI assay. Accelerates FRAP recovery in cells at a concentration of 1 muM.",468.59
IBMX,[28822-58-4],O=C1C2=C(N=CN2)N(CC(C)C)C(N1C)=O,Enzymes,Phosphodiesterases,,PDE inhibitor (non-selective),"Phosphodiesterase inhibitor (IC50 values are 13, 18, 19, 32 and 50 muM for PDE4, PDE3, PDE1, PDE5 and PDE2 respectively). Suppresses alpha-adrenoceptor-mediated 5-HT release from neuroendocrine epithelial cells (IC50 = 1.3 muM). Facilitates differentiation of neural progenitor cells in vitro.",222.24
Ibudilast,[50847-11-5],CC(C)C(=O)C1=C2C=CC=CN2N=C1C(C)C,Enzymes,Phosphodiesterases,,PDE inhibitor (non-selective),"Phosphodiesterase inhibitor (IC50 values are 53, 35, 48, 12 and 10 muM for PDE Ia, II, III, IV and V respectively). Inhibits platelet aggregation and is an orally-active cerebral vasodilator, bronchodilator and antiallergic agent.",230.31
Ibutilide hemifumarate,[122647-32-9],CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1.O=C(/C=C/C(O)=O)O.CCCCCCCN(CC)CCCC(O)C2=CC=C(NS(C)(=O)=O)C=C2,Ion Channels,Other Channel Modulators,,"Blocks IKr, hERG and L-type Ca2+ channels; class III antiarrhythmic",Class III antiarrhythmic. Blocks the rapid component of delayed rectifier K+ current (IKr); also blocks hERG channels and L-type Ca2+ channels. Shown to activate a slow inward Na+ current in guinea pig ventricular cells. Used to terminate atrial fibrillation and atrial flutter; can prolong QT.,442.61
ICA 069673,[582323-16-8],ClC1=NC=C(NC(C2=CC(F)=C(F)C=C2)=O)C=N1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV7.2/KV7.3 channel opener,"Selective KV7.2/KV7.3 (KCNQ2/3) channel opener (EC50 = 0.69 muM). Exhibits 20-fold selectivity for KV7.2/KV7.3 over KV7.3/KV7.5, with no measurable activity over a panel of cardiac ion channels. Hyperpolarizes resting membrane potential and inhibits spontaneous action potentials in guinea pig detrusor muscle (DSM) isolated cells. Orally active in animal models of epilepsy.",269.63
ICA 110381,[325457-99-6],O=C(NC2=CC=C(Cl)N=C2)C1=CC=C(Cl)C=C1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV7.2/7.3 activator; displays anticonvulsant properties,"KV7.2/7.3 activator (EC50 = 0.38 muM). Decreases neuronal excitability in CA1 hippocampal neurons. Exhibits anticonvulsive properties in amygdala-kindled rats, a model for complex partial seizures.",267.11
ICA 121431,[313254-51-2],O=S(C1=CC=C(NC(C(C4=CC=CC=C4)C3=CC=CC=C3)=O)C=C1)(NC2=NC=CS2)=O,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Potent and selective NaV1.3 and NaV1.1 channel blocker,"Potent and selective inhibitor of human NaV1.3 and NaV1.1 channels (IC50 values are 13 and 23 nM respectively). Exhibits up to 1,000 fold selectivity against other TTX-sensitive or resistant sodium channels (IC50 values are >10 muM for human NaV1.5 and NaV1.8 channels). Interacts with an inhibitory interaction site distinct from those bound by TTX and local anesthetic-like modulators.",449.55
"ICI 182,780",[129453-61-8],OC1=CC=C2C(C[C@@H](CCCCCCCCCS(CCCC(F)(C(F)(F)F)F)=O)C3([H])[C@@]([H])2CC[C@@]4(C)[C@@](CC[C@@H]4O)3[H])=C1,Nuclear Receptors,Estrogen and Related Receptors,,Estrogen receptor antagonist,"A high affinity estrogen receptor antagonist (IC50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo. Also high affinity agonist at the membrane estrogen receptor GPER.",606.77
"ICI 192,605",[117621-64-4],OC(=O)CC\C=C/C[C@@H]1CO[C@@H](O[C@@H]1C1=C(O)C=CC=C1)C1=C(Cl)C=CC=C1,7-TM Receptors,Prostanoid Receptors,,Potent thromboxane A2/TP receptor antagonist,Potent thromboxane A2 receptor (TP receptor) antagonist. Competitively inhibits contractile responses to U 46619 (Cat. No. 1932).,402.87
"ICI 199,441 hydrochloride",[115199-84-3],ClC1=C(Cl)C=C(CC(N([C@@]([H])([C@]3=CC=CC=C3)CN2CCCC2)C)=O)C=C1.Cl,7-TM Receptors,Opioid Receptors,Kappa Opioid Receptors,Potent kappa agonist,"Highly potent kappa agonist, 146-fold more active than U-50488 (Cat. No. 0495) in vitro.",427.8
ICI 63197,[27277-00-5],CCCN1C2=NC(N)=NN2C=C(C)C1=O,Enzymes,Phosphodiesterases,,PDE4 inhibitor,Potent phosphodiesterase (PDE) 4 inhibitor (IC50 = 35 nM for inhibition of [3H]-rolipram binding to rat brain). Antidepressant following systemic administration in vivo.,207.23
iCRT 14,[677331-12-3],CC(N(C4=CN=CC=C4)C(C)=C3)=C3/C=C(SC2=O)/C(N2C1=CC=CC=C1)=O,Signal Transduction,Wnt Signaling,Beta-catenin,Inhibits beta-catenin-responsive transcription (CRT),Potent inhibitor of beta-catenin-responsive transcription (CRT) (IC50 = 40.3 nM in assays of Wnt pathway activity). Thought to directly influence the interaction between beta-catenin and TCF4. Induces marked G0/G1 cell cycle arrest in HCT-116 and HT29 cell lines.,375.44
ID 8,[147591-46-6],CC2=C([N+]([O-])=O)C1=CC=C(O)C=C1N2C3=CC=C(OC)C=C3,Stem Cells,Stem Cell Proliferation,,Sustains self-renewal and pluripotency of ESCs,Sustains self-renewal and pluripotency of mouse embryonic stem cells (ESCs) in vitro. Stimulates proliferation at a steady rate (observed in serum-free media supplemented with 10 muM over a 30 day period). Also supports human PSC maintenance in combiantions with Wnt3a. DYRK inhibitor,298.29
IDRA 21,[22503-72-6],CC1NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Inhibits AMPA desensitization,Inhibits AMPA receptor desensitization and enhances cognition by a related mechanism. More able to cross the blood-brain barrier than cyclothiazide (Cat. No. 0713).,232.68
IEM 1460,[121034-89-7],[Br-].Br.C[N+](C)(C)CCCCCNCC12CC3CC(C1)CC(C2)C3,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Open-channel blocker of AMPA currents; selective for non-GluA2-containing receptors,"Voltage-dependent open-channel blocker of AMPA receptors. Selective for GluR2 subunit-lacking (Ca2+-permeable) receptors over GluA2-containing receptors (IC50 values are 2.6 and 1102 muM, respectively). Selectively blocks fast spiking interneuron but not medium spiny projection neuron in mouse striatum. Also blocks NMDA receptor-mediated currents. Anticonvulsant in vivo.",454.33
IKK 16,[1186195-62-9],Cl.O=C(N1CCC(CC1)N1CCCC1)C1=CC=C(NC2=NC=CC(=N2)C2=CC3=CC=CC=C3S2)C=C1,Enzymes,Kinases,IkB Kinase,Selective inhibitor of IKK,"Selective inhibitor of IkappaB kinase (IKK) (IC50 values are 40, 70 and 200 nM for IKKbeta, IKK complex and IKKalpha respectively). Inhibits TNF-alpha-stimulated IkappaB degradation and expression of adhesion molecules E-selectin, ICAM and VCAM (IC50 values are 1.0, 0.5, 0.3 and 0.3 muM respectively). Inhibits LPS-induced TNF-alpha release in vivo and neutrophil extravasion in thioglycollate-induced peritonitis.",520.09
Imatinib mesylate,[220127-57-1],CS(O)(=O)=O.CN1CCN(CC1)CC2=CC=C(C(NC3=CC=C(C(NC4=NC=CC(C5=CN=CC=C5)=N4)=C3)C)=O)C=C2,Enzymes,Kinases,Abl Kinase,Potent and selective v-Abl tyrosine kinase inhibitor; also inhibits PDGFR and c-kit,Potent and selective v-Abl tyrosine kinase inhibitor (IC50 = 38 nM). Also inhibits PDGFR and c-kit. Exhibits selectivity for v-Abl over a panel of other tyrosine and serine/threonine protein kinases. Selectively inhibits PDGF-stimulated growth of v-abl-transformed PB-3 cells and v-sis-transformed BALB/c 3T3 cells in vitro. Exhibits antitumor effects in mice bearing AMuLV or BABL/c 3T3 v-sis cells.,589.71
INCA-6,[3519-82-2],O=C1C=CC(=O)C2=C1C1C3=C(C=CC=C3)C2C2=C1C=CC=C2,Enzymes,Phosphatases,Protein Ser/Thr Phosphatases,Inhibitor of calcineurin-substrate association,Inhibitor of interaction between calcineurin and its substrate nuclear factor of activated T cells (NFAT); blocks at the substrate recognition site but not at the catalytic site (Kd = 0.8 mM). Inhibits NFAT dephosphorylation and nuclear import. Also prevents induction of cytokine mRNAs that are downstream targets of NFAT.,284.31
Indatraline hydrochloride,[96850-13-4],ClC(C=C3)=C(Cl)C=[C@@]3[C@H]2C1=CC=CC=C1[C@H](NC)C2.Cl,Transporters,Neurotransmitter Transporters,5-HT Transporters,Potent 5-HT uptake inhibitor; also inhibits dopamine and noradrenalin uptake,"Potent monoamine uptake inhibitor. Inhibits transporters for 5-HT (SERT), dopamine (DAT) and noradrenalin (NET) (Ki values are 0.42, 1.7 and 5.8 nM respectively). Centrally active following systemic administration in vivo.",328.67
IOX 1,[5852-78-8],OC2=CC=C(C(O)=O)C1=CC=CN=C12,Enzymes,Demethylases,Histone Demethylases,Histone demethylase inhibitor; cell permeable,"Histone demethylase JMJD inhibitor (IC50 values are 0.12, 0.17, 0.2, 0.3, 0.6 and 1 muM for JMJD3, JMJD1A, JMJD2A, JMJD2E, JMJD2C and UTX respectively). Cell permeable; inhibits JMJD2A-mediated H3K9me3 demethylation in HeLa cells.",189.17
IOX 2,[931398-72-0],OC(C1=CC=CC=C1N2CC3=CC=CC=C3)=C(C(NCC(O)=O)=O)C2=O,Enzymes,Hydroxylases,,"Potent, selective HIF-1alpha prolyl hydroxylase-2 (PHD2) inhibitor","Potent inhibitor of HIF-1alpha prolyl hydroxylase-2 (PHD2) (IC50 = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3. Cell permeable.",352.34
Irbesartan,[138402-11-6],O=C(C1(CCCC1)N=C2CCCC)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,Potent AT1 antagonist,Potent angiotensin II type 1 receptor (AT1) antagonist (IC50 = 1.3 nM). Displays antihypertensive activity. Orally bioavailable.,428.53
Iressa,[184475-35-2],FC(C=C3)=C(Cl)C=C3NC2=NC=NC1=CC(OC)=C(OCCCN4CCOCC4)C=C12,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,"Orally active, selective EGFR inhibitor","Orally active, selective inhibitor of EGFR tyrosine kinase (IC50 = 23 - 79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts. Also inhibits growth of brain metastases in mouse model of non-small cell lung cancer. View information regarding the usage of Iressa for non-clinical studies.",446.9
Irsogladine maleate,[84504-69-8],OC(=O)\C=C/C(O)=O.NC1=NC(=NC(N)=N1)C1=CC(Cl)=CC=C1Cl,Enzymes,Phosphodiesterases,,PDE4 inhibitor; antiulcer agent,Phosphodiesterase 4 (PDE4) inhibitor that displays gastroprotective properties. Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Activates gap-junctional intercellular communication improving gastric mucosal barrier function. Inhibits superoxide production in human neutrophils and inhibits in vitro and in vivo angiogenesis.,372.18
ISO 1,[478336-92-4],OC(C=C2)=CC=C2C1=NOC(CC(OC)=O)C1,Signal Transduction,Cytokine and NF-kB Signaling,Cytokines,Macrophage migration inhibitory factor (MIF) inhibitor,Macrophage migration inhibitory factor (MIF) inhibitor (IC50 = 7 muM); inhibits MIF tautomerase activity in vitro and in vivo. Protective against mouse models of streptozotocin-induced diabetes mellitus; blocks anti-inflammatory response following LPS exposure and increases survival. Inhibits airway remodeling in a mouse model of chronic asthma. Cell permeable; orally bioavailable.,235.24
Isradipine,[75695-93-1],COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV1.x blocker,"Potent and selective L-type voltage-gated Ca2+ channel blocker. EC50 and pA2 values are 1.4 nM and 10.3 for relaxation of depolarization- and Ca2+-induced contractions of rabbit aorta respectively; EC25 = 0.45 nM for reduction in rate of spontaneously beating guinea pig right atria. Long-acting antihypertensive agent in vivo, exerting primary effects on vascular tissue with secondary negative chronotropic action.",371.39
ISX 9,[832115-62-5],O=C(NC2CC2)C1=NOC(C3=CC=CS3)=C1,Stem Cells,Stem Cell Differentiation,Neural Stem Cells,Neurogenic agent; induces neuronal differentiation of SVZ progenitors and also induces cardiomyogenic differentiation,"Neurogenic agent. Mediates neuroD reporter gene induction via activation of Ca2+ influx; increases expression of neurogenic differentiation 1 (NeuroD1) transcription factor. Induces neuronal differentiation in human cortical neuronal cells (HCN), adult mouse whole brain (MWB) and subventricular zone (SVZ) progenitors. Also shown to induce cardiomyogenic differentiation of Notch-activated epicardium-derived cells in vitro.",234.27
IT1t dihydrochloride,[1092776-63-0],CC1(C)CN(C(CS/C(NC4CCCCC4)=N/C3CCCCC3)=CS2)C2=N1.Cl.Cl,7-TM Receptors,Chemokine Receptors,Chemokine CXC Receptors,Potent CXCR4 antagonist,"Potent CXCR4 antagonist (IC50 = 1.1 nM in calcium mobilization assays). Orally available. Blocks interaction with the HIV envelope protein, gp120 (IC50 = 7 nM, inhibition of X4-tropic HIV-1IIIB attachment).",479.57
ITD 1,[1099644-42-4],CC(C3)(C)CC(C1=C3NC(C)=C(C(OCC)=O)C1C2=CC=C(C4=CC=CC=C4)C=C2)=O,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Selective inhibitor of TGF-beta signaling; induces cardiomyocyte differentiation in ESCs,"Selective inhibitor of TGF-beta signaling (IC50 = 0.85 muM); displays little or no inhibition of activin, Wnt or BMP signaling pathways. Induces proteasomal degradation of the TGF-beta type II receptor. Inhibits TGF-beta-induced mesoderm formation from mouse embryonic stem cells (ESCs) during early differentiation; selectively promotes the differentiation of ESCs to cardiomyocytes in vitro between days 3-5. Does not induce differentiation of vascular smooth muscle cells or endothelial cells.",415.52
ITE,[448906-42-1],COC(=O)C1=CSC(=N1)C(=O)C1=CNC2=CC=CC=C12,Nuclear Receptors,Aryl Hydrocarbon Receptors,,Endogenous agonist for the transcription factor aryl hydrocarbon receptor,Endogenous aryl hydrocarbon receptor (AhR) agonist (Ki = 3 nM). Decreases Oct4 levels in U87 glioblastoma cells. Induces stem-like cancer cell differentiation in U87 tumor spheres and inhibits ovarian cancer cell proliferation in vitro. Suppresses tumor growth in U87 and OVCAR-3 cell xenografts in mice. Also inhibits TGF-beta-induced human myofibroblast differentiation.,286.3
JHW 007 hydrochloride,[202645-74-7],[H][C@@]12CC[C@@](C[C@H](OC(C4=CC=C(F)C=C4)C3=CC=C(F)C=C3)C2)([H])N1CCCC.Cl,Transporters,Neurotransmitter Transporters,Dopamine Transporters,High affinity dopamine uptake inhibitor,Dopamine uptake inhibitor; displays high affinity for the dopamine transporter (DAT) (Ki = 25 nM compared to 1330 and 1730 for NET and SERT respectively). Suppresses the effects of cocaine administration in a dose-dependent manner and decreases cocaine and methamphetamine self-administration in rats.,421.95
JIB 04,[199596-05-9],ClC(C=C3)=CN=C3N/N=C(C2=CC=CC=C2)/C1=CC=CC=N1,Enzymes,Demethylases,Histone Demethylases,Pan Jumonji inhibitor; active in vivo,"Pan Jumonji histone demethylase inhibitor (IC50 values are 230, 340, 435, 445, 855 and 1100 nM for JARID1A, JMJD2E, JMJD2B, JMJD2A, JMJD3 and JMJD2C respectively). Exhibits negligible activity at PHD2 and TET1. Selectively blocks cancer cell growth in vitro and diminishes tumor growth in H358 and A549 mouse xenograft models in vivo. Prolongs survival in a mouse model of breast cancer.",308.76
JK 184,[315703-52-7],CC2=C(C3=CSC(NC4=CC=C(OCC)C=C4)=N3)N1C=CC=CC1=N2,Enzymes,Dehydrogenases,Alcohol Dehydrogenase,Alcohol dehydrogenase 7 inhibitor; inhibits downstream Hh signaling pathway,Potent downstream hedgehog (Hh) signaling inhibitor that prevents Gli-dependent transcriptional activity (IC50 = 30 nM). Exhibits antiproliferative activity in a range of cancer cell lines (GI50 = 3 - 21 nM) and in human xenografts in vivo. Inhibits alcohol dehydrogenase 7 (Adh7) (IC50 = 210 nM) and acts as a microtubule depolymerizing agent in vitro.,350.44
JNJ 10191584 maleate,[869497-75-6],O=C(O)/C=C\C(O)=O.ClC(C=C3)=CC2=C3N=C(N2)C(N1CCN(C)CC1)=O,7-TM Receptors,Histamine Receptors,Histamine H4 Receptors,Selective H4 antagonist; orally active,Highly selective histamine H4 receptor silent antagonist; binds with high affinity to the human H4 receptor (Ki = 26 nM). > 540-fold selective over the H3 receptor (Ki = 14.1 muM). Inhibits mast cell and eosinophil chemotaxis in vitro with IC50 values of 138 and 530 nM respectively. Orally active in vivo.,394.81
JNJ 10397049,[708275-58-5],O=C(N[C@@H]2[C@H](C3=CC=CC=C3)OC(C)(C)OC2)NC1=C(Br)C=C(Br)C=C1,7-TM Receptors,Peptide Receptors,Orexin Receptors,Selective OX2 receptor antagonist,Selective OX2 receptor antagonist (pIC50 = 7.4 for chimeric OX2 receptors; pKB values are 5.9 and 8.5 for OX1 and OX2 receptors respectively). Shows no significant activity in a panel of over 50 other neurotransmitters and neuropeptide receptors. Achieves high level of OX2 receptor occupancy in the rat brain; exhibits sleep-promoting effects in rats.,484.18
JNJ 16259685,[409345-29-5],O=[C@@]([C@@H]4CC[C@H](OC)CC4)C(C=C3)=CC1=C3N=C(OCCC2)C2=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,"Highly potent, mGlu1-selective non-competitive antagonist","Sub-nanomolar potent, non-competitive mGlu1 antagonist (Ki = 0.34 nM). Inhibits glutamate-induced Ca2+ response at the human mGlu1 receptor with an IC50 value of 0.55 nM. Selective over mGlu5 (> 400-fold) and displays no activity at mGlu2, mGlu3, mGlu4, mGlu6, AMPA or NMDA receptors (IC50 > 10 muM). Centrally active following systemic administration.",325.41
JNJ 1661010,[681136-29-8],O=C(NC3=CC=CC=C3)N1CCN(C2=NC(C4=CC=CC=C4)=NS2)CC1,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),"Selective, reversible FAAH inhibitor","Selective, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12 nM). Brain penetrant and active in vivo.",365.45
JNJ 17203212,[821768-06-3],O=C(NC3=NC=C(C(F)(F)F)C=C3)N(CC2)CCN2C1=C(C(F)(F)F)C=CC=N1,Ion Channels,Transient Receptor Potential Channels,TRPV,"Reversible, competitive and potent TRPV1 antagonist","Reversible, competitive and potent TRPV1 antagonist (pKi values are 6.5, 7.1 and 7.3 at rat, guinea pig and human TRPV1 respectively). Inhibits capsaicin- and H+-induced channel activation (pIC50 values are 6.32 and 7.23 respectively) and exhibits antitussive and analgesic activity in vivo.",419.32
JNJ 27141491,[871313-59-6],FC1=CC([C@H](CC)N2C(C(OC)=O)=C(C3=CC=NO3)NC2=S)=CC=C1F,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,Potent and selective human CCR2 antagonist,"Potent, noncompetitive human CCR2 antagonist; inhibits MCP-1-induced Ca2+ mobilization in hCCR2-CHO cells (IC50 = 13 nM). Exhibits selectivity for CCR2 over CCR1, CCR3-8 and CXCR1-3. Delays onset and reduces neurological signs in an experimental autoimmune encephalomyelitis model of multiple sclerosis in hCCR2 knock-in mice. Orally active.",379.38
JNJ 47965567,[1428327-31-4],O=C(NCC4(CCOCC4)N3CCN(C5=CC=CC=C5)CC3)C1=CC=CN=C1SC2=CC=CC=C2,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Potent and selective P2X7 antagonist; brain penetrant,"Potent and selective P2X7 antagonist (pIC50 values are 8.3, 7.5 and 7.2 for human, mouse and rat receptors respectively). Selective over a panel of 50 other receptors, ion channels and transporters. Reduces BzATP-induced IL-1beta release from monocytes in vitro and from rat brain in vivo. Attenuates amphetamine-induced hyperactivity in rats. Brain penetrant.",488.64
JNJ 7777120,[459168-41-3],ClC1=CC=C(NC(C(N3CCN(C)CC3)=O)=C2)C2=C1,7-TM Receptors,Histamine Receptors,Histamine H4 Receptors,Selective H4 antagonist,Histamine H4 receptor antagonist; displays high affinity (Ki = 4.5 nM) and is >1000-fold selective for H4 over other histamine receptors.,277.75
JTC 801,[244218-51-7],Cl.CCC1=CC=C(OCC2=CC=CC=C2C(=O)NC2=CC3=C(N)C=C(C)N=C3C=C2)C=C1,7-TM Receptors,Opioid Receptors,NOP Receptors,Selective NOP antagonist,"High affinity, selective NOP receptor antagonist (Ki = 8.2 nM). Displays approximately 12.5-, 129- and 1055-fold selectivity over human mu-, kappa- and delta-opioid receptors respectively. Exhibits anti-nociceptive effects in acute pain models in vivo. Orally active.",447.96
JTE 013,[383150-41-2],CC(C)C1=C2C(C)=NN(C)C2=NC(NNC(=O)NC2=CC(Cl)=NC(Cl)=C2)=C1,7-TM Receptors,Sphingosine-1-phosphate Receptors,,S1P2 receptor antagonist,"Sphingosine-1-phosphate (S1P) receptor antagonist, highly selective for S1P2 (EDG-5). Inhibits S1P binding to human S1P2 receptors with an IC50 value of 17.6 nM. At concentrations up to 10 muM, displays 4.2% inhibition of S1P3 and does not antagonize S1P1. Enhances S1P-induced angiogenesis in vivo.",408.29
JTE 607 dihydrochloride,[188791-09-5],ClC1=C(OCCN2CCN(C)CC2)C(Cl)=CC(C(N[C@@H](CC3=CC=CC=C3)C(OCC)=O)=O)=C1O.Cl.Cl,Signal Transduction,Cytokine and NF-kB Signaling,Cytokines,Cytokine release inhibitor; anti-inflammatory,"Cytokine release inhibitor. Inhibits production of IL-1beta, IL-8, IL-6, IL-10 and TNFalpha (IC50 values are 5.9, 7.3, 8.8, 9.1 and 11.0 nM, respectively) from LPS-stimulated PBMCs. Reduces proinflammatory cytokine-release and attenuates lung permeability in a rat lung injury model. Induces apoptosis in leukemia cells in vitro and prolongs survival in a mouse leukemia model.",597.36
JTE 907,[282089-49-0],CCCCCOC1=C2NC(=O)C(=CC2=CC=C1OC)C(=O)NCC1=CC2=C(OCO2)C=C1,7-TM Receptors,Cannabinoid Receptors,CB2 Receptors,Selective CB2 receptor inverse agonist,"Highly selective cannabinoid CB2 receptor inverse agonist. Binds with high affinity to rat, mouse and human CB2 receptors (Ki values are 0.38, 1.55 and 35.9 nM respectively). Produces anti-inflammatory effects in vivo.",438.48
JW 55,[664993-53-7],O=C(NCC2(C3=CC=C(OC)C=C3)CCOCC2)C1=CC=C(NC(C4=CC=CO4)=O)C=C1,Enzymes,Polymerases,Tankyrase,Tankyrase inhibitor,Inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). Activity results in stabilization of Axin2 and increased degradation of beta-catenin; inhibits the beta-catenin signaling pathway. Also shown to decrease canonical Wnt signaling in SW480 and HCT-15 colon carcinoma cell lines; reduces cell cycle progression and proliferation in SW480 cells in vitro.,434.48
JW 642,[1416133-89-5],O=C(OC(C(F)(F)F)C(F)(F)F)N(CC3)CCN3CC1=CC(OC2=CC=CC=C2)=CC=C1,Enzymes,Hydrolases,MAGL,MAGL inhibitor,Potent and selective monoacylglycerol lipase (MAGL) inhibitor (IC50 = 3.7 nM). Displays >1000-fold selectivity for MAGL over fatty acid amide hydrolase (IC50 = 20.6 muM). Analog of JZL 195 (Cat. No. 4715).,462.39
JW 67,[442644-28-2],O=C1NC6=C(C=CC=C6)C21OCC3(COC(C(NC5=C4C=CC=C5)=O)4OC3)CO2,Signal Transduction,Wnt Signaling,Other Wnt Signaling,Wnt pathway inhibitor; induces degradation of active beta-catenin,Inhibitor of canonical Wnt pathway signaling (IC50 = 1.17 muM); targets the beta-catenin destruction complex (GSK-3beta/AXIN/APC) to induce beta-catenin degradation. Selective for the canonical Wnt pathway over the Sonic hedgehog (Shh) and NF-kappaB pathways. Blocks G1/S cell cycle progression in colorectal cancer (CRC) cell lines (GI50 = 7.8 muM).,394.38
JW 74,[863405-60-1],COC1=CC=C(N2C(SCC3=NC(C4=CC=C(C)C=C4)=NO3)=NN=C2C5=CC=NC=C5)C=C1,Signal Transduction,Wnt Signaling,Other Wnt Signaling,Wnt pathway inhibitor,Inhibitor of canonical Wnt signaling (IC50 = 790 nM). Targets the beta-catenin destruction complex (GSK-3ß/AXIN/APC). Increases AXIN2 and decreases active beta-catenin levels in colorectal cancer (CRC) cells. Also arrests cell cycle in G1 and inhibits proliferation of CRC cells in vitro. Inhibits tumor growth and formation in mouse models.,456.52
JX 401,[349087-34-9],COC1=C(C=CC(SC)=C1)C(=O)N1CCC(CC2=CC=CC=C2)CC1,Enzymes,Kinases,MAPK Family,"Potent, reversible p38alpha inhibitor","Potent, reversible inhibitor of p38alpha that displays no activity on the p38gamma isoform (IC50 values are 32 nM and > 10 muM respectively). Inhibits the differentiation of myoblasts to myotubes in mammalian cells in culture.",355.49
JZL 184,[1101854-58-3],O=C(OC6=CC=C([N+]([O-])=O)C=C6)N(CC5)CCC5C(C2=CC=C(OCO3)C3=C2)(O)C1=CC(OCO4)=C4C=C1,Enzymes,Hydrolases,MAGL,Potent MAGL inhibitor,Potent and selective MAGL inhibitor. Blocks hydrolysis of the endocannabinoid 2-arachidonyl glycerol (2-AG) in vivo in the mouse brain (IC50 = 8 nM). Potentiates depolarization-induced suppression of excitability in cerebellar Purkinje neurons. Exhibits >300-fold selectivity for MAGL over FAAH in vitro. Attenuates nociception in neuropathic and inflammatory pain models. Also reduces free fatty acid levels in primary tumors.,520.49
JZL 195,[1210004-12-8],O=C(OC4=CC=C([N+]([O-])=O)C=C4)N(CC3)CCN3CC1=CC(OC2=CC=CC=C2)=CC=C1,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),Dual FAAH and MAGL inhibitor,Dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (IC50 values are 2 and 4 nM respectively). Elevates anandamide and 2-arachidonoylglycerol levels in vivo. Shown to impair short-term memory in mice.,433.46
K 02288,[1431985-92-0],NC1=NC=C(C3=CC=CC(O)=C3)C=C1C2=CC(OC)=C(OC)C(OC)=C2,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),BMP and Other Activin Receptors,Type 1 BMP receptor inhibitor,"Potent and selective inhibitor of type I bone morphogenic protein (BMP) receptors (IC50 values are 1.1, 1.8, 6.4, 34.4, 220, 302 and 321 nM for ALK2, ALK1, ALK6, ALK3, ActRIIA, ALK4 and ALK5 respectively). Reduces BMP4-induced Smad1/5/8 phosphorylation in vitro (IC50 = 100 nM) and induces dorsalization of zebrafish embryos.",352.38
Kartogenin,[4727-31-5],O=C(NC2=CC=C(C3=CC=CC=C3)C=C2)C1=CC=CC=C1C(O)=O,Stem Cells,Stem Cell Differentiation,Mesenchymal Stem Cells,Potently induces chondrogenesis in MSCs,Potently induces differentiation of human mesenchymal stem cells into chondrocytes (EC50 = 100 nM). Reduces disease severity in a mouse model of osteoarthritis; displays protective effects against osteoarthritic stimuli in mature chondrocytes in vitro.,317.34
KB SRC 4,[1380088-03-8],NC1=C2C(N(C4=CC=CC(C5=CN=NN5CC6=CC(C7=CC=CC=C7)=CC=C6)=C4)N=C2C3=CC=C(Cl)C=C3)=NC=N1,Enzymes,Kinases,Src Kinases,Potent and selective c-Src inhibitor,"Potent and selective c-Src inhibitor (Ki = 44 nM); does not inhibit c-Abl at concentrations up to 125 muM. Selective between Src family members (Kd values are 86, 160, 240, 720, 3200, 4400, and >40,000 nM for c-Src, Lck, Fgr, Yes, Lyn, Hck and Fyn respectively). Significantly inhibits cell growth in 4T1 mammary carcinoma tumor cells.",555.03
KB-R7943 mesylate,[182004-65-5],CS(O)(=O)=O.NC(=N)SCCC1=CC=C(OCC2=CC=C(C=C2)[N+]([O-])=O)C=C1,Transporters,Ion Pumps/Transporters,Na+/Ca2+ Exchanger,Na+/Ca2+ exchange inhibitor (reverse mode),"Potent, selective inhibitor of the reverse mode of the Na+/Ca2+ exchanger (IC50 = 0.7 muM). Also inhibits the mitochondrial Ca2+ uniporter (MCU; IC50 = 5.5 muM). Does not affect Na+-dependent transport systems or ionotropic glutamate receptors.",427.49
Kenpaullone,[142273-20-9],BrC1=CC=C2NC3=C(CC(=O)NC4=CC=CC=C34)C2=C1,Enzymes,Kinases,Glycogen Synthase Kinase 3,GSK-3beta inhibitor; also inhibits cdks,"GSK-3beta inhibitor (IC50 = 0.23 muM). Also inhibits cyclin dependent kinases (cdks) in the sub micromolar range (reported IC50 values are 0.4, 0.68-7 and 0.85 muM for cdk1, cdk2 and cdk5, respectively). Generates induced pluripotent stem cells (iPSCs) from somatic cells when used in combination with reprogramming factors; can replace Klf4.",327.18
KF 38789,[257292-29-8],COC1=CC=C(C2CC(=NCCS2)C2=C(O)C=C(C)OC2=O)C(OC)=C1,Extracellular Matrix and Adhesion Molecules,Cell Adhesion Molecules,,Selective inhibitor of P-selectin-mediated cell adhesion,Selective inhibitor of P-selectin-mediated cell adhesion (IC50 = 1.97 muM) that displays no effects on L-selectin- and E-selectin-mediated adhesion. Blocks P-selectin-mediated binding in vitro and leukocyte accumulation in vivo.,375.44
KG 5,[877874-85-6],NC1=NC(SC)=NC(OC(C=C4)=CC=C4C3=NN=C(N3)NC2=CC(C(F)(F)F)=CC=C2)=C1,Enzymes,Kinases,Raf Kinase,"PDGFRbeta, B-Raf, c-Raf, FLT3 and KIT inhibitor","PDGFRbeta and B-Raf allosteric inhibitor. Also inhibits c-Raf, FLT3 and KIT. Disrupts blood vessel formation in zebrafish embryos and inhibits angiogenesis in a mouse angiogenesis model. Inhibits growth of renal and pancreatic tumors in mice. Also arrests cells in prometaphase. Orally available.",459.45
KHS 101 hydrochloride,,CC(C)CNC1=NC(NCC2=CSC(C3=CC=CC=C3)=N2)=NC=C1.Cl,Stem Cells,Stem Cell Differentiation,Neural Stem Cells,Selective inducer of neuronal differentiation in hippocampal neural progenitors,Selective inducer of neuronal differentiation; induces neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs) by interacting with TACC3 (EC50 ~1 muM). Suppresses astrocyte formation. Also induces acceleration of neuronal differentiation in the hippocampal dentate gyrus in vivo.,375.92
Ki 20227,[623142-96-1],O=C(NC(C)C3=NC=CS3)NC(C(OC)=C2)=CC=C2OC1=C4C(C=C(OC)C(OC)=C4)=NC=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Other RTKs,c-Fms inhibitor; suppresses osteolysis and osteoclast accumulation,"Inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRbeta and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model.",480.54
Ki 8751,[228559-41-9],COC1=C(OC)C=C2C(OC3=CC=C(NC(=O)NC4=CC=C(F)C=C4F)C(F)=C3)=CC=NC2=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,"Potent, selective VEGFR-2 inhibitor","Potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC50 = 0.9 nM). Displays some inhibitory activity towards c-Kit, PDGFRalpha and FGFR-2 (IC50 values range from 40 to 170 nM) but is highly selective over other receptor tyrosine kinases (IC50 > 10000 nM for FGFR-2, EGFR and HGFR). Inhibits VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) and inhibits tumor growth in vivo; antiangiogenic.",469.41
KL 001,[309928-48-1],OC(CN(CC4=CC=CO4)S(C)(=O)=O)CN2C1=CC=CC=C1C3=C2C=CC=C3,Signal Transduction,Transcription Factors,Other Transcription Factors,Cryptochrome protein stabilizer; lengthens circadian period,Cryptochrome protein (CRY) stabilizer; blocks proteasome-mediated degradation of CRY1 and CRY2. Lengthens circadian period in mouse NIH-3T3 fibroblasts without altering casein kinase activity. Represses glucagon-induced hepatic gluconeogenesis through the induction of Pck1 and G6pc expression.,398.48
Ko 143,[461054-93-3],O=C(N[C@H]4CCC(OC(C)(C)C)=O)[C@]3([H])CC1=C([C@H](CC(C)C)N3C4=O)NC2=C1C=CC(OC)=C2,Transporters,Multidrug Transporters,,Potent and selective BCRP inhibitor,Potent and selective breast cancer resistance protein multidrug transporter (BCRP) inhibitor (EC90 = 26 nM). Displays > 200-fold selectivity over P-gp and MRP-1 transporters. Increases intracellular drug accumulation and reverses BCRP-mediated multidrug resistance. Inhibits ABCB1 and ABCC1 at higher concentrations. Rapidly metabolized in rat plasma.,469.57
KRCA 0008,[1472795-20-2],ClC1=C(NC2=C(OC)C=C(N3CCN(C(C)=O)CC3)C=C2)N=C(NC4=CC=C(N5CCN(C(C)=O)CC5)C=C4OC)N=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),ALK,Potent Ack1 and ALK dual inhibitor; orally bioavailable,Potent Ack1 and anaplastic lymphoma kinase (ALK) dual inhibitor (IC50 values are 4 and 12 nM respectively). Inhibits lung cancer H3122 cell proliferation (IC50 = 80 nM). Attenuates H3122 cell xenograft tumor growth in mice. Orally bioavailable.,609.12
KS 176,[1253452-78-6],OCCC1=CC=C(NC(C2=C(NC(C3=CC=C([N+]([O-])=O)C=C3)=O)C=CC=C2)=O)C=C1,Transporters,Multidrug Transporters,,Selective BCRP inhibitor,Selective inhibitor of the breast cancer resistance protein (BCRP) multidrug transporter (IC50 values are 0.59 and 1.39 muM in Pheo A and Hoechst 33342 assays respectively). Displays no inhibitory activity against P-gp or MRP1.,405.4
KU 60019,[925701-46-8],O=C(CN4C[C@H](C)O[C@H](C)C4)NC(C=C3)=CC2=C3SC1=C(C5=CC(C=C(N6CCOCC6)O5)=O)C=CC=C1C2,Enzymes,Kinases,ATM & ATR Kinase,Potent ATM kinase inhibitor,Potent ATM kinase inhibitor (IC50 = 6.3 nM). Exhibits little to no nonspecific target effects against a panel of 229 protein kinases; displays similar target selectivity to KU 55933 (Cat. No. 3544). Inhibits migration and invasion of human glioma cells in vitro.,547.67
KU14R,[189224-48-4],CCC1(CC2=CC=CC=C2O1)C1=NC=CN1,Other Pharmacology,Imidazoline Receptors,I3 Receptors,Antagonist of pancreatic imidazoline receptor,Antagonist of the atypical imidazoline binding site (putative I3 receptor) of pancreatic beta-cells. Selectively blocks efaroxan-induced insulin secretion in vitro and in vivo.,214.27
KW 3902,[136199-02-5],O=C1C2=C(NC(C34CC(CC4C5)CC5C3)=N2)N(CCC)C(N1CCC)=O,7-TM Receptors,Adenosine Receptors,Adenosine A1 Receptors,Selective A1 antagonist,Selective adenosine A1 receptor antagonist; displays 890-fold selectivity for rat A1 receptors over A2A receptors (Ki values are 0.19 and 170 nM respectively). Displays no effect on recombinant rat A3 receptors expressed on CHO cells at concentrations up to 10 muM. Exhibits diuretic and renal protective effects in rats.,356.46
KY 02111,[1118807-13-8],O=C(CCC3=CC=C(OC)C(OC)=C3)NC2=NC1=CC=C(Cl)C=C1S2,Stem Cells,Stem Cell Differentiation,Cardiomyocyte Stem Cells,Inhibits canonical Wnt signaling. Promotes differentiation of human ESCs and iPSCs into cardiomyocytes,Promotes differentiation of human ESCs and iPSCs into cardiomyocytes when used after day three in culture; differentiation efficiency increases when used after initial culture with CHIR 99021 (Cat. No. 4423). Induces downregulation of Wnt signaling target genes; inhibits canonical Wnt signaling in a manner distinct from other known Wnt inhibitors.,376.86
Kynurenic acid,[492-27-3],OC(=O)C1=CC(O)=C2C=CC=CC2=N1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Broad spectrum glutamatergic antagonist,Broad spectrum EAA antagonist. Putative GPR35 ligand. Sodium Salt also available.,189.17
L 760735,[188923-01-5],FC(C=C3)=CC=[C@@]3[C@@H]1N(CC4=C(CN(C)C)NN=N4)CCO[C@@H]1O[C@H](C)C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2.Cl,7-TM Receptors,Peptide Receptors,Tachykinin Receptors,High affinity NK1 antagonist,High affinity NK1 receptor antagonist (IC50 = 0.19 nM at human NK1 receptors). Selective (>300-fold) over h-NK2 and h-NK3 receptors. Exhibits anxiolytic and antidepressant-like effects. Orally active.,611.98
"L-152,804",[6508-43-6],CC1(C)CC(=O)C(C2C3=C(OC4=C2C(=O)CC(C)(C)C4)C=CC=C3)C(=O)C1,7-TM Receptors,Peptide Receptors,NPY Receptors,"Potent, selective non-peptide NPY Y5 receptor antagonist","Potent, selective non-peptide neuropeptide Y Y5 receptor antagonist (Ki = 26 nM for hY5). Displays > 300-fold selectivity over hY1, hY2, and hY4 receptors. Causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure. Centrally active upon oral administration in vivo.",366.46
"L-161,982",[147776-06-5],CCCCC1=NN(C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)S(=O)(=O)NC(=O)C1=C(C)C=CS1)C1=C(C=CC=C1)C(F)(F)F,7-TM Receptors,Prostanoid Receptors,,Selective EP4 receptor antagonist,"EP4 receptor antagonist that is selective over all other members of the prostanoid receptor family (Ki values are 0.024, 0.71, 1.90, 5.10, 5.63, 6.74, 19 and 23 muM for human EP4, TP, EP3, DP, FP, IP, EP1 and EP2 receptors respectively). Suppresses PGE2-induced bone formation in rats and prevents the nociceptive response induced by misoprostol in formalin-injected mice.",654.72
"L-165,041",[79558-09-1],CCCC1=C(O)C(CC=O)=CC=C1OCCCOC1=CC=C(OCC(O)=O)C=C1,Nuclear Receptors,PPARs,PPARdelta Receptors,Potent PPARdelta agonist,"Potent PPARdelta agonist (Ki = 6 nM); displays > 100-fold selectivity for both mouse and human PPARdelta receptors over other subtypes. Raises plasma cholesterol levels in vivo, in insulin-resistant db/db mice. Neuroprotective in models of cerebral infarction and Parkinson's disease.",402.44
"L-168,049",[191034-25-0],CCCOC1=C(C=C(Br)C=C1)C1=C(NC(=C1)C1=CC=C(Cl)C=C1)C1=CC=NC=C1,7-TM Receptors,Peptide Receptors,Glucagon and Related Peptide Receptors,"Potent, orally active human glucagon receptor antagonist","Very potent and selective, non-competitive antagonist of the human glucagon receptor (hGR). Binds with high affinity to human GR (IC50 = 3.7 nM), and moderate affinity to murine and canine GRs (IC50 values are 63 and 60 nM respectively). In contrast, displays poor affinity for rat, guinea pig, and rabbit glucagon receptors (IC50 > 1 muM). In functional studies, inhibits glucagon-stimulated cAMP synthesis in CHO cells expressing hGR (IC50 = 41 nM), and in murine liver membranes. Orally active in vivo.",467.79
"L-368,899 hydrochloride",[160312-62-9],CC(C=CC=C2)=C2N1CCN(S(CC34CCC(C(C)4C)C[C@@H]3NC([C@@H](N)CCS(C)(=O)=O)=O)(=O)=O)CC1.Cl,7-TM Receptors,Peptide Receptors,Oxytocin Receptors,"Potent, non-peptide oxytocin receptor antagonist","Potent, non-peptide and orally active oxytocin receptor antagonist (IC50 = 8.9 nM) that displays > 40-fold selectivity over vasopressin V1a and V2 receptors (IC50 values are 370 and 570 nM respectively). Antagonizes oxytocin-induced uterine contractions in vitro and in vivo.",591.23
"L-655,708",[130477-52-0],O=C(N3[C@]([H])2CCC3)C4=C(C=CC(OC)=C4)N1C2=C(C(OCC)=O)N=C1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Benzodiazepine inverse agonist; selective for alpha5-containing GABAA receptors,"Potent, selective inverse agonist for the benzodiazepine site of GABAA receptors containing the alpha5 subunit (Ki = 0.45 nM). Displays 50-100-fold selectivity over GABAA receptors containing alpha1, alpha2, alpha3 or alpha6 subunits in combination with beta3 and gamma2. Enhances LTP in a mouse hippocampal slice model and increases spatial learning, without displaying proconvulsant activity.",341.37
"L-701,324",[142326-59-8],OC1=C(C(=O)NC2=CC(Cl)=CC=C12)C1=CC=CC(OC2=CC=CC=C2)=C1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,NMDA antagonist; acts at glycine site,An orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor.,363.8
"L-732,138",[148451-96-1],O=C(N[C@@](CC2=CNC3=C2C=CC=C3)([H])C(OCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)=O)C,7-TM Receptors,Peptide Receptors,Tachykinin Receptors,Potent and selective NK1 antagonist,Potent and highly selective competitive tachykinin NK1 receptor antagonist (IC50 = 2.3 nM).,472.39
"L-755,507",[159182-43-1],O=S(C1=CC=C(NC(NCCCCCC)=O)C=C1)(NC2=CC=C(CCNC[C@H](O)COC3=CC=C(O)C=C3)C=C2)=O,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-3 Receptors,Very potent and selective beta3 partial agonist,"Potent beta3-adrenergic receptor partial agonist > 1000-fold selective over beta1- and beta2-adrenoceptors (EC50 values are 0.43, 580 and > 10000 nM for activation of cloned human beta3-, beta1- and beta2-adrenoceptors respectively). Stimulates lipolysis in rhesus adipocytes in vitro (EC50 = 3.9 nM). Enhances CRISPR-mediated homology-directed repair (HDR) efficiency 2-3-fold for large fragments and ~9-fold for point mutations, in human induced pluripotent stem cells (iPSCs).",584.73
"L-798,106",[244101-02-8],O=C(NS(C4=C(OC)C=CC(Br)=C4)(=O)=O)/C=C/C1=CC=CC=C1CC3=CC2=CC=CC=C2C=C3,7-TM Receptors,Prostanoid Receptors,,Potent and highly selective EP3 antagonist,"Potent and highly selective prostanoid EP3 receptor antagonist (Ki values are 0.3, 916, > 5000 and > 5000 nM at EP3, EP4, EP1 and EP2 respectively). Attenuates sulprostone-induced inhibition of EFS-evoked twitch and contractile responses in vivo.",536.44
"L-838,417",[286456-42-6],FC(C=CC(F)=C3)=C3C1=NN=C2N1N=C(OCC4=NC=NN4C)C(C(C)(C)C)=C2,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,GABAA partial agonist; displays subtype selectivity,"Subtype-selective GABAA receptor partial agonist. Selectively binds to alpha1, alpha2, alpha3 and alpha5 subunits (Ki values are 0.79, 0.67, 0.67 and 2.25 nM respectively) but displays no efficacy at alpha1 (alpha1-sparing). Exhibits non-sedative anxiolytic, antinociceptive and anti-inflammatory activity in vivo.",399.4
L-NAME hydrochloride,[51298-62-5],N=C(NCCC[C@H](N)C(OC)=O)N[N+]([O-])=O.Cl,Enzymes,Synthases/Synthetases,NO Synthases,Non-selective NOS inhibitor,NO synthase inhibitor.,269.69
Lazabemide hydrochloride,[103878-83-7],Cl.NCCNC(=O)C1=NC=C(Cl)C=C1,Enzymes,Oxygenases/Oxidases,Monoamine Oxidase,Selective MAO-B inhibitor,"Selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 muM for MAO-B and MAO-A respectively). Inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 muM for noradrenalin, serotonin and dopamine uptake respectively).",236.1
LB 42708,[226929-39-1],O=C(N4CCOCC4)C1=CN(CC5=CN=CN5CC6=CC=C(Br)C=C6)C=C1C2=CC=CC3=C2C=CC=C3,Enzymes,Transferases,Protein Prenyltransferases,Selective farnesyltransferase (FTase) inhibitor,"Selective inhibitor of farnesyltransferase (FTase). Blocks farnesylation of H-Ras, N-Ras and K-Ras4B (IC50 values are 0.8, 1.2 and 2.0 nM respectively). Displays >50,000-fold selectivity for FTase over geranylgeranyltransferase (GGTase) I. Inhibits VEGF-induced Ras activation; suppresses angiogenesis in vivo and in vitro (IC50 = 75 nM). Orally active.",555.46
LDN 209929 dihydrochloride,[1784281-97-5],ClC1=CC=C(N=C(C=CC(OC)=C3)C3=C2SCCCN)C2=C1.Cl.Cl,Enzymes,Kinases,Haspin,Potent and selective haspin inhibitor,Potent and selective haspin kinase inhibitor (IC50 = 55 nM). Displays 180-fold selectivity over DYRK2.,405.77
LDN 27219,[312946-37-5],O=C(NN)CSC(N1C2=CC=CC=C2)=NC3=C(C(C4=CC=CC=C4)=CS3)C1=O,Enzymes,Transferases,Other Transferases,Transglutaminase 2 (TG2) inhibitor; reversible,Transglutaminase 2 (TG2) inhibitor (IC50 = 0.25 muM). Binds at GTPase site; reversible.,408.5
LE 135,[155877-83-1],CN1C2=C(C=C3C(=C2)C(C)(C)CCC3(C)C)N=C(C2=CC=C(C=C2)C(O)=O)C2=C1C=CC=C2,Nuclear Receptors,Retinoic Acid Receptors,,Selective RARbeta antagonist,Retinoic acid antagonist; displays moderate selectivity for RARbeta over RARalpha (Ki values are 0.22 and 1.4 muM respectively). Highly selective over RARgamma and RXRalpha. Inhibits human HL-60 leukemia cell differentiation induced by Am80 (IC50 = 150 nM).,438.56
Letrozole,[112809-51-5],N#CC(C=C2)=CC=C2C(N3N=CN=C3)C1=CC=C(C#N)C=C1,Enzymes,Cytochrome P450,,"Potent, reversible non-steroidal aromatase inhibitor","Potent, reversible non-steroidal aromatase inhibitor (IC50 = 11.5 nM). Displays antitumor effects in several animal models. Suppresses the endogenous aromatase-induced proliferation of MCF-7 cells.",285.3
Levetiracetam,[102767-28-2],O=C1N([C@@H](CC)C(N)=O)CCC1,Signal Transduction,"Translocation, Exocytosis & Endocytosis",,Antiepileptic; binds SV2A,Antiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3- exchange. Deuterated analog also available.,170.21
Levonorgestrel,[797-63-7],[H][C@@]12C(CC[C@]3([H])[C@@]([H])2CC[C@@]4(CC)[C@]([H])3CC[C@@](C#C)4O)=CC(CC1)=O,Nuclear Receptors,Progesterone Receptor,,Synthetic progesterone analog,"Synthetic progesterone analog; binds to the progesterone receptor (relative binding affinities are < 0.02, 7.5, 17, 58 and 323 % for estrogen receptors, glucocorticoid receptors, mineralocorticoid receptors, androgen receptors and progesterone receptors respectively).",312.45
LH 846,[639052-78-1],O=C(CC3=CC=CC=C3)NC(S2)=NC1=C2C=C(C)C(Cl)=C1,Enzymes,Kinases,Casein Kinase 1,Selective casein kinase 1delta inhibitor,"Selective inhibitor of casein kinase (CK) 1delta (IC50 values are 290 nM, 1.3 muM and 2.5 muM for CK1delta, epsilon and alpha); displays no inhibitory activity at CK2. Inhibits CK1delta-dependent phosphorylation and degradation of PER1 protein. Shown to lengthen the circadian period in U2OS cells, with minimal effect on amplitude.",316.81
Liarozole dihydrochloride,,ClC1=CC(C(N4C=CN=C4)C2=CC=C(N=CN3)C3=C2)=CC=C1.Cl.Cl,Nuclear Receptors,Retinoic Acid Receptors,,Blocks retinoic acid metabolism,"Cytochrome P450 inhibitor. Inhibits several cytochrome P450 enzymes including aromatase (CYP19) and retinoic acid 4-hydroxylase (CYP26). Blocks retinoic acid metabolism (retinoic acid metabolism blocking agent, RAMBA). Displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.",381.69
Licarbazepine,[29331-92-8],NC(N2C1=CC=CC=C1C(O)CC3=C2C=CC=C3)=O,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Active metabolite of oxcarbazepine (Cat. No. 3864),Active metabolite of oxcarbazepine (Cat. No. 3864). Produces dose-dependent inhibition of glutamatergic excitatory postsynaptic potentials (EPSPs). Displays anticonvulsant activity; exhibits minor potentiation of GABAA receptor currents.,254.28
LIMKi 3,[1338247-35-0],FC(F)C1=NN(C2=C(Cl)C=CC=C2Cl)C(C3=CN=C(NC(C(C)C)=O)S3)=C1,Enzymes,Kinases,LIMK,Potent LIM kinase inhibitor; antitumor,Potent LIM kinase inhibitor (IC50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.,431.29
Linezolid,[165800-03-3],FC1=CC(N3C[C@H](CNC(C)=O)OC3=O)=CC=C1N2CCOCC2,Cell Metabolism,"DNA, RNA and Protein Synthesis",,Antibiotic; inhibits protein synthesis in gram-positive bacteria,Oxazolidinone antibiotic. Inhibits bacterial protein synthesis prior to chain initiation. Displays potent antibacterial activity against a variety of multidrug-resistant gram-positive microbes in vitro and in vivo.,337.35
Linopirdine dihydrochloride,[113168-57-3],Cl.Cl.O=C1N(C2=CC=CC=C2C1(CC1=CC=NC=C1)CC1=CC=NC=C1)C1=CC=CC=C1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV7 (KCNQ) channel blocker,Blocker of KV7 (KCNQ) voltage-gated potassium channels; blocks KV7.1 + 7.3 (KCNQ2 + 3) / M-currents (IC50 = 4 - 7 muM) and KV7.1 (KCNQ1) homomeric channels (IC50 = 8.9 muM). Augments hippocampal ACh release and is a cognitive enhancer following oral administration in vivo.,464.39
LM 22A4,[37988-18-4],O=C(NCCO)C1=CC(C(NCCO)=O)=CC(C(NCCO)=O)=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Trk Receptors,Potent TrkB agonist,"Potent tropomyosin-related kinase B (TrkB) agonist. Induces activation of Trk, Akt and ERK in mouse hippocampus and striatum and exhibits neurotrophic activity. Reverses deficits in motor task learning in mice following traumatic brain injury; restores respiratory function in a rat model of Rett syndrome.",339.34
LMK 235,[1418033-25-6],CC1=CC(C(NOCCCCCC(NO)=O)=O)=CC(C)=C1,Enzymes,Histone Deacetylases,Class II HDACs,Selective HDAC4/HDAC5 inhibitor,"Selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor (IC50 values are 4.22, 11.9, 55.7, 320, 852, 881, and 1278 nM for HDAC 5, 4, 6, 1, 11, 2, and 8, respectively). Demonstrates activity against chemoresistant cancer cell lines in an MTT assay for cytotoxicity using human ovarian cancer cell lines A2780 and cisplatin resistant A2780CisR (IC50 = 0.49 and 0.32 muM respectively).",294.35
Lomeguatrib,[192441-08-0],NC1=NC(OCC3=CC(Br)=CS3)=C2C(N=CN2)=N1,Enzymes,Transferases,DNA Methyltransferases,MGMT inhibitor,Inhibitor of O6-methylguanine-DNA methyltransferase (MGMT); (IC50 = 0.009 muM in cell-free extracts from HeLa S3 cells); attenuates MGMT activity in vitro and in vivo. Enhances the antitumor activity of temozolomide (Cat. No. 2706) in both human melanoma and MCF-7 xenografts.,326.17
Lonidamine,[50264-69-2],OC(=O)C1=NN(CC2=C(Cl)C=C(Cl)C=C2)C2=CC=CC=C12,Enzymes,Kinases,Hexokinases,Mitochondrial hexokinase inhibitor,Anticancer and antispermatogenic agent in vitro and in vivo. Inhibits cellular energy metabolism in some cells via inhibition of mitochondrial hexokinase. Also blocks CFTR Cl- channels in vitro.,321.16
Loratidine,[79794-75-5],CCOC(=O)N1CC\C(CC1)=C1/C2=NC=CC=C2CCC2=C1C=CC(Cl)=C2,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,Peripheral H1 antagonist; antiallergic agent,Peripheral histamine H1 receptor antagonist (Ki = 35 nM); devoid of central effects. Orally active antiallergic agent.,382.88
Losartan potassium,[124750-99-8],CCCCC1=NC(Cl)=C(CO)N1CC2=CC=C(C3=CC=CC=C3C(N=N4)=NN4[K])C=C2,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,"Selective, non-peptide AT1 antagonist",Selective non-peptide angiotensin AT1 receptor antagonist. Inhibits the contractile effects of angiotensin II on rabbit aorta and jugular vein (pA2 = 8.27). Orally active antihypertensive agent.,461
Lovastatin,[75330-75-5],[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC,Enzymes,Reductases,HMG-CoA Reductase,Potent HMG-CoA reductase inhibitor,"Potent, competitive inhibitor of HMG-CoA reductase (Ki = 0.6 nM) therefore decreases cholesterol biosynthesis, in vitro and in vivo. Indirectly inhibits Rho-GTPase activity by depleting intracellular pool of isoprene residues. Decreases CDK2, 4, 6 and cyclin E levels and induces G1 arrest and apoptosis in tumor cell lines in vitro. Inactive lactam prodrug of lovastatin hydroxy acid, naturally bioactivated in vivo following oral administration.",404.54
LRRK2-IN-1,[1234480-84-2],O=C2C3=C(C=CC=C3)N(C)C1=NC(NC4=C(OC)C=C(C(N5CCC(N6CCN(C)CC6)CC5)=O)C=C4)=NC=C1N2C,Enzymes,Kinases,RIP kinase family,Potent and selective LRRK2 inhibitor,"Potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2). Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC50 values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-gamma-induced monocyte maturation in vitro.",570.09
LSN 2463359,[1401031-52-4],O=C(NC(C)C)C(C=C2)=NC=C2C#CC1=CC=NC=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Potent and selective positive allosteric modulator of mGlu5 receptors,"Potent and selective positive allosteric modulator at the mGlu5 receptor (EC50 = 24 nM). Has no activity at mGlu1-4, mGlu8 and GABAB receptors. Reverses methylazoxymethanol acetate (MAM)-induced deficits in reversal learning memory and normalizes SDZ 220-581 and RO 63-1908-induced alterations in instrumental responses in rat models. Promotes wakefulness in vivo. Brain penetrant and orally active.",265.31
Lu AA 47070,[913842-25-8],FC1=C(NC(CC(C)(C)C)=O)C(F)=CC(C(/N=C2\SC=CN2COP(O)(O)=O)=O)=C1,7-TM Receptors,Adenosine Receptors,Adenosine A2A Receptors,Prodrug of a potent and selective adenosine A2A receptor antagonist,"Prodrug of a potent and selective adenosine A2A receptor antagonist (Ki values are 5.9, 260, 410 and <10,000 nM for A2A, A2B, A1 and A3 receptors respectively. Reverses parkinsonian motor impairment and motivational effects produced by dopamine D2 receptor blockade in rats. Orally bioavailable.",463.39
LUF 5834,[333962-91-7],NC1=NC(SCC3=NC=CN3)=C(C#N)C(C2=CC=C(O)C=C2)=C1C#N,7-TM Receptors,Adenosine Receptors,Adenosine A2A Receptors,Potent adenosine A2A and A2B receptor partial agonist,Potent A2A and A2B adenosine receptor partial agonist ( Ki = 2.6 nM and EC50 = 12 nM respectively). Also exhibits selectivity for A1 over A3 (Ki values are 2.6 and 538 nM respectively).,348.38
LY 2183240,[874902-19-9],CN(C)C(=O)N1N=NN=C1CC1=CC=C(C=C1)C1=CC=CC=C1,Transporters,Neurotransmitter Transporters,Cannabinoid Transporters,Highly potent anandamide uptake inhibitor; also inhibits FAAH,"Novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). Inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). Following i.p. administration in rats, increases brain anandamide concentration and exerts antinociceptive effects in formalin model of pain.",307.35
LY 225910,[133040-77-4],CC(C)OC1=CC=CC(=C1)N1C(CCC2=CNC3=CC=C(Br)C=C23)=NC2=C(C=CC=C2)C1=O,7-TM Receptors,Peptide Receptors,Cholecystokinin (CCK) Receptors,Potent CCK2 antagonist,Potent CCK2 receptor antagonist (IC50 = 9.3 nM for inhibition of 125I-labeled CCK-8 sulfate binding at mouse brain membranes).,502.41
LY 2365109 hydrochloride,[1779796-27-8],CC(C)(C)C1=C(OCCN(C)CC(O)=O)C=CC(C2=CC(OCO3)=C3C=C2)=C1.Cl,Transporters,Neurotransmitter Transporters,Glycine Transporters,Potent and selective GlyT1 inhibitor,"Potent and selective glycine transporter 1 (GlyT1) inhibitor (IC50 values are 15.8 and > 30 000 nM at GlyT1 and GlyT2 respectively). Induces a dose-dependent elevation in CSF levels of glycine, and enhances acetylcholine and dopamine release in the striatum and prefrontal cortex respectively. Produces profound locomotor and respiratory impairments at higher doses.",421.91
LY 255283,[117690-79-6],CCC1=C(OCCCCCC(C)(C)C2=NN=NN2)C=C(O)C(=C1)C(C)=O,7-TM Receptors,Leukotriene and Related Receptors,,"Selective, competitive BLT2 receptor antagonist","Selective, competitive antagonist of BLT2 receptors (IC50 values are ~ 1 and > 10 muM at human recombinant BLT2 and BLT1 receptors respectively). Inhibits LTB4-induced contraction of lung parenchyma (pA2 = 7.2), and reduces LTB4-mediated airway obstruction in guinea pigs following i.v. and oral administration. .",360.46
LY 266097 hydrochloride,[172895-39-5],CC1=CC=C(NC3=C2CCNC3CC4=CC=C(OC)C(OC)=C4Cl)C2=C1.Cl,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Selective 5-HT2B antagonist,Selective 5-HT2B receptor antagonist (pKi = 9.3). More than 100-fold selective over 5-HT2A and 5-HT2C. Attenuates amphetamine-induced locomotion in the rat.,407.33
LY 294002 hydrochloride,[934389-88-5],Cl.O=C1C=C(OC2=C1C=CC=C2C1=CC=CC=C1)N1CCOCC1,Enzymes,Kinases,PI 3-Kinase,Prototypical PI 3-kinase inhibitor; also inhibits other kinases,"Prototypical PI 3-kinase inhibitor (IC50 values are 0.31, 0.73, 1.06 and 6.60 muM for PI 3-Kbeta, PI 3-Kalpha, PI 3-Kdelta and PI 3-Kgamma respectively). Also inhibits other kinases including, CK2, mTOR, PLK1, PIM1 and PIM3. Inhibits proliferation and induces apoptosis in human colon cancer cells in vitro and in vivo. Suppresses proliferation of mESCs. Inhibits autophagic sequestration in rat hepatocytes. Negative Control also available. ",343.81
LY 303511,[154447-38-8],O=C1C=C(OC2=C(C=CC=C12)C1=CC=CC=C1)N1CCNCC1,Enzymes,Kinases,PI 3-Kinase,Negative control of LY 294002 (Cat. No. 1130),"Negative control compound for LY 294002 PI 3-kinase inhibitory activity. Blocks voltage-gated potassium (Kv) channels (IC50 = 64.6 muM) and inhibits IL-1beta-stimulated NF-kappaB activation, attenuating MCP-1 expression. Antiproliferative. Also inhibits the BET bromodomain proteins BRD2, BRD3 and BRD4. Active Analog also available.",306.36
LY 344864 hydrochloride,[1217756-94-9],Cl[H].CN(C)[C@@H]1CCC2=C(C1)C1=CC(NC(=O)C3=CC=C(F)C=C3)=CC=C1N2,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Potent and selective 5-HT1F agonist,"Potent, selective 5-HT1F receptor agonist (EC50 = 3 nM). Displays > 80-fold selectivity over other 5-HT receptors (Ki values are 0.006, 0.53, 0.55, 0.56, 1.42, 1.70, 3.50, 3.94 and 4.85 muM for 5-HT1F, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2B, 5-HT2C, 5-HT2A and 5-HT7 receptors respectively). Inhibits neurogenic dural inflammation in vivo following i.v. and oral administration.",387.88
LY 364947,[396129-53-6],N1C=C(C(=N1)C1=CC=CC=N1)C1=CC=NC2=CC=CC=C12,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Selective inhibitor of TGF-betaRI,"Selective inhibitor of TGF-beta type-I receptor (TGF-beta RI, TGFR-I, TbetaR-I, ALK-5) (IC50 values are 59, 400 and 1400 nM for TGR-beta RI, TGF-beta RII and MLK-7K respectively). Inhibits TGF-beta-dependent luciferase production in mink lung cells (p3TP lux) and growth in mouse fibroblasts (NIH 3T3) (IC50 values are 47 and 89 nM respectively). Suppresses invasion of MDA-MB-231 breast cancer cells in a matrigel invasion assay.",272.31
LY 404187,[211311-95-4],N#CC1=CC=C(C2=CC=C(C(C)CNS(C(C)C)(=O)=O)C=C2)C=C1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Selective positive allosteric modulator of AMPA receptors,"Selective AMPA receptor positive allosteric modulator (IC50 values are 0.15, 0.21, 1.66 and 5.65 muM for GluA2i, GluA4i, GluA3i and GluA1i respectively). Potentiates glutamate and AMPA-evoked currents in pre frontal cortex (PFC) pyramidal neurons in vitro. Has no effect on NMDA- or kainate-evoked currents; also has no effect on K+ or Na+ ion channels. Potentiates PFC glutamatergic synaptic transmission in vitro and in vivo. Induces neurite growth in combination with (S)-AMPA (Cat. No. 0254) in SH-SY5Y human neuroblastoma cells in vitro. Also reduces MPTP-induced toxicity in mice. Brain penetrant.",342.46
LY 456236 hydrochloride,[338736-46-2],Cl.COC1=CC=C(NC2=C3C=C(OC)C=CC3=NC=N2)C=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Selective mGlu1 antagonist,Selective mGlu1 receptor antagonist (IC50 values are 143 nM and > 10 muM for mGlu1 and mGlu5 receptors respectively). Reduces hyperalgesic behavior induced by formalin in both mouse and rat with ED50 values of 28 and 16.3 mg/kg respectively.,317.77
M 25,,O=C(C(CCC)CCC)NCC1=CC=C(N(C3=CC=CC=C3OC)N=C2)C2=C1,7-TM Receptors,Smoothened Receptors,,Potent Smoothened (Smo) receptor antagonist,"Potent Smoothened (Smo) receptor antagonist (IC50 = 5 nM). Inhibits the Hedgehog signaling pathway. Inhibits Shh induced Gli luciferase reporter activity in Shh-light 2 cells (IC50 = 5 nM). Antagonizes GSA-10 and SAG-mediated differentiation of the C3H10T1/2 cell line (IC50 values are 69 and 115 nM, respectively).",379.5
M 344,[251456-60-7],O=C(NCCCCCCC(NO)=O)C1=CC=C(N(C)C)C=C1,Enzymes,Histone Deacetylases,Non-selective HDACs,Histone deacetylase inhibitor,Histone deacetylase inhibitor (IC50 = 100 nM). Induces terminal cell differentiation and causes an increase in hyperacetylated histone H4. Antiproliferative agent; suppresses the growth of human endometrial and ovarian cancer cells by inducing cell cycle arrest and apoptosis.,307.39
m-3M3FBS,[200933-14-8],CC1=CC(C)=C(C(C)=C1)S(=O)(=O)NC1=CC=CC(=C1)C(F)(F)F,Enzymes,Esterases,Phospholipases,Phospholipase C activator,"Activator of phospholipase C (PLC). Stimulates superoxide generation, Ca2+ release and inositol phosphate formation in a variety of cell types. Also inhibits growth of the leukemic cell lines U937 and THP-1. Negative Control also available.",343.36
M8 B hydrochloride,[883976-12-3],COC1=C(OCC2=CC=CC=C2)C=CC(CN(CCN)C(C3=CC=CS3)=O)=C1.Cl,Ion Channels,Transient Receptor Potential Channels,TRPM,Potent and selective TRPM8 channel blocker,Potent and selective TRPM8 channel blocker. Blocks cold- and icilin-induced TRPM8 activation in vitro (IC50 values are 7.8 and 26.9 nM respectively). Exhibits no effect at other TRP channels (IC50 > 20 muM). Reduces body temperature in vivo.,432.96
Maraviroc,[376348-65-1],O=C(C4CCC(F)(F)CC4)N[C@@H](CCN2C3CCC2CC(N5C(C)=NN=C5C(C)C)C3)C1=CC=CC=C1,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,Selective CCR5 antagonist,"Selective CCR5 antagonist; displays potent anti-HIV-1 activity. Prevents the interaction of HIV-1 gp120 and CCR5 (IC50 = 6.4 nM), inhibiting HIV-1 entry. Exhibits antinociceptive effects in a rat model of neuropathic pain. Also inhibits CCL3 (MIP-1alpha) binding to CCR5. Orally bioavailable.",513.67
MaxiPost,[187523-35-9],O=C2[C@]([C@]3=CC(Cl)=CC=C3OC)(F)C1=CC=C(C(F)(F)F)C=C1N2,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,Potassium channel modulator; exerts subtype-specific effects,Potassium channel modulator. Acts as a positive modulator at neuronal Kv7 channels and calcium-activated K+ channels (BKCa) in HEK293 cells. Displays negative modulatory activity at Kv7.1 channels (Ki = 3.7 muM) and GABAA receptors. Displays anxiolytic activity in vivo.,359.7
MCOPPB trihydrochloride,[1108147-88-1],CC5(CCCCCCC5)N(CC4)CCC4N2C1=CC=CC=C1N=[C@@]2[C@H]3CNCCC3.Cl.Cl.Cl,7-TM Receptors,Opioid Receptors,NOP Receptors,Potent NOP receptor agonist,"High affinity NOP receptor agonist (pKi = 10.07 for the human NOP receptor). Exhibits anxiolytic effects with no effect on memory or locomotion. Regarded as one of the most potent, non-peptide NOP full agonists in vitro.",534.05
MDL 100907,[139290-65-6],FC(C=C3)=CC=C3CCN(CC2)CCC2[C@@H](O)C1=C(OC)C(OC)=CC=C1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Potent and selective 5-HT2A antagonist,Potent and selective 5-HT2A receptor antagonist (Ki = 0.36 nM). Exhibits > 80-fold selectivity for 5-HT2A over other serotonergic receptor subtypes. Antipsychotic agent in vivo.,373.46
"MDL 11,939",[107703-78-6],OC(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2A antagonist,"Orally active 5-HT2A receptor antagonist; displays selectivity for 5-HT2A receptors over 5-HT2C receptors (Ki values are 0.54, 2.5, 81.6 and ~10,000 nM at rabbit 5-HT2A, human 5-HT2A, rabbit 5-HT2C and human 5-HT2C receptors respectively).",295.42
MDL 72222,[40796-97-2],CN1C2CCC1CC(C2)OC(=O)C1=CC(Cl)=CC(Cl)=C1,Ion Channels,Ligand-gated Ion Channels,5-HT3 Receptors,5-HT3 antagonist,5-HT3 antagonist.,314.21
ME 0328,[1445251-22-8],O=C2NC(CCC(N[C@@H](C)C3=CC=CC=C3)=O)=NC1=CC=CC=C12,Enzymes,Polymerases,Poly(ADP-ribose) Polymerase,Selective PARP-3 inhibitor,"Inhibitor of PARP-3 (IC50 = 0.89 muM). Displays selectivity for PARP-3 over PARP-1, PARP-2 and other ARDT enzymes (IC50 values are 6.3, 10.8 and >30 muM respectively). Enhances CRISPR-Cas9-mediated HER2 mutation frequency, resulting in increased reduction in proliferation of HER2-positive breast cancer cells. Cell permeable.",321.37
Meclizine dihydrochloride,[1104-22-9],CC1=CC(CN(CC4)CCN4C(C3=CC=C(Cl)C=C3)C2=CC=CC=C2)=CC=C1.Cl.Cl,Nuclear Receptors,Pregnane X Receptor,,Human pregnane X receptor agonist; H1 antagonist,Human pregnane X receptor (hPXR) agonist; stronger activator of hPXR than rat PXR. Increases hPXR target gene expression in human hepatocyte primary cultures. Also acts as a histamine H1 receptor antagonist. Confers neuroprotection in models of polyQ toxicity.,463.87
Medetomidine hydrochloride,[86347-15-1],CC(C2=CN=CN2)C1=C(C)C(C)=CC=C1.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,Potent and highly selective alpha2 agonist,"Potent, highly selective alpha2-adrenoceptor agonist (Ki values are 1.08 and 1750 nM for alpha2- and alpha1-adrenoceptors respectively). Displays greater selectivity over alpha1-adrenoceptors than clonidine and UK 14,304 (1620-, 220- and 300-fold respectively). Inhibits twitch response in electrically stimulated mouse vas deferens (pD2 = 9.0). Active in vivo; displays hypotensive, bradycardic, sedative, anxiolytic, hypothermic and analgesic effects. Active Isomer also available.",236.74
Melatonin,[73-31-4],O=C(C)NCCC2=CNC1=CC=C(OC)C=C12,7-TM Receptors,Melatonin (MT) Receptors,,Endogenous hormone; agonist at MT1 and MT2,"Endogenous hormone that acts as an agonist at melatonin receptors MT1 and MT2. Exhibits a prominent role in the control of circadian rhythm, displays immunomodulatory activity and acts as a powerful antioxidant in vivo.",232.28
Melperone hydrochloride,[1622-79-3],Cl.CC1CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2A antagonist; also D2 antagonist; neuroleptic,Atypical neuroleptic; 5-HT2A/D2 receptor antagonist (Ki values are 120 and 180 nM respectively). Causes an increase in dopamine levels in the medial prefrontal cortex (mPFC) and nucleus accumbens and an increase in ACh in the mPFC. Also binds adrenergic alpha1 and alpha2 receptors (Ki values are 180 and 150 nM respectively).,299.81
Meptazinol hydrochloride,[59263-76-2],OC1=CC=CC(C2(CC)CN(C)CCCC2)=C1.Cl,7-TM Receptors,Opioid Receptors,Mu Opioid Receptors,mu1 partial agonist,Centrally active opioid analgesic. Partial agonist at the mu1 opioid receptor. Also shown to inhibit acetylcholinesterase.,269.81
Metergoline,[17692-51-2],[H][C@](CNC(OCC5=CC=CC=C5)=O)1C[C@@](C2=CC=CC3=C2C(C4)=CN3C)([H])[C@]4([H])N(C1)C,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7,Antagonist at 5-HT1/5-HT2 with activity at 5-HT1D. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.,403.52
Metformin hydrochloride,[1115-70-4],NC(NC(N(C)C)=N)=N.Cl,Enzymes,Kinases,AMPK,Activator of LKB1/AMPK; antidiabetic agent,Antidiabetic agent; lowers plasma glucose levels and improves insulin sensitivity. Inhibits hepatic gluconeogenesis via activation of the LKB1/AMPK pathway. Displays antiproliferative effects in cancer cell lines. Activates the aPKC-CBP pathway in neural precursors to promote neurogenesis. Activates autophagy. Deuterated analog also available.,165.62
Methiothepin maleate,[19728-88-2],[H]OC(=O)\C=C/C(=O)O[H].CSC1=CC2=C(SC3=C(CC2N2CCN(C)CC2)C=CC=C3)C=C1,7-TM Receptors,5-HT Receptors,Non-selective 5-HT,5-HT1 and 5-HT2 antagonist; also has moderate affinity for 5-ht5 and high affinity for 5-HT6 and 5-HT7,"5-HT2 antagonist (pKi = 8.7 - 9.2) ; also active as 5-HT1 antagonist (pKi values are 7.1 - 8.5). Also displays affinity for rodent 5-HT5B, 5-HT5A, 5-HT7 and 5-HT6 receptors (pKi values are 6.6, 7.0, 8.4 - 9.0 and 8.7 - 9.4, respectively).",472.62
Methyllycaconitine citrate,[351344-10-0],OC(=O)CC(O)(CC(O)=O)C(O)=O.[H][C@@]12C[C@H]3[C@H](OC)[C@]1([H])[C@](O)(C[C@@H]3OC)[C@]1(O)[C@@H](OC)C3[C@@]22[C@H]1N(CC)C[C@]3(COC(=O)C1=CC=CC=C1N1C(=O)C[C@H](C)C1=O)CC[C@@H]2OC,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Selective alpha7 neuronal nAChR antagonist,Potent antagonist for alpha7-containing neuronal nicotinic receptors (Ki = 1.4 nM). Interacts with alpha4beta2 and alpha6beta2 receptors at concentrations > 40 nM. Attenuates METH-induced neurotoxicity in mouse striatum in vivo.,874.93
Methylprednisolone,[83-43-2],O=C1C=C[C@@]2(C)C([C@@H](C)C[C@]3([H])[C@@]([H])2[C@@H](O)C[C@@]4(C)[C@]([H])3CC[C@](C(CO)=O)4O)=C1,Nuclear Receptors,Glucocorticoid Receptor,,Glucocorticoid receptor agonist,Glucocorticoid receptor (GR) agonist. Displays anti-inflammatory and antioxidant properties. Attenuates apoptosis in oligodendrocytes after injury stimuli. Upregulates expression of Bcl-xL via direct binding of the GR/STAT5 complex. Neuroprotective.,374.47
Metoprolol tartrate,[56392-17-7],O=C(O)C(O)C(O)C(O)=O.OC(CNC(C)C)COC1=CC=C(CCOC)C=C1.OC(CNC(C)C)COC2=CC=C(CCOC)C=C2,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-1 Receptors,Selective beta1 antagonist,"Selective beta1-adrenoceptor antagonist (Ki values are 47, 2960 and 10100 nM for beta1, beta2 and beta3 adrenoceptors respectively). Inhibits spontaneous endothelin-1 production in vitro and displays antihypertensive and antianginal activity in vivo.",342.4
Metyrapone,[54-36-4],O=C(C2=CN=CC=C2)C(C)(C)C1=CC=CN=C1,Enzymes,Hydroxylases,,11-beta hydroxylase inhibitor,Cytochrome P450 inhibitor. Blocks glucocorticoid synthesis via inhibition of steroid 11-beta hydroxylase (CYP11B1) activity (IC50 = 7.83 muM). Also inhibits CYP3A4 and cytochrome P450-mediated omega/omega-1 hydroxylase activity.,226.27
Mevastatin,[73573-88-3],[H][C@@]12C(C=C[C@H](C)[C@@]([H])2CC[C@@]3([H])OC(C[C@]([H])(O)C3)=O)=CCC[C@@H]1OC([C@@H](C)CC)=O,Enzymes,Reductases,HMG-CoA Reductase,HMG-CoA reductase inhibitor,"Inhibitor of HMG-CoA reductase; decreases cholesterol biosynthesis, in vitro and in vivo. Induces apoptosis, arrests cancer cells in G1 phase and downregulates cdk 2, 4, and 6, cyclin D1 and E1, p21 and p27. Inactive lactam prodrug of mevastatin hydroxy acid, naturally bioactivated in vivo following oral administration.",390.52
Mexiletine hydrochloride,[5370-01-4],Cl.CC(N)COC1=C(C)C=CC=C1C,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Na+ channel blocker; antiarrhythmic agent,"Use-dependent sodium channel blocker (IC50 values are 75.3 and 23.6 muM for tonic and use-dependent block respectively). Class Ib antiarrhythmic, neuroprotective and antimyotonic agent.",215.72
MG 624,[77257-42-2],[I-].CC[N+](CC)(CC)CCOC1=CC=C(\C=C\C2=CC=CC=C2)C=C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,alpha7 neuronal nAChR antagonist,A selective antagonist for neuronal alpha7 subunit- containing nAChR subtypes. Inhibits alpha-Bgtx binding to chick alpha7 and alpha4beta2 subtypes with Ki values of 106 nM and 84 muM respectively.,451.39
MI 14,[1715934-43-2],CC2=C(C3=CC=CC(S(N(C)C)(=O)=O)=C3)N1N=C(Cl)C=C(NCCNC(C)=O)C1=N2,Enzymes,Kinases,Other Kinases,Potent and selective PI 4-kinase IIIbeta inhibitor,"Potent and selective PI 4-K IIIbeta inhibitor (IC50 = 54 nM). Exhibits >1,800-fold selectivity for PI 4-K IIIbeta over PI 4-K IIIalpha and PI 4-K IIalpha, respectively. Exhibits antiviral activity against single-stranded positive sense RNA viruses in HeLa cell-based assays.",450.94
Mibefradil dihydrochloride,[116666-63-8],Cl.Cl.COCC(=O)O[C@]1(CCN(C)CCCC2=NC3=C(N2)C=CC=C3)CCC2=C(C=CC(F)=C2)[C@@H]1C(C)C,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV3.x blocker,Ca2+ channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50 values of 2.7 muM and 18.6 muM for T-type and L-type channels respectively. Antihypertensive agent.,568.56
Miconazole nitrate,[22832-87-7],ClC1=CC(Cl)=CC=C1COC(CN3C=CN=C3)C2=CC=C(Cl)C=C2Cl.O[N+]([O-])=O,Other Pharmacology,Miscellaneous Compounds,,Antifungal agent,Antifungal agent. Inhibits lanosterol demethylase and induces formation of reactive oxygen species. Enhances the generation of mature oligodendrocytes from progenitor cells in vitro and promotes myelination in vivo. Attenuates disease severity in a mouse model of multiple sclerosis. Brain penetrant.,479.14
Mifepristone,[84371-65-3],[H][C@@]23CCC1=CC(CCC1=C2[C@@H]([C@]5=CC=C(N(C)C)C=C5)C[C@@]4(C)[C@]([H])3CC[C@@](C#CC)4O)=O,Nuclear Receptors,Progesterone Receptor,,Progesterone and glucocorticoid receptor antagonist,Selective antagonist at progesterone (PR) and glucocorticoid (GR) receptors in vitro and in vivo. Is a silent antagonist at PR and has a higher affinity than progesterone. Has higher affinity for GR than dexamethasone (Cat. No. 1126).,429.6
Miglitol,[72432-03-2],OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,Enzymes,Glycosylases,,alpha-glucosidase inhibitor,Inhibitor of alpha-glucosidase; antihyperglycemic. Suppresses postprandial hyperglycemia in vivo and reduces plasma glucose concentration in normal rats and in several animal models of diabetes. Shown to inhibit the loss of pancreatic beta cells in type 2 diabetic rats. Also inhibits apoptosis and mitochondrial overproduction of reactive oxygen species in endothelial cells in vitro.,207.22
Minoxidil,[38304-91-5],NC1=CC(=NC(N)=[N+]1[O-])N1CCCCC1,Ion Channels,Potassium Channels,Inward rectifier Potassium Channels,Kir6 channel (KATP) opener,Antihypertensive. Antialopecia agent. Kir6 channel (KATP) activator.,209.25
Mirin,[1198097-97-0],OC(C=C1)=CC=C1/C=C2/C(NC(S2)=N)=O,Enzymes,Kinases,ATM & ATR Kinase,MRN-ATM pathway inhibitor,Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11. Prevents ATM activation in response to double strand breaks (IC50 = 12 muM) and induces G2 cell cycle arrest. Also blocks homology-directed repair in vitro.,220.25
Mirtazapine,[85650-52-8],CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,"Potent 5-HT2 antagonist; also 5-HT3, H1 and alpha2 antagonist; antidepressant","Antidepressant agent; potent 5-HT2, 5-HT3 and histamine H1 receptor antagonist and moderately potent alpha2-adrenoceptor antagonist (pKi values are 8.05, ~ 8.1, 9.3 and 6.95 respectively). Enhances noradrenalin (NA) release in rat brain via inhibition of alpha2-adrenergic autoreceptors and displays only weak affinity for monoamine transporters (pKi values are 5.6, < 5 and < 5.1 for inhibition of NA, dopamine and 5-HT uptake respectively). Increases hippocampal NA and 5-HT levels in rats following systemic administration in vivo.",265.36
MJ 15,[944154-76-1],ClC1=CC(Cl)=CC=C1N2C(C3=CC=C(Cl)C=C3)=C(C)C(C(NCC4=CC=CN=C4)=O)=N2,7-TM Receptors,Cannabinoid Receptors,CB1 Receptors,Potent and selective CB1 antagonist,"Potent and selective CB1 receptor antagonist (Ki = 27.2 pM, IC50 = 118.9 pM for rat CB1 receptors). Exhibits potency in obesity and hyperlipidemia models; inhibits food intake and increases in body weight in diet-induced obese rats and mice.",471.77
MK 0343,[233275-76-8],FC(C=CC=C3F)=C3C1=NN=C2N1N=C(OCC5=NC=NN5C)C(C4CCC4)=C2,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,GABAA partial agonist; displays subtype selectivity,"Subtype-selective GABAA partial agonist (Ki values are 0.21, 0.22, 0.23 and 0.40 for alpha3, alpha1, alpha5 and alpha2 respectively); occupies the benzodiazepine site of GABAA receptors. Displays greater agonist efficacy at alpha3 compared to alpha1. Exhibits anxiolytic and non-sedating properties in rodent models. Brain penetrant.",397.38
MK 0677,[159752-10-0],O=S(N2C1=CC=CC=C1C3(CCN(C([C@H](NC(C(C)(N)C)=O)COCC4=CC=CC=C4)=O)CC3)C2)(C)=O.CS(O)(=O)=O,7-TM Receptors,Peptide Receptors,Ghrelin Receptors,High affinity ghrelin receptor agonist,High affinity ghrelin receptor agonist (pKi = 8.14). Growth hormone (GH) secretagog; stimulates GH release from rat pituitary cells in vitro (EC50 = 1.3 nM) and enhances GH plasma levels in vivo. Also attenuates isoproterenol-induced lipolysis in rat adipocytes in vitro. Orally bioavailable.,624.77
MKT 077,[147366-41-4],CN(C1=CC=CC=C1S2)/C2=C4/C(N(CC)/C(S4)=C\C3=CC=CC=[N+]3CC)=O.[Cl-],Signal Transduction,Heat Shock Proteins,Hsp70,Binds mot-2; selectively cytotoxic in cancer cells,"Occupies mortalin-2 (mot-2), a member of the Hsp70 family, at its p53 binding site and enables p53 translocation to the nucleus. Selectively cytotoxic; causes growth arrest of cancer cells in culture. Also inhibits telomerase activity and cross-links F-actin.",432
ML 10302 hydrochloride,[186826-17-5],ClC1=CC(C(OCCN2CCCCC2)=O)=C(OC)C=C1N.Cl,7-TM Receptors,5-HT Receptors,5-HT4 Receptors,Potent and selective 5-HT4 partial agonist,Potent 5-HT4 partial agonist (EC50 = 4 nM) that displays > 680-fold selectivity over 5-HT3 receptors (Ki values are 1.07 and 730 nM respectively). Increases sAPPalpha levels in the cortex in an animal model of Alzheimer's disease and exhibits progastrokinetic effects in vivo.,349.25
ML 130,[799264-47-4],NC2=NC1=CC=CC=C1N2S(=O)(C3=CC=C(C)C=C3)=O,Signal Transduction,Cytokine and NF-kB Signaling,NF-kB/IkB,Inhibits NOD1-induced NF-kappaB activation,Potent and selective inhibitor of NOD1; displays 36-fold selectivity for NOD1 over NOD2 (IC50 values are 0.56 and >20 muM for NOD1 and NOD2 respectively). Inhibits NOD1-induced NF-kappaB activation in HEK293 cells with no cytotoxicity. Shown to alter subcellular targeting of NOD1; also thought to alter the conformation of NOD1 protein in vitro.,287.34
ML 141,[71203-35-5],COC(C=C4)=CC=C4C1CC(C3=CC=CC=C3)=NN1C2=CC=C(S(=O)(N)=O)C=C2,Enzymes,GTPases,Small Monomeric GTPases,Selective Cdc42 Rho family inhibitor,"Allosteric inhibitor of Cdc42 GTPase (EC50 = 2.1 muM). Selective for Cdc42 over other members of the Rho GTPase family including Rac1, Rab2 and Rab7. Inhibits ovarian cancer cell migration in vitro.",407.49
ML 161,[423735-93-7],O=C(NC2=CC(NC(CCC)=O)=CC=C2)C1=CC=CC=C1Br,7-TM Receptors,Peptide Receptors,Protease-Activated Receptors,Inhibits PAR1-mediated platelet activation,Inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 muM for the inhibition of platelet P-selectin expression on human platelets). Thought to act allosterically. Also inhibits thrombin-induced platelet activation.,361.23
ML 179,,O=C(C=C(N3CCN(C4=CC=CC(C(F)(F)F)=C4)CC3)NC2=O)N2C1CCCCC1,Nuclear Receptors,Other Nuclear Receptors,,Selective liver receptor homolog 1 (LRH1) inverse agonist,"Selective liver receptor homolog 1 (LRH1, NR5A2) inverse agonist (IC50 = 320 nM and maximum efficacy of 64% repression). Exhibits >31-fold selectivity over SF1.",422.44
ML 193,[713121-80-3],CC2=CC(C)=CC1=C(C(NC4=CC=C(S(=O)(NC5=C(C)C(C)=NO5)=O)C=C4)=O)C=C(C3=CC=CC=N3)N=C12,7-TM Receptors,GPR55,,"Potent, selective GPR55 antagonist","Selective GPR55 antagonist (IC50 = 221 nM). Exhibits >27-, >145- and >145-fold selectivity for GPR55 over CB1, GPR35 and CB2, respectively. Inhibits ERK signaling in vitro.",527.59
ML 213,[489402-47-3],O=C(NC3=C(C)C=C(C)C=C3C)C1CC2CCC1C2,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV7.2 and KV7.4 channel opener,"Selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener (EC50 values are 230 and 510 nM for KV7.2 and KV7.4 respectively). Displays > 80-fold selectivity against KV7.1, KV7.3 and KV7.5 in a thallium-based fluorescence assay. Hyperpolarizes resting membrane potential in an in vitro spinal cord preparation.",257.37
ML 218 hydrochloride,[2319922-08-0],CC(C)(C)CCN1C[C@@]2([H])[C@@]([C@@H]2CNC(C3=CC(Cl)=CC(Cl)=C3)=O)([H])C1.Cl,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV3.x blocker,"Selective inhibitor of T-type calcium channels (IC50 values are 270 and 310 nM for Cav3.3 and Cav3.2 respectively in a patch EP assay). Decreases burst activity in STN neurons; reduces cataleptic behaviour in an in vivo rat model of Parkinson's disease. Displays no significant inhibition of L- or N-type calcium channels, Kir6 (KATP) or KV11.1 (hERG) potassium channels. Orally active.",405.79
ML 228,[1357171-62-0],C1(C2=NC(NCC4=CC=C(C5=CC=CC=C5)C=C4)=C(C3=CC=CC=C3)N=N2)=NC=CC=C1,Signal Transduction,Transcription Factors,Hypoxia Inducible Factors,HIF pathway activator,"HIF pathway activator (EC50 values are 1.23 and 1.4 muM for HRE gene reporter assay and HIF-1alpha nuclear translocation assay respectively); acts via chelation of iron, independently of PHD. Also exhibits > 80% inhibition of the human A3 receptor, dopamine transporter, mu receptor, hERG and 5-HT2B receptor, and rat sodium channel site 2, at a concentration of 10 muM.",415.49
ML 277,[1401242-74-7],O=[C@@]([C@H]3CCCCN3S(C4=CC=C(C)C=C4)(=O)=O)NC1=NC(C2=CC=C(OC)C=C2)=CS1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,Selective KV7.1 (KCNQ1) potassium channel activator; augments IKs current,"Selective Kv7.1 (KCNQ1) potassium channel activator (EC50 = 260 nM). Exhibits >100-fold selectivity versus KCNQ2, KCNQ4 and hERG potassium channels. Augments IKs current of cultured human cardiomyocytes and shortens action potential duration.",471.59
ML 281,[1404437-62-2],CC(C)C1=CC(C2=NC(C=CC=C3)=C3NC2=O)=C(NC(C4=CC=CS4)=O)C=C1,Enzymes,Kinases,Other Kinases,STK33 inhibitor,Inhibitor of the serine/threonine kinase STK33 (IC50 = 14 nM). Exhibits >700-fold selectivity for STK33 over the structurally related protein kinase A (PKA); also exhibits 550-fold selectivity over Aurora kinase B.,389.47
ML 297,[1443246-62-5],O=C(NC2=CC(C)=NN2C3=CC=CC=C3)NC1=CC(F)=C(F)C=C1,Ion Channels,Potassium Channels,Inward rectifier Potassium Channels,Selective Kir3.1/3.2 (GIRK1/2) channel activator,"Selective Kir3.1/3.2 (GIRK1/2) channel activator (IC50 values are 160, 887 and 914 nM for GIRK1/2, GIRK1/4 and GIRK1/3 respectively). Exhibits no effect on GIRK2, GIRK2/3, Kir2.1 and Kv7.4 channels, and has minimal effect on a panel of other ion channels, receptors and transporters. Prevents PTZ-induced epileptic seizures in mice. Brain penetrant.",328.32
ML 298 hydrochloride,,O=C(NCCN2CCC(C(NCN3C4=CC(F)=CC=C4)=O)3CC2)C1=CC=C(F)C(F)=C1.Cl,Enzymes,Esterases,Phospholipases,Selective PLD2 inhibitor,"Selective inhibitor of phospholipase D2 (PLD2) (IC50 values are 355 and >20,000 nM for PLD2 and PLD1, respectively). Decreases invasive migration in U87-MG glioblastoma cells, without affecting cell viability.",468.9
ML 3403,[549505-65-9],FC(C=C3)=CC=C3C(N=C(SC)N2)=C2C1=CC=NC(NC(C)C4=CC=CC=C4)=C1,Enzymes,Kinases,MAPK Family,p38 inhibitor,p38 MAPK inhibitor (IC50 = 0.38 muM). Inhibits the release of IL-1beta and TNF-alpha in a peripheral blood mononuclear cell (PBMC) assay (IC50 values are 0.039 and 0.16 muM respectively).,404.5
ML 347,[1062368-49-3],COC(C=C3)=CC=C3C(C=N2)=CN1C2=C(C4=CC=CC5=C4C=CC=N5)C=N1,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),BMP and Other Activin Receptors,Potent and selective ALK1 and ALK2 inhibitor,"Potent and selective ALK2 and ALK1 inhibitor (IC50 values are 32 and 46 nM, respectively); displays >200 fold selectivity over ALK3 and ALK6 and >400 fold selectivity over VEGF2. Exhibits no activity at ALK4, ALK5 or in a panel of related kinases. Inhibits BMP4 signaling in a functional assay (IC50 = 152 nM).",352.39
ML 348,[899713-86-1],ClC1=C(NC(CN2CCN(C(C3=CC=CO3)=O)CC2)=O)C=C(C(F)(F)F)C=C1,Enzymes,Hydrolases,Other Hydrolases,Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor,Selective and reversible lysophospholipase 1 (LYPLA1) inhibitor (IC50 = 210 nM). Exhibits 14-fold selectivity for LYPLA1 over LYPLA2. Also selective over a panel of ~30 other serine hydrolases.,415.79
ML 365,[947914-18-3],CC1=CC=CC(C(NC2=CC(NC(C3=CC=CC=C3OC)=O)=CC=C2)=O)=C1,Ion Channels,Potassium Channels,Two-P Potassium Channels,Potent and selective K2P3.1 (TASK-1) channel blocker,"Potent and selective TASK-1 (K2P3.1/KCNK3) channel blocker (IC50 values are 4 and 390 nM at TASK-1 and TASK-3, respectively). Displays little or no inhibition at Kir2.1, voltage-gated potassium channels, KCNQ2 and KV11.1 (hERG).",360.41
ML 786 dihydrochloride,[1237536-18-3],O=C(N[C@@H]2CCC(C=CC(OC4=C(CC5)C(NC=C4)=NC5=O)=C3)=C3C2)C1=CC(C(F)(F)F)=CC(C(N)(C)C)=C1.Cl.Cl,Enzymes,Kinases,Raf Kinase,Potent Raf kinase inhibitor; orally bioavailable,"Potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively). Also inhibits Abl-1, DDR2, EPHA2 and RET tyrosine kinase activity. Inhibits pERK formation and attenuates tumor growth in melanoma cell xenografts expressing the B-RafV600E mutation in vivo. Orally bioavailable.",611.48
ML 9 hydrochloride,[105637-50-1],Cl.ClC1=C2C=CC=C(C2=CC=C1)S(=O)(=O)N1CCCNCC1,Enzymes,Kinases,Myosin Light Chain Kinase,Myosin light chain kinase inhibitor,"Selective MLCK inhibitor (Ki values are 4, 32 and 54 muM for MLCK, PKA and PKC respectively). Also inhibits STIM1-plasma membrane interactions, preventing store-operated Ca2+ entry (SOCE).",361.29
MLR 1023,[41964-07-2],CC1=CC(OC2=CNC(N=C2)=O)=CC=C1,Enzymes,Kinases,Src Kinases,Selective allosteric activator of Lyn kinase,"Selective allosteric activator of Lyn kinase (EC50 = 63 nM); displays no significant activity against a range of 47 other kinases, including other Src family kinases such as Fyn, Lck and Src kinase. Reduces blood glucose levels without affecting in vivo insulin secretion. Orally bioavailable.",202.21
MM 11253,[345952-44-5],CC1(C)C2=C(C=C(C5(SCCS5)C3=CC(C=CC(C(O)=O)=C4)=C4C=C3)C=C2)C(C)(C)CC1,Nuclear Receptors,Retinoic Acid Receptors,,RARgamma-selective antagonist,Selective RARgamma antagonist. Blocks the growth inhibitory ability of RARgamma-selective agonists in squamous cell carcinoma (SCC)-25 cells.,462.67
Moclobemide,[71320-77-9],O=C(NCCN2CCOCC2)C1=CC=C(Cl)C=C1,Enzymes,Oxygenases/Oxidases,Monoamine Oxidase,Reversible MAO-A inhibitor,Reversible monoamine oxidase A (MOA-A) inhibitor.,268.74
Monastrol,[254753-54-3],CCOC(=O)C1=C(C)NC(=S)NC1C1=CC(O)=CC=C1,Enzymes,ATPases,Kinesin,Selective inhibitor of mitotic kinesin Eg5,"Potent, cell-permeable, small molecule mitosis inhibitor that does not interact with tubulin. Arrests cells in mitosis and specifically inhibits the motility of the mitotic kinesin Eg5, a motor protein required for mitotic spindle formation and maintenance (IC50 = 14 muM).",292.35
Mosapride citrate,[112885-42-4],O=C(O)C(O)(CC(O)=O)CC(O)=O.ClC1=C(N)C=C(OCC)C(C(NCC2OCCN(CC3=CC=C(F)C=C3)C2)=O)=C1,7-TM Receptors,5-HT Receptors,5-HT4 Receptors,5-HT4 agonist and 5-HT3 antagonist,"5-HT4 receptor agonist and 5-HT3 receptor antagonist. Displays no activity at D2, alpha1, alpha2, 5-HT1 and 5-HT2 receptors. Gastroprokinetic agent; increases gastric emptying in rats and stimulates gastric motor actvity in conscious dogs.",614.02
Moxonidine hydrochloride,[75536-04-8],Cl.COC1=NC(C)=NC(Cl)=C1NC1=NCCN1,Other Pharmacology,Imidazoline Receptors,I1 Receptors,I1 receptor and alpha2-adrenoceptor agonist (I1 > alpha2),Mixed I1 imidazoline receptor and alpha2-adrenergic agonist; displays 40-fold higher affinity for I1 receptors versus alpha2-adrenoceptors. Centrally acting antihypertensive agent.,278.14
MPC 6827 hydrochloride,[917369-31-4],CC2=NC1=CC=CC=C1C(N(C)C3=CC=C(OC)C=C3)=N2.Cl,Cytoskeleton and Motor Proteins,Microtubules,,Inhibitor of microtubule polymerization; antimitotic and antitumor,Potent inhibitor of microtubule formation (IC50 = 1.5 - 3.4 nM); inhibits polymerization of tubulin in vitro and disrupts microtubule formation in several cancer cell lines. Inhibits tumor growth in vitro and in vivo; exhibits pro-apoptotic characteristics. Brain penetrant.,315.8
MPEP hydrochloride,[219911-35-0],Cl.CC1=CC=CC(=N1)C#CC1=CC=CC=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Potent mGlu5 antagonist; also positive allosteric modulator of mGlu4 receptors,Potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. Centrally active following systemic administration in vivo. Reverses mechanical hyperalgesia in the inflamed rat hind paw. Also available as part of the Group I mGlu Receptor Tocriset™.,229.71
Mps BAY 2a,[1382477-96-4],CC(C)CNC1=NC(C2=CC=CC3=C2C=CC=N3)=CN4C1=NC=C4C5=CC=C(C(NC6CC6)=O)C=C5,Enzymes,Kinases,Monopolar Spindle 1 Kinase,Potent and selective Mps1 kinase inhibitor,Potent and selective Mps1 inhibitor (IC50 = 1 nM for human enzyme). Selective for Mps1 over a panel of 220 kinases. Differentially inhibits human colon carcinoma cell proliferation. Blocks cell cycle progression by preventing spindle assembly checkpoint activation. Induces apoptosis.,476.57
Mps1-IN-1 dihydrochloride,,CC(C)S(C(C=CC=C3)=C3NC1=CC(NC4=C(OC)C=C(N5CCC(O)CC5)C=C4)=NC2=C1C=CN2)(=O)=O.Cl.Cl,Enzymes,Kinases,Monopolar Spindle 1 Kinase,Selective Mps1 kinase inhibitor,Selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 367 nM); exhibits >1000 fold-selectivity against a panel of 352 kinases with the exceptions of ALK and Ltk. Disrupts the recruitment of Mad2 to kinetochores. Increases frequency of multipolar mitosis in U2OS cells.,608.58
MRK 016,[342652-67-9],CC(C)(C)C2=C1C=NN=C(C4=NOC(C)=C4)N1N=C2OCC3=NC=NN3C,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,alpha5-selective GABAA inverse agonist,"GABAA receptor inverse agonist selective for the alpha5-subtype (EC50 = 3 nM). Exhibits affinity at benzodiazepine binding site of recombinant human GABAA receptors (Ki values are 0.77 nM, 0.83 nM, 0.85 nM and 1.4 nM for alpha3-, alpha1-, alpha2-, and alpha5-containing respectively). Increases long-term potentiation (LTP) in mouse hippocampal slices. Exhibits no anxiogenic or proconvulsant activity.",368.39
MRK 560,[677772-84-8],ClC(C=C3)=CC=C3[S@]([C@@]1([C@]2=C(F)C=CC(F)=C2)CC[C@@H](NS(=O)(C(F)(F)F)=O)CC1)(=O)=O,Enzymes,Proteases,Gamma-Secretase,gamma-secretase inhibitor; attenuates amyloid plaque deposition,gamma-secretase inhibitor; inhibits proteolytic cleavage of amyloid precursor protein (APP) over the Notch pathway. Reduces levels of Abeta in the brain (inhibits Abeta40 and Abeta42 in SH-SY5Y neuroblastoma cells with an IC50 of 0.65 nM); attenuates plaque deposition. Orally bioavailable.,517.92
MRS 1220,[183721-15-5],ClC1=CC=C2N=C(NC(=O)CC3=CC=CC=C3)N3N=C(N=C3C2=C1)C1=CC=CO1,7-TM Receptors,Adenosine Receptors,Adenosine A3 Receptors,Highly potent and selective hA3 antagonist,"A potent and highly selective antagonist at the human A3 adenosine receptor (Ki values are 0.65, 305, and 52 nM at hA3, rA1 and rA2A respectively. Displays an IC50 value > 1 muM for inhibition of binding to rat A3 receptors).",403.83
MRS 3777 hemioxalate,[1186195-57-2],OC(=O)C(O)=O.C1CCC(CC1)NC1=C2N=CNC2=NC(OC2=CC=CC=C2)=N1.C1CCC(CC1)NC1=C2N=CNC2=NC(OC2=CC=CC=C2)=N1,7-TM Receptors,Adenosine Receptors,Adenosine A3 Receptors,"High affinity, selective A3 antagonist","High affinity adenosine A3 receptor antagonist (Ki = 47 nM) that displays > 200-fold selectivity versus A1, A2A and A2B receptors.",354.39
MY-5445,[78351-75-4],ClC1=CC(NC2=C3C=CC=CC3=C(N=N2)C2=CC=CC=C2)=CC=C1,Enzymes,Phosphodiesterases,,PDE5 inhibitor,"Specific inhibitor of cyclic GMP phosphodiesterase, selective for PDE5 (IC50 = 0.5 muM).",331.8
Mycophenolate mofetil,[128794-94-5],O=C(OC2)C1=C2C(C)=C(OC)C(C/C=C(C)/CCC(OCCN3CCOCC3)=O)=C1O,Enzymes,Dehydrogenases,Other Dehydrogenases,Inosine monophosphate dehydrogenase inhibitor,"Immunosuppressant prodrug of mycophenolic acid (MPA) (Cat. No. 1505). Hydrolyzed by esterases to release MPA (a reversible inhibitor of inosine monophosphate dehydrogenase). Used to prevent organ rejection after transplantation. Displays inhibitory activity of lymphocyte functions. Inhibits type 1 collagen expression, enhances MMP-1 expression, and reduces alpha-smooth muscle actin gene expression.",433.49
Mycophenolic acid,[24280-93-1],COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(O)=O,Enzymes,Dehydrogenases,Other Dehydrogenases,Inosine monophosphatase dehydrogenase inhibitor,"Immunosuppressive agent with antiviral and antitumor effects in vitro and in vivo. Potently inhibits inosine monophosphate dehydrogenase, thus inhibiting de novo GTP synthesis leading to decreased RNA and DNA synthesis. Reversibly inhibits proliferation of T and B lymphocytes and antibody formation.",320.34
N-Acetyltryptamine,[1016-47-3],CC(=O)NCCC1=CNC2=CC=CC=C12,Enzymes,Transferases,Other Transferases,Substrate for serotonin N-acetyl transferase,A partial agonist for melatonin receptors in the retina. Also used for determination of serotonin N-acetyl transferase.,202.26
NAB 2,[1504588-00-4],O=C(NCC4=C(Cl)C=CC=C4)C1=CC=C2C(N=CN2C3=CC(C)=CC=C3C)=C1,Enzymes,Ligases,Ubiquitin E3 Ligases,Protects against alpha-synuclein toxicity; promotes Rsp5/Nedd4-dependent endosomal transport,Protects against alpha-synuclein toxicity. Reverses the alpha-synuclein-induced pathological phenotype in Parkinson's disease cortical neurons. Promotes E3 ubiquitin ligase Rsp5/Nedd4-dependent endosomal transport.,389.88
NAD 299 hydrochloride,[184674-99-5],FC1=C2C(C[C@@H](N(C4CCC4)C3CCC3)CO2)=C(C(N)=O)C=C1.Cl,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,"Selective, high affinity 5-HT1A antagonist","Selective, high affinity 5-HT1A receptor antagonist (Ki = 0.6 nM in vitro). Enhances the action of selective 5-HT reuptake inhibitors and reverses citalopram-induced (Cat. No. 1427) inhibition of serotonergic cell firing.",354.85
Nafamostat mesylate,[82956-11-4],CS(=O)(O)=O.NC(C1=CC=C2C(C=CC(OC(C3=CC=C(NC(N)=N)C=C3)=O)=C2)=C1)=N.CS(=O)(O)=O,Enzymes,Proteases,Other Proteases,"Serine protease inhibitor, inhibits tryptase","Broad spectrum serine protease inhibitor. Displays selectivity for human tryptase when used at relatively low concentrations. Reduces eosinophil infiltration, mast cell activation and airway responsiveness in a murine model of asthma.",539.59
Naftopidil hydrochloride,[1164469-60-6],Cl.COC1=C(C=CC=C1)N1CCN(CC(O)COC2=C3C=CC=CC3=CC=C2)CC1,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,alpha1 antagonist,"An alpha1-adrenoceptor antagonist with only weak antagonism at post-junctional alpha2 receptors; a potent, persistent antihypertensive and vasodilator.",428.96
Nalmefene hydrochloride,[58895-64-0],C=C3[C@H]5[C@]24C1=C(O5)C(O)=CC=C1C[C@@H](N(CC6CC6)CC4)[C@@](O)2CC3.Cl,7-TM Receptors,Opioid Receptors,Miscellaneous/Non-selective Opioids,Opioid receptor antagonist,Opioid receptor antagonist; displays a longer half life than Naloxone. Exhibits neuroprotective effects after traumatic brain injury in the rat. Deuterated analog also available.,375.89
Naltriben mesylate,[122517-78-6],CS(=O)(O)=O.O[C@@]24[C@]3([C@@H]7C(O6)=C(C5=C6C=CC=C5)C4)C1=C(O7)C(O)=CC=C1CC2N(CC8CC8)CC3,7-TM Receptors,Opioid Receptors,Delta Opioid Receptors,Standard delta2 selective antagonist,"Selective and potent delta-opioid receptor antagonist (Ki values are 0.013, 19 and 152 nM for delta, mu and kappa receptors respectively). Displays selectivity for the delta2 subtype in vivo.",511.59
Napabucasin,[83280-65-3],O=C(C1=C2C=C(C(C)=O)O1)C3=CC=CC=C3C2=O,Signal Transduction,Cytokine and NF-kB Signaling,STAT,STAT3 inhibitor; also blocks cancer stem cell self-renewal,"STAT3 inhibitor. Blocks spherogenesis of cancer stem cells (CSC), but not hematopoietic stem cells. Inhibits PaCa-2 xenograft tumor growth in mice, even after cessation of treatment, and decreases population of CSCs in PaCa-2 tumors from treated mice. Also blocks spleen and liver metastases of colon cancer cells in a mouse model.",240.21
Nateglinide,[105816-04-4],O=[C@](N[C@@H](C(O)=O)CC2=CC=CC=C2)[C@H]1CC[C@H]([C@H](C)C)CC1,Ion Channels,Potassium Channels,Inward rectifier Potassium Channels,Kir6 (KATP) blocker; displays high affinity for SUR1/Kir6.2 channels,Kir6 (KATP) blocker. Exhibits in vitro tissue selectivity for pancreatic beta-cell-type Kir6 channels over cardiovascular Kir6 channels; displays high affinity for SUR1/Kir6.2 channels. Hypoglycemic agent; stimulates insulin secretion from pancreatic beta-cells by increasing cytosolic Ca2+ concentration. Also agonist at the orphan receptor MRGPRX4.,317.42
NAV 26,[1198160-14-3],O=C2C1=CC=CC=C1C(C(NCC4=CC=C(OC(F)(F)F)C=C4)=O)N2C3CCOCC3,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Selective Nav1.7 channel blocker,Selective Nav1.7 channel blocker (IC50 = 370 nM). Exhibits >85-fold selectivity for Nav1.7 over Nav1.5 and hERG channels. Reduces nociceptive behavior in rat models of pain.,434.41
NBI 27914 hydrochloride,[1215766-76-9],Cl.CCCN(CC1CC1)C1=C(Cl)C(NC2=C(Cl)C=C(Cl)C=C2Cl)=NC(C)=N1,7-TM Receptors,Peptide Receptors,CRF Receptors,Selective non-peptide CRF1 antagonist,"Selective, non-peptide corticotropin-releasing factor1 (CRF1) receptor antagonist (Ki = 1.7 nM); has no activity at CRF2 receptors. Blocks behavioral seizures in vivo.",470.66
NBQX,[118876-58-7],NS(=O)(=O)C1=CC=CC2=C3NC(=O)C(=O)NC3=CC(=C12)[N+]([O-])=O,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Potent AMPA antagonist; more selective than CNQX (Cat. No. 0190),"Potent, selective and competitive AMPA receptor antagonist. Neuroprotective and anticonvulsant; active in vivo. Disodium Salt also available.",336.28
NDT 9513727,[439571-48-9],CCCCN1C(C6=CC=CC=C6)=NC(C7=CC=CC=C7)=C1CN(CC3=CC(OCO5)=C5C=C3)CC2=CC=C(OCO4)C4=C2,Signal Transduction,Complement,,"Potent, selective human C5a receptor negative allosteric modulator (NAM)",Potent C5a receptor (C5aR) negative allosteric modulator (NAM) (IC50 = 11.6 nM); selective for human C5aR (IC50 values for rat and mouse C5aR are > 10 muM). Exhibits inverse agonist pharmacokinetics. Blocks degranulation response in C5a-stimulated U937 cells (IC50 = 7.1 nM). Exhibits selectivity for primate and gerbil receptor over other species. Orally bioavailable.,573.68
NE 100 hydrochloride,[149409-57-4],CCCN(CCC)CCC1=CC=C(OC)C(OCCC2=CC=CC=C2)=C1.Cl,Other Pharmacology,Sigma Receptors,Sigma1 Receptors,Selective sigma1 antagonist,"Potent and selective sigma1 receptor antagonist (Ki = 0.86 nM) that displays > 55-fold selectivity over sigma2 receptors and > 6000-fold selectivity over D1, D2, 5-HT1A, 5-HT2 and PCP receptors. Exhibits reversible binding (Kd = 1.2 nM) and displays antipsychotic activity in vivo. Orally active.",391.97
Nebivolol hydrochloride,[152520-56-4],FC(C=C4)=CC3=C4O[C@@](CC3)([H])[C@H](O)CNC[C@@H](O)[C@]2([H])CCC1=CC(F)=CC=C1O2.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-1 Receptors,Highly selective beta1-adrenoceptor antagonist,"Highly selective beta1-adrenoceptor antagonist (Ki values are 0.88, 20, 44, 700, 1160, 2400 and 4000 nM at beta1, 5-HT1A, beta2, 5-HT2, alpha1, H1 and D2 receptors respectively). Induces vasodilation via a nitric oxide- and cGMP-dependent mechanism (EC50 = 11.36 muM in renal arteries) and displays antihypertensive activity in vivo. GRK/beta -arrestin biased agonist at the beta2 adrenoceptor.",441.9
NECA,[35920-39-9],O[C@@H]1[C@@H]([C@](NCC)=O)O[C@@H](N2C=NC3=C2N=CN=C3N)[C@@H]1O,7-TM Receptors,Adenosine Receptors,Non-selective Adenosine,High affinity adenosine agonist,"High affinity adenosine receptor agonist (Ki values are 6.2, 14, and 20 nM for human A3, A1 and A2A receptors respectively; EC50 = 2.4 muM for human A2B). Inhibits platelet aggregation and is centrally active in vivo.",308.3
Necrostatin-1,[4311-88-0],CN1C(=S)NC(CC2=CNC3=CC=CC=C23)C1=O,Enzymes,Kinases,RIP kinase family,RIP1 kinase inhibitor; inhibits necroptosis,"ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM). Blocks non-apoptotic cell death via inhibition of a specific cellular pathway, necroptosis, which leads to necrosis (EC50 = 494 nM). Reduces ischemic brain injury in a mouse model of stroke.",259.33
Nefiracetam,[77191-36-7],O=C(NC2=C(C)C=CC=C2C)CN1C(CCC1)=O,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Cognitive enhancer,"Cognitive enhancer that displays various pharmacological effects. Activates L/N-type calcium channels, cholinergic, monoaminergic and GABAergic systems. Displays potent neuroprotective action in the retinal ischemia-reperfusion model in vivo.",246.3
Nemonapride,[75272-39-8],O=C(C3=C(OC)C=C(NC)C(Cl)=C3)N[C@@H]1CCN(CC2=CC=CC=C2)[C@@H]1C.O=C(C6=C(OC)C=C(NC)C(Cl)=C6)N[C@H]4CCN(CC5=CC=CC=C5)[C@H]4C,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,Highly potent D2-like antagonist; also 5-HT1A agonist,Highly potent dopamine D2-like receptor antagonist; selective over D1-like receptors (Ki values are 0.1 and 740 nM for D2-like and D1-like receptors respectively). Also potent 5-HT1A receptor agonist (IC50 = 34 nM) and has affinity for sigma receptors.,387.91
Neurodazine,[937807-66-4],ClC1=CC=CC(C(O3)=CC=C3C2=NC(C5=CC=C(OC)C=C5)=C(C4=CC=C(OC)C=C4)N2)=C1,Stem Cells,Reprogramming,,Induces neurogenesis in mature skeletal muscle cells,Induces neurogenesis of non-pluripotent C2C12 myoblasts and cells derived from mature human skeletal muscle. Upregulates the expression of neuron-specific markers in C2C12 cells.,456.92
Neuropathiazol,[880090-88-0],O=C(OCC)C1=CC=C(N(C2=CSC(C3=CC=CC=C3)=N2)C)C=C1,Stem Cells,Stem Cell Differentiation,Neural Stem Cells,Selective inducer of neuronal differentiation in hippocampal neural progenitors,"Selective inducer of neuronal differentiation in cultured hippocampal neural progenitor cells (NPCs). Selectively suppresses astrocyte differentiation when induced by LIF, BMP2 and FBS compared to retinoic acid. Enhances maturation of NPC derived neurons.",338.42
NGB 2904,[189061-11-8],Cl.ClC1=C(Cl)C(=CC=C1)N1CCN(CCCCNC(=O)C2=CC=C3C(CC4=CC=CC=C34)=C2)CC1,7-TM Receptors,Dopamine Receptors,D3 Receptors,Potent and selective D3 antagonist,"Potent and selective dopamine D3 receptor antagonist (Ki values are 1.4, 217, 223, 642, > 5000, > 10000 and > 10000 nM for D3, D2, 5-HT2, alpha1, D4, D1 and D5 receptors respectively). Potently antagonizes quinpirole-stimulated mitogenesis (IC50 = 6.8 nM). Attenuates cocaine's rewarding effects and inhibits relapse to drug-seeking behavior.",530.92
NGD 98-2 hydrochloride,,CC1=NC(NC(CC)CC)=C(OC)N=C1C2=CC=C(OC(F)(F)F)C=C2OC.Cl,7-TM Receptors,Peptide Receptors,CRF Receptors,High affinity CRF1 antagonist,High affinity antagonist of corticotropin-releasing factor receptor 1 (CRF1) (Ki = 1 nM). Orally available and brain penetrant.,435.87
NHI 2,[1269802-97-2],ON2C1=CC(C3=CC=CC=C3)=CC(C(F)(F)F)=C1C=C2C(OC)=O,Enzymes,Dehydrogenases,Lactate Dehydrogenase A,LDHA inhibitor,LDHA inhibitor; reduces lactate production in HeLa cells. Inhibits cell growth of LPC006 and PANC-1 cells in vitro. Enhances the antiproliferative effects of Gemcitabine (Cat. No. 3259) on LPC006 and PANC-1 cells. Also inhibits ferroptosis.,335.28
NI 57,,O=S(NC1=CC=C(N(C)C(C(C)=C2)=O)C2=C1)(C3=C(OC)C=C(C#N)C=C3)=O,Epigenetics,Bromodomains,,Potent and selective BRPF bromodomain inhibitor,"Potent and selective BRPF bromodomain inhibitor (Kd values are 31, 108 and 408 nM, for BRPF1B, 2 and 3, respectively. Exhibits >32-fold selectivity for BRPFs over BRD9 and other non-Class IV bromodomains.",383.42
NIDA 41020,[502486-89-7],O=C(NN3CCCCC3)C1=NN(C2=CC=C(Cl)C=C2Cl)C(C4=CC=C(OC)C=C4)=C1C,7-TM Receptors,Cannabinoid Receptors,CB1 Receptors,High affinity CB1 antagonist,High affinity CB1 receptor antagonist (Ki = 4.1 nM). Exhibits significantly reduced lipophilicity compared to other CB1 antagonists.,459.37
Nitrendipine,[39562-70-4],CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV1.x blocker,L-type calcium channel blocker. Induces autophagy.,360.37
NK 252,[1414963-82-8],O=C(NC2=NN=C(C3=CC=CO3)O2)NCC1=CC=CC=N1,Signal Transduction,Transcription Factors,Nrf2,Nrf2 activator,Nrf2 activator; interacts with the Nrf2-binding site of Keap1. Downregulates the expression of fibrogenic genes and increases antioxidant effects in NASH rat models of liver disease.,285.26
NKY 80,[299442-43-6],NC(N=C2)=NC1=C2C(CC(C3=CC=CO3)C1)=O,Enzymes,Cyclases,Adenylyl Cyclase,Adenylyl cyclase inhibitor,"Inhibitor of adenylyl cyclase (AC). Exhibits greater affinity for AC5 over AC3 and AC2 (IC50 values are 8.3 muM, 132 muM and 1.7 mM respectively).",229.23
NMS 873,[1418013-75-8],CC1=C(C2=CC=C(S(C)(=O)=O)C=C2)C=CC(OCC3=NN=C(N3C4=CN=CC=C4)SC5CCCC5)=C1,Enzymes,ATPases,p97 ATPase,Potent and selective p97 ATPase (VCP) allosteric inhibitor,"Potent p97 ATPase (VCP) allosteric inhibitor (IC50 = 30 nM). Selective over all other AAA ATPases, HSP90 and kinases tested (IC50 >10 muM). Activates the unfolded protein response (UPR) and modulates autophagosome maturation. Exhibits antiproliferative activity in cancer cells in vitro (IC50 values are 400 and 700 nM for HCT116 and HeLa cells respectively). Reduces p97-sensitization to trypsin digestion.",520.67
NNC 05-2090 hydrochloride,[184845-18-9],Cl.COC1=C(C=CC=C1)C1(O)CCN(CCCN2C3=C(C=CC=C3)C3=C2C=CC=C3)CC1,Transporters,Neurotransmitter Transporters,GABA Transporters,GABA uptake inhibitor; moderately BGT-1 selective,"GABA uptake inhibitor that displays moderate selectivity for BGT-1 (mGAT-2) transporters (Ki values are 1.4, 15, 19 and 41 muM for hBGT-1, hGAT-3, hGAT-1 and hGAT-2 respectively). Anticonvulsive; inhibits sound-induced tonic and clonic convulsions in DBA/2 mice. Also displays affinity at alpha1- and D2-receptors (IC50 values are 266 and 1632 nM respectively).",451.01
NNC 63-0532,[250685-44-0],COC(=O)CN1CN(C2=CC=CC=C2)C2(CCN(CC3=CC=C4C=CC=CC4=C3)CC2)C1=O,7-TM Receptors,Opioid Receptors,NOP Receptors,Potent non-peptide NOP agonist; brain penetrant,"Potent non-peptide agonist for the NOP receptor (EC50 = 305 nM, Ki = 7.3 nM); ~ 12-fold selective over other receptors. Centrally active following systemic administration in vivo.",443.54
NNC 711,[145645-62-1],O=C(C1=CCCN(CCO/N=C(C3=CC=CC=C3)/C2=CC=CC=C2)C1)O.Cl,Transporters,Neurotransmitter Transporters,GABA Transporters,Selective GAT-1 inhibitor,"Potent and selective inhibitor of GABA uptake by GAT-1 (IC50 values are 0.04, 171, 1700 and 622 muM for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Anticonvulsant following systemic administration in vivo. Also exhibits cognition-enhancing activity.",386.88
Nocodazole,[31430-18-9],COC(=O)NC1=NC2=CC(=CC=C2N1)C(=O)C1=CC=CS1,Cytoskeleton and Motor Proteins,Microtubules,,Microtubule inhibitor,Microtubule inhibitor; inhibits mitosis. Also inhibits autophagosome-lysosome fusion. Enhances homology-directed repair (HDR) efficiency 9 to 31% (depending on cell cycle phase) and increases Cas9-mediated gene editing frequencies.,301.32
nor-Binaltorphimine dihydrochloride,[113158-34-2],Cl.Cl.OC1=CC=C2C[C@H]3N(CC4CC4)CC[C@@]45[C@@H](OC1=C24)C1=C(C[C@@]35O)C2=C(N1)[C@@H]1OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@H](C4)[C@]1(O)C2,7-TM Receptors,Opioid Receptors,Kappa Opioid Receptors,Selective kappa antagonist,A selective kappa-opioid receptor antagonist.,734.72
NPPB,[107254-86-4],OC(=O)C1=CC(=CC=C1NCCCC1=CC=CC=C1)[N+]([O-])=O,Ion Channels,Chloride Channels,Ca2+-Activated Chloride Channels,Inhibits calcium-sensitive chloride currents,Inhibits calcium-sensitive chloride currents (10 muM). Putative GPR35 agonist.,300.31
NPS 2143 hydrochloride,[324523-20-8],CC(NC[C@@H](O)COC3=C(C#N)C(Cl)=CC=C3)(C)CC2=CC1=CC=CC=C1C=C2.Cl,7-TM Receptors,Calcium-Sensing Receptor,,Selective calcium-sensing receptor (CaSR) antagonist; orally active calcilytic agent,Selective Ca2+-sensing receptor antagonist. Blocks increases in cytoplasmic Ca2+ concentrations elicited by human Ca2+ receptors expressed in HEK293 cells (IC50 = 43 nM). Also stimulates parathyroid hormone secretion from bovine parathyroid cells (EC50 = 41 nM). Orally active calcilytic compound.,445.38
NPY 5RA972,[439861-56-0],CC1=C(NC(N4CCOCC4)=O)C=CC3=C1C2=CC=CC=C2N3C(C)C,7-TM Receptors,Peptide Receptors,NPY Receptors,Potent and selective NPY Y5 antagonist,"Potent and selective neuropeptide Y Y5 receptor antagonist (IC50 values are 3.1, >10000, >10000 and >10000 nM for Y5, Y1, Y2 and Y4 receptors respectively). Does not block NPY-induced feeding in vivo. Orally active and brain penetrant.",351.44
NS 11021,[956014-19-0],BrC1=CC(C2=NN=NN2)=C(NC(NC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=S)C=C1,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Activator of BKCa (KCa1.1) channels,"Activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1). Exhibits no modulatory effect on a variety of K+ (KV), Na+ and Ca2+ currents at concentrations <10 muM. Alters gating kinetics, but does not affect single channel conductance. Shown to bind BKCa in open and closed conformations; thought to bind the alpha subunit.",511.24
NS 1643,[448895-37-2],OC1=C(NC(NC2=C(O)C=CC(C(F)(F)F)=C2)=O)C=C(C(F)(F)F)C=C1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV11.1 (hERG) channel activator; antiarrhythmic,Human ether-a-go-go related gene (hERG) KV11.1 channel activator (EC50 = 10.5 muM). Exhibits different molecular mechanisms of action at KV11.1 (hERG1) and KV11.2 (hERG2) channels. Displays antiarrhythmic activity in vitro.,380.24
NS 19504,[327062-46-4],NC1=NC=C(CC2=CC=C(Br)C=C2)S1,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Activator of BKCa (KCa1.1) channels,"Selective activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1) (EC50 = 11 muM). Activates BK channels in native smooth muscle cells from guinea pig bladder and reduces spontaneous phasic contractions in bladder strips ex vivo. Displays no effect on contractions induced by a high K+ concentration or at 65 other receptors tested, including L- and N- type Ca2+ channels, Nav, KATP and hERG channels.",269.16
NS 309,[18711-16-5],ClC1=C2C(C(C(N2)=O)=NO)=CC=C1Cl,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Positive modulator of KCa2 and KCa3.1 channels,Positive modulator of small- and intermediate- conductance Ca2+-activated K+ channels (KCa2 and KCa3.1 channels); increases Ca2+ sensitivity. Displays no activity at BK channels.,231.04
NS 3623,[343630-41-1],BrC1=CC(C2=NN=NN2)=C(NC(NC3=CC(C(F)(F)F)=CC=C3)=O)C=C1,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV11.1 (hERG) and KV4.3 channel activator; antiarrhythmic,"KV11.1 (hERG) and KV4.3 channel activator. Activates the IKr and Ito currents and displays antiarrhythmic activity. May also act as a partial blocker of KV11.1 channels. Displays selectivity over the key cardiac potassium channels, KV7.1 (KCNQ1) and KV1.5. Suitable for both in vitro and in vivo use.",427.18
NS 3861,[216853-60-0],CN1C2CCC1CC(C3=C(Br)C=CS3)=C2.OC(/C=C/C(O)=O)=O,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,alpha3beta2 full agonist; also alpha3beta4 partial agonist,"alpha3beta2 full agonist (EC50 = 1.6 muM). Also alpha3beta4 partial agonist (EC50 = 1 muM). Exhibits minimal activity at alpha4beta2 and alpha4beta4. Displays high affinity for alpha3beta4, alpha4beta4, alpha3beta2 and alpha4beta2 (Ki values are 0.62, 7.8, 25 and 55 nM respectively).",400.29
NS 5806,[426834-69-7],BrC1=CC(Br)=CC(C2=NN=NN2)=C1NC(NC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)=O,Ion Channels,Potassium Channels,Voltage-Gated Potassium Channels,KV4.3 channel activator,KV4.3 channel activator; mediates the transient outward K+ current (Ito). Increases IKv4.3 peak current amplitude in CHO-K1 cells expressing KV4.3 and KChIP2 (EC50 = 5.3 muM). Inhibits KV1.4-mediated currents independently of KChIP2. Also slows the decay of KV4.2 and KV4.3 currents in the presence of KChIP2.,574.07
NS 8593 hydrochloride,[875755-24-1],C12=CC=CC=C1N=C(N[C@H]3C(C=CC=C4)=C4CCC3)N2.Cl,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Selective KCa2 (SK) channel negative modulator; inhibits SK currents,"Selective KCa2 (SK) channel negative modulator; inhibits SK channel currents (Kd values are 0.42, 0.6 and 0.73 muM for SK1, SK2 and SK3 respectively at 0.5 muM Ca2+). Exhibits selectivity for SK channels over KCa1.1 (BK), KCa3.1 (IK), Kv, Nav and Cav channels. Inhibits afterhyperpolarization in hippocampal slices.",299.8
NS 9283,[913830-15-6],N#CC1=CC(C2=NC(C3=CN=CC=C3)=NO2)=CC=C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Positive allosteric modulator of alpha4beta2 nAChRs,Positive allosteric modulator of alpha4beta2 receptor; increases the potency of Ach-evoked currents ~60 fold without effecting the maximum efficacy (HEK293-halpha4beta2 cells). Reduces the rate of recovery from desensitization and slows the rate of deactivation. Displays a synergistic effect on the Emax when given with NS206 at 3alpha:2beta receptors.,248.24
NSC 23766,[1177865-17-6],Cl.Cl.Cl.CCN(CC)CCCC(C)NC1=NC(C)=CC(NC2=CC=C3N=C(C)C=C(N)C3=C2)=N1,Enzymes,GTPases,Small Monomeric GTPases,Selective inhibitor of Rac1-GEF interaction; antioncogenic,Selective inhibitor of Rac1-GEF interaction. Prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1 (IC50 ~ 50 muM) without affecting Cdc42 or RhoA activation. Inhibits Rac1-mediated cell functions and is reported to reverse tumor cell phenotypes in prostate cancer cells.,530.97
NSC 319726,[71555-25-4],C/C(C1=NC=CC=C1)=N\NC(N2CCC2)=S,Cell Cycle,p53,,Reactivator of mutant p53,Reactivator of mutant p53. Restores wild type p53 structure and function to the p53R175 mutant. Inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM). Also inhibits growth of xenograft tumors expressing the p53R175 mutation in vivo.,234.32
NSC 405020,[7497-07-6],ClC1=CC=C(C(NC(C)CCC)=O)C=C1Cl,Enzymes,Histone Deacetylases,Class I HDACs,Histone deacetylase inhibitor,"Membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor (IC50 > 100 mumol/L). Directly interacts with the hemopexin domain (PEX) of MT1-MMP, affecting homodimerization and repressing its pro-tumorigenic activity in vivo. Displays no effect on the catalytic activity of MT1-MMP or MMP-2.",260.16
NSC 632839 hydrochloride,[157654-67-6],O=C(/C(CNC3)=C/C2=CC=C(C)C=C2)/C3=C/C1=CC=C(C)C=C1.Cl,Enzymes,Proteases,Deubiquitinating Enzymes,Inhibitor of ubiquitin isopeptidase activity,Inhibitor of ubiquitin isopeptidase activity that displays no effect on the proteolytic activity of the proteasome. Induces apoptosis via a Bcl-2-dependent and apoptosome-independent pathway of caspase activation (IC50 values are 15.65 and 16.23 muM in E1A and E1A/C9CN cells respectively).,339.86
NSC 663284,[383907-43-5],ClC1=C(NCCN2CCOCC2)C(=O)C2=NC=CC=C2C1=O,Enzymes,Phosphatases,Cdc25 Phosphatase,"Potent, selective Cdc25 phosphatase inhibitor","Potent, selective inhibitor of Cdc25 dual specificity phosphatases (Ki values are 29, 95 and 89 nM for human Cdc25A, Cdc25B2 and Cdc25C respectively); > 20- and > 450-fold selective over VHR and PTP1B phosphatases respectively. Arrests cells at both G1 and G2/M phase and blocks cdk2 and cdk1 activation. Blocks proliferation of a range of human tumor cell lines (IC50 = 0.2 - 35 muM).",321.76
NSC 697923,[343351-67-7],CC(C=C2)=CC=C2S(C1=CC=C([N+]([O-])=O)O1)(=O)=O,Enzymes,Ligases,Ubiquitin/Ubl E2 Conjugating Enzymes,Selective UBE2N inhibitor,Selective inhibitor of the E2 ubiquitin (Ub) conjugating enzyme UBE2N (Ubc13). Inhibits UBE2N-Ub conjugation and activity of the UBE2N-Ueva1A complex. Has no effect on UbcH5c activity. Inhibits NF-kappaB activation in diffuse large B-cell lymphoma (DLBCL) cells. Inhibits cell growth and induces apoptosis in DLBCL and neuroblastoma (NB) cell lines. Supresses NB cell xenograft tumor growth in vivo.,267.26
NSC 74859,[501919-59-1],CC1=CC=C(S(OCC(NC2=CC=C(C(O)=O)C(O)=C2)=O)(=O)=O)C=C1,Signal Transduction,Cytokine and NF-kB Signaling,STAT,Selective STAT3 inhibitor,"Selectively inhibits STAT3 DNA-binding activity in vitro (IC50 values are 86, 160, and >300 muM for STAT3-STAT3, STAT1-STAT3 and STAT1-STAT1 DNA-binding activity respectively). Blocks growth and induces apoptosis preferentially in tumor cells that contain persistently active STAT3 in vitro and arrests tumor growth in a murine xenograft model in vivo.",365.36
NTRC 824,[1623002-61-8],O=C(C(F)(F)F)C2=CN(CC(N[C@@H](CC(C)C)C(O)=O)=O)C1=CC=C(NS(C3=CC=C(C)C=C3)(=O)=O)C=C12,7-TM Receptors,Peptide Receptors,Neurotensin Receptors,Potent and selective non-peptide NTS2 antagonist,Potent and selective non-peptide neurotensin (NTS) type-2 receptor antagonist (IC50 = 38 nM). Exhibits >150-fold selectivity for NTS2 over NTS1.,553.55
nTZDpa,[118414-59-8],OC(=O)C1=C(SC2=CC=CC=C2)C2=CC(Cl)=CC=C2N1CC1=CC=C(Cl)C=C1,Nuclear Receptors,PPARs,PPARgamma Receptors,"Potent, selective PPARgamma partial agonist","Potent, selective non-thiazolidinedione PPARgamma partial agonist (EC50 = 57 nM); produces ~25% maximum efficacy. Antagonizes full agonist activity by ~60% (IC50 ~ 285 nM). Displays no activity at PPARalpha or PPARdelta receptors. Produces altered receptor conformation, and regulates adipocyte development and gene expression, in a differential manner to full PPARgamma agonists. Modulates metabolism and insulin sensitivity without causing cardiac hypertrophy in mice in vivo.",428.33
NU 1025,[90417-38-2],CC1=NC2=C(O)C=CC=C2C(=O)N1,Enzymes,Polymerases,Poly(ADP-ribose) Polymerase,Potent PARP inhibitor,"Novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP). Ki and IC50 values are 48 and 400 nM respectively.",176.17
NU 2058,[161058-83-9],NC1=NC(OCC3CCCCC3)=C2C(NC=N2)=N1,Enzymes,Kinases,Cyclin-dependent Kinase,Cdk1 and cdk2 inhibitor,Cyclin-dependent kinase (cdk) 1 and cdk2 inhibitor (Ki values are 5 and 12 muM respectively). Inhibits growth of human tumor cells in vitro (mean GI50 = 13 muM). Also inhibits DNA topoisomerase II ATPase activity (IC50 = 300 muM).,247.3
Nutlin-3,[548472-68-0],ClC1=CC=[C@@]([C@@H]3[C@@H](N(C(N5CC(NCC5)=O)=O)C(C4=CC=C(OC)C=C4OC(C)C)=N3)[C@]2=CC=C(Cl)C=C2)C=C1,Enzymes,Ligases,Ubiquitin E3 Ligases,MDM2 antagonist; inhibits MDM2-p53 interaction,MDM2 antagonist; inhibits the MDM2-p53 interaction (IC50 = 0.09 muM) and activates p53. Antiproliferative agent; induces apoptosis in cancer cells.,581.49
NVP 231,[362003-83-6],O=C(C3=CC=CC=C3)NC2=NC(C=C1)=C(S2)C=C1NC(C45CC(C6)CC(CC6C5)C4)=O,Enzymes,Kinases,Other Kinases,"Potent, selective and reversible CerK inhibitor","Potent, selective and reversible ceramide kinase (CerK) inhibitor (IC50 = 12 nM in vitro). Displays selectivity for CerK over sphingosine kinases (IC50 greater than or equal to100 muM) and other lipid kinases.",431.55
NVP ADW 742,[475488-23-4],NC1=NC=NC2=C1C(C4=CC(OCC5=CC=CC=C5)=CC=C4)=CN2[C@@H]3C[C@@H](CN6CCCC6)C3,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Insulin and insulin-like Receptors,ATP-competitive inhibitor of IGF1R,"ATP-competitive inhibitor of IGF1R (IC50 in the range of 0.1-0.2 muM). Also inhibits c-Kit kinase activity (IC50 in the range of 3-5 muM). Exhibits a synergistic effect with Imatinib, enhancing the sensitivity of multiple small cell lung cancer cell lines to the chemotherapeutics etoposide (Cat. No. 1226) and carboplatin (Cat. No. 2626).",453.58
O-1918,[536697-79-7],COC1=CC(C)=CC(OC)=C1[C@@H]1C=C(C)CC[C@H]1C(C)=C,7-TM Receptors,Cannabinoid Receptors,Other Cannabinoids,Silent antagonist for putative abnormal-CBD (Cat. No. 1297) receptor,"Selective, silent antagonist of a putative endothelial anandamide receptor distinct from CB1 or CB2 receptors. Inhibits vasodilation and cell migration induced by abnormal-cannabidiol (abn-CBD; Cat. No. 1297).",286.41
o-3M3FBS,[313981-55-4],CC1=CC(C)=C(C(C)=C1)S(=O)(=O)NC1=C(C=CC=C1)C(F)(F)F,Enzymes,Esterases,Phospholipases,Inactive analog of m-3M3FBS (Cat. No. 1941),Inactive analog of m-3M3FBS. Used as a negative control. Active Analog also available.,343.36
O4I1,[175135-47-4],N#CCC1=CC=C(OCC2=CC=C(OC)C=C2)C=C1,Stem Cells,Reprogramming,,Oct3/4 inducer,"Oct3/4 inducer. Increases Oct3/4 mRNA levels in HEK293 cells by 2.5- and 4-fold at 10 muM and 20 muM, respectively. Also increases expression of Oct3/4 in human adult and neonatal fibroblasts.",253.3
O4I2,[165682-93-9],ClC(C=C2)=CC=C2NC1=NC(C(OCC)=O)=CS1,Stem Cells,Reprogramming,,Oct3/4 inducer; induces expression of pluripotent-associated genes,"Oct3/4 inducer; promotes Oct3/4 expression and stabilizes the Oct3/4 protein in HEK293 cells. Induces expression of pluripotent-associated genes Lin28, Sox2 and Nanog, and suppresses Rex1. Induces 15-fold increase in Oct3/4 expression in human primary fibroblasts.",282.75
OAC-1,[300586-90-7],O=C(C3=CC=CC=C3)NC1=NC=C2C(C=CN2)=C1,Stem Cells,Reprogramming,,Oct4 activator; enhances iPSC reprogramming efficiency,"Oct4 activator. Enhances and accelerates iPSC reprogramming in the presence of 4F (Oct4, Sox2, c-Myc and Klf4) by ~20-fold compared to 4F alone. Induces mRNA expression of Oct4, Sox2 and Nanog and also Tet1. Displays no effects on p53-p21 pathway or Wnt-beta-catenin signaling.",237.26
ODQ,[41443-28-1],O=C1ON=C2C=NC3=C(C=CC=C3)N12,Signal Transduction,Nitric Oxide Signaling,Other Nitric Oxide,Selective inhibitor of NO-sensitive guanylyl cyclase,A potent and selective inhibitor of NO-sensitive guanylyl cyclase.,187.16
OF 1,[919973-83-4],CN1C2=C(C=C(OC)C(NS(C3=C(C)C=C(Br)C=C3)(=O)=O)=C2)N(C)C1=O,Epigenetics,Bromodomains,,Selective BRPF1B and BRPF2 inhibitor,Selective BRPF1B and BRPF2 bromodomain inhibitor (Kd values are 100 and 500 nM respectively). Exhibits 39-fold selectivity for BRPF1B and BRPF2 over BRD4. Accelerates FRAP recovery at 5 muM in a BRPF2 FRAP assay.,440.31
OICR 9429,[1801787-56-3],CN(CC4)CCN4C1=C(NC(C5=CNC(C=C5C(F)(F)F)=O)=O)C=C(C2=CC(CN3CCOCC3)=CC=C2)C=C1,Enzymes,Transferases,Lysine Methyltransferases,High affinity and selective WDR5 antagonist,"High affinity WDR5 antagonist (Kd = 93 nM; IC50 = 64 nM); disrupts WDR5-MLL interaction. Exhibits selectivity for WDR5 over 22 methyltransferases and a panel of kinases, GPCRs, ion channels, and transporters. Reduces viability of acute myeloid leukemia cells in vitro. Also disrupts MLL1-RbBP5 interaction. To request the negative control for OICR 9429, please fill out the OICR 0547 request form on the SGC website.",555.59
Olanzapine,[132539-06-1],CC4=CC2=C(S4)NC1=CC=CC=C1N=C2N3CCN(C)CC3,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2A antagonist; also D2 antagonist; atypical antipsychotic,"Antagonist of 5-HT2A and dopamine D2 receptors (Ki values are 4 and 11 nM respectively). Also displays affinity for a range of other receptors including D1 and D4, 5-HT2C, alpha1, H1 and M1-4 receptors (Ki values range between 1.9 and 31 nM) . Atypical antipsychotic. Displays anticholinergic properties. Also a highly potent activator of hM4Di DREADDs (EC50 values are 5 nM in vitro and 7 nM in vivo).",312.43
Olmesartan,[144689-24-7],CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,Potent AT1 antagonist,Potent angiotensin II type I (AT1) receptor antagonist (IC50 = 6.7 nM at hAT1 receptors). Improves cognitive function in a mouse model of hypertension- and hyperlipidemia-associated cognitive decline; ameliorates arterial stiffness in a rat model of chronic renal failure.,446.5
Olopatadine hydrochloride,[140462-76-6],O=C(CC(C=C3)=CC/1=C3OCC(C=CC=C2)=C2C1=C\CCN(C)C)O.Cl,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,H1 antagonist; ocular antiallergic agent,"Histamine H1 receptor antagonist (Ki = 31.6 nM). Inhibits the release of histamine, prostaglandin D2 and tryptase in a concentration-dependent manner. Mast cell stabilizer; inhibits mast cell mediator release. Also suppresses inflammation by inhibition of cytokine production.",373.87
Olvanil,[58493-49-5],CCCCCCCC\C=C/CCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1,Ion Channels,Transient Receptor Potential Channels,TRPV,Potent vanilloid receptor agonist,Potent vanilloid receptor agonist (pEC50 values are 8.1 and 7.7 at rat and human VR1 receptors respectively). Also blocks anandamide uptake (IC50 = 9 muM) and may bind to CB1 cannabinoid receptors. Antinociceptive following systemic administration. Also available as part of the Vanilloid TRPV1 Receptor Tocriset™.,417.63
ONO 8130,[459841-96-4],CC(C)CN(S(C3=NC(C)=CS3)(=O)=O)C1=C(OCC4=CC=C(C(O)=O)C=C4)C=C(CCC2)C2=C1,7-TM Receptors,Prostanoid Receptors,,EP1 receptor antagonist,EP1 receptor antagonist. Exhibits analgesic effect in a mouse mode of cystitis. Orally bioavailable.,500.63
OPC 21268,[131631-89-5],O=C2N(C3CCN(C(C4=CC=C(OCCCNC(C)=O)C=C4)=O)CC3)C1=CC=CC=C1CC2,7-TM Receptors,Peptide Receptors,Vasopressin Receptors,Orally active vasopressin V1 antagonist,Nonpeptide vasopressin V1 receptor antagonist. Displays greater affinity for rat V1 than human V1 (Ki values are 25 and 8800 nM respectively). Exhibits 1000-fold selectivity for V1 receptors over V2 receptors. Orally active.,449.54
Org 25543 hydrochloride,[495076-64-7],O=C(NCC2(N(C)C)CCCC2)C1=CC(OC)=C(OCC3=CC=CC=C3)C(OC)=C1.Cl,Transporters,Neurotransmitter Transporters,Glycine Transporters,Potent and selective GlyT2 inhibitor,"Potent and selective glycine transporter type 2 (GlyT2) inhibitor (IC50 = 16 nM for hGlyT2). Displays no activity at GlyT1 or 56 other common biological targets (greater than or equal to 100 muM), in a glycine uptake assay in CHO cells. Ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice.",448.98
OXA 06 dihydrochloride,,FC1=CC=CC=C1CNCC(C=C4)=CC=C4C2=C3C(NC=C3)=NC=C2.Cl.Cl,Enzymes,Kinases,Rho-kinases,Potent ROCK inhibitor,Potent ROCK inhibitor (IC50 = 10 nM). Suppresses pMYPT1 and pCofilin levels in non-small cell lung carcinoma (NSCLC) cell lines. Also inhibits anchorage-independent growth of NSCLC cell lines in vitro.,404.31
OXF BD 02,[1429129-68-9],OC1=CC(C2=C(C)ON=C2C)=CC(C(O)C3=CC=CC=C3)=C1,Epigenetics,Bromodomains,,Selective BRD4(1) inhibitor,Selective inhibitor of the first bromodomain of BRD4 (BRD4(1)) (IC50 = 382 nM). Exhibits 2-3-fold selectivity for BRD4(1) over the CBP bromodomain and has little affinity for a range of other bromodomains. Reduces viability of lung adenocarcinoma cell lines and attenuates proliferation of MV-4-11 leukemia cells. Cell permeable.,295.33
Oxotremorine sesquifumarate,[17360-35-9],OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.O=C1CCCN1CC#CCN1CCCC1.O=C1CCCN1CC#CCN1CCCC1,7-TM Receptors,Acetylcholine Muscarinic Receptors,Non-selective Muscarinics,Muscarinic agonist,Muscarinic agonist.,380.4
P 22077,[1247819-59-5],CC(C1=CC([N+]([O-])=O)=C(SC2=CC=C(F)C=C2F)S1)=O,Enzymes,Proteases,Deubiquitinating Enzymes,USP7 inhibitor,Inhibitor of ubiquitin-specific protease (USP) 7 (EC50 = 8.6 muM); also inhibits the closely related deubiquitinase (DUB) USP47. Demonstrates downstream inhibition of HDM2 and claspin in vitro. Inhibits USP7-mediated p53 deubiquitination. Blocks deubiquitination of Tip60 (KAT5) histone lysine acetyltransferase.,315.32
PAC 1,[315183-21-2],O=C(N/N=C/C3=CC=CC(CC=C)=C3O)CN(CC2)CCN2CC1=CC=CC=C1,Enzymes,Proteases,Caspases,Activator of procaspase-3; pro-apoptotic,Procaspase-activating compound; activates procaspase-3 to produce caspase-3 (EC50 = 0.22 muM). Also activates procaspase-7 in a less efficient manner (EC50 = 4.5 muM). Pro-apoptotic; induces apoptosis in both cancerous and non-cancerous cells dependent on procaspase-3 concentration (IC50 values are 0.003 - 1.41 and 5.02 - 9.98 muM respectively).,392.5
PAOPA,[114200-31-6],O=C1[C@H](N[C@]([C@H]2NCCC2)=O)CCN1CC(N)=O,7-TM Receptors,Dopamine Receptors,D2 Receptors,Allosteric modulator of D2 receptors,Allosteric modulator of dopamine D2 receptors. Prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized animal model of schizophrenia.,254.29
Parthenolide,[20554-84-1],C/C1=C\CC[C@]2(C)[C@@H](O2)[C@@H](OC([C@]3=C)=O)[C@H]3CC1,7-TM Receptors,5-HT Receptors,5-HT-Related,5-HT release inhibitor,"The active principle of feverfew (Chrysanthemum parthenium). Antisecretory, anti-inflammatory and spasmolytic; inhibits the release of 5-HT from blood platelets. Also inhibits activation of NF-kappaB, and generation of leukotriene B4 and thromboxane B2.",248.32
PCA 4248,[123875-01-4],COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSC1=CC=CC=C1,7-TM Receptors,Platelet-activating Factor (PAF) Receptors,,PAF receptor antagonist,"A specific PAF antagonist, more potent than the ginkolide BN-52021. Inhibits rabbit platelet aggregation with an IC50 value of 1.05 muM and has no significant activity on Ca2+ channels. Active in vivo, antagonizing PAF-induced systemic hypotension and protein-plasma extravasation in rats.",361.46
PCI 29732,[330786-25-9],NC1=C2C(N(C4CCCC4)N=C2C3=CC=C(OC5=CC=CC=C5)C=C3)=NC=N1,Enzymes,Kinases,Brutons Tyrosine Kinase (BTK),Potent BTK inhibitor,Potent BTK inhibitor (IC50 = 0.3 nM). Blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells.,371.44
PCI 34051,[950762-95-5],O=C(NO)C1=CC=C2C(N(CC3=CC=C(OC)C=C3)C=C2)=C1,Enzymes,Histone Deacetylases,Class I HDACs,Potent and selective HDAC8 inhibitor,"Potent and selective histone deacetylase 8 (HDAC8) inhibitor (IC50 = 10 nM). Displays >200 fold selectivity over HDAC isoforms 1, 2, 3, 6 and 10. Induces apoptosis in cell lines derived from T cell lymphomas or leukemias.",296.32
PD 102807,[23062-91-1],CCOC(=O)C1=C(C)NC2=CC=C3OC4N(CCC5=CC(OC)=CC=C45)CC3=C12,7-TM Receptors,Acetylcholine Muscarinic Receptors,M4 Receptors,Selective M4 antagonist,"Selective M4 muscarinic receptor antagonist. IC50 values are 91, 6559, 3441, 950 and 7412 nM for human M4, M1, M2, M3, and M5 receptors respectively. Promotes self-renewal of erythroid progenitors.",392.45
PD 158780,[171179-06-9],CNC1=NC=C2N=CN=C(NC3=CC=CC(Br)=C3)C2=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,Potent ErbB receptor family inhibitor,"Potent inhibitor of ErbB receptor family tyrosine kinases (IC50 values are 0.008, 49 and 52 nM for EGFR, ErbB2 and ErbB2/ErbB4 respectively) that does not inhibit FGF or PDGF-mediated tyrosine phosphorylation. Induces G1 cell cycle arrest in MCF10A cells and is antiproliferative in A431 human epidermal carcinoma cells.",330.18
PD 160170,[181468-88-2],CC(C)C1=CC=CC=C1S(=O)(=O)C1=CC(N)=C2N=CC=CC2=C1[N+]([O-])=O,7-TM Receptors,Peptide Receptors,NPY Receptors,Selective non-peptide NPY Y1 receptor antagonist,"Potent, selective non-peptidic neuropeptide Y1 receptor antagonist (Ki = 48 nM); selective over Y2 and Y5 receptors (Ki > 10 muM). Antagonizes NPY-mediated inhibition of cAMP accumulation in SK-N-MC cells (IC50 = 8.2 nM).",371.41
PD 161570,[192705-80-9],ClC1=CC=CC(Cl)=C1C3=CC2=CN=C(NCCCCN(CC)CC)N=C2N=C3NC(NC(C)(C)C)=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),FGFR,Selective FGFR inhibitor,"Selective FGFR inhibitor (IC50 values are 40, 262 and 3700 nM for FGFR, PDGFR and EGFR respectively). Inhibits FGFR receptor phosphorylation (IC50 = 622 nM) and growth of A121 cells in vitro.",532.51
PD 166285 dihydrochloride,[212391-63-4],CN(C1=NC(NC4=CC=C(OCCN(CC)CC)C=C4)=NC=C1C=C2C3=C(Cl)C=CC=C3Cl)C2=O.Cl.Cl,Enzymes,Kinases,Src Kinases,"Potent Src inhibitor; also inhibits FGFR1, PDGFRbeta and Wee1","Potent inhibitor of the tyrosine kinases c-Src, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor beta (PDGFRbeta) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). Also inhibits the checkpoint kinases Wee1 and Myt1; abolishes Cdc2 phosphorylation in numerous tumor cell lines and abrogates the G2 checkpoint.",585.35
PD 166793,[199850-67-4],BrC1=CC=C(C2=CC=C(S(N[C@@H]([C@H](C)C)C(O)=O)(=O)=O)C=C2)C=C1,Enzymes,Proteases,Matrix Metalloprotease,Broad spectrum MMP inhibitor,"Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.",412.3
PD 168568 dihydrochloride,[1782532-06-2],CC1=C(C)C=CC(N2CCN(CCC(N4)C3=CC=CC=C3C4=O)CC2)=C1.Cl.Cl,7-TM Receptors,Dopamine Receptors,D4 Receptors,Potent and selective D4 antagonist,Potent and selective dopamine D4 receptor antagonist (Ki values are 8.8 and 1842 nM at D4 and D2 receptors respectively). Reverses amphetamine-stimulated locomotion in vivo and is orally active.,422.39
PD 173074,[219580-11-7],O=C(NC(C)(C)C)NC2=NC1=NC(NCCCCN(CC)CC)=NC=C1C=C2C3=CC(OC)=CC(OC)=C3,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),FGFR,FGFR1 and -3 inhibitor,"Selective FGFR1 and FGFR3 inhibitor (IC50 values are 5, 21.5, ~100, 17600 and 19800 nM for FGFR3, FGFR1, VEGFR2, PDGFR and c-Src respectively, and > 50000 nM for EGFR, InsR, MEK and PKC). Inhibits VEGF- and FGF-induced angiogenesis in the mouse cornea model of angiogenesis. Inhibits proliferation and differentiation of oligodendrocyte progenitors. Also promotes mESC self-renewal, facilitates the conversion of mouse epiblast stem cells to an earlier pluripotency state and inhibts differentiation of miPSCs to cardiomyocytes. Suppresses cell proliferation in cell lines expressing mutated FGFR3 protein. Blocks tumor growth in H510 and H69 SCLC xenograft models.",523.67
PD 173212,[217171-01-2],CC(C)(C)C1=CC=C(CN(C)[C@H](C(N[C@H]([C@](NC(C)(C)C)=O)CC2=CC=C(OCC3=CC=CC=C3)C=C2)=O)CC(C)C)C=C1,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,Potent CaV2.2 blocker,"Potent N-type voltage-gated calcium channel blocker (IC50 = 36 nM). Displays selectivity over K+, Na+ and L-type Ca2+ channels. Prevents tonic seizures in the audiogenic seizure model in vivo.",599.85
PD 407824,[622864-54-4],OC1=CC2=C(NC3=C2C2=C(C(=O)NC2=O)C(=C3)C2=CC=CC=C2)C=C1,Enzymes,Kinases,Checkpoint Kinases,Potent and selective inhibitor of Chk1 and Wee1,"Potent and selective inhibitor of checkpoint kinases Chk1 and Wee1 (IC50 values are 47 and 97 nM respectively). Displays selectivity over a range of other protein kinases; IC50 values are 3.4, 3.75, > 5, > 50, > 50 and > 50 muM for PKC, CDK4, other CDKs, c-Src, PDGFR and FGFR respectively. Also sensitizes hESCs to BMP4 to induce differentiation.",328.32
PD 98059,[167869-21-8],COC1=C(N)C(=CC=C1)C1=CC(=O)C2=CC=CC=C2O1,Enzymes,Kinases,MEK,MEK inhibitor,"Inhibitor of mitogen-activated protein kinase kinase (MKK / MEK). Acts by binding to the inactivated form of MEK, thereby preventing its phosphorylation by cRAF or MEK kinase (IC50 = 2-7 muM). Inhibits cell growth and proliferation in acute myelogenous leukemia (AML) cell lines; causes G1 arrest by blocking p53-dependent p21 induction. Enhances embryonic stem cell self-renewal. Also available as part of the MAPK Cascade Inhibitor Tocriset™ and MAPK Inhibitor Tocriset™.",267.28
PDP-EA,[861891-72-7],CCCCCCCCCCCCCCCC1=CC(OCC(NCCO)=O)=CC=C1,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),FAAH activator,FAAH activator; proposed to enhance amidohydrolase activity of FAAH by reducing negative feedback mechanisms.,405.61
PF 03814735,[942487-16-3],[H][C@@]3(N5C(CNC(C)=O)=O)CC[C@@]5([H])C(C3=C4)=CC=C4NC1=NC(NC2CCC2)=C(C(F)(F)F)C=N1,Enzymes,Kinases,Aurora Kinases,Aurora kinase A and B inhibitor,"ATP-competitive inhibitor of Aurora kinases A and B (IC50 values are 0.8 and 5 nM for recombinant Aurora B and Aurora A, respectively). Inhibits phosphorylation of Aurora B, histone H3 and Aurora A in cultured MDA-MB-231 cells (IC50 values are approximately 20, 50 and 150 nM respectively). Shown to block cytokinesis; inhibits cellular proliferation in several human tumor cell lines, including HCT-116, HL-60, A549 and H125, and in human xenograft mouse models. Orally available.",474.48
PF 04418948,[1078166-57-0],FC(C=C4)=CC=C4C(N(C3)CC3(C(O)=O)COC2=CC1=CC=C(OC)C=C1C=C2)=O,7-TM Receptors,Prostanoid Receptors,,Potent and selective EP2 receptor antagonist,"Potent EP2 receptor antagonist (IC50 = 16 nM for human EP2 receptors). Displays over 2000-fold selectivity for EP2 receptors over EP1, EP3, EP4, DP1 amd CRTH2 receptors; exhibits <30% binding at a diverse panel of GPCRs and ion channels at a concentration of 10 muM. Inhibits PGE2-induced increases in intracellular cAMP; reverses PGE2-invoked relaxation of mouse trachea (IC50 = 2.7 nM).",409.41
PF 04691502,[1013101-36-4],O=C2C(C4=CC=C(OC)N=C4)=CC1=C(C)N=C(N)N=C1N2[C@@H]3CC[C@@H](OCCO)CC3,Enzymes,Kinases,PI 3-Kinase,Potent and selective dual PI 3-K/mTOR inhibitor,"Potent and selective dual ATP-competitive PI 3-K/mTOR inhibitor (Ki values are 1.6, 1.8, 1.9, 2.1 and 16 nM for human PI 3-K delta, alpha, gamma, beta, and mTOR, respectively). Displays no significant inhibitory activity at more than 80 protein kinases (concentration greater than or equal to 10 muM) including hVps34, PI 3-K downstream kinases, and MAPK family members. Orally available. Induces robust cell cycle arrest at the G1 phase in U87MG cancer cells and antitumor activity in SKOV3 ovarian cancer xenograft models.",425.48
PF 04885614,,CC(C)(N)C1=NC(C2=CC=C(OC(F)(F)F)C=C2)=CN1,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Potent and selective NaV1.8 channel blocker; active in vivo,"Potent NaV1.8 inhibitor (IC50 = 53 nM for human NaV1.8 channel). Exhibits selectivity for hNaV1.8 over hNaV1.6, hNaV1.7, hNaV1.1, hNaV1.2 and hNaV1.5 (IC50 values are 4.2, 7.0, 11, 16 and 27 muM respectively). Orally bioavailable.",285.26
PF 04937319,[1245603-92-2],CC1=CC2=C(OC3=CN=C(C(N(C)C)=O)N=C3)C=C(C(NC4=CN=C(C)C=N4)=O)C=C2O1,Enzymes,Kinases,Hexokinases,Glucokinase partial activator,Glucokinase partial activator (EC50 = 174 nM). Enhances glucose-stimulated insulin secretion in islet cell cultures and translocation of glucokinase from the nucleus to the cytoplasm in hepatocytes in vitro. Reduces post-prandial plasma glucose levels in an oral glucose tolerance test in rats.,432.43
PF 06447475,[1527473-33-1],N#CC1=CC(C3=CNC2=NC=NC(N4CCOCC4)=C23)=CC=C1,Enzymes,Kinases,RIP kinase family,Potent LRRK2 inhibitor; neuroprotective,Potent LRRK2 inhibitor (IC50 = 3 nM). Attenuates alpha-synuclein-induced dopaminergic neurodegeneration and neuroinflammation in G2019S-LRRK2 expressing rats. Also neuroprotective in wild type rats. Brain penetrant.,305.33
PF 06463922,[1454846-35-5],C[C@@H](O3)C4=C(C=CC(F)=C4)C(N(C)CC1=NN(C)C(C#N)=C1C2=CC3=C(N)N=C2)=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),ALK,High affinity and selective ALK and ROS1 inhibitor,"High affinity and selective ALK and ROS1 inhibitor (Ki values are <0.02, <0.07 and 0.7 nM for ROS1, wild-type ALK and ALK-L1196M, respectively). Exhibits >100-fold selectivity for ROS1 over a panel of 204 other kinases. Inhibits proliferation of BaF3 cells containing crizotinib-resistant ROS1 mutation in vitro. Inhibits tumor growth in relevant mouse models. Orally available and brain penetrant.",406.41
PF 3845,[1196109-52-0],O=C(NC2=CN=CC=C2)N1CCC(CC3=CC=CC(OC4=NC=C(C(F)(F)F)C=C4)=C3)CC1,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),Selective FAAH inhibitor,Selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 muM). Reduces inflammatory pain via a cannabinoid receptor-dependent mechanism. Highly efficacious and selective in vivo. Displays no activity at FAAH-2 (IC50 >10 muM).,456.46
PF 429242 dihydrochloride,[2248666-66-0],O=C(C2=CC=C(CN(CC)CC)C=C2)N(CCC3=CC=CC=C3OC)[C@@H]1CCNC1.Cl.Cl,Signal Transduction,Transcription Factors,SREBP,Competitive inhibitor of SREBP site 1 protease,"Reversible, competitive inhibitor of sterol regulatory element-binding protein (SREBP) site 1 protease (IC50 = 0.175 muM). Selective for site 1 protease against a panel of serine proteases. Inhibits rate of cholesterol synthesis in CHO cells (IC50 = 0.53 muM). Also displays antiviral activity. Cell permeable.",482.49
PF 431396,[717906-29-1],O=C2NC1=CC=C(NC3=NC=C(C(F)(F)F)C(NCC4=CC=CC=C4N(C)S(=O)(C)=O)=N3)C=C1C2,Enzymes,Kinases,Focal Adhesion Kinase,Dual FAK/PYK2 inhibitor,"Dual focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2) inhibitor (IC50 values are 2 and 11 nM respectively). Promotes osteoblast recruitment and activity, and stimulates bone formation in ovariectomized rats.",506.5
PF 4708671,[1255517-76-0],CCC(C=NC=N2)=C2N1CCN(CC4=NC3=CC(C(F)(F)F)=CC=C3N4)CC1,Enzymes,Kinases,RSK,S6K1 inhibitor,"Cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) (Ki = 20 nM; IC50 = 160 nM). Suppresses the S6K1-mediated phosphorylation of S6, Rictor and mTOR in response to IGF1; displays no effect on the activity of RSK and MSK in vivo. Exhibits no significant inhibition of S6K2 or other AGC kinases (e.g. Akt, PKA and ROCK) in vitro.",390.41
PF 477736,[952021-60-2],O=C([C@H](N)C4CCCCC4)NC1=CC3=C(C(C=NNC3=O)=C(C5=CN(C)N=C5)N2)C2=C1,Enzymes,Kinases,Checkpoint Kinases,Selective Chk1 inhibitor,Selective checkpoint kinase 1 (Chk1) inhibitor (Ki values are 0.49 and 47 nM for Chk1 and Chk2 respectively). Abrogates cell cycle arrest at S and G2-M checkpoints; sensitizes cells to DNA damage. Enhances docetaxel (Cat. No. 4056) efficacy in tumor cells and xenografts.,419.48
PF 4800567 hydrochloride,[1391052-28-0],NC1=C(C(COC4=CC(Cl)=CC=C4)=NN2C3CCOCC3)C2=NC=N1.Cl,Enzymes,Kinases,Casein Kinase 1,Selective casein kinase 1epsilon inhibitor,Selective casein kinase 1epsilon inhibitor; displays 22-fold greater potency towards CK1epsilon than CK1delta (IC50 values are 32 and 711 nM for CK1epsilon and CK1delta respectively). ATP competitive. Displays minimal effect on the circadian clock.,396.27
PF 5274857 hydrochloride,[1613439-62-5],CC1=CN=C(C2=CC(N3CCN(C(CCS(C)(=O)=O)=O)CC3)=NC=C2Cl)C(C)=C1.Cl,7-TM Receptors,Smoothened Receptors,,High affinity and selective Smoothened (Smo) receptor antagonist,"High affinity and selective Smoothened (Smo) receptor antagonist (Ki = 4.6 nM). Exhibits >1000-fold selectivity for Smo over a panel of other receptors, ion channels and enzymes. Inhibits Shh-induced Hedgehog signaling in MEF cells. Induces tumor regression in a medulloblastoma allograft mouse model. Orally available and brain penetrant.",473.42
PF 573228,[869288-64-2],O=C(N3)CCC1=C3C=CC(NC2=NC(NCC4=CC=CC(S(=O)(C)=O)=C4)=C(C(F)(F)F)C=N2)=C1,Enzymes,Kinases,Focal Adhesion Kinase,Potent and selective FAK inhibitor,Potent and selective inhibitor of focal adhesion kinase (FAK) (IC50 = 4 nM). Displays 50 - 250-fold selectivity for FAK over other protein kinases. Blocks serum and fibronectin-directed migration and decreases focal adhesion turnover in vitro.,491.49
PF 670462,[950912-80-8],NC1=NC=CC(C2=C(C4=CC=C(F)C=C4)N=CN2C3CCCCC3)=N1.Cl.Cl,Enzymes,Kinases,Casein Kinase 1,Potent and selective CK1epsilon and CK1delta inhibitor,Potent and selective casein kinase 1epsilon (CK1epsilon) and CK1delta inhibitor (IC50 values are 7.7 and 14 nM respectively) that displays > 30-fold selectivity over 42 other common kinases. Inhibits PER protein nuclear translocation (EC50 = 290 nM) causing phase shifts in circadian rhythms and attenuates methamphetamine-stimulated locomotion in vivo.,410.32
PF 750,[959151-50-9],O=C(NC4=CC=CC=C4)N(CC3)CCC3CC2=CC1=CC=CC=C1N=C2,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),Selective FAAH inhibitor,Irreversible fatty acid amide hydrolase (FAAH) inhibitor (IC50 = 16.2 nM) that displays no activity at a range of other serine hydrolases. Selectively inhibits FAAH within the central nervous system. Orally active.,345.44
PF 915275,[857290-04-1],NC1=NC(NS(C(C=C3)=CC=C3C2=CC=C(C#N)C=C2)(=O)=O)=CC=C1,Enzymes,Dehydrogenases,11b-Hydroxysteroid Dehydrogenase,Potent and selective 11beta-hydroxysteroid dehydrogenase inhibitor,Potent and selective 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) inhibitor (Ki = 2.3 nM) that displays little activity at 11betaHSD2 (1.5% inhibition at 10 muM). Inhibits the conversion of prednisone to prednisolone in human hepatocytes in vitro (EC50 = 15 nM) and has antidiabetic activity in vivo. Orally active.,350.39
PFI 1,[1403764-72-6],O=C2NC1=CC=C(NS(C3=CC=CC=C3OC)(=O)=O)C=C1CN2C,Epigenetics,Bromodomains,,BET bromodomain inhibitor,Potent BET bromodomain inhibitor; exhibits inhibitory activity at bromodomain-containing protein (BRD) 2 and BRD4 (IC50 values are 98 and 220 nM respectively). Induces apoptosis and G1 cell cycle arrest in BET inhibitor-sensitive cell lines (MV4;11). Also downregulates Aurora B expression in MV4;11 cells. Cell permeable.,347.39
PFI 3,[1819363-80-8],O=C(C3=C(O)C=CC=C3)/C=C/N1[C@H](C4)CN(C2=NC=CC=C2)[C@H]4C1,Epigenetics,Bromodomains,,Potent and selective SMARCA2/4 and polybromo 1 inhibitor,Potent and selective polybromo 1 and SMARCA4 inhibitor (Kd values are 48 and 89 nM respectively). Also inhibits SMARCA2. Displays 30-fold selectivity over other sub-family branches. Accelerates FRAP recovery in cells at a concentration of 1 muM.,321.37
PFI 4,[900305-37-5],CN(C1=CC(NC(C2=C(OC)C=CC=C2)=O)=C(N3CCCC3)C=C1N4C)C4=O,Epigenetics,Bromodomains,,Potent and selective BRPF1 bromodomain inhibitor,"Potent and selective BRPF1 bromodomain inhibitor (IC50 = 80 nM). Exhibits >100-fold selectivity for BRPF1 over a panel of other bromodomains including BRPF2 (BRD1), BRPF3 and BRD4. Disrupts BRPF1 binding to histone H3.3. Cell permeable.",380.44
PHA 568487,[527680-57-5],O=C(C3=CC=C(OCCO4)C4=C3)N[C@@H]1C2CCN(CC2)C1.O=C(/C=C/C(O)=O)O,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Selective alpha7 nAChR agonist,"Agonist of the alpha7 nicotinic acetylcholine receptor (Ki values are 44 and 2800 for alpha7 and 5-HT3 respectively, IC50 values are > 100 muM for alpha3beta4 and alpha1beta1deltagamma respectively, and % inhibition is < 1 and 5% for alpha4beta2 and hERG respectively). Orally active and brain penetrant.",404.41
PHA 767491 hydrochloride,[942425-68-5],O=C1NCCC2=C1C=C(C3=CC=NC=C3)N2.Cl,Enzymes,Kinases,MK2,MK2 inhibitor; also cdk inhibitor; potently inhibits cdk9,"ATP-competitive cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 0.034 - 0.75, 0.24 - 1.2, 0.25 - 1.1 and 0.46 - 1 muM for cdk9, cdk2, cdk1 and cdk5, respectively). Also inhibits mitogen-activated protein kinase-activated protein kinase-2 (MK2; IC50 = 171 nM). Prevents initiation of DNA replication. Inhibits cell proliferation in a variety of human cell lines and induces apoptosis in a p53-independent manner in vivo.",249.7
PHCCC,[179068-02-1],O=C(NC4=CC=CC=C4)C3(C2C3)OC1=CC=CC=C1/C2=N/O,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Potent group I mGlu antagonist,Group I metabotropic glutamate receptor antagonist (IC50 ~ 3 muM); 67 times more potent than (S)-4-carboxyphenylglycine (Cat. No. 0323). Also a positive allosteric modulator for mGlu4a; potentiates L-AP4-mediated inhibition of striatopallidal synaptic transmission in vitro. Displays antiParkinsonian effects in rats in vivo.,294.31
PhiKan 083,[880813-36-5],CCN1C3=C(C=CC=C3)C2=C1C=CC(CNC)=C2.Cl,Cell Cycle,p53,,p53 stabilizing agent,p53 stabilizing agent; preferentially binds mutated (Y220C) p53 over wild-type p53 at a site distinct from functional DNA/protein interaction regions. Slows rate of thermal denaturation of p53-Y220C.,274.79
PHP 501 trifluoroacetate,[1781880-44-1],ON1N=CC(C3CCNCC3)=C1C2=CC=CC(C4=CC=CC=C4)=C2.FC(F)(C(O)=O)F,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Potent GABAA antagonist,"Potent GABAA antagonist (Ki = 0.0028 muM at rat GABAA receptors; IC50 = 0.024 muM at human alpha1beta2gamma2 GABAA-expressing tsA201 cells). Displays no inhibitory activity at hGAT-1, hGAT-2, hGAT-3 or hBGT-1 GABA transporters.",433.42
PHT 427,[1191951-57-1],O=S(C(C=C1)=CC=C1CCCCCCCCCCCC)(NC2=NN=CS2)=O,Enzymes,Kinases,Akt (Protein Kinase B),Dual Akt and PDK1 inhibitor; antitumor,"Dual Akt and PDK1 inhibitor; binds the pleckstrin homology (PH) domain of Akt and PDK1 (Ki values are 2.7 and 5.2 muM, respectively). Inhibits Akt phosphorylation and Akt downstream targets; also induces apoptosis in vitro. Displays synergistic antitumor effect when combined with chemotherapeutics in breast cancer mouse models.",409.61
PHTPP,[805239-56-9],OC1=CC=C(C=C1)C1=C2N=C(C=C(N2N=C1C1=CC=CC=C1)C(F)(F)F)C(F)(F)F,Nuclear Receptors,Estrogen and Related Receptors,,Selective ERbeta antagonist,"Selective estrogen ERbeta receptor antagonist that displays 36-fold selectivity over ERalpha. Exhibits full antagonism at ERbeta in a cotransfection assay in human endometrial cancer cells (HEC-1), with minimal effects on ERalpha.",423.31
PI 828,[942289-87-4],O=C2C=C(N3CCOCC3)OC1=C(C4=CC=C(N)C=C4)C=CC=C12,Enzymes,Kinases,PI 3-Kinase,"PI 3-kinase inhibitor, more potent than LY 294002 (Cat. No. 1130)","PI 3-Kinase inhibitor (IC50 values are 0.098, 0.183, 0.227 and 1.967 muM for p110beta, p110alpha, p110delta and p110gamma respectively) that displays higher potency than LY 294002 (Cat No. 1130). Can be immobilized onto a solid phase.",322.36
Piclamilast,[144035-83-6],O=C(NC3=C(Cl)C=NC=C3Cl)C1=CC(OC2CCCC2)=C(OC)C=C1,Enzymes,Phosphodiesterases,,Potent and selective PDE4 inhibitor,"Potent and selective inhibitor of phosphodiesterase (PDE) 4 (IC50 = 1 nM at PDE4 from human neutrophils). Displays >19,000-fold selectivity over other PDE isoenzymes. Exhibits anti-inflammatory effects in models of allergic inflammation. Also inhibits LTB4 synthesis in human neutrophils (IC50 = 2 nM).",381.25
Pilocarpine hydrochloride,[54-71-7],O=C1[C@@]([H])(CC)[C@](CC2=CN=CN2C)([H])CO1.Cl,7-TM Receptors,Acetylcholine Muscarinic Receptors,Non-selective Muscarinics,Muscarinic agonist,Muscarinic agonist.,244.72
PIM-1 Inhibitor 2,[477845-12-8],NC1=NC=CC(C3=CC2=C(C4=CC=C(Cl)C=C4)ON=C2C=C3)=N1,Enzymes,Kinases,Pim Kinase,Pim-1 kinase inhibitor,Potent Pim-1 kinase inhibitor (Ki = 91 nM).,322.75
Pimozide,[2062-78-4],FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,D2-like antagonist; also high affinity 5-HT7 antagonist,Dopamine D2-receptor antagonist and antipsychotic which binds with very high affinity to the cloned rat 5-HT7 receptor (Ki = 0.5 nM).,461.55
Pioglitazone hydrochloride,[112529-15-4],O=C(S3)NC(C3CC(C=C2)=CC=C2OCCC1=NC=C(CC)C=C1)=O.Cl,Nuclear Receptors,PPARs,PPARgamma Receptors,Selective PPARgamma agonist; antidiabetic agent,Selective PPARgamma agonist (EC50 = 0.69 muM). Thiazolidinedione (TZD) derivative and antidiabetic agent; improves insulin sensitivity. Also enhances proliferation and survival of mESCs and acts synergistically with Y-27632 (Cat.No. 1254) to improve survival of dissociated single hPSCs and increase colony formation.,392.9
Pitavastatin calcium,[147526-32-7],[Ca++].O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC([O-])=O.O[C@H](C[C@H](O)\C=C\C1=C(C2=CC=C(F)C=C2)C2=CC=CC=C2N=C1C1CC1)CC([O-])=O,Enzymes,Reductases,HMG-CoA Reductase,HMG-CoA reductase inhibitor,"Synthetic inhibitor of HMG-CoA reductase (Ki = 1.7 nM). Lowers low-density lipoprotein (LDL) cholesterol levels. Displays minimal metabolism by cytochrome P450 enzymes, with little involvement of CYP3A4. Shown to improve cardiac function and survival in a rat model of hypertensive heart failure.",440.5
PJ 34 hydrochloride,[344458-15-7],Cl.CN(C)CC(=O)NC1=CC2=C(NC(=O)C3=CC=CC=C23)C=C1,Enzymes,Polymerases,Poly(ADP-ribose) Polymerase,Potent PARP inhibitor,Potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC50 = 20 nM). ~1000-fold more potent than 3-Aminobenzamide (Cat. No. 0788). Protects primary neuronal cells from oxygen-glucose deprivation in vitro and reduces infarct size following focal cerebral ischemia in vivo. Displays protective effects against cisplatin-induced kidney injury. Also displays activity at Pim-1 and Pim-2 kinases at higher concentrations (IC50 values are 3.7 and 16 muM respectively).,331.8
PK 11195,[85532-75-8],CCC(C)N(C)C(=O)C1=NC(C2=CC=CC=C2Cl)=C2C=CC=CC2=C1,Other Pharmacology,Translocator Protein,,Antagonist at peripheral benzodiazepine receptors,"Possesses high affinity for the peripheral benzodiazepine receptor (PBR, TSPO) without binding to other known neurotransmitter receptors. Also inhibits the human constitutive androstane receptor (hCAR).",352.86
PK 44 phosphate,[1017682-66-4],N[C@@H](CC(N4CC3=NN=C(C(F)(F)F)N3CC4)=O)CC2=NNC1=C(F)C(F)=CC=C12.OP(O)(O)=O,Enzymes,Proteases,Dipeptidyl Peptidase IV (DPP-IV),Potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor,Potent inhibitor of dipeptidyl peptidase IV (DPP-IV) (IC50 = 15.8 nM). Displays >1000-fold selectivity for DPP-IV over DPP-8 and DPP-9. Improves glucose tolerance in a mouse oral glucose tolerance assay.,527.34
PK-THPP,[1332454-07-5],O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N(C3)CCC4=C3C(N5CCC(C(CCC)=O)CC5)=NC=N4,Ion Channels,Potassium Channels,Two-P Potassium Channels,Potent K2P9.1 (TASK-3) channel blocker,Potent TASK-3 channel blocker (IC50 = 35 and 300 nM for TASK-3 and TASK-1 respectively). Increases breathing rate and induces respiratory alkalosis in rats.,468.59
PluriSln 1,[91396-88-2],O=C(NNC2=CC=CC=C2)C1=CC=NC=C1,Enzymes,Oxygenases/Oxidases,Stearoyl-CoA 9-desaturase,SCD-1 inhibitor,"Stearoyl-CoA desaturase 1 (SCD1) inhibitor. Used to selectively eliminate undifferentiated human pluripotent stem cells (hPSCs) from culture; induces ER stress, attenuates protein synthesis and induces apoptosis in hPSCs. Prevents teratoma formation in immunocompromised mice.",213.24
PLX 647 dihydrochloride,[1779796-38-1],FC(C(C=C4)=CC=C4CNC(N=C3)=CC=C3CC2=CNC1=NC=CC=C12)(F)F.Cl.Cl,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Other RTKs,Potent dual Fms/KIT inhibitor,"Potent dual KIT/Fms inhibitor (IC50 values are 16 and 28 nM respectively). Inhibits BCR-FMS cell proliferation and osteoclast differentiation in vitro (IC50 values are 92 and 170 nM respectively). Attenuates LPS-induced TNFalpha and IL-6 release, mast cell activation and macrophage kidney proliferation in vivo.",455.3
PNU 177864 hydrochloride,[1783978-03-9],O=S(C1=CC=C(OC(F)(F)F)C=C1)(NC2=CC=C(CCNCCC)C=C2)=O.Cl,7-TM Receptors,Dopamine Receptors,D3 Receptors,Highly selective D3 antagonist,Highly selective dopamine D3 receptor antagonist. Induces phospholipidosis and exhibits antischizophrenic activity in vivo.,438.89
PNU 282987,[711085-63-1],O=C(C2=CC=C(Cl)C=C2)N[C@@H]1C3CCN(CC3)C1,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Selective alpha7 nAChR agonist,"Highly selective alpha7 nAChR agonist (Ki = 26 nM) displaying negligible blockade of alpha1beta1gammadelta and alpha3beta4 nAChRs (IC50 greater than or equal to 60 muM). Found to be inactive against a panel of 32 receptors at 1 muM, except 5-HT3 receptors (Ki = 930 nM).",264.75
PNU 74654,[113906-27-7],O=C(N/N=C/C2=CC=C(C)O2)C1=C(OC3=CC=CC=C3)C=CC=C1,Signal Transduction,Wnt Signaling,Beta-catenin,beta-catenin binder; inhibits Wnt signaling,Binds to beta-catenin (KD = 450 nM). Inhibits the interaction between beta-catenin and T cell factor 4 (Tcf4) and disrupts the Wnt signaling pathway.,320.34
PP 121,[1092788-83-4],NC1=C2C(N(C5CCCC5)N=C2C3=CN=C(NC=C4)C4=C3)=NC=N1,Enzymes,Kinases,PI 3-Kinase,Dual kinase inhibitor; inhibits PI 3-K family kinases,"Dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 muM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 muM for p110alpha, DNA-PK and mTOR). Exhibits no significant effect on receptor serine/threonine kinases (RSTKs). Blocks the proliferation of tumor cells by direct inhibition of PI 3-K, mTOR, Src and the VEGF receptor.",319.36
PP 2,[172889-27-9],CC(C)(C)N1N=C(C2=C(N)N=CN=C12)C1=CC=C(Cl)C=C1,Enzymes,Kinases,Src Kinases,"Potent, selective Src family kinase inhibitor",Selective inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 4 and 5 nM respectively). Displays > 10000-fold selectivity over ZAP-70 and JAK2. Moderately inhibits CSK (IC50 = 0.73 muM). Negative Control also available.,301.78
PPT,[263717-53-9],CCCC1=C(N(N=C1C1=CC=C(O)C=C1)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1,Nuclear Receptors,Estrogen and Related Receptors,,Subtype-selective ERalpha agonist,"Potent, subtype-selective estrogen receptor agonist (EC50 ~ 200 pM); displays 410-fold selectivity for ERalpha over ERbeta. Prevents ovariectomy-induced weight gain and loss of bone mineral density, and induces gene expression in the hypothalamus following systemic administration in vivo.",386.45
PPY A,[875634-01-8],O=C(N(C)C)C1=CN=CC(C2=CN=C(NC=C3C4=C(OC)C=CC=C4)C3=C2)=C1,Enzymes,Kinases,Abl Kinase,Potent inhibitor of Abl T315l mutant and wild-type Abl kinases,"Potent inhibitor of T315l mutant and wild-type Abl kinases (IC50 values are 9 and 20 nM, respectively). Inhibits growth of cells transformed with either the Bcr-Abl T315l mutant or wild-type Bcr-Abl gene.",372.42
PQ 401,[196868-63-0],O=C(NC3=C(OC)C=CC(Cl)=C3)NC2=CC(C)=NC1=CC=CC=C12,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Insulin and insulin-like Receptors,IGF1R inhibitor,Insulin-like growth factor receptor (IGF1R) inhibitor. Suppresses IGF-stimulated IGF-IR autophosphorylation with an IC50 value of 12 muM. Inhibits growth of MCF-7 breast cancer cells in vitro and in vivo.,341.79
Pramipexole dihydrochloride,[104632-25-9],NC(S2)=NC1=C2C[C@@H](NCCC)CC1.Cl.Cl,7-TM Receptors,Dopamine Receptors,D3 Receptors,Selective D3 agonist,"Dopamine receptor agonist exhibiting selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits negligible affinity for D1 and D5 receptors. Displays activity in the treatment of Parkinson's disease.",284.25
Pravastatin sodium salt,[81131-70-6],[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O,Enzymes,Reductases,HMG-CoA Reductase,HMG-CoA reductase inhibitor,"Water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A (HMG-CoA) reductase. Potently blocks cholesterol synthesis in vivo (Ki~ 1 nM) and displays cardioprotective properties.",446.51
Prazosin hydrochloride,[19237-84-4],Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1=CC=CO1,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,alpha1 and alpha2B antagonist; also MT3 antagonist,alpha1 and alpha2B-adrenoceptor antagonist. Also a potent antagonist at the melatonin MT3 receptor (Ki = 10.2 nM). Also available as part of the alpha1-Adrenoceptor Tocriset™ and Mixed Adrenergic Tocriset™.,419.87
PRE-084 hydrochloride,[138847-85-5],Cl.O=C(OCCN1CCOCC1)C1(CCCCC1)C1=CC=CC=C1,Other Pharmacology,Sigma Receptors,Sigma1 Receptors,Highly selective sigma1 agonist,"High affinity, selective sigma1 agonist (Ki values are 2.2 and 13091 nM for sigma1 and sigma2 receptors respectively). Selective over PCP receptors (IC50 > 100000 nM) and several other receptor systems. Produces antiamnesic and antitussive effects in vivo. Also exhibits protective effects in PC6.3 cells expressing mutant huntingtin by activating NF-kappaB signaling.",353.89
Pregnanolone,[128-20-1],C[C@@]12[C@@](CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@H]4C(C)=O)([H])C[C@H](O)CC1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Postitive allosteric modulator of GABAA receptors,GABAA receptor positive allosteric modulator. Neuroactive steroid.,318.49
Probenecid,[57-66-9],O=S(C1=CC=C(C(O)=O)C=C1)(N(CCC)CCC)=O,Transporters,Multidrug Transporters,,MRP inhibitor,Inhibitor of multidrug resistance-associated proteins (MRP). Inhibits organic acid transport in the kidney and other organs. Also exhibits inhibitory activity against pannexin 1 channels (IC50 ~ 150 muM).,285.36
Procaterol hydrochloride,[62929-91-3],O=C1C=CC2=C(C(O)=CC=C2[C@@]([H])(O)[C@@](NC(C)C)(CC)[H])N1.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-2 Receptors,Potent beta2 agonist,Specific and very potent beta2 agonist.,326.82
Prochlorperazine dimaleate,[84-02-6],O=C(O)/C=C\C(O)=O.ClC4=CC2=C(C=C4)SC1=CC=CC=C1N2CCCN3CCN(C)CC3.O=C(O)/C=C\C(O)=O,7-TM Receptors,Dopamine Receptors,D2 Receptors,D2 receptor antagonist; also 5-HT3 and nAChR antagonist,"D2 receptor antagonist. Also interacts with 5-HT3 and nAChR. Displays antipsychotic, antispasmodic, antiemetic and antinociceptive activity in vivo.",606.09
Proxyfan oxalate,[1620017-81-3],OC(=O)C(O)=O.C(COCC1=CC=CC=C1)CC1=CN=CN1,7-TM Receptors,Histamine Receptors,Histamine H3 Receptors,High affinity H3 ligand,"High affinity histamine H3 receptor ligand (pKi = 8.62) that acts as a protean agonist at recombinant and native receptors. In functional studies, activity ranges from full agonist to inverse agonist depending on system used. Displays partial agonist effects on cAMP inhibition and MAPK activity, neutral antagonist activity on histamine release and partial inverse agonism of [3H]-arachidonic acid release.",306.32
PRT 4165,[31083-55-3],O=C(C2=CC=CC=C2C3=O)/C3=C\C1=CC=CN=C1,Enzymes,Ligases,Ubiquitin E3 Ligases,Inhibitor of Bmi1/Ring1A; blocks histone H2A ubiquitination,"Inhibitor of Bmi1/Ring1A, subunits of the polycomb repressive complex 1 (PRC1); inhibits self-ubiquitination (IC50 = 3.9 muM) but does not increase cellular levels of either subunit. Prevents Bmi1/Ring1A-mediated ubiquitination and drug-induced degradation of topoisomerase 2alpha (Top2alpha). Also shown to inhibit the in vitro E3 ubiquitin ligase activity of RNF2 and a Bmi1/RNF2 complex, inhibiting H2A/H2AX ubiquitination. Blocks polycomb repressor complex (PRC) 1-mediated histone H2A ubiquitination in vitro and in vivo.",235.24
PSB 11 hydrochloride,[453591-58-7],Cl[H].CC[C@@H]1CN2C(=N1)C1=C(N=C(N1)C1=CC=CC=C1)N(C)C2=O,7-TM Receptors,Adenosine Receptors,Adenosine A3 Receptors,"Potent, selective hA3 receptor antagonist/inverse agonist","Potent and selective antagonist for the human adenosine A3 receptor, with low affinity for the rat A3 receptor (Ki values are 2.3 and > 10000 nM respectively). Displays > 1000-fold selectivity over human A1 and A2A receptors (Ki values are 4.1 and 3.3 muM respectively) and > 180-fold selectivity over rat A1, rat A2A and mouse A2B receptors. Acts as an inverse agonist in the [35S]GTPgammaS binding assay in hA3-CHO cells (IC50 = 36 nM).",331.8
PSB 36,[524944-72-7],CCCCN1C(=O)N(CCCO)C2=C(NC(=N2)C23CC4CC2CC(C3)C4)C1=O,7-TM Receptors,Adenosine Receptors,Adenosine A1 Receptors,Potent and selective A1 antagonist,"Potent and selective A1 adenosine receptor antagonist. Displays binding affinities of 0.12, 187, 552, 6500 and 2300 nM for rA1, hA2B, rA2A, rA3 and hA3 receptors respectively. Demonstrates greater selectivity than DPCPX (Cat. No. 0439).",386.49
PSB 603,[1092351-10-4],O=C(NC2=C1NC(C3=CC=C(S(N4CCN(C5=CC=C(Cl)C=C5)CC4)(=O)=O)C=C3)=N2)N(CCC)C1=O,7-TM Receptors,Adenosine Receptors,Adenosine A2B Receptors,Highly selective A2B antagonist,"Adenosine A2B receptor antagonist that displays > 17000-fold selectivity over other adenosine receptors (Ki values are 0.553, > 10000, > 10000 and > 10000 nM for A2B, A1, A2A and A3 receptors respectively).",529.01
PSN 375963 hydrochloride,[1781834-82-9],CCCCC(CC3)CCC3C1=NC(C2=CC=NC=C2)=NO1.Cl,7-TM Receptors,GPR119,,GPR119 receptor agonist,GPR119 receptor agonist (EC50 values are 8.4 and 7.9 muM at human and mouse receptors respectively). Displays similar potency to the endogenous ligand oleylethanolamide (OEA) (Cat. No. 1484).,321.84
PSNCBAM-1,[877202-74-9],ClC1=CC=C(NC(NC2=CC(C3=CC=CC(N4CCCC4)=N3)=CC=C2)=O)C=C1,7-TM Receptors,Cannabinoid Receptors,CB1 Receptors,Negative allosteric modulator of CB1 receptors,"CB1 receptor negative allosteric modulator (IC50 values are 45 and 209 nM for the inhibition of CP 55,940 and WIN 55,212-2 respectively). Has no effect at the CB2 receptor. Decreases food intake and body weight in rats.",392.88
Purmorphamine,[483367-10-8],C1(OC4=CC=CC5=C4C=CC=C5)=NC(NC3=CC=C(N6CCOCC6)C=C3)=C2C(N(C7CCCCC7)C=N2)=N1,7-TM Receptors,Smoothened Receptors,,Smo receptor agonist,"Smoothened (Smo) receptor agonist (EC50 ~ 1 muM). Induces osteogenesis in mouse mesenchymal progenitor cells (C3H10T1/2). When combined with BMP-4, can transdifferentiate pre-adipocytes (3T3-L1) and myoblasts (C2C12) into osteoblasts. Induces differentiation of multipotent mesenchymal progenitor cells into osteoblasts.",520.62
Purvalanol A,[212844-53-6],ClC1=CC=CC(NC2=C3C(N(C(C)C)C=N3)=NC(N[C@H]([C@@H](C)C)CO)=N2)=C1,Enzymes,Kinases,Cyclin-dependent Kinase,"Cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5","Cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 4, 4 - 70, 75 - 240 and 100 nM for cdk1, cdk2, cdk5 and cdk 7, respectively). Reversibly arrests synchronised cells in G1 and G2, and inhibits cell proliferation and cell death.",388.9
Purvalanol B,[212844-54-7],CC(C)[C@H](CO)NC1=NC(NC2=CC(Cl)=C(C=C2)C(O)=O)=C2N=CN(C(C)C)C2=N1,Enzymes,Kinases,Cyclin-dependent Kinase,"Selective cdk inhibitor; potently inhibits cdk1, cdk2 and cdk5","Cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 6 nM for cdk1 and cdk5, and 6 - 9 nM for cdk2, depending on binding partner). Selective over a range of other protein kinases (IC50 >10,000 nM). Shown to have antiproliferative properties, mediated by ERK1 and ERK2.",432.91
Pyrimethamine,[58-14-0],ClC1=CC=C(C2=C(N)N=C(N)N=C2CC)C=C1,Transporters,Multidrug Transporters,,Potent inhibitor of multidrug and toxin extrusion (MATE) transporters; also DHFR and STAT3 inhibitor,Potent inhibitor of multidrug and toxin extrusion (MATE) transporters (Ki values are 46 and 77 nM for human MATE2-K-HEK293 and MATE1-HEK293 cells respectively). Also inhibits dihydrofolate reductase (DHFR) and STAT3. Decreases proliferation of human autosomal dominant polycystic kidney disease cells.,248.71
Pyrintegrin,[1228445-38-2],OC(C=C3)=CC2=C3N(CCC2)C1=NC(NC4=CC=C(S(NCC5CC5)(=O)=O)C=C4)=NC=C1,Stem Cells,Stem Cell Proliferation,,Enhances survival of human ESCs following enzymatic dissociation,"Enhances survival of human embryonic stem cells (hESCs) following enzymatic dissociation. Thought to enhance cell-ECM adhesion and activate integrin signaling. Increases adhesion of hESCs to matrigel- and laminin-coated plates, but not to gelatin-coated plates. Also podocyte-protective agent and prevents LPS-induced proteinuria in mice.",451.54
Pyroxamide,[382180-17-8],O=C(CCCCCCC(NO)=O)NC1=CC=CN=C1,Enzymes,Histone Deacetylases,Class I HDACs,Histone deacetylase inhibitor,Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.,265.31
Quetiapine hemifumarate,[111974-72-2],OCCOCCN(CC4)CCN4C2=NC1=CC=CC=C1SC3=C2C=CC=C3.O=C(/C=C/C(O)=O)O.OCCOCCN(CC8)CCN8C6=NC5=CC=CC=C5SC7=C6C=CC=C7,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2 antagonist; also D2 antagonist; atypical antipsychotic,Atypical antipsychotic. Displays antagonist activity at serotonin (5-HT2) and dopamine (D2) receptors (IC50 values are 148 and 329 nM respectively). Lacks affinity at either D1 or muscarinic receptors.,441.54
R 1485 dihydrochloride,,FC(C=CC=C4)=C4S(N2CCOC1=C(N3CCNCC3)C=CC=C12)(=O)=O.Cl.Cl,7-TM Receptors,5-HT Receptors,5-HT6 Receptors,Selective and high affinity 5-HT6 antagonist,Selective and high affinity 5-HT6 antagonist (pKi = 8.9); displays low hERG inhibition. Exhibits >100 fold selectivity against a panel of 50 targets including other 5-HT receptor subtypes. Brain penetrant.,450.35
R 1530,[882531-87-5],FC(C(OC)=C1)=CC2=C1NC3=NNC(C)=C3N=C2C4=C(Cl)C=CC=C4,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Other RTKs,Multi-RTK inhibitor; inhibits angiogenesis,"Multi-kinase inhibitor. Exhibits inhibitory activity against Chk2, KDR, FGFR, Aurora A kinase and Cdk2 (IC50 values are 24, 34, 50, 58 and 88 nM respectively). Also binds VEGFR-2, FGFR1 and PDGFRbeta (Kd values are 0.015, 0.061 and 0.088 muM respectively). Displays antiproliferative activity in vitro; inhibits mitosis and angiogenesis. Orally bioavailable.",356.78
R 268712,[879487-87-3],OCCN1N=CC(C2=C(F)C=CC(C3=CNN=C3C4=CC=CC(C)=N4)=C2)=C1,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Potent and selective inhibitor of TGF-betaRI,"Potent and selective inhibitor of the TGF-beta type I receptor/ALK5 (IC50 = 2.5 nM). Exhibits ~5000-fold selectivity over p38 MAPK. Suppresses development of renal fibrosis in a unilateral ureteral obstruction model. Also reduces proteinuria, glomerulosclerosis and improves renal function in an anti-Thy1 glomerulonephritis model. Orally bioavailable.",363.39
R 568 hydrochloride,[177172-49-5],ClC(C=CC=C2)=C2CCCN[C@H](C)C1=CC=CC(OC)=C1.Cl,7-TM Receptors,Calcium-Sensing Receptor,,Positive allosteric modulator of human calcium-sensing receptor (CaSR),Positive allosteric modulator and allosteric agonist of the human calcium-sensing receptor (hCaSR). Exhibits calcimimetic activity. Has the ability to restore function to hCaSR mutants that cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT). Exerts a suppressive effect on parathyroid (PT) hormone secretion; inhibits PT cell proliferation in rats with renal insufficiency.,340.29
R 59-022,[93076-89-2],CC1=C(CCN2CC\C(CC2)=C(/C2=CC=CC=C2)C2=CC=C(F)C=C2)C(=O)N2C=CSC2=N1,Enzymes,Kinases,Diacylglycerol Kinase,Diacylglycerol kinase inhibitor; increases PKC activity,Diacylglycerol (DAG) kinase inhibitor (IC50 = 2.8 muM); increases protein kinase C activity. Potentiates thrombin-induced platelet aggregation and induces neutrophil chemotaxis. Inhibits U46619-induced contractions in mouse aorta and porcine coronary artery.,459.58
R-96544 hydrochloride,[167144-80-1],Cl[H].COC1=CC=CC(CCC2=C(OCC[C@@H]3C[C@@H](O)CN3C)C=CC=C2)=C1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,"Potent, selective 5-HT2A antagonist","Potent, selective 5-HT2 receptor antagonist; displays some selectivity for 5-HT2A receptors (Ki = 1.6 nM). IC50 values are 2.2, 310, 2400, 3700, > 5000 and > 5000 nM for 5-HT2, alpha1-adrenergic, D2 dopamine, 5-HT1, 5-HT3 and beta-adrenergic receptors respectively. Inhibits 5-HT-induced platelet aggregation and pressor responses in vivo.",391.94
rac BHFF,[123557-91-5],CC(C)(C)C1=C2C(C(O)(C(F)(F)F)C(O2)=O)=CC(C(C)(C)C)=C1,7-TM Receptors,GABAB Receptors,,Potent and selective postitive allosteric modulator of GABAB receptors,Potent and selective GABAB receptor positive allosteric modulator that increases the potency and efficacy of GABA ( > 15-fold and > 149% respectively). Exhibits anxiolytic activity in vivo and is orally active.,330.34
Raclopride,[84225-95-6],ClC1=C(OC)C(C(NC[C@H]2N(CC)CCC2)=O)=C(O)C(Cl)=C1,7-TM Receptors,Dopamine Receptors,Non-selective Dopamine,Potent and selective D2 and D3 antagonist,"Selective and potent dopamine D2/D3 receptor antagonist (Ki values are 1.8, 3.5, 2400 and 18000 nM for D2, D3, D4 and D1 receptors respectively). Centrally active following systemic administration in vivo.",347.24
Ralfinamide mesylate,[202825-45-4],FC(C=CC=C2)=C2COC1=CC=C(CN[C@@H](C)C(N)=O)C=C1.CS(=O)(O)=O,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,Na+ channel blocker,Sodium channel blocker. Suppresses tetrodotoxin (TTX)-resistant Na+ currents approximately twice as selectively as TTX-sensitive currents. Antinociceptive; displays analgesic effects in animal models of inflammatory and neuropathic pain.,398.45
Raloxifene hydrochloride,[82640-04-8],Cl.OC1=CC=C(C=C1)C1=C(C(=O)C2=CC=C(OCCN3CCCCC3)C=C2)C2=CC=C(O)C=C2S1,Nuclear Receptors,Estrogen and Related Receptors,,Selective estrogen receptor modulator (SERM),"Selective estrogen receptor modulator (SERM) that binds to ERalpha and ERbeta, and tissue-dependently activates or blocks estrogen-induced transcription. Acts as an antiestrogen in breast and uterine tissue, but displays estrogen agonist activity in bone. In D12 rat hypothalamic cells, inhibits progesterone receptor induction by estrogen with an IC50 of 1 nM.",510.04
Ramipril,[87333-19-5],[H][C@@]12CCC[C@@]([H])1N(C([C@H](C)N[C@H]([C@@](OCC)=O)CCC3=CC=CC=C3)=O)[C@H]([C@@](O)=O)C2,Enzymes,Proteases,Angiotensin-Converting Enzyme,"Non-peptide, competitive angiotensin-converting enzyme (ACE) inhibitor","Non-peptide, competitive angiotensin converting enzyme (ACE) inhibitor (IC50 = 5 nM). Prodrug which is hydrolyzed in vivo to the active metabolite ramiprilat. Displays protective effects on endothelium against high-glucose induced dysfunction. Exhibits antihypertensive effects.",416.51
Ranolazine dihydrochloride,[95635-56-6],COC1=CC=CC=C1OCC(CN2CCN(CC(NC3=C(C)C=CC=C3C)=O)CC2)O.Cl.Cl,Enzymes,Dehydrogenases,Other Dehydrogenases,"Antianginal, activates pyruvate dehydrogenase","Antianginal agent with antiarrhythmic properties that acts as a partial fatty acid oxidation inhibitor. Activates pyruvate dehydrogenase in ischemic myocytes to promote glucose oxidation, switching substrate utilization from fatty acids to glucose. Also shown to inhibit late INa and IKr currents.",500.46
Rasagiline mesylate,[161735-79-1],C#CCN[C@@H]2CCC1=CC=CC=C12.CS(=O)(O)=O,Enzymes,Oxygenases/Oxidases,Monoamine Oxidase,Selective and irreversible MAO-B inhibitor,Selective irreversible MAO-B inhibitor. Displays antiParkinsonian activity; exhibits neuroprotective and antiapoptotic activity against several neurotoxins in cell culture.,267.34
Rauwolscine hydrochloride,[6211-32-1],[H][C@]12C4=C(C(C=CC=C5)=C5N4)CCN1C[C@]3([H])[C@]([C@H]([C@](OC)=O)[C@@H](O)CC3)([H])C2.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,alpha2 antagonist,"Standard alpha2-adrenergic antagonist (Ki values are 3.5, 4.6, and 0.6 nM at cloned human alpha2A, alpha2B, and alpha2C-adrenoceptors respectively). Partial agonist at 5-HT1A receptors. Available as part of the alpha2-Adrenoceptor Tocriset™. Diastereomer also avilable.",390.91
RBC8,[361185-42-4],NC1=C(C#N)C(C5=C(OC)C=CC(OC)=C5)C(C(C3=CC=C(C=CC=C4)C4=C3)=NN2)=C2O1,Enzymes,GTPases,Small Monomeric GTPases,RalA and RalB inhibitor,RalA and RalB GTPase inhibitor (EC50 ~3.5 muM). Inhibits the binding of Ral to RaLBP1. Exhibits no detectable inhibition of Ras or RhoA activity. Suppresses growth of xenograft tumors in mice. Cell permeable.,424.45
Reboxetine mesylate,[98769-84-7],[H][C@]2(OCCNC2)[C@@H]([C@]3=CC=CC=C3)OC1=C(OCC)C=CC=C1.[H][C@@]5(OCCNC5)[C@H]([C@]6=CC=CC=C6)OC4=C(OCC)C=CC=C4.CS(=O)(O)=O.CS(=O)(O)=O,Transporters,Neurotransmitter Transporters,Adrenergic Transporters,Potent and selective noradrenalin uptake inhibitor; orally active,"Potent and selective inhibitor of noradrenalin uptake (Ki values are 1.1, 129 and > 10000 nM for rat NET, SERT and DAT respectively). Displays > 1000-fold selectivity over alpha-adrenoceptors, 5-HT, dopamine and muscarinic ACh receptors. Orally active antidepressant.",409.5
Rec 15/2615 dihydrochloride,[1782573-48-1],NC2=NC(N3CCN(C(COC4=C(OC)C=CC=C4C(C)C)=O)CC3)=NC1=CC(OC)=C(OC)C=C12.Cl.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,Selective alpha1B antagonist,"Selective alpha1B-adrenoceptor antagonist (Ki values are 0.3, 1.9 and 2.6 nM at human alpha1B, alpha1A and alpha1D receptors respectively).",568.49
Remodelin,[949912-58-7],N#CC(C=C1)=CC=C1C2=CSC(N/N=C3CCCC/3)=N2,Enzymes,Transferases,Other Transferases,N-acetyltransferase 10 (NAT10) inhibitor,N-acetyltransferase 10 (NAT10) inhibitor. Improves nuclear shape in HGPS (Hutchinson-Gilford progeria syndrome) cells and lamin A/C depleted cells.,282.36
Repaglinide,[135062-02-1],O=C(CC3=CC(OCC)=C(C(O)=O)C=C3)N[C@@H](CC(C)C)C1=CC=CC=C1N2CCCCC2,Ion Channels,Potassium Channels,Inward rectifier Potassium Channels,Kir6 (KATP) channel blocker,Kir6 (KATP) channel blocker that binds with high affinity for SUR1 when co-expressed with Kir6.2 (Kd = 0.42 nM). Antidiabetic glucose regulator with hypoglycaemic effect in vivo.,452.59
RepSox,[446859-33-2],CC1=NC(C2=NNC=C2C4=NC3=CC=CN=C3C=C4)=CC=C1,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Potent and selective inhibitor of TGF-betaRI,"Potent and selective inhibitor of the TGF-beta type I receptor/ALK5 (IC50 values are 4 and 23 nM for TGF-beta type I receptor autophosphorylation and binding respectively). Selective for TGF-beta type I receptor over a range of kinases, including p38 MAPK, JNK1 and GSK3 (IC50 > 16 muM). Enhances the efficiency of cellular reprogramming; replaces Sox2 by inducing Nanog expression.",287.32
Resiquimod,[144875-48-9],NC1=C3C(N(CC(C)(O)C)C(COCC)=N3)=C2C(C=CC=C2)=N1,Enzyme-Linked Receptors,Toll-like Receptors,,Toll-like receptor 7 (TLR7) agonist,"Toll-like receptor 7 (TLR7) agonist. Induces upregulation of IL-6, IL-12, IFN-gamma and iNOS expression in mouse bone marrow-derived macrophages (BMMs). Inhibits RANKL-induced osteoclast differentiation in mouse BMMs and human peripheral blood monocytes. Also promotes the differentiation of MDSCs into macrophages and dendritic cells. Proinflammatory and antiviral.",314.38
Resveratrol,[501-36-0],OC1=CC=C(C=C1)\C=C\C1=CC(O)=CC(O)=C1,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Cyclooxygenase inhibitor,"A phytoestrogen with antitumor, antioxidant, antiplatelet, anti-inflammatory and antifungal effects. Inhibits cytochrome P450 1A1 (IC50 = 23 muM) and displays mixed agonist/antagonist actions at ERalpha and ERbeta estrogen receptors. Converted into the anticancer agent piceatannol (Cat. No. 1554) by cytochrome P450 1B1. Activates autophagy. Also activates TRPA1 in prostate cancer-associated fibroblasts. Also SIRT1 activator.",228.25
Reversan,[313397-13-6],O=C(NCCCN5CCOCC5)C2=C1N=C(C4=CC=CC=C4)C=C(C3=CC=CC=C3)N1N=C2,Transporters,Multidrug Transporters,,Selective MRP1 and P-gp inhibitor,"Selective inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp). Increases the sensitivity of MRP1-overexpressing tumor cells (MCF7/VP) to doxorubicin (Cat. No. 2252), vincristine (Cat. No. 1257) and etoposide (Cat. No. 1226) by 3.8-, 14.6- and 11.6-fold respectively. Increases the efficacy of vincristine and etoposide in murine models of neuroblastoma in vivo. Does not sensitize MRP2, MRP3, MRP4 or MRP5 transporters to known substrates.",441.52
RG 108,[48208-26-0],O=C(C(C=CC=C4)=C4C3=O)N3[C@H](C(O)=O)CC2=CNC1=CC=CC=C12,Enzymes,Transferases,DNA Methyltransferases,Non-nucleoside DNA methyltransferase inhibitor,Non-nucleoside DNA methyltransferase inhibitor that blocks the enzyme active site. Inhibits DNA methylation in human cancer cell lines in vitro without detectable toxicity. Demethylates and reactivates epigenetically silenced tumor suppressor genes. Enhances the efficiency of induced pluripotent stem cell (iPS) generation.,334.33
RHC 80267,[83654-05-1],O=C(NCCCCCCNC(O/N=C2\CCCCC2)=O)O/N=C1CCCCC/1,Cell Metabolism,Lipid Metabolism,Other Lipid Metabolism,Diacylglycerol lipase inhibitor,Inhibitor of diacylglycerol lipase (IC50 values are 1.1 and 4 muM in rat cardiac myocytes and canine platelets respectively). Weakly inhibits phospholipases C and A2. Potentiates acetylcholine evoked relaxation in mesenteric arteries by the inhibition of cholinesterase activity (IC50 = 4 muM).,394.51
Ribavirin,[36791-04-5],O[C@@H]1[C@@H](CO)O[C@@H](N2C=NC(C(N)=O)=N2)[C@@H]1O,Enzymes,GTPases,Protein-synthesizing GTPases,Blocks eIF4E activity; antiviral guanosine analog,"Antiviral guanosine ribonucleoside analog; misincorporated into mRNA by viral-dependent RNA polymerases. Binds to and redistributes mammalian eIF4E from the nucleus to the cytoplasm (Ki ~ 0.3 muM for the active metabolite, ribavirin triphosphate). Represses colony formation of primary AML-M5 progenitor cells (IC50 ~ 1 muM); reduces disease severity in acute myeloid leukemia (AML). Orally available.",244.2
Ritanserin,[87051-43-2],O=C1N3C(SC=C3)=NC(C)=C1CCN4CC/C(CC4)=C(C5=CC=C(F)C=C5)/C2=CC=C(F)C=C2,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Potent 5-HT2 antagonist,Potent and long-acting 5-HT2 receptor antagonist (Ki = 0.39 nM). Anxiolytic in vivo.,477.57
Rivastigmine tartrate,[129101-54-8],O[C@H]([C@@H](O)C(O)=O)C(O)=O.CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C,Enzymes,Esterases,Cholinesterases,Dual AChE and BChE inhibitor,Dual cholinesterase inhibitor (ChEI); inhibits both butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). Brain penetrant.,400.42
Rizatriptan benzoate,[145202-66-0],CN(CCC2=CNC1=CC=C(CN3N=CN=C3)C=C12)C.O=C(C4=CC=CC=C4)O,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Potent 5-HT1B and 5-HT1D agonist,5-HT1B/1D agonist. Antimigraine agent; attenuates effects of CGRP on light aversion in mice. Orally bioavailable.,391.47
RKI 1447 dihydrochloride,,O=C(NCC3=CC=CC(O)=C3)NC1=NC(C2=CC=NC=C2)=CS1.Cl.Cl,Enzymes,Kinases,Rho-kinases,Potent and selective ROCK inhibitor; antitumor,"Potent and selective ROCK inhibitor (IC50 values are 6.2 and 14.5 nM for ROCK2 and ROCK1 respectively); suppresses phosphorylation of ROCK substrates MLC-2 and MYPT-1 in human cancer cells, but has no effect on the phosphorylation levels of Akt, MEK, and S6 kinase. Displays anti-invasive and antitumor activities in breast cancer cells.",399.29
RN 1 dihydrochloride,[1781835-13-9],O=C(N4CCN(C)CC4)CN[C@@H]1C[C@H]1[C@]2=CC=C(OCC3=CC=CC=C3)C=C2.Cl.Cl,Enzymes,Demethylases,Histone Demethylases,LSD1 inhibitor,"Potent lysine specific demethylase 1 (LSD1) inhibitor (IC50 = 70 nM). Exhibits selectivity for LSD1 over MAO-A and MAO-B (IC50 values are 0.51 and 2.79 muM for MAO-A and MAO-B, respectively). Impairs long-term, but not short-term memory in mice. Brain penetrant following systemic administration.",452.42
RN 1734,[946387-07-1],CC(C)NCCN(C(C)C)S(C1=C(Cl)C=C(Cl)C=C1)(=O)=O,Ion Channels,Transient Receptor Potential Channels,TRPV,Selective TRPV4 antagonist,"Selective TRPV4 antagonist (IC50 values are 2.3, 3.2 and 5.9 muM for hTRPV4, rTRPV4 and mTRPV4 receptors respectively). Displays selectivity for TRPV4 over other TRP channels (IC50 values are 2.3, >30, >30 and >100 muM for TRPV4, TRPV3, TRPM8 and TRPV1 respectively). Blocks TRPV4-mediated arteriole vasodilation and increases myogenic tone ex vivo.",353.31
Ro 04-5595 hydrochloride,[64047-73-0],Cl.COC1=CC2=C(C=C1O)C(CCC1=CC=C(Cl)C=C1)N(C)CC2,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,GluN2B-selective NMDA antagonist,Selective antagonist for GluN2B (formally NR2B) containing NMDA receptors (Ki = 31 nM). Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.,368.3
Ro 10-5824 dihydrochloride,[189744-94-3],Cl.Cl.CC1=NC=C(CN2CCC(=CC2)C2=CC=CC=C2)C(N)=N1,7-TM Receptors,Dopamine Receptors,D4 Receptors,Selective D4 partial agonist,"Selective dopamine D4 receptor partial agonist (EC50 = 205 nM) that binds with high affinity (Ki = 5.2 nM). Displays 250-fold selectivity over D3 receptors and > 1000-fold selectivity over D2, D1 and D5 receptors.",353.29
Ro 106-9920,[62645-28-7],O=S(C1=CC=CC=C1)C1=NN2N=NN=C2C=C1,Signal Transduction,Cytokine and NF-kB Signaling,NF-kB/IkB,Inhibitor of NF-kappaB activation,"Inhibitor of NF-kappaB activation, possibly via selective inhibition of LPS- and TNF-alpha-induced IkappaBalpha ubiquitination (IC50 = 3 muM). Blocks subsequent production of TNF-alpha, IL-1beta and IL-6. Inhibits mucin production in an in vitro model of COPD, and is anti-inflammatory following oral administration in vivo. Also weakly inhibits EGFR, 5-lipoxygenase and iNOS.",245.26
Ro 1138452 hydrochloride,,CC(C)OC1=CC=C(CC2=CC=C(NC3=NCCN3)C=C2)C=C1.Cl,7-TM Receptors,Prostanoid Receptors,,Selective prostacyclin IP receptor antagonist,"Selective prostacyclin IP receptor antagonist (pKi = 8.3). Exhibits no affinity at other prostanoid receptors (EP1-4, FP and TP) in a radioligand binding assay. Demonstrates analgesic activity in rats. Orally bioavailable.",345.87
Ro 19-4603,[99632-94-7],CN1CC2=C(N=CN2C2=C(SC=C2)C1=O)C(=O)OC(C)(C)C,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Benzodiazepine inverse agonist,Benzodiazepine inverse agonist. Binds with high affinity to both diazepam-sensitive (DS) and diazepam-insensitive (DI) GABAA receptors (Ki values are ~ 0.2 and ~ 2.6 nM for DS and DI receptors respectively). Antagonizes effects of ethanol on locomotor behavior and suppresses ethanol intake in alcohol-preferring rats.,319.38
Ro 20-1724,[29925-17-5],CCCCOC1=CC(CC2CNC(=O)N2)=CC=C1OC,Enzymes,Phosphodiesterases,,PDE4 inhibitor,"Widely used inhibitor of cyclic nucleotide phosphodiesterase, selective for PDE4 (IC50 = 2.0 muM). Also available as part of the Phosphodiesterase Inhibitor Tocriset™.",278.35
Ro 25-6981 maleate,[1312991-76-6],OC(=O)\C=C/C(O)=O.C[C@@H](CN1CCC(CC2=CC=CC=C2)CC1)[C@@H](O)C1=CC=C(O)C=C1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,GluN2B-selective NMDA antagonist,Potent and selective activity-dependent blocker of NMDA receptors containing the GluN2B (formally NR2B) subunit. IC50 values are 0.009 and 52 muM for cloned receptor subunit combinations GluN1C/GluN2B and GluN1C/GluN2A respectively. Displays neuroprotectant effects in vivo and in vitro. Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.,455.55
Ro 31-8220 mesylate,[138489-18-6],CS(O)(=O)=O.CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(CCCSC(N)=N)C2=CC=CC=C12,Enzymes,Kinases,Broad Spectrum Protein Kinase Inhibitors,Protein kinase inhibitor,"Protein kinase C inhibitor, with activity at other protein kinases (IC50 values are 33, 3, 8, 15 and 38 nM for PKCalpha, MAPKAP-K1b, MSK1, GSK3beta and S6K1 respectively). Activates JNK and glycogen synthase, and inhibits MAPK and ERK2, in rat adipocytes and L6 myotubes. Also inhibits voltage-dependent Na+ channels in the micromolar range.",553.65
Ro 3280,[1062243-51-9],COC1=C(C=CC(C(NC2CCN(CC2)C)=O)=C1)NC3=NC=C4N(C(C(F)(CN(C4=N3)C5CCCC5)F)=O)C,Enzymes,Kinases,Polo-like Kinase,Potent and selective PLK1 inhibitor,Potent and selective PLK inhibitor (IC50 = 3 nM). Exhibits selectivity for PLK1 over a panel of other kinases. Inhibits growth of a range of tumor cells lines in vitro and induces apoptosis in leukemia cells. Exhibits antitumor activity in mouse colorectal and nasopharyngeal cancer models in vivo.,543.61
Ro 3306,[872573-93-8],O=C2/C(SC(NCC3=CC=CS3)=N2)=C/C1=CC=C(N=CC=C4)C4=C1,Enzymes,Kinases,Cyclin-dependent Kinase,Cdk1 inhibitor,"ATP-competitive cyclin-dependent kinase 1 (cdk1) inhibitor (Ki values range from 35 to 240 nM depending on cdk1 binding partner). Also reported to inhibit other cdks (Ki values are 0.89-1.32, 0.03 and >2 muM for cdk2, cdk3 and cdk4, respectively). Induces G2/M phase cell cycle arrest and apoptosis. Downregulates the expression of antiapoptotic proteins such as Bcl-2 and survivin and enhances downstream p53 signaling in acute myeloid leukemia (AML).",351.45
Ro 48-8071 fumarate,[189197-69-1],FC1=C(C(C2=CC=C(Br)C=C2)=O)C=CC(OCCCCCCN(C)CC=C)=C1.OC(/C=C/C(O)=O)=O,Cell Metabolism,Lipid Metabolism,Other Lipid Metabolism,"2,3-Oxidosqualene cyclase (OSC) inhibitor; blocks cholesterol synthesis","2,3-Oxidosqualene cyclase (OSC) inhibitor (IC50 = 6.5 nM); blocks cholesterol synthesis in HepG2 cells. Reduces viability of breast cancer cell lines. Also inhibits Ebola virus (EBOV) cell entry (IC50 = 1.74 muM).",564.44
Ro 60-0175 fumarate,[169675-09-6],O=C(O)/C=C/C(O)=O.FC1=C(Cl)C=C(N(C[C@H](C)N)C=C2)C2=C1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,"Potent, selective 5-HT2C agonist","Potent, selective 5-HT2 receptor agonist; shows selectivity for the 5-HT2C subtype (pKi values are 9, 7.5, 5.4, 5.2 and 5.6 for human 5-HT2C, 2A, 1A, 6 and 7 receptors respectively). Centrally active following oral or systemic administration in vivo.",342.75
Ro 61-8048,[199666-03-0],O=S(NC1=NC(C2=CC=CC([N+]([O-])=O)=C2)=CS1)(C3=CC=C(OC)C(OC)=C3)=O,Enzymes,Reductases,Kynurenine 3-monooxygenase,Potent kynurenine 3-monooxygenase (KMO) inhibitor,"Potent and competitive kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor (Ki = 4.8 nM, IC50 = 37 nM). Increases kynurenic acid levels to concentrations that antagonize the glycine site of NMDA receptors. Brain penetrant and exhibits antidystonic, anticonvulsant and neuroprotective activities.",421.45
Ro 67-7476,[298690-60-5],FC(C=C2)=CC=[C@@]2[C@@H]1CCCN1S(C3=CC=C(C)C=C3)(=O)=O,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Positive allosteric modulator of mGlu1 receptors,Positive allosteric modulator of mGlu1 receptors. Potentiates glutamate-induced calcium release (EC50 = 60.1 nM at rat mGluR1a). Displays no activity at human mGlu1 receptors.,319.39
Ro 90-7501,[293762-45-5],NC1=CC=C(C=C1)C1=NC2=CC=C(C=C2N1)C1=NC2=CC=C(N)C=C2N1,Cell Metabolism,Amyloid Beta Peptides,,Inhibitor of Abeta42 fibril formation,Inhibitor of amyloid beta42 (Abeta42) fibril assembly; reduces Abeta42-induced toxicity (EC50 = 2 muM).,340.39
RO-3,[1026582-88-6],NC1=NC(N)=NC=C1CC2=C(C(C)C)C=C(OC)C(OC)=C2,Ion Channels,Ligand-gated Ion Channels,P2X Receptors,Selective P2X3 and P2X2/3 antagonist,"Selective homomeric P2X3 and heteromeric P2X2/3 receptor antagonist (pIC50 values are 7.0 and 5.9 respectively) that exhibits no activity at P2X1, P2X2, P2X4, P2X5 and P2X7 receptors (IC50 > 10 muM). Attenuates nociceptive sensitivity in animal models of pain. Orally active and brain penetrant.",302.37
Rolipram,[61413-54-5],COC1=CC=C(C=C1OC1CCCC1)C1CNC(=O)C1,Enzymes,Phosphodiesterases,,PDE4 inhibitor,Selective inhibitor of cAMP phosphodiesterase (PDE4) (IC50 = 2.0 muM). Discriminates between two conformational states of PDE4 isoenzymes. R-enantiomer and S-enantiomer also available.,275.35
Rosiglitazone,[122320-73-4],CN(CCOC1=CC=C(CC2SC(NC2=O)=O)C=C1)C3=CC=CC=N3,Nuclear Receptors,PPARs,PPARgamma Receptors,Potent and selective PPARgamma agonist; antidiabetic agent,Potent and selective PPARgamma agonist (EC50 = 60 nM); exhibits no activity at PPARalpha and PPARbeta. Promotes differentiation of pluripotent C3H10T1/2 stem cells into adipocytes. Exhibits antihyperglycemic activity in diabetic ob/ob mouse model. Antidiabetic agent.,357.43
Rostafuroxin,[156722-18-8],O[C@]4(C5=COC=C5)CC[C@]3(O)[C@]2([H])CC[C@]1([H])C[C@@H](O)CC[C@@](C)1[C@]([H])2CC[C@@]34C,Enzymes,ATPases,Na+/K+ ATPase,Na+/K+ ATPase modulator; antihypertensive agent,Na+/K+ ATPase modulator. Inhibits the Normalizes renal Na+/K+ ATPase pump function in mutant adducin- and endogenous ouabain-dependent forms of hypertension. Reduces blood pressure in Milan hypertensive rats. Controls mania-like behaviors in Myshkin mice having a Na+/K+ ATPase alpha3 subunit mutation. Antagonizes the effects of Ouabain (Cat.No. 1076) on myogenic tone and Ca2+ signaling in rat hippocampal neurons.,374.51
Rotigotine hydrochloride,[125572-93-2],CCCN(CCC3=CC=CS3)[C@H]2CCC1=C(O)C=CC=C1C2.Cl,7-TM Receptors,Dopamine Receptors,D2 Receptors,D2 and D3 agonist,Dopamine D2 and D3 receptor agonist. Ki values are 13 and 0.71 nM for D2 and D3 respectively. Also has significant affinity for 5-HT1A and adrenergic alpha2B receptors. Exhibits antiparkinsonian acitivity.,351.93
RP 001 hydrochloride,[1781880-34-9],CC(C)OC1=C(C#N)C=C(C2=NC(C3=C(CCC4NCCC(O)=O)C4=CC=C3)=NO2)C=C1.Cl,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Potent S1P1 agonist,Potent agonist of S1P1 receptors (EC50 = 9 pM). Induces internalization and polyubiquitination of S1P1 in vitro. Selective for S1P1 over S1P2 - S1P4.,468.93
RQ 00203078,[1254205-52-1],ClC1=C(N(S(C3=CC=C(C(O)=O)C=C3)(=O)=O)CC2=CC=C(OC(F)(F)F)C=C2)N=CC(C(F)(F)F)=C1,Ion Channels,Transient Receptor Potential Channels,TRPM,Potent and selective TRPM8 antagonist; orally active,"Potent TRPM8 antagonist (IC50 values are 5.3 and 8.3 nM for rat and human channels respectively). Exhibits >350-fold selectivity for TRPM8 over TRPV4, TRPV1 and TRPA1. Reduces HSC3 and HSC4 oral squamous carcinoma cell migration and invasion in vitro. Also attenuates icilin-induced wet dog shakes in rats. Orally active.",554.85
RS 102221 hydrochloride,[187397-18-8],Cl.COC1=CC(OC)=C(NS(=O)(=O)C2=CC=C(C=C2)C(F)(F)F)C=C1C(=O)CCCCN1CCC2(CC1)NC(=O)NC2=O,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Selective 5-HT2C antagonist,"Potent and selective 5-HT2C antagonist (pKi = 8.7). Displays ~ 100-fold selectivity over the 5-HT2A and 5-HT2B subtypes and is > 100-fold selective over other 5-HT receptors, alpha- and beta-adrenergic and muscarinic ACh receptors.",649.08
RS 102895 hydrochloride,[1173022-16-6],Cl.FC(F)(F)C1=CC=C(CCN2CCC3(CC2)OC(=O)NC2=CC=CC=C32)C=C1,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,CCR2b chemokine receptor antagonist,"CCR2-selective chemokine receptor antagonist (IC50 values are 0.36 and 17.8 muM for inhibition of human recombinant CCR2b and CCR1 receptors respectively). Blocks MCP-1-stimulated calcium influx and chemotaxis with IC50 values of 32 nM and 1.7 muM respectively. Also inhibits alpha1A, alpha1D and 5-HT1A receptors.",426.86
RS 17053 hydrochloride,[169505-93-5],Cl.CC(C)(CC1=CNC2=CC=C(Cl)C=C12)NCCOC1=C(OCC2CC2)C=CC=C1,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,alpha1A antagonist,"alpha1A-adrenoceptor antagonist, with very high affinity for alpha1A receptors (pKi and pA2 estimates of 9.1 - 9.9) and a 30 - 100 fold selectivity over the alpha1B and alpha1D subtypes (pKi and pA2 estimates 7.7 - 7.8).",449.42
RU-SKI 43 hydrochloride,,O=C(CNCC(CC)C)N1CCC3=C(C=CS3)C1COC2=CC(C)=CC=C2.Cl,Signal Transduction,Hedgehog Signaling,,Hedgehog acyltransferase (Hhat) inhibitor; cell permeable,Hedgehog acyltransferase (Hhat) inhibitor (IC50 = 850 nM). Inhibits Sonic Hedgehog N (ShhN) palmitoylation in vitro. Has no effect on porcupine-induced fatty acid acylation of Wnt39a. Attenuates pancreatic cancer cell proliferation. Cell permeable.,423.01
RWJ 21757,[121288-39-9],O[C@@H]1[C@@H](CO)O[C@@H](N(C(N3CC=C)=O)C2=C3C(NC(N)=N2)=O)[C@@H]1O,Enzyme-Linked Receptors,Toll-like Receptors,,Toll-like receptor 7 (TLR7) agonist,Toll-like receptor 7 (TLR7) agonist; induces immune cell activation and increases cytokine production. Displays antitumor and antiviral activity in various animal models.,339.3
RWJ 50271,[162112-37-0],CC1=C(C(NCCCO)=O)C=NN1C2=NC(C3=CC(C(F)(F)F)=CC=C3)=CS2,Enzyme-Linked Receptors,Integrins,,Inhibitor of LFA-1/ICAM mediated cell adhesion,Selective inhibitor of LFA-1 (lymphocyte function-associated antigen-1) adhesion to soluble intercellular adhesion molecule (sICAM) (IC50 = 5 muM in HL60 cells).,410.41
RWJ 67657,[215303-72-3],FC(C=C4)=CC=C4C(N=C(C#CCCO)N2CCCC3=CC=CC=C3)=C2C1=CC=NC=C1,Enzymes,Kinases,MAPK Family,"Potent, selective p38alpha and p38beta inhibitor","Selective p38alpha and p38beta inhibitor (IC50 values are 1 and 11 muM respectively) that displays no activity at p38gamma, p38delta and a range of other kinases. Potently inhibits TNF-alpha and IL-1beta release (IC50 values are 3 and 11 nM respectively) and suppresses HIV-1 replication in T cells in vitro. Displays cardioprotective and anti-inflammatory activity in vivo. Orally active.",425.5
RX 821002 hydrochloride,[109544-45-8],Cl.COC1(COC2=CC=CC=C2O1)C1=NCCN1,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,"Potent, selective alpha2D antagonist","Potent, selective alpha2-adrenoceptor antagonist with very low affinity for imidazoline sites. Displays selectivity for the alpha2D over the alpha2A subtypes (pKd values are 9.7 and 8.2 respectively).",270.72
Ryuvidine,[265312-55-8],CC1=NC2=C(S1)C(=O)C=C(NC1=CC=C(C)C=C1)C2=O,Enzymes,Transferases,Lysine Methyltransferases,SETD8 inhibitor; also CDK4 inhibitor,Inhibitor of SETD8 protein lysine methyltransferase (PKMT) (IC50 = 0.5 muM); suppresses H4K20 monomethylation in vitro. Also inhibits cyclin-dependent kinase (CDK) 4 (IC50 = 6.0 muM at CDK4/cyclin D1). Induces S phase accumulation in HEK293T cells. Cytotoxic against a range of human cancer cells.,284.33
s,[1796596-46-7],O=S(C1=CC=C(C([O-])=O)C=C1)(NC2CCCCC2)=O.[Na+],Stem Cells,Stem Cell Proliferation,,Potently promotes HSC expansion ; p18INK inhibitor,p18INK inhibitor. Potently promotes hematopoietic stem cell (HSC) expansion (ED50 = 5.21 nM). Exhibits no effect on leukemia cell proliferation.,305.33
S 07662,[883226-64-0],CC2=C(CNC(NCC3=CC=CS3)=O)C1=CC=CC=C1O2,Nuclear Receptors,Constitutive Androstane Receptor,,Constitutive androstane receptor (CAR) inverse agonist,Inverse agonist of the constitutive androstane receptor (CAR). Inhibits CAR activity via recruitment of nuclear receptor co-repressor (NCoR). Suppresses CITCO-induced CYP2B6 gene expression in human primary hepatocytes.,300.38
S 14506 hydrochloride,[286369-38-8],Cl.COC1=CC2=C(C=CC=C2C=C1)N1CCN(CCNC(=O)C2=CC=C(F)C=C2)CC1,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Highly potent 5-HT1A agonist; displays unique binding mechanism,"Highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo.",443.94
S 18886,[165538-40-9],CC1=CC=C(C[C@H](NS(C2=CC=C(Cl)C=C2)(=O)=O)CC3)C3=C1CCC(O)=O,7-TM Receptors,Prostanoid Receptors,,Potent thromboxane A2 (TP) antagonist,Potent thromboxane A2 (TP) inhibitor (IC50 = 16.4 nM). Inhibits U 46619 (Cat. No. 1932) induced human platelet aggregation and contraction of isolated rabbit saphenous vein in vitro. Also inhibits U 46619 induced increase in tracheal pressure in guinea pigs. Orally available.,407.91
S26948,[353280-43-0],O=C(C3=CC=CC=C3)C1=CC=C(N(CCOC4=CC=C(CC(C(OC)=O)C(OC)=O)C=C4)C(S2)=O)C2=C1,Nuclear Receptors,PPARs,PPARgamma Receptors,Selective PPARgamma agonist; antidiabetic agent,Selective PPARgamma agonist (EC50 = 8.83 nM). Drives normal adipocyte differentiation and exhibits a lipid-lowering effect; reduces atherosclerosis in E2-KI mice. Displays antidiabetic properties and improves hepatic insulin sensitivity in intralipid-infusion (IL) rats.,519.57
S4,[1330061-67-0],NS(OC1=CC=C(NC(NC2=CC(C)=CC(C)=C2)=O)C=C1)(=O)=O,Enzymes,Lyases,Carbonic anhydrases,High affinity and selective CA IX and CA XII inhibitor,"High affinity and selective CA IX and CA XII inhibitor (Ki values are 2, 7, 547 and 5600 nM for CA XII, IX, II and I, respectively). Inhibits migration and proliferation of breast cancer cells in vitro. Inhibits lung metastasis in mice bearing breast tumor xenografts, without affecting primary tumor.",335.38
SA 4503 dihydrochloride,[165377-44-6],COC1=C(OC)C=CC(CCN2CCN(CCCC3=CC=CC=C3)CC2)=C1.Cl.Cl,Other Pharmacology,Sigma Receptors,Sigma1 Receptors,Selective sigma1 receptor agonist,Selective sigma1 receptor agonist (IC50 = 17.4 nM). Exhibits selectivity for sigma1 over sigma2 receptors. Inhibits angiotensin II-induced cardiomyocyte hypertrophy in vitro and attenuates myocardial hypertrophy in vivo. Enhances brain plasticity and sensorimotor function in a rat model of experimental stroke.,441.43
SA 47,[792236-07-8],CC1=CC=CC(N2CCC(CCNC(OCC(NC)=O)=O)CC2)=N1,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),Selective FAAH inhibitor,Selective inhibitor of fatty acid amide hydrolase (FAAH). Exhibits greater selectivity for FAAH than URB 597 against multiple carboxylesterases.,334.41
SAHA,[149647-78-9],O=C(CCCCCCC(NO)=O)NC1=CC=CC=C1,Enzymes,Histone Deacetylases,Non-selective HDACs,Class I and II HDAC inhibitor,"Inhibits Class I and II histone deacetylases (HDACs); induces accumulation of acetylated histones H2A, H2B, H3 and H4 in transformed cultured cells. Suppresses cell growth in a range of cancer cell lines; induces apoptosis in cutaneous T cell lymphoma cells in vitro. Activates autophagy.",264.32
Sal 003,[1164470-53-4],S=C(NC(NC(/C=C/C2=CC=CC=C2)=O)C(Cl)(Cl)Cl)NC1=CC=C(Cl)C=C1,Enzymes,Phosphatases,Protein Ser/Thr Phosphatases,Cell-permeable inhibitor of eIF2alpha dephosphorylation,Cell-permeable inhibitor of cellular phosphatase complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha). Analog of salubrinal (Cat. No. 2347) with improved aqueous solubility. Shown to prevent the induction of hippocampal long-term potentiation (LTP) and memory formation (LTM) in mice.,463.21
Salmeterol xinafoate,[94749-08-3],OC(C2=CC(CO)=C(O)C=C2)CNCCCCCCOCCCCC1=CC=CC=C1.OC4=C(C(O)=O)C=CC3=CC=CC=C34,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-2 Receptors,Long-acting beta2 agonist; bronchodilator,"Long-acting beta2 adrenergic receptor agonist. Inhibits the release of histamine, leukotrienes and prostaglandin D2, and blocks GM-CSF production from human cultured mast cells. Exhibits efficacious bronchodilatory activity in patients with asthma or chronic obstructive pulmonary disease (COPD).",603.75
Salubrinal,[405060-95-9],S=C(NC(NC(/C=C/C3=CC=CC=C3)=O)C(Cl)(Cl)Cl)NC1=C2C(C=CC=N2)=CC=C1,Enzymes,Phosphatases,Protein Ser/Thr Phosphatases,Selective inhibitor of eIF2alpha dephosphorylation,"Cell-permeable, selective inhibitor of cellular phosphatase complexes that dephosphorylate eukaryotic translation initiation factor 2 subunit alpha (eIF2alpha). Protects cells from endoplasmic reticulum stress-induced apoptosis (EC50 ~ 15 muM).",479.81
SANT-1,[304909-07-7],CC1=NN(C(C)=C1\C=N\N1CCN(CC2=CC=CC=C2)CC1)C1=CC=CC=C1,Signal Transduction,Hedgehog Signaling,,Inhibitor of hedgehog (Hh) signaling; antagonizes smoothened activity,"Potent, cell-permeable inhibitor of Sonic hedgehog (Shh) signaling; high affinity antagonist of smoothened activity (KD = 1.2 nM). Inhibits smoothened agonist effects with an IC50 of 20 nM (in Shh-LIGHT2 cells). Has been used in protocols to generate pancreatic beta cells from hPSCs.",373.5
SANT-2,[329196-48-7],ClC1=CC=C(NC(C4=CC(OCC)=C(OCC)C(OCC)=C4)=O)C=C1C3=NC2=CC=CC=C2N3,Signal Transduction,Hedgehog Signaling,,Inhibitor of Hedgehog (Hh) signaling; antagonizes smoothened activity,Inhibitor of Sonic hedgehog (Shh) signaling; antagonizes smoothened receptor activity (KD = 12 nM). Displays allosteric binding characteristics similar to SANT-1 (Cat. No. 1974). Displaces smo-[3H]SAG-1.3 and -[3H]Cyclopamine binding (Ki values are 7.8 nM and 8.4 nM respectively).,479.96
Saquinavir mesylate,[149845-06-7],O=C(N[C@@H](CC(N)=O)C(N[C@@H](CC4=CC=CC=C4)[C@H](O)CN3C[C@](CCCC5)([H])[C@]5([H])C[C@H]3[C@@](NC(C)(C)C)=O)=O)C2=NC1=CC=CC=C1C=C2.CS(=O)(O)=O,Enzymes,Proteases,Other Proteases,HIV protease inhibitor,Inhibitor of human immunodeficiency virus (HIV) protease (Ki values are <0.1 and 0.12 nM for HIV-2 and HIV-1 protease respectively). Exhibits high antiviral activity and low cytotoxicity.,766.95
Sarpogrelate hydrochloride,[135159-51-2],O=C(CCC(O)=O)OC(CN(C)C)COC1=CC=CC=C1CCC2=CC(OC)=CC=C2.Cl,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Selective 5-HT2A antagonist,"Selective 5-HT2A receptor antagonist (pKi values are 8.52, 7.43 and 6.57 for 5-HT2A, 5-HT2C and 5-HT2B receptors respectively). Displays selectivity over 5-HT1, 5-HT3, 5-HT4 H1, H2, M3, alpha1-adrenergic, alpha2-adrenergic and beta-adrenergic receptors. Displays cardioprotective activity in vivo.",465.97
SB 200646 hydrochloride,[143797-62-0],Cl.CN1C=CC2=CC(NC(=O)NC3=CN=CC=C3)=CC=C12,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2C/2B antagonist,"5-HT2C/2B receptor antagonist, selective over 5-HT1A. Affinities are 7.4 (pA2), 6.9 (pKi) and 5.2 (pKi) for 5-HT2B, 2C and 2A respectively. Orally active in vivo.",302.76
SB 202190,[152121-30-7],OC1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1,Enzymes,Kinases,MAPK Family,"Potent, selective inhibitor of p38 MAPK","A highly selective, potent and cell-permeable inhibitor of p38 MAP kinase. Binds within the ATP pocket of the active kinase (Kd = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38alpha and beta isoforms (IC50 = 50 and 100 nM at SAPK2a/p38 and SAPK2b/p38beta2 respectively). Promotes stability of naive human pluripotent stem cells in culture. Also available as part of the MAPK Inhibitor Tocriset™.",331.35
SB 203580,[152121-47-6],CS(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=NC=C1)C1=CC=C(F)C=C1,Enzymes,Kinases,MAPK Family,Selective inhibitor of p38 MAPK,"Selective inhibitor of p38 MAPK (IC50 values are 50 and 500 nM for SAPK2a/p38 and SAPK2b/p38beta2 respectively). Displays 100-500-fold selectivity over LCK, GSK-3beta and PKBalpha. Shown to inhibit IL-2-induced T cell proliferation, cyclooxygenase-1 and -2, and thromboxane synthase. Enhances clonal growth of skin epithelial progenitor cells; stimulates neural stem cell (NSC) proliferation. Essential component of medium for maintaining stem cells in naive pluripotent state. Available as part of the MAPK Cascade Inhibitor Tocriset™ and MAPK Inhibitor Tocriset™. Water-soluble Salt also available.",377.44
SB 205384,[160296-13-9],CC#CCOC(=O)C1=C(C)N=C2SC3=C(CCC(O)C3)C2=C1N,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,GABAA modulator; slows current decay,"GABAA receptor modulator; slows current decay. Potentiates alpha6, alpha3 and alpha5-subunit-containing receptors (EC50 values are 280, 695 and 730 nM respectively). Displays little effect on receptors containing alpha1 or alpha2 subunits.",330.4
SB 206553 hydrochloride,[1197334-04-5],Cl.CN1C=CC2=CC3=C(CCN3C(=O)NC3=CC=CN=C3)C=C12,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,Potent and selective 5-HT2B and 5-HT2C antagonist; orally active,"Potent and selective 5-HT2B/5-HT2C receptor antagonist (rat 5-HT2B pA2 = 8.89, human 5-HT2C pKi = 7.92). Displays > 80-fold selectivity over all other 5-HT receptor subtypes and a variety of other receptors (pKi < 6). Centrally active following oral administration in vivo.",328.8
SB 218078,[135897-06-2],O=C1NC(=O)C2=C1C1=C3N(C4CCC(O4)N4C5=C(C=CC=C5)C2=C34)C2=CC=CC=C12,Enzymes,Kinases,Checkpoint Kinases,Chk1 inhibitor,"Inhibitor of checkpoint kinase 1 (Chk1) that displays selectivity over other protein kinases (IC50 values are 15, 250 and 1000 nM for Chk1, cdc2 and PKC respectively). Abrogates G2 cell cycle arrest caused by gamma-irradiation and topoisomerase I inhibition. Potentiates cytotoxicity of DNA-damaging drugs, enhancing the efficacy of some chemotherapeutics.",393.39
SB 218795,[174635-53-1],COC(=O)[C@H](NC(=O)C1=C2C=CC=CC2=NC(=C1)C1=CC=CC=C1)C1=CC=CC=C1,7-TM Receptors,Peptide Receptors,Tachykinin Receptors,"Potent, selective non-peptide NK3 antagonist","Potent, selective and competitive non-peptide NK3 receptor antagonist (Ki = 13 nM at hNK3). Displays 90-fold and 7000-fold selectivity over hNK2 and hNK1 receptors respectively. Active in vivo, inhibiting agonist-induced pupillary constriction.",396.44
SB 222200,[174635-69-9],O=C(C2=C(C)C(C4=CC=CC=C4)=NC3=CC=CC=C23)N[C@@H](CC)C1=CC=CC=C1,7-TM Receptors,Peptide Receptors,Tachykinin Receptors,"Potent, selective non-peptide NK3 antagonist. Brain penetrant","Potent and selective non-peptide NK3 receptor antagonist (Ki values are 4.4, > 100,000 and 250 nM for human NK3, NK1 and NK2 receptors respectively). Antihypertensive in vivo. Brain penetrant.",380.48
SB 225002,[182498-32-4],OC1=CC(=CC=C1NC(=O)NC1=CC=CC=C1Br)[N+]([O-])=O,7-TM Receptors,Chemokine Receptors,Chemokine CXC Receptors,Potent and selective CXCR2 antagonist,Potent and selective CXCR2 chemokine receptor antagonist (IC50 = 22 nM) that displays > 150-fold selectivity over CXCR1 receptors. Causes inhibition of IL-8 and GROalpha-mediated calcium mobilization in HL60 cells (IC50 values are 8 and 10 nM respectively). Prevents IL-8-induced neutrophil chemotaxis in vitro and sequestration in vivo. Inhibits HIV replication in lymphocytes and macrophages.,352.14
SB 228357,[181629-93-6],COC1=C(C=C2N(CCC2=C1)C(=O)NC1=CC(F)=CC(=C1)C1=CC=CN=C1)C(F)(F)F,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,5-HT2C/2B antagonist/inverse agonist,"5-HT2C/2B receptor antagonist (pKi values are 7.0, 8.1 and 9.1 at 5-HT2A, 2B and 2C receptors respectively). Displays inverse agonism in a 5-HT-stimulated PI hydrolysis model of 5-HT2C receptor function. Orally active in vivo.",431.39
SB 268262,[217438-17-0],O=S(C2=NC=CS2)C1=CC=C(C(N(C)C3=CC=CC=C3C)=O)C=C1[N+]([O-])=O,7-TM Receptors,Peptide Receptors,Calcitonin and Related Receptors,Selective non-peptide CGRP antagonist,Selective non-peptide CGRP1 antagonist. Inhibits [125I]CGRP binding and CGRP-activated adenylyl cyclase stimulation in SK-N-MC cell membranes (IC50 values are 0.24 and 0.83 nM respectively).,401.46
SB 269970 hydrochloride,[261901-57-9],OC1=CC(S(N2[C@@H](CCN3CCC(C)CC3)CCC2)(=O)=O)=CC=C1.Cl,7-TM Receptors,5-HT Receptors,5-HT7 Receptors,Potent and selective 5-HT7 antagonist; brain penetrant,"Potent and selective 5-HT7 receptor antagonist (pKi values are 8.9, 7.2 and 6.0 for 5-HT7A, 5-HT5A and 5-HT1B and < 6.0 for 5-HT1A, 5-HT1D, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT4 and 5-HT6 receptors respectively). Brain penetrant in vivo.",388.95
SB 271046 hydrochloride,[209481-24-3],CC2=C(S(NC3=CC=C(OC)C(N4CCNCC4)=C3)(=O)=O)SC1=CC=C(Cl)C=C12.Cl,7-TM Receptors,5-HT Receptors,5-HT6 Receptors,Selective 5-HT6 antagonist; orally active,"Selective, orally active 5-HT6 antagonist (pKi values are 9.02-8.92, 6.55, 6.35, 6.27, 6.05, 5.95, 5.76, 5.73, 5.62, 5.55, 5.41, 5.39, 5.27 and < 4.99 at 5-HT6, 5-HT1D, 5-HT1A, D3, 5-HT1B, 5-HT1F, alpha1B, 5-HT2C, 5-HT2A, D2, 5-HT2B, 5-HT7, 5-HT4 and 5-HT1E respectively) and is > 200-fold selective over 55 other receptors, enzymes and ion channels. Increases extracellular glutamate and aspartate in the frontal cortex, and exhibits anticonvulsant activity (EC50 = 0.16 muM).",488.45
SB 297006,[58816-69-6],O=C(C2=CC=CC=C2)N[C@H](C(OCC)=O)CC1=CC=C([N+]([O-])=O)C=C1,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,Potent and selective CCR3 antagonist,"Potent and selective CCR3 antagonist (IC50 = 39 nM). Displays 250-fold selectivity for CCR3 over other chemokine receptors, including CXCR1, CXCR2, CCR1 and CCR7 (IC50 >27 muM). Inhibits calcium mobilization induced by MCP-4, eotaxin-2 and eotaxin in RBL-2H3 cells transfected with CCR3 (IC50 values are 80, 90 and 210 nM respectively).",342.35
SB 328437,[247580-43-4],O=C(C2=CC=CC3=C2C=CC=C3)N[C@H](C(OC)=O)CC1=CC=C([N+]([O-])=O)C=C1,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,Potent and selective CCR3 antagonist,"Potent and selective CCR3 antagonist (IC50 = 4 nM). Displays > 2500-fold selectivity over C5aR, LTD4, CCR7, CXCR1 and CXCR2 receptors. Inhibits eotaxin-, eotaxin-2- and MCP-4-induced Ca2+ mobilization (IC50 values are 38, 35 and 20 nM respectively) and inhibits eotaxin-, eotaxin-2- and MCP-4-induced eosinophil chemotaxis with similar potencies.",378.38
SB 334867,[792173-99-0],CC1=NC2=CC=C(NC(=O)NC3=CC=NC4=CC=CN=C34)C=C2O1,7-TM Receptors,Peptide Receptors,Orexin Receptors,Selective non-peptide OX1 antagonist,Selective non-peptide orexin OX1 receptor antagonist. pKb values are 7.2 and < 5 for inhibition of intracellular Ca2+ release in CHO cells expressing human OX1 and OX2 receptors respectively. Blocks orexin-A induced grooming and feeding following systemic administration in vivo.,319.32
SB 366791,[472981-92-3],COC1=CC=CC(NC(=O)\C=C\C2=CC=C(Cl)C=C2)=C1,Ion Channels,Transient Receptor Potential Channels,TRPV,"Potent, selective, competitive TRPV1 antagonist","Potent, selective and competitive vanilloid TRPV1 receptor antagonist (pA2 = 7.71 at hVR1); antagonizes hTRPV1 receptors activated by agonists, noxious heat, but not protons. Displays selectivity over a wide range of receptors and systems including CB1 and CB2 receptors, voltage-gated Ca2+ channels and the hyperpolarization-activated current (Ih). Also available as part of the Vanilloid TRPV1 Receptor Tocriset™.",287.75
SB 399885 hydrochloride,[402713-81-9],Cl.ClC1=CC(Cl)=CC(NS(C2=CC(N3CCNCC3)=C(OC)C=C2)(=O)=O)=C1OC,7-TM Receptors,5-HT Receptors,5-HT6 Receptors,Potent and selective 5-HT6 antagonist,"Potent, brain penetrant, orally active 5-HT6 antagonist. Displays > 200-fold selectivity for 5-HT6 over other 5-HT receptors (pKi values are 9.11, 8.81 and 9.02 for human recombinant, native rat and native human 5-HT6 receptors respectively).",482.81
SB 408124,[288150-92-5],CN(C)C1=CC=C(NC(=O)NC2=CC(C)=NC3=C(F)C=C(F)C=C23)C=C1,7-TM Receptors,Peptide Receptors,Orexin Receptors,Selective non-peptide OX1 antagonist,Selective non-peptide orexin OX1 receptor antagonist (Kb values are 21.7 and 1405 nM for human OX1 and OX2 receptors respectively). Blocks orexin-A induced grooming following oral administration in vivo.,356.37
SB 431542,[301836-41-9],NC(=O)C1=CC=C(C=C1)C1=NC(=C(N1)C1=CC=CC=N1)C1=CC2=C(OCO2)C=C1,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,"Potent, selective inhibitor of TGF-betaRI, ALK4 and ALK7","Potent and selective inhibitor of the transforming growth factor-beta (TGF-beta) type I receptor/ALK5 (IC50 = 94 nM), and its relatives ALK4 and ALK7. Suppresses TGF-beta-induced proliferation of human osteosarcoma cells. Replaces SOX2 in reprogramming of fibroblasts into iPSCs. Stimulates proliferation, differentiation and sheet formation of ESC-derived endothelial cells. Inhibits TGF-beta-induced EMT, migration, invasion and VEGF secretion in several human cancer cell lines. SB 431542 synthesized to cGMP guidelines also available.",384.39
SB 452533,[459429-39-1],CC1=CC(N(CC)CCNC(NC2=CC=CC=C2Br)=O)=CC=C1,Ion Channels,Transient Receptor Potential Channels,TRPV,Potent TRPV1 receptor antagonist,"Potent TRPV1 antagonist against capsaicin (pKb = 7.7), noxious heat and acid-mediated (pIC50 = 7.0) receptor activation (pKi = 6.22 at the recombinant hTRPV1 receptor). Exhibits analgesic properties.",376.29
SB 525334,[356559-20-1],CC1=NC(C4=C(NC(C(C)(C)C)=N4)C2=CC=C(N=CC=N3)C3=C2)=CC=C1,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Selective inhibitor of TGF-betaRI,"Selective inhibitor of transforming growth factor-beta receptor I (ALK5, TGF-betaRI) (IC50 = 14.3 nM). Inhibits TGF-beta1-induced smad2/3 nuclear localization and TGF-betaRI-induced mRNA expression in kidney cells. Attenuates bleomycin-induced pulmonary fibrosis.",343.42
SB 612111 hydrochloride,[371980-94-8],CC1=CC=CC2=C1CC[C@H](CN3CCC(C4=C(Cl)C=CC=C4Cl)CC3)C[C@@H]2O.Cl,7-TM Receptors,Opioid Receptors,NOP Receptors,Selective NOP antagonist,"Selective NOP receptor antagonist (Ki values are 0.33, 57.6, 160.5 and 2109 nM for NOP, mu-, kappa- and delta-receptors respectively). Antagonizes the pronociceptive action of nociceptin (Cat. No. 0910) in an acute pain model. Potentiates the action of morphine in morphine-tolerant animals and blocks hyperalgesia in an inflammatory pain model.",454.86
SB 657510,[474960-44-6],BrC1=CC(OC)=C(OC)C=C1S(NC2=CC=C(Cl)C(O[C@H]3CN(C)CC3)=C2)(=O)=O,7-TM Receptors,Peptide Receptors,Urotensin-II Receptors,Selective urotensin-II (UT) receptor antagonist,"Selective urotensin-II (UT) receptor antagonist (Ki values are 61, 17, 30, 65 and 56 nM at human, monkey, cat, rat and mouse receptors respectively). Inhibits U-II-induced intracellular Ca2+ mobilization (IC50 = 180 nM) and antagonizes the contractile action of U-II in isolated mammalian arteries and aortae (EC50 = 50 - 189 nM).",505.81
SB 743921 hydrochloride,[940929-33-9],ClC1=CC=C2C(OC([C@@H]([C@H](C)C)N(C(C4=CC=C(C)C=C4)=O)CCCN)=C(CC3=CC=CC=C3)C2=O)=C1.Cl,Enzymes,ATPases,Kinesin,Potent kinesin spindle protein (KSP) inhibitor,"Potent kinesin spindle protein (KSP) inhibitor (Ki = 0.1 nM). Induces cell mitotic arrest and apoptosis in vitro. Inhibits the growth of a range of tumor cells in vitro, including colon (HCT 116), prostate (PC-3) and leukemia (K-562) cancer cell lines. Causes tumor regression in human tumor xenograft models in vivo, including colon (Colo205), lung (H69) and breast (MCF7) cancer cell xenografts.",553.52
SB 747651A dihydrochloride,[1781882-72-1],NC1=NON=C1C3=NC2=CN=CC(CNC4CCNCC4)=C2N3CC.Cl.Cl,Enzymes,Kinases,Other Kinases,Potent MSK1 inhibitor; also inhibits other AGC group kinases,"Potent, ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor (IC50 = 11 nM in an in vitro kinase assay); targets the N-terminal kinase domain. Inhibits MSK1, MSK2, PKA, PKB, RSK and p70S6K activity in cells. Blocks IL-10 production in macrophages.",415.32
SB 772077B dihydrochloride,[607373-46-6],NC1=NON=C1C3=NC2=CN=CC(C(N4CC[C@H](N)C4)=O)=C2N3CC.Cl.Cl,Enzymes,Kinases,Rho-kinases,Potent Rho-kinase inhibitor; vasodilator,Potent Rho-kinase (ROCK) inhibitor (IC50 value of approximately 5.6 nM at recombinant human ROCK1 and 2). Decreases pulmonary and systemic arterial blood pressures and increases cardiac output. Exhibits vasodilator activity that is more potent than Y-27632 (Cat.No 1254) or Fasudil (Cat.No. 0541).,415.28
SBE 13 hydrochloride,[1052532-15-6],ClC(N=C3)=CC=C3COC1=C(OC)C=C(CNCCC2=CC(OC)=C(OC)C=C2)C=C1.Cl,Enzymes,Kinases,Polo-like Kinase,Potent and selective PLK1 inhibitor,"Selective inhibitor of PLK1 (IC50 values are 200 pM, 875 nM and 66 muM for PLK1, PLK3 and PLK2 respectively). Exhibits no effect on Aurora kinase A activity. Binds and stabilizes the inactive form of PLK1. Delays cell cycle progression, reduces cell proliferation and induces apoptosis in a range of human cancer cell lines. Transiently arrests cells cycle at G0/G1 in primary cells.",479.4
SBHA,[38937-66-5],O=C(CCCCCCC(NO)=O)NO,Enzymes,Histone Deacetylases,Class I HDACs,HDAC1/3 inhibitor,Histone deacetylase (HDAC) inhibitor (ID50 values are 0.25 and 0.3 muM for HDAC1 and HDAC3 respectively). Potentiates the cytostatic effects of 5-Fluorouracil (Cat. No. 3257) in colorectal cancer cells.,204.22
SC 144 hydrochloride,[917497-70-2],O=C(C4=CN=CC=N4)NNC1=NC(C=C(F)C=C3)=C3N2C1=CC=C2.Cl,Signal Transduction,Cytokine and NF-kB Signaling,Cytokines,gp130 inhibitor; blocks cytokine-triggered gp130 signaling,"Inhibitor of gp130 (IC50 = 0.72 muM); blocks cytokine-triggered gp130 signaling. Induces gp130 phosphorylation and down regulates gp130 glycosylation; also abrogates STAT3 phosphorylation, nuclear translocation and inhibits the expression of downstream target genes. Delays tumor growth in a mouse xenograft model of human ovarian cancer. Orally active.",358.76
SC 19220,[19395-87-0],CC(=O)NNC(=O)N1CC2=C(OC3=CC=C(Cl)C=C13)C=CC=C2,7-TM Receptors,Prostanoid Receptors,,Selective EP1 receptor antagonist,Selective EP1 receptor antagonist (IC50 = 6.7 muM for inhibition of [3H]-PGE2 binding to EP1 transfected COS cells).,331.76
SC 236,[170569-86-5],ClC(C=C3)=CC=C3C1=CC(C(F)(F)F)=NN1C2=CC=C(S(=O)(N)=O)C=C2,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Selective cyclooxygenase-2 (COX-2) inhibitor,Selective COX-2 inhibitor (IC50 values are 0.005 and 17.8 muM for COX-2 and COX-1 respectively). Displays anti-inflammatory properties and potent antimetastatic activity against both experimental metastases and spontaneous metastases arising following primary tumor excision.,401.79
SC 51089,[146033-02-5],ClC3=CC2=C(C=C3)OC1=CC=CC=C1CN2C(NNC(CCC4=CC=NC=C4)=O)=O.Cl,7-TM Receptors,Prostanoid Receptors,,Selective EP1 receptor antagonist,"Selective EP1 prostanoid receptor antagonist (Ki values are 1.3, 11.2, 17.5, 61.1, > 100, > 100, > 100, >100 and > 100 muM for EP1, TP, EP3, EP2, EP4, FP and DP receptors respectively). Attenuates PGE2-induced neuronal cell death in vitro and slows tumor growth in vivo.",459.33
SC 51322,[146032-79-3],O=C(NNC(CCSCC4=CC=CO4)=O)N3CC1=CC=CC=C1OC2=CC=C(Cl)C=C23,7-TM Receptors,Prostanoid Receptors,,Potent EP1 receptor antagonist,Potent EP1 prostanoid receptor antagonist (Ki = 13.8 nM). Displays analgesic properties in vivo.,457.93
SC 560,[188817-13-2],COC1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Cl)C=C1)C(F)(F)F,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Cyclooxygenase-1 (COX-1) inhibitor,"Highly selective cyclooxygenase-1 (COX-1) inhibitor (IC50 values are 0.009 and 6.3 muM for COX-1 and COX-2 respectively). Inhibits COX-1-derived platelet thromboxane B2, gastric PGE2 and dermal PDE2 production. Significantly reduces ovarian surface epithelial tumor growth in vivo. Orally active.",352.74
SC-9,[102649-78-5],ClC1=C2C=CC=C(C2=CC=C1)S(=O)(=O)NCCCCCCC1=CC=CC=C1,Enzymes,Kinases,Protein Kinase C,Protein kinase C activator,A potent activator of protein kinase C.,401.95
SCH 202676 hydrobromide,[265980-25-4],C\N=C1SN(C3=CC=CC=C3)C(C2=CC=CC=C2)=N/1.Br,Enzymes,GTPases,Heterotrimeric G-protein GTPases,Inhibitor of ligand binding to G-protein-coupled receptors,"Sulphydryl-reactive compound that inhibits agonist and antagonist binding to G-protein-coupled receptors. Inhibits a variety of GPCRs including adenosine, opioid, muscarinic, adrenergic and dopaminergic receptors (IC50 values are 0.1-1.8 muM).",348.26
SCH 221510,[322473-89-2],OC1(C2=CC=CC=C2)CC3N(C(C5=CC=CC=C5C)C4=C(C)C=CC=C4)C(CC3)C1,7-TM Receptors,Opioid Receptors,NOP Receptors,Potent and selective NOP agonist,"Potent and selective nociceptin opioid receptor (NOP) agonist (EC50 values are 12, 693, 683 and 8071 nM, and Ki values are 0.3, 65, 131 and 2854 nM at NOP, mu-, kappa- and delta-opioid receptors respectively). Exhibits anxiolytic-like activity at doses that have no effect on overt behaviors such as locomotion in vivo. Orally active.",397.55
SCH 51344,[171927-40-5],CC1=NN=C(N3)C1=C(NCCOCCO)C2=C3C=CC(OC)=C2,Enzymes,Hydrolases,MutT homolog-1 (MTH1),Potent MTH1 inhibitor,Potent MTH1 inhibitor (Kd = 49 nM). Inhibits Ras-induced malignant transformation and increases alpha-actin promoter-driven CAT activity in Ras-transformed cells. Has no effect on Ras-induced ERK and JNK activation. Inhibits Ras-induced membrane ruffling in REF-52 fibroblasts and blocks anchorage-independent growth of Ras-transformed tumor cell lines. Also induces DNA damage in SW480 colon cancer cells.,316.35
SCH 58261,[160098-96-4],NC1=NC2=C(C=NN2CCC2=CC=CC=C2)C2=NC(=NN12)C1=CC=CO1,7-TM Receptors,Adenosine Receptors,Adenosine A2A Receptors,"Potent, highly selective A2A antagonist","Potent and selective A2A adenosine receptor competitive antagonist (Ki = 1.3 nM). Displays 323-, 53- and 100-fold selectivity over A1, A2B and A3 receptors, respectively.",345.36
SCIO 469 hydrochloride,,O=C(C(N(C)C)=O)C2=CN(C)C1=CC(Cl)=C(C(N3[C@H](C)CN(CC4=CC=C(F)C=C4)[C@@H](C)C3)=O)C=C12.Cl,Enzymes,Kinases,MAPK Family,Selective p38 MAPK inhibitor,"Selective, ATP-competitive p38 inhibitor (IC50 = 9 nM for p38alpha in vitro). Displays approximately 10-fold selectivity for p38alpha over p38beta and 2000-fold selectivity for p38alpha over 20 other kinases. Reduces p38alpha phosphorylation in multiple myeloma cells in vitro and in vivo; activity results in decreased tumor burden and angiogenesis in murine models of multiple myeloma. Also enhances bortezomib-induced cytotoxicity against multiple myeloma cells.",549.46
SCS,[3232-36-8],OC1=CC=CC=C1\C=N\NC(=O)C1=CC=CC=C1O,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Potent GABAA antagonist; beta1-subunit selective,"Potent and selective partial inhibitor of beta1-containing GABAA receptors (IC50 values are 4.5, 5.3 and 7.9 nM at alpha2beta1gamma1theta, alpha2beta1gamma1 and alpha2beta1gamma2s GABAA receptors respectively). May bind allosterically to a novel site on GABAA receptor.",256.26
SD 208,[627536-09-8],FC(C=CC(Cl)=C3)=C3C2=NC1=NC=CN=C1C(NC4=CC=NC=C4)=N2,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Potent ATP-competitive TGF-betaRI inhibitor,"Potent, orally active ATP-competitive transforming growth factor-beta receptor 1 (TGF-betaRI) inhibitor (IC50 = 49 nM). Displays > 100-fold and > 17-fold selectivity over TGF-betaRII and other common kinases respectively. Exhibits anti-inflammatory and antitumor activity. Also promotes an antiglioma immune response. Ameliorates germinal matrix hemorrhage-induced neurological deficits in neonatal rats.",352.75
SD 2590 hydrochloride,[226395-93-3],O=S(C1(C(NO)=O)CCN(CCOC)CC1)(C2=CC=C(OC3=CC=C(OC(F)(F)F)C=C3)C=C2)=O.Cl,Enzymes,Proteases,Matrix Metalloprotease,Potent MMP inhibitor,"Potent MMP inhibitor (IC50 values are <0.1, <0.1, 0.18, 1.7, 13 and 28.7 nM for MMP-2, -13, -9, -8, -14 and -3 respectively). Exhibits 100,000-fold selectivity for MMP-2 and -13 over MMP-1. Reduces left ventricular dilation in a myocardial infarction rat model. Orally bioavailable.",554.96
SDZ 220-581,[174575-17-8],OC([C@@H](N)CC1=CC(C2=CC=CC=C2Cl)=CC(CP(O)(O)=O)=C1)=O,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Competitive NMDA antagonist,Competitive NMDA receptor antagonist (pKi = 7.7). Centrally active following oral administration (ED50 < 3.2 mg/kg for protection against MES-induced seizures).,369.74
SDZ NKT 343,[180046-99-5],O=C(NC3=C([N+]([O-])=O)C=CC=C3)N1[C@H]([C@@](N[C@H]([C@@](N(C)CC4=CC=CC=C4)=O)CC2=CC=C(C=CC=C5)C5=C2)=O)CCC1,7-TM Receptors,Peptide Receptors,Tachykinin Receptors,Highly selective human NK1 antagonist,Highly selective human tachykinin NK1 receptor antagonist (IC50 values are 0.62 and 451 nM for human and rat receptors respectively) that displays > 130-fold selectivity over human NK2 and NK3 receptors. Potently antagonizes SP-induced Ca2+ efflux in vitro and inhibits mechanical hyperalgesia in vivo.,579.65
SDZ WAG 994,[130714-47-5],O[C@@H]1[C@@H](CO)O[C@@H](N(C=N4)C2=C4C(NC3CCCCC3)=NC=N2)[C@@H]1OC,7-TM Receptors,Adenosine Receptors,Adenosine A1 Receptors,"Potent, selective A1 agonist","Potent and selective A1 adenosine receptor agonist (Ki values are 23, > 10000 and 25000 nM for A1, A2A and A2B receptors respectively). Causes a sustained fall in blood pressure and heart rate in spontaneous hypertensive rats and inhibits adenosine deaminase-stimulated lipolysis in rat adipocytes (Ki = 8 nM).",363.41
Selexipag,[475086-01-2],CC(C)N(CCCCOCC(NS(C)(=O)=O)=O)C1=NC(C3=CC=CC=C3)=C(C2=CC=CC=C2)N=C1,7-TM Receptors,Prostanoid Receptors,,Selective prostacyclin IP1 receptor agonist,"6243Selective prostacyclin IP1 receptor agonist (Ki values are 260 and 2100 nM and for human and rat IP receptors, and >10 muM for EP1-4, DP, FP, and TP receptors). Prodrug for the active form of MRE 269. Ameliorates vascular endothelial dysfunction and increases femoral skin blood flow in rats. Orally available.",496.62
SEN 1269,[956128-01-1],OC1=CC(NC2=NC=C(OC3=CC=CC(N(C)C)=C3)C=N2)=CC=C1,Cell Metabolism,Amyloid Beta Peptides,,Amyloid-beta aggregation inhibitor,Amyloid-beta (Abeta) aggregation inhibitor; blocks Abeta(1-42) aggregation and protects neuronal cell lines exposed to Abeta(1-42). Reduces Abeta oligomer-induced LTP and memory deficits in vivo.,322.36
Sertraline hydrochloride,[79559-97-0],ClC(C(Cl)=C3)=CC=[C@@]3[C@H]2C1=CC=CC=C1[C@@H](NC)CC2.Cl,Transporters,Neurotransmitter Transporters,5-HT Transporters,5-HT reuptake inhibitor,"Potent, orally active selective serotonin re-uptake inhibitor (SSRI); antidepressant.",342.69
SF 11,[443292-81-7],S=C(N2CCC(C(C4=CC=CC=C4)(O)C3=CC=CC=C3)CC2)NC1=CC=C(OCC)C=C1,7-TM Receptors,Peptide Receptors,NPY Receptors,NPY Y2 receptor antagonist,NPY Y2 antagonist (IC50 = 199 nM). Displays no affinity for Y1 receptor at concentrations up to 35 muM. Causes significant lethality in mice. Brain penetrant.,446.6
SGC 0946,[1561178-17-3],O[C@H]([C@H](O)[C@@H](CN(C(C)C)CCCNC(NC4=CC=C(C(C)(C)C)C=C4)=O)O3)[C@@H]3N1C2=C(C(N)=NC=N2)C(Br)=C1,Enzymes,Transferases,Lysine Methyltransferases,Highly potent and selective DOT1L inhibitor; cell permeable,"Highly potent DOT1L methyltransferase inhibitor (Kd = 0.06 nM, IC50 = 0.3 nM in a radioactive assay); blocks H3K79 methylation in A431 cells and MCF10A cells. Inactive at 12 histone methyltransferases and DNMT1. Selectively kills cells transformed with the MLL-AF9 fusion oncogene in an in vitro model of leukemia; lowers levels of MLL target genes HOXA9 and Meis1. To request the negative control for SGC0946, please fill out the SGC0649 request form on the SGC website.",618.57
SGC 707,,O=C(NCC(N1CCCC1)=O)NC2=CC3=CC=NC=C3C=C2,Enzymes,Transferases,Protein Arginine Methyltransferases,Potent and selective allosteric inhibitor of PRMT3,Potent allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) (IC50 = 31 nM). Inhibits PRMT3-mediated methyltransferase activity in vitro. Displays >100-fold selectivity against 31 other methyltransferases and 250 other non-epigenetic targets. Decreases H4R3me2a levels in HEK293 cells in vitro.,298.34
SHA 68,[847553-89-3],O=C(NCC4=CC=C(F)C=C4)N1CC2N(C(OC(C5=CC=CC=C5)2C3=CC=CC=C3)=O)CC1,7-TM Receptors,Peptide Receptors,Neuropeptide S Receptors,Selective Neuropeptide S receptor antagonist,"Selective neuropeptide S receptor (NPSR) antagonist (IC50 values are 22.0 and 23.8 nM for human NPSR Asn107 and Ile107 variants respectively). Displays no activity against a range of 14 GPCRs, including vasopressin and oxytocin receptors.",445.49
SID 7969543,[868224-64-0],O=C2C1=CC=CC(OC(C)C(OCC)=O)=C1C=CN2CC(NC3=CC=C(OCCO4)C4=C3)=O,Nuclear Receptors,Other Nuclear Receptors,,"Selective steroidogenic factor-1 (SF-1, NR5A1) inhibitor","Selective steroidogenic factor-1 (SF-1, NR5A1) inhibitor (IC50 values are 0.76, >33 and >33 muM at SF-1, RORalpha and VP16 respectively). Inhibits SF-1-dependent luciferase expression in HEK 293T cells in vitro (IC50 = 30 nM).",452.46
Siguazodan,[115344-47-3],CN\C(NC#N)=N/C1=CC=C(C=C1)C1=NNC(=O)CC1C,Enzymes,Phosphodiesterases,,PDE3 inhibitor,"Phosphodiesterase inhibitor, selective for PDE3 (IC50 = 117 nM).",284.32
Sildenafil citrate,[171599-83-0],O=C(O)C(O)(CC(O)=O)CC(O)=O.CN1CCN(S(C2=CC=C(OCC)C(C(NC4=C3N(C)N=C4CCC)=NC3=O)=C2)(=O)=O)CC1,Enzymes,Phosphodiesterases,,"Orally active, potent PDE5 inhibitor","Orally active, potent inhibitor of phosphodiesterase 5 (PDE5) (IC50 = 4 nM). Enhances nitric oxide-dependent relaxation of human corpus cavernosum in vitro.",666.7
Simvastatin,[79902-63-9],[H][C@@]12C(C=C[C@H](C)[C@@H]2CC[C@@H]3C[C@@H](O)CC(O3)=O)=C[C@H](C)C[C@@H]1OC(C(C)(C)CC)=O,Enzymes,Reductases,HMG-CoA Reductase,HMG-CoA reductase inhibitor,"HMG-CoA reductase inhibitor; decreases levels of low density lipoprotein. Has multiple biological effects including bone formation stimulation, inhibition of smooth muscle cell proliferation and migration, induction of ferroptosis, and anticancer and anti-inflammatory activity. Inactive lactone prodrug of simvastatin hydroxy acid, naturally bioactivated in vivo following oral administration. Deuterated analog also available.",418.57
Sipatrigine,[130800-90-7],ClC1=CC(Cl)=C(Cl)C(C2=C(N)N=C(N3CCN(C)CC3)N=C2)=C1,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,NaV blocker; neuroprotective,Blocker of voltage-dependent sodium channels (NaV). Inhibits glutamate release; displays neuroprotective activity in rat models of cerebral ischemia. Also thought to block Ca2+ channels. Analog of lamotrigine (Cat. No. 1611).,372.68
SirReal 2,[709002-46-0],CC1=CC(C)=NC(SCC(NC2=NC=C(CC3=CC=CC4=C3C=CC=C4)S2)=O)=N1,Enzymes,Histone Deacetylases,Class III HDACs (Sirtuins),Selective inhibitor of SIRT2,Selective SIRT2 inhibitor (IC50 = 140 nM). Has minimal effect on SIRT1 and SIRT3-6. Increases alpha-tubulin acetylation levels in HeLa cells.,420.55
SIS3,[521984-48-5],O=C(N4CCC(C=C(OC)C(OC)=C5)=C5C4)/C=C/C2=C(C3=CC=CC=C3)N(C)C1=NC=CC=C12.Cl,Enzyme-Linked Receptors,Receptor Serine/Threonine Kinases (RSTKs),TGF-beta Receptors,Selective Smad3 inhibitor; inhibits TGF-betaR1 signaling,"Selective Smad3 inhibitor; attenuates TGF-beta1-dependent Smad3 phosphorylation and DNA binding. Has no effect on Smad2, p38 MAPK, ERK or PI 3-kinase signaling. Inhibits TGF-beta1-induced myofibroblast differentiation of dermal fibroblasts. Also inhibits TGF-beta2-induced endothelial cell differentiation in iPSCs.",489.99
Sivelestat sodium salt,[150374-95-1],[Na+].CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=C1C(=O)NCC([O-])=O,Enzymes,Proteases,Elastase,Selective leukocyte elastase inhibitor,"Selective leukocyte elastase inhibitor (IC50 = 44 nM) that displays no activity at a range of other proteases. Inhibits NF-kappaB activation and LTB4-induced neutrophil transmigration in vitro. Significantly attenuates ischemia-induced spinal cord injury, decreases serum cytokine levels and reduces acute inflammatory lung injury in vivo.",456.44
SJ 172550,[431979-47-4],O=C(N(C3=CC=CC=C3)N=C2C)/C2=C/C1=CC(OCC)=C(OCC(OC)=O)C(Cl)=C1,Cell Cycle,p53,,MDMX inhibitor. Disrupts MDMX-p53 interaction,MDMX inhibitor. Reversibly binds MDMX (EC50 = 2.3 muM). Inhibits the MDMX-p53 interaction in cultured retinoblastoma cells; frees p53 to induce apoptosis.,428.87
SKA 31,[40172-65-4],NC3=NC2=C(S3)C=CC1=CC=CC=C12,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Activator of KCa3.1 and KCa2 channels,"Activator of KCa3.1 and KCa2 channels (EC50 values are 260, 2900, 2900 nM for KCa3.1, KCa2.1 and KCa2.2 respectively). Potentiates acetylcholine-induced EDHF-type dilations of mouse carotid arteries and lowers blood pressure in normotensive and hypertensive mice.",200.26
SKF 81297 hydrobromide,[67287-39-2],Br.OC1=C(O)C(Cl)=C2CCNCC(C3=CC=CC=C3)C2=C1,7-TM Receptors,Dopamine Receptors,D1 and D5 Receptors,D1 agonist,Dopamine D1-like receptor agonist. Centrally active following systemic administration in vivo.,370.67
SKF 83566 hydrobromide,[108179-91-5],Br.CN1CCC2=CC(Br)=C(O)C=C2C(C1)C1=CC=CC=C1,7-TM Receptors,Dopamine Receptors,D1 and D5 Receptors,Potent and selective D1-like antagonist; also inhibits adenylyl cyclase 2,Potent and selective D1-like dopamine receptor antagonist (Ki~ 0.56 nM for D1; KB = 2 muM for D2). Also antagonist at the vascular 5-HT2 receptor (Ki = 11 nM). Displays selective inhibition of adenylyl cyclase 2 (AC2); inactive against AC1 or AC5. Centrally active following systemic administration in vivo.,413.15
SKF 89976A hydrochloride,[85375-15-1],Cl[H].OC(=O)C1CCCN(CC\C=C(\C2=CC=CC=C2)C2=CC=CC=C2)C1,Transporters,Neurotransmitter Transporters,GABA Transporters,Potent GAT-1 inhibitor; brain penetrant,"A potent GABA uptake inhibitor, selective for GAT-1 (IC50 values are 0.13, 550, 944 and 7210 muM for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively). Inhibits transport current competitively (Ki = 7 muM) and transmitter-gated current non-competitively (Ki = 0.03 nM). Able to pass the blood-brain barrier after systemic administration and is active in vivo.",371.91
SKF 91488 dihydrochloride,[68941-21-9],CN(CCCCSC(=N)N)C.Cl.Cl,Enzymes,Transferases,Other Transferases,Histamine N-methyltransferase inhibitor,Homolog of dimaprit (Cat. No. 0506); strong inhibitor of histamine N-methyltransferase. Exhibits no histamine agonist activity.,248.21
SMER 28,[307538-42-7],C=CCNC2=NC=NC1=CC=C(Br)C=C12,Cell Metabolism,Autophagy,,Positive regulator of autophagy,"Positive regulator of autophagy in a mechanism independent from the mTOR pathway. Increases autophagosome synthesis and enhances clearance of model autophagy substrates such as mutant huntingtin and A53T alpha-synuclein, associated with Huntington's and Parkinson's diseases, respectively. Promotes reprogramming of fibroblasts to neural stem-like cells in combination with other chemical reagents.",264.12
SN 2,[823218-99-1],CC1=CC(C)=CC(C)=C1C2=NOC3C2C4CCC3C4,Ion Channels,Transient Receptor Potential Channels,TRPML,Selective TRPML3 channel activator,Selective TRPML3 channel activator (EC50 = 1.13 muM).,255.35
SN 38,[86639-52-3],OC1=CC=C(N=C(C(N3C4)=CC([C@](CC)(O)C(OC5)=O)=C5C3=O)C4=C2CC)C2=C1,Enzymes,Isomerases,DNA Topoisomerase,DNA topoisomerase I inhibitor; antitumor,"Active metabolite of CPT-11 (Cat. No. 2688) that inhibits DNA topoisomerase I (IC50 values are 0.74 and 1.9 muM in P388 and Ehrlich cells respectively). Inhibits DNA and RNA synthesis (IC50 values are 0.077 and 1.3 muM respectively) but does not affect protein synthesis. Displays potent antitumor activity against a range of human tumor cell lines (IC50 values are 3.3, 13, 19 and 22 nM for HCT-116, BEL-7402, HL60 and HELA cells respectively).",392.4
SN-6,[415697-08-4],CCOC(=O)C1CSC(CC2=CC=C(OCC3=CC=C(C=C3)[N+]([O-])=O)C=C2)N1,Transporters,Ion Pumps/Transporters,Na+/Ca2+ Exchanger,Selective Na+/Ca2+ exchange inhibitor (reverse mode),"Selective Na+/Ca2+-exchange (NCX) inhibitor; displays some selectivity for NCX1. IC50 values are 2.9, 16 and 8.6 muM for inhibition of intracellular Na+-dependent 45Ca2+ uptake by cells expressing NCX1, NCX2 and NCX3 respectively. Has some affinity for mACh receptors (IC50 = 18 muM) but minimal activity against NCKX2 and various receptors and ion channels (IC50 > 30 muM). Preferentially blocks Ca2+ influx mode and is more selective for NCX isoforms than KB-R7943 (Cat. No. 1244). Anti-ischemic; potently protects against hypoxia-induced renal tubular cell damage (IC50 = 0.63 muM).",402.16
SNC 80,[156727-74-1],[H][C@@](N1C[C@@H](C)N(CC=C)C[C@@H]1C)(C1=CC=C(C=C1)C(=O)N(CC)CC)C1=CC=CC(OC)=C1,7-TM Receptors,Opioid Receptors,Delta Opioid Receptors,Highly selective non-peptide delta agonist,"A highly selective and potent non-peptide delta-opioid agonist, 2000-fold selective over mu-opioid receptors.",449.64
SNS 314 mesylate,[1146618-41-8],O=C(NC4=CC(Cl)=CC=C4)NC3=NC=C(S3)CCNC1=NC=NC2=C1SC=C2.CS(=O)(O)=O,Enzymes,Kinases,Aurora Kinases,Potent pan-Aurora kinase inhibitor,"Potent, ATP-competitive Aurora kinase inhibitor (IC50 values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both in vitro and in vivo activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin (Cat. No. 2626), gemcitabine (Cat. No. 3259) and 5-fluorouracil (Cat. No. 3257).",527.04
Sodium 4-Phenylbutyrate,[1716-12-7],[Na+].[O-]C(=O)CCCC1=CC=CC=C1,Enzymes,Histone Deacetylases,Non-selective HDACs,Histone deacetylase inhibitor,"Histone deacetylase inhibitor that displays anticancer activity. Inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. Also inhibits protein isoprenylation, depletes plasma glutamine, increases production of fetal hemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.",186.18
SP 100030,[154563-54-9],O=C(NC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)C1=C(C(F)(F)F)N=C(Cl)N=C1,Signal Transduction,Cytokine and NF-kB Signaling,NF-kB/IkB,NF-kappaB and AP-1 dual inhibitor,"Potent dual inhibitor of NF-kappaB and AP-1 transcriptional activity (IC50 = 50 nM). Blocks production of IL-2, IL-8 and TNF-alpha from Jurkat T cells. Inhibits cytokine production selectively in T cells; exhibits minimal inhibition of cytokine production in other cell types. Decreases arthritic severity in a mouse model of collagen-induced arthritis. Also ameliorates muscle wasting in a rat model of cancer cachexia.",437.65
SP 141,[1253491-42-7],COC1=CC=C(NC2=C3C=CN=C2C4=CC=CC5=C4C=CC=C5)C3=C1,Enzymes,Ligases,Ubiquitin E3 Ligases,High affinity MDM2 inhibitor,High affinity MDM2 inhibitor (Ki = 28 nM); directly binds MDM2. Inhibits MDM2 expression and induces MDM2 autoubiquitination and proteasomal degradation. Attenuates growth of breast cancer xenograft tumors. Cell permeable.,324.38
Spautin 1,[1262888-28-7],FC1=CC=C(N=CN=C2NCC3=CC=C(F)C=C3)C2=C1,Enzymes,Proteases,Deubiquitinating Enzymes,USP10 and USP13 inhibitor; inhibits autophagy,Inhibitor of autophagy; inhibits USP10 and USP13 activity (IC50 values are 0.6 and 0.7 muM respectively) and promotes degradation of Vps34 (class III PI 3-kinase) complexes. Selectively promotes apoptosis of cancer cells under starvation conditions. Prevents the PDGF-induced conversion from the contractile to synthetic phenotype in vascular smooth muscle cells.,271.26
Spironolactone,[52-01-7],O=C1CC[C@@]2(C)C(C[C@@H](SC(C)=O)[C@]3([H])[C@@]([H])2CC[C@@]4(C)[C@]([H])3CC[C@@]54OC(CC5)=O)=C1,Nuclear Receptors,Mineralocorticoid Receptor,,Mineralocorticoid receptor antagonist,Competitive mineralocorticoid (aldosterone) receptor antagonist that exhibits antihypertensive activity in vivo. Also displays antiandrogen activity and inhibits steroid hormone biosynthesis.,416.57
SPP 86,[1357349-91-7],CC(C)N1N=C(C#CC3=CC=CC=C3)C2=C1N=CN=C2N,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),Other RTKs,Potent RET inhibitor,"Potent RET inhibitor (IC50 = 8 nM). Also exhibits inhibitory activity at EphA1, FGFR1, Flt4, Lck and Yes. Inhibits proliferation of HCT 116 and TPC1 cells in vitro. Cell permeable.",277.32
SQ 22536,[17318-31-9],NC1=C2N=CN(C3CCCO3)C2=NC=N1,Enzymes,Cyclases,Adenylyl Cyclase,Adenylyl cyclase inhibitor,Inhibitor of adenylyl cyclase (IC50 = 1.4 muM). Inhibits PGE1-stimulated increases in cAMP levels in intact human platelets. Cell permeable.,205.22
SR 1078,[1246525-60-9],OC(C(F)(F)F)(C(F)(F)F)C(C=C1)=CC=C1NC(C2=CC=C(C(F)(F)F)C=C2)=O,Nuclear Receptors,Retinoic Acid-related Orphan Receptors,,RORalpha/gamma agonist,Agonist of retinoic acid receptor-related orphan receptors (ROR) RORalpha/gamma. Increases transcription of RORalpha target genes; thought to increase p53 stability.,431.25
SR 11237,[146670-40-8],CC1(C)C2=C(C=CC(C4(OCCO4)C3=CC=C(C(O)=O)C=C3)=C2)C(C)(C)CC1,Nuclear Receptors,Retinoid X Receptor,,Pan RXR agonist,Pan retinoid X receptor (RXR) agonist that is devoid of any RAR activity.,380.48
SR 140333,[153050-21-6],O=C(N2C[C@@](CC[N+]3(CC5)CCC(C4=CC=CC=C4)5CC3)([C@]6=CC=C(Cl)C(Cl)=C6)CCC2)CC1=CC(OC(C)C)=CC=C1.[Cl-],7-TM Receptors,Peptide Receptors,Tachykinin Receptors,Potent NK1 antagonist,Potent NK1 receptor antagonist (Ki = 0.74 nM. IC50 = 1.6 nM). Inhibits substance P-invoked calcium mobilization and outward current (IC50 = 1.3 nM); blocks NK1-mediated nitric oxide-dependent vasodilation in vivo.,656.12
SR 2211,[1359164-11-6],FC(C=C(C(O)(C(F)(F)F)C(F)(F)F)C=C4)=C4C(C=C3)=CC=C3CN(CC2)CCN2CC1=CC=NC=C1,Nuclear Receptors,Retinoic Acid-related Orphan Receptors,,Selective RORgamma inverse agonist,"Selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (RORgamma) (Ki = 105 nM; IC50 ~320 nM). Exhibits weak activity at liver X receptor alpha (LXRalpha); does not affect the transcriptional activity of farnesoid X receptors (FXR), and has no impact on the transcriptional activity of RORalpha.",527.48
SR 2640 hydrochloride,[146662-42-2],Cl.OC(=O)C1=CC=CC=C1NC1=CC(OCC2=CC=C3C=CC=CC3=N2)=CC=C1,7-TM Receptors,Leukotriene and Related Receptors,,"Potent, selective LTD4 /LTE4 receptor antagonist",Potent and selective competitive leukotriene D4 and E4 receptor antagonist. Inhibits LTD4- but not histamine-induced guinea pig ileum and trachea contraction (pA2 = 8.7). Also inhibits LTD4-attenuation of human PMN chemotaxis. Orally active in vivo.,406.87
SR 27897,[136381-85-6],OC(=O)CN1C(=CC2=CC=CC=C12)C(=O)NC1=NC(=CS1)C1=CC=CC=C1Cl,7-TM Receptors,Peptide Receptors,Cholecystokinin (CCK) Receptors,Potent and selective CCK1 antagonist,"Potent, non-peptide CCK1 receptor antagonist that displays > 33-fold selectivity over CCK2 receptors (EC50 values are 6 and 200 nM respectively). Causes an increase in plasma leptin levels and increases food intake in rats in vivo.",411.86
SR 33805 oxalate,[121346-33-6],O=C(O)C(O)=O.O=S(C2=C(C(C)C)C1=CC=CC=C1N2C)(C3=CC=C(OCCCN(C)CCC4=CC=C(OC)C(OC)=C4)C=C3)=O,Ion Channels,Calcium Channels,Voltage-gated Calcium Channels,CaV1.x blocker; binds allosterically to distinct site,"Potent Ca2+ channel antagonist; binds allosterically to the a1-subunit of L-type Ca2+ channels (Kd = 20 pM), at a site distinct from other types of blocker. Shows some selectivity for vascular smooth muscle, inducing vasorelaxation without producing inotropic or chronotropic effects. Inhibits PDGF-stimulated smooth muscle cell proliferation.",654.77
SR 3576,[1164153-22-3],O=C(NC3=CC(OC)=C(OC)C(OC)=C3)C1=CC=CC(N2C=C(NC(NC4=CC=CC(C)=C4)=O)C=N2)=C1,Enzymes,Kinases,MAPK Family,Highly potent and selective JNK3 inhibitor,Highly potent and selective JNK3 inhibitor (IC50 = 7 nM); exhibits > 2800-fold selectivity over p38.,501.53
SR 3677 dihydrochloride,[1781628-88-3],O=C(C3COC(C=CC=C4)=C4O3)NC1=CC=C(C2=CNN=C2)C=C1OCCN(C)C.Cl.Cl,Enzymes,Kinases,Rho-kinases,"Potent, selective Rho-kinase (ROCK) inhibitor",Potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).,481.37
SR 49059,[150375-75-0],O=S(C1=CC(OC)=C(OC)C=C1)(N2[C@@H]([C@@](N5CCC[C@H]5[C@@](N)=O)=O)[C@](C4=CC=CC=C4Cl)(O)C3=C2C=CC(Cl)=C3)=O,7-TM Receptors,Peptide Receptors,Vasopressin Receptors,"Selective, orally active vasopressin V1A receptor antagonist",Potent and selective non-peptide vasopressin V1A receptor antagonist; devoid of agonist activity. Displays high affinity and efficacy at both rat (Ki = 1.6 nM) and human (Ki = 1.1 - 6.3 nM) V1A receptors. Potently antagonizes arginine vasopressin-induced effects in vitro (IC50 = 3.7 nM for inhibition of human platelet aggregation) and is orally active in vivo.,620.5
SR 58611A hydrochloride,[121524-09-2],O=C(OCC)COC1=CC=C(CC[C@H](NC[C@H](O)C3=CC(Cl)=CC=C3)C2)C2=C1.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-3 Receptors,beta3 agonist; displays anxiolytic and antidepressant effects,Selective beta3-adrenergic receptor agonist. Displays both anxiolytic and antidepressant effects in rodent models. Orally active and brain penetrant.,440.36
SR 59230A hydrochloride,[1135278-41-9],O[C@@H](CN[C@H]2CCCC3=C2C=CC=C3)COC1=C(CC)C=CC=C1.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-3 Receptors,Potent and selective beta3 antagonist,"Potent and selective beta3 adrenoceptor antagonist (IC50 values are 40, 408 and 648 nM for beta3, beta1 and beta2 receptors respectively). Orally active in vivo. Also available as part of the beta-Adrenoceptor Antagonist Tocriset™.",361.91
SR 95531 hydrobromide,[104104-50-9],Br.COC1=CC=C(C=C1)C1=NN(CCCC(O)=O)C(=N)C=C1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Competitive and selective GABAA antagonist,"Selective, competitive GABAA receptor antagonist. Displaces [3H]-GABA from rat brain membranes with a Ki of 150 nM. Unlike bicuculline, selectively antagonizes GABA-induced Cl- currents with little action on pentobarbitone-induced currents. Also acts as a low affinity glycine receptor antagonist.",368.23
Src I1,[179248-59-0],COC(C(OC)=C3)=CC1=C3N=CN=C1NC2=CC=C(OC4=CC=CC=C4)C=C2,Enzymes,Kinases,Src Kinases,Dual site Src kinase inhibitor,"Potent, competitive dual site (ATP- and peptide-binding) Src kinase inhibitor (IC50 values are 44 and 88 nM for Src and Lck respectively). Inhibits VEGFR2 and c-fms at higher concentrations (IC50 values are 0.32 and 30 muM respectively). Can be used in parallel with PP 1 (Cat. No. 1397) and PP 2 (Cat. No. 1407) to inhibit Src family kinases.",373.4
SRPIN340,[218156-96-8],O=C(C3=CC=NC=C3)NC1=C(N2CCCCC2)C=CC(C(F)(F)F)=C1,Enzymes,Kinases,Other Kinases,Selective SRPK1 inhibitor,"Selective serine arginine protein kinase (SRPK) 1 inhibitor (Ki = 0.89 muM). Inhibits SRPK2 at higher concentrations. Does not significantly inhibit other SRPKs such as CLK1 and CLK4, or other classes of SR kinases. Down-regulates expression of VEGF165 but does not affect VEGF165b expression.",349.35
SSR 180711 hydrochloride,[446031-79-4],O=C(N1C2CCN(CC2)CC1)OC3=CC=C(Br)C=C3.Cl,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Selective alpha7 nAChR partial agonist,Partial agonist at alpha7 nAChR. Enhances episodic memory and reverses MK-801-induced deficits in retention of episodic memory. Increases extracellular dopamine levels in rat prefrontal cortex. Also exhibits antidepressant-like properties.,361.66
ST 91,[4749-61-5],CCC2=C(C(CC)=CC=C2)/N=C1NCCN/1.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,"alpha2 agonist, putative alpha2C agonist",alpha2-adrenoceptor agonist that does not cross the blood brain barrier. Displays ~ 120-fold selectivity for alpha2 receptors over alpha1 receptors and acts predominantly at non-alpha2A-adrenoceptors which may be of the alpha2C subtype. Antinociceptive; increases tail-flick latencies in Sasco and Harlan rats.,253.77
Stavudine,[3056-17-5],[H]C1=C([H])[C@@H](O[C@@H]1CO)N1C=C(C)C(=O)NC1=O,Other Pharmacology,Antivirals,,Nucleoside analog; antiviral,Nucleoside analog; antiviral that inhibits HIV replication in vitro. Orally bioavailable.,224.21
STF 118804,[894187-61-2],O=C(C2=CC=C(C3=NC(CS(C4=CC=C(C)C=C4)(=O)=O)=C(C)O3)C=C2)NCC1=CN=CC=C1,Enzymes,Transferases,NAMPT,NAMPT inhibitor; depletes leukemia stem cells,"NAMPT inhibitor (nicotinamide phosphoribosyltransferase, visfatin, PBEF1); inhibits NAD+ synthesis from nicotinamide. Potently inhibits the viability of multiple B-cell acute lymphoplastic leukemia (B-ALL) cell lines (IC50 < 10 nM); induces apoptosis in MF-411 cells. Induces regression of ALL xenografts and eliminates leukemia stems cells from bone marrow in mice.",461.53
STF 31,[724741-75-7],O=C(NC2=CN=CC=C2)C1=CC=C(CNS(C3=CC=C(C(C)(C)C)C=C3)(=O)=O)C=C1,Enzymes,Transferases,NAMPT,NAMPT inhibitor; also GLUT1 inhibitor,Inhibitor of GLUT1; inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells. Activity causes necrotic cell death in von Hippel-Lindau (VHL)-deficient RCC cells. Also NAMPT inhibitor. Eliminates human pluripotent stem cells from culture with limited toxicity towards differentiated cells.,423.53
SU 11274,[658084-23-2],CC1=C(\C=C(C3=CC(S(N(C)C5=CC(Cl)=CC=C5)(=O)=O)=CC=C3N4)/C4=O)NC(C)=C1C(N2CCN(C)CC2)=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),MET Receptors,Selective inhibitor of MET kinase activity,Selective inhibitor of MET tyrosine kinase activity (IC50 = 0.01 muM in vitro). Reduces cell growth in a dose-dependent manner; induces cell cycle arrest and apoptosis. Abrogates cell motility and migration in vitro and tumor angiogenesis in vivo.,568.09
SU 16f,[251356-45-3],O=C2NC1=CC(C4=CC=CC=C4)=CC=C1/C2=C/C3=C(C)C(CCC(O)=O)=C(C)N3,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),PDGFR,Potent and selective PDGFRbeta inhibitor,"Potent and selective platelet-derived growth factor receptor beta (PDGFRbeta) inhibitor (IC50 = 10 nM) that displays > 14-fold, > 229-fold and > 10000-fold selectivity over VEGFR2, FGFR1 and EGFR respectively. Inhibits proliferation of HUVEC and NIH3T3 cells in vitro (IC50 = 0.11 muM).",386.44
SU 3327,[40045-50-9],NC2=NN=C(S2)SC1=NC=C([N+]([O-])=O)S1,Enzymes,Kinases,MAPK Family,Selective JNK inhibitor,Selective inhibitor of c-Jun N-terminal kinase (JNK) (IC50 = 0.7 muM). Inhibits the protein-protein interaction between JNK and JIP (IC50 = 239 nM). Displays selectivity over p38 MAPK and Akt. Restores insulin sensitivity in a mouse model of type-2 diabetes.,261.3
SU 5416,[204005-46-9],O=C2NC1=CC=CC=C1/C2=C/C3=C(C)C=C(C)N3,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,"VEGFR inhibitor. Also inhibits KIT, RET, MET and FLT3","Inhibitor of vascular endothelial growth factor receptor (VEGFR) that also inhibits other tyrosine kinases KIT, MET, FLT3 and RET. Displays no activity against EGFR, HER2, IGF1R and PDGFR. Inhibits tumor vascularization and growth of multiple tumor types.",238.28
SU 6668,[252916-29-3],O=C2NC1=CC=CC=C1/C2=C/C3=C(C)C(CCC(O)=O)=C(C)N3,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),PDGFR,"PDGFR, VEGFR and FGFR inhibitor","ATP-competitive PDGFR, VEGF and FGFR inhibitor (IC50 values are 0.06, 2.43, 3.04 and > 100 muM at PDGFRbeta, VEGFR2, FGFR1 and EGFR respectively). Inhibits proliferation of HUVEC and NIH3T3 cells in vitro (IC50 values are 0.41, 9.3 and 16.5 muM for VEGF, FGF and PDGF-stimulated growth respectively) and induces > 75% growth inhibition against a broad range of tumor types in vivo. Exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity and is orally active.",310.35
SU 9516,[377090-84-1],O=C2NC1=CC=C(OC)C=C1/C2=C/C3=CNC=N3,Enzymes,Kinases,Cyclin-dependent Kinase,Cdk inhibitor; potently inhibits cdk1 and cdk2,"Cyclin-dependent kinase (cdk) inhibitor (reported IC50 values are 0.02 - 0.03, 0.04 - 0.2, 0.2 - 1.7 and 0.9 muM for cdk2, cdk1, cdk4 and cdk9, respectively). Inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1 and G2-M cell cycle arrest. Transcriptionally downregulates Mcl-1 and has antiproliferative, cytostatic and pro-apoptotic effects in vitro.",241.25
Sulfasalazine,[599-79-1],OC1=CC=C(/N=N/C2=CC=C(S(NC3=NC=CC=C3)(=O)=O)C=C2)C=C1C(O)=O,Signal Transduction,Cytokine and NF-kB Signaling,NF-kB/IkB,Inhibitor of NF-kappaB activation; also inhibits SXC and folate transporter 1,"Inhibitor of NF-kappaB activation. Inhibits in vitro growth of the human pancreatic cancer cell lines MIA PaCa-2 and PANC-1, and induces apoptosis in glioblastoma cell lines. Also inhibits the cystine-glutamate antiporter, system Xc (SXC). Inhibitor of folate transporter 1 (SLC19A1); inhibits cellular uptake of Methotrexate (Cat. No. 1230) and cyclic dinucleotides, including 2',3'-cGAMP (Cat.No. 5945). Anti-inflammatory. Induces ferroptosis.",398.39
Sumatriptan succinate,[103628-48-4],O=S(CC1=CC=C(NC=C2CCN(C)C)C2=C1)(NC)=O.O=C(CCC(O)=O)O,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,"5-HT1A, 5-HT1B and 5-HT1D agonist","5-HT1 receptor agonist (Ki values are 17, 27 and 100 nM at 5-HT1D, 5-HT1B and 5-HT1A receptors respectively). Antimigraine agent.",413.49
SUN 11602,[704869-38-5],NC1=C(C)C(C)=C(NCC(N(C)C2CCN(CC3=CC=C(C(N)=O)C=C3)CC2)=O)C(C)=C1C,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),FGFR,Basic fibroblast growth factor (bFGF) mimetic; neuroprotective,"Basic fibroblast growth factor (bFGF) mimetic. Mimics the neuroprotective effects of bFGF; prevents glutamate-induced neuronal death. Increases levels of CALB1 gene expression in cerebrocortical neurons. Triggers phosphorylation of FGFR, ERK1 and ERK2.",451.61
SUN-B 8155,[345893-91-6],O=C1C=C(C)C(/C(C)=N/C2=C(N)C=CC=C2)=C(O)N1O,7-TM Receptors,Peptide Receptors,Calcitonin and Related Receptors,Non-peptide calcitonin agonist,Non-peptide calcitonin (CT) receptor agonist that fully stimulates cAMP production in CHO/hCTR cells (EC50 = 21 muM). Causes a significant reduction in serum calcium concentrations in vivo following i.p. administration.,273.29
Sunitinib malate,[341031-54-7],O=C(NCCN(CC)CC)C1=C(C)NC(/C=C2\C(NC3=C2C=C(F)C=C3)=O)=C1C.OC(C[C@H](O)C(O)=O)=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,"Potent VEGFR, PDGFRbeta and KIT inhibitor","Potent, ATP-competitive VEGFR, PDGFRbeta and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRbeta and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.",532.56
T 0070907,[313516-66-4],[O-][N+](=O)C1=CC=C(Cl)C(=C1)C(=O)NC1=CC=NC=C1,Nuclear Receptors,PPARs,PPARgamma Receptors,Highly potent and selective covalent PPARgamma antagonist,Potent and selective irreversible PPARgamma antagonist (IC50 = 1 nM). Displays > 800-fold selectivity for PPARgamma over PPARalpha and PPARdelta. Blocks transcriptional activity of PPARgamma in vitro and inhibits rosiglitazone-induced adipogenesis.,277.67
T 0156 hydrochloride,[324572-93-2],Cl.COC(=O)C1=C(C2=CC(OC)=C(OC)C(OC)=C2)C2=CC=NC(OCC3=NC=CC=N3)=C2C(=O)N1CC1=CC=NC(C)=C1,Enzymes,Phosphodiesterases,,"Highly potent, selective PDE5 inhibitor","Potent and selective inhibitor of phosphodiesterase type 5 (PDE5); more selective than sildenafil (IC50 values are 0.23, 56 and > 63000 nM for T 0156 and 3.6, 29 and > 270 nM for sildenafil at PDE5, PDE6 and PDEs 1 - 4 respectively). Selective over 30 other enzymes and receptors (IC50 > 10 mM) and potentiates electrical field stimulation-induced relaxation of isolated rabbit corpus cavernosum. Active in vivo.",620.06
T 5601640,[924473-59-6],O=C(C2=CC=CC(NC(C3=CC(C)=NO3)=O)=C2)NC1=CC(C(F)(F)F)=CC=C1,Enzymes,Kinases,LIMK,Selective LIMK2 inhibitor; antitumor,Selective LIM kinase 2 (LIMK2) inhibitor; inhibits cofilin phosphorylation in cells that overexpress LIMK2 but not LIMK1. Attenuates the growth of several cancer cell lines. Reduces phospho-cofilin levels and Panc-1 tumor size in a mouse xenograft model.,389.33
TAK 165,[366017-09-6],FC(C(C=C2)=CC=C2/C=C/C1=NC(COC3=CC=C(CCCCN4C=CN=N4)C=C3)=CO1)(F)F,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),EGFR,Potent and selective ErbB2 inhibitor,"Potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC50 = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.",468.47
TAK 715,[303162-79-0],CCC1=NC(C3=CC(C)=CC=C3)=C(C2=C(NC(C4=CC=CC=C4)=O)N=CC=C2)S1,Enzymes,Kinases,MAPK Family,Potent p38 MAPK inhibitor; anti-inflammatory,"Inhibitor of p38 MAPK (IC50 = 7.1 nM for p38 MAPKalpha). Also inhibits Wnt-3a-stimulated beta-catenin signaling. Inhibits 22 kinases by more than 80%, including CK1delta/epsilon. Anti-inflammatory and anti-rheumatoid arthritis agent. Orally bioavailable.",399.51
TAK 960 hydrochloride,[2108449-45-0],O=C1C(F)(F)CN(C3CCCC3)C(N=C(NC4=CC(F)=C(C(NC5CCN(C)CC5)=O)C=C4OC)N=C2)=C2N1C.Cl,Enzymes,Kinases,Polo-like Kinase,Potent and selective PLK1 inhibitor,"Potent PLK1 inhibitor (IC50 values are 0.8, 16.9 and 50.2 nM for PLK1, PLK2 and PLK3 respectively). Exhibits >20-fold selectivity for PLK1 over FAK, MLCK and FES, and has minimal activity against a panel of 282 other kinases. Inhibits proliferation of a range of cancer cell lines in vitro and inhibits tumor growth of multiple human cancer cell xenografts in vivo. Orally bioavailable.",598.06
Talampanel,[161832-65-1],NC(C=C4)=CC=C4C1=NN(C(C)=O)[C@H](C)CC2=C1C=C(OCO3)C3=C2,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Non-competitive non-NMDA iGluR antagonist,Non-competitive AMPA/kainate receptor antagonist that displays 2.3-3-fold more potent activity than GYKI 52466 (Cat. No. 1454). Potentiates the anticonvulsive activity of antiepileptic drugs in animal models of seizures. Orally active.,337.37
Talniflumate,[66898-62-2],FC(F)(F)C1=CC(NC2=NC=CC=C2C(=O)OC2OC(=O)C3=CC=CC=C23)=CC=C1,Ion Channels,Chloride Channels,Ca2+-Activated Chloride Channels,CaCC blocker and Cl-/HCO3- exchange inhibitor,Calcium-activated chloride channel (CaCC) (hCLCA1/mCLCA3) blocker; reduces mucin synthesis and release in cell culture and animal models. Possesses anti-inflammatory actions via inhibition of cyclooxygenases and inhibits Cl-/HCO3- exchanger activity. Increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.,414.34
Talopram hydrochloride,[7013-41-4],CC2(C)OC(C3=CC=CC=C3)(CCCNC)C1=CC=CC=C12.Cl,Transporters,Neurotransmitter Transporters,Adrenergic Transporters,"Potent, selective inhibitor of noradrenalin transporters","Potent, selective inhibitor of the noradrenalin transporter (NET) (IC50 = 2.9 nM). Exhibits selectivity for NET against SERT (5-HT transporters) and DAT (dopamine transporters). Displays a similar structure but different pharmacological profile to citalopram (Cat. No. 1427).",331.88
Tamoxifen citrate,[54965-24-1],CC/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)/C1=CC=C(OCCN(C)C)C=C1.O=C(O)CC(O)(C(O)=O)CC(O)=O,Nuclear Receptors,Estrogen and Related Receptors,,Estrogen receptor partial agonist/antagonist,Estrogen receptor antagonist/partial agonist. Selective and potent inhibitor of mammalian sterol isomerase. Neuroprotective in female rats in vivo. Also high affinity agonist at the membrane estrogen receptor GPER. Tamoxifen (Cat.No. 6432) is also available.,563.65
Tamsulosin hydrochloride,[106463-17-6],C[C@@H](NCCOC2=CC=CC=C2OCC)CC1=CC=C(OC)C(S(=O)(N)=O)=C1.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-1 Receptors,Selective alpha1A antagonist,"Selective alpha1A-adrenoceptor antagonist (pKi values are 9.97, 9.64 and 8.86 for alpha1A, alpha1B and alpha1D subtypes respectively). Decreases resting maximal urethral pressure with negligable effect on mean arterial blood pressure in vivo.",444.97
Tandospirone hydrochloride,[99095-10-0],[H][C@]13[C@](C(N(CCCCN4CCN(C5=NC=CC=N5)CC4)C3=O)=O)([H])[C@@H]2CC[C@H]1C2.Cl,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Selective 5-HT1A partial agonist,"5-HT1A receptor partial agonist (Ki = 27 nM) that displays selectivity over 5-HT2, 5-HT1C, alpha1, alpha2, D1 and D2 receptors (Ki values ranging from 1300 - 41000 nM). Inactive at 5-HT uptake sites, 5-HT1B, beta-adrenergic, muscarinic and benzodiazepine receptors. Displays anxiolytic activity.",419.95
Taxol,[33069-62-4],O=C2[C@@]3(C)C([C@@]4(OC(C)=O)[C@H](OC4)C[C@@H]3O)[C@H](OC(C7=CC=CC=C7)=O)[C@@]1(O)[C@](C)(C)C([C@H]2OC(C)=O)=C(C)[C@@H](OC([C@H](O)[C@H]([C@]5=CC=CC=C5)NC(C6=CC=CC=C6)=O)=O)C1,Cytoskeleton and Motor Proteins,Microtubules,,Promotes assembly and inhibits disassembly of microtubules,"Antitumor agent; promotes and stabilizes tubulin polymerization, causing cell cycle arrest. Induces autocatalytic activation of caspase-10 in CCRF-HSB-2 cells, triggering apoptosis.",853.92
TBB,[17374-26-4],BrC1=C2NN=NC2=C(Br)C(Br)=C1Br,Enzymes,Kinases,Casein Kinase 2,Selective cell-permeable CK2 inhibitor,"A cell-permeable, selective inhibitor of casein kinase-2 (CK2) (IC50 = 0.9 and 1.6 muM for rat liver and human recombinant CK2 respectively). Exhibits modest discrimination between CK2 subunits, with Ki values ranging from 80 nM to 210 nM. Acts in an ATP/GTP-competitive manner and displays one to two orders of magnitude selectivity over a panel of 33 protein kinases.",434.71
TC ASK 10,[1005775-56-3],O=C(C4=CC=C(C(C)(C)C)C=C4)NC1=CN2C(C=CC(N3C=NC=C3)=C2)=N1.Cl.Cl,Enzymes,Kinases,ASK1,Potent and selective ASK1 inhibitor; orally bioavailable,"Potent ASK1 inhibitor (IC50 = 14 nM); displays selectivity for ASK1 over other kinases including ASK2 (IC50 = 0.51 muM), MEKK1, TAK1, IKKbeta, ERK1, JNK1, p38alpha, GSK-3beta, PKCtheta and B-raf (IC50 values are > 10 muM). Blocks downstream JNK1/p38 phosphorylation in cells. Orally bioavailable.",432.35
TC LPA5 4,[1393814-38-4],ClC(C=C(C3=CC(C(O)=O)=NN3C4=CC=CC(OC)=C4)C=C2)=C2C1CCCCC1,7-TM Receptors,Lysophosphatidic Acid Receptors,,LPA5 receptor antagonist,LPA5 receptor antagonist (IC50 = 0.8 muM in LPA5-RH7777 cells). Inhibits LPA-induced aggregation of isolated human platelets. Exhibits selectivity for LPA5 against 80 other screened targets.,410.89
TC Mps1 12,[1206170-62-8],NC1=C(C#N)C(NC(C)(C)C)=NC(NC2=CC=C(C(N)=O)C=C2)=C1,Enzymes,Kinases,Monopolar Spindle 1 Kinase,Potent and selective Mps1 kinase inhibitor,Potent and selective monopolar spindle 1 (Mps1) inhibitor (IC50 = 6.4 nM). Selective for Mps1 over a panel of 95 kinases including JNK. Inhibits A549 lung carcinoma cell proliferation and attenuates A549 cell xenograft growth in mice. Orally active.,324.38
TC NTR1 17,[1146757-96-1],O=C(N[C@@H](CC(C)C)C(O)=O)C2=NN(C(C3=C(OC)C=CC=C3OC)=C2)C1=C(C=CC(Cl)=C4)C4=NC=C1,7-TM Receptors,Peptide Receptors,Neurotensin Receptors,Selective NTS1 partial agonist,Non-peptide neurotensin receptor 1 (NTS1) partial agonist (EC50 <15.6 nM and Emax = 63% of neurotensin response in Ca2+ mobilization assay). Exhibits over 50-fold selectivity for NTS1 over NTS2 and GPR35.,522.98
TC OT 39,[479232-57-0],O=C(N5[C@H]([C@](N6CCN(C)CCC6)=S)CCC5)NCC(C(C)=C2)=CC=C2C(N1C(C=CC=C3)=C3NC(N(C)N=C4)=C4C1)=O,7-TM Receptors,Peptide Receptors,Oxytocin Receptors,Potent non-peptide oxytocin receptor partial agonist; also V1a receptor antagonist,Potent non-peptide oxytocin receptor partial agonist (EC50 values are 33 nM and 850 nM for the oxytocin receptor and V2 vasopressin receptor respectively). Also a V1a vasopressin receptor antagonist (Ki = 330 nM). Active in vivo in a rat model of uterine response.,600.78
TC-A 2317 hydrochloride,[1245907-03-2],CC1=CC(NC2=NNC(C)=C2)=NC(NC(C)CCCC(C)(C)O)=C1C#N.Cl,Enzymes,Kinases,Aurora Kinases,"Potent, selective Aurora kinase A inhibitor",Potent Aurora kinase A inhibitor (Ki = 1.2 nM compared to 101 nM for inhibition of Aurora kinase B). Selective over 60 other kinases (IC50 values > 1000 nM). Exhibits good cell permeability and antitumor activity.,392.93
TC-E 5002,[1453071-47-0],O=C(N(CCC(O)=O)O)CCCCCCCCC1CC1,Enzymes,Demethylases,Histone Demethylases,Selective KDM2/7 inhibitor,"Selective histone demethylase KDM2/7 subfamily inhibitor (IC50 values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 muM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). Inhibits growth of HeLa and KYSE-150 cancer cells in vitro.",285.38
TC-E 5006,[1257395-14-4],CC(CC1)CCN1C(C2=C(C3=CC=C(C(F)(F)F)C=C3)C=C(C(C)C(O)=O)C=C2)C4=CC=C(F)C=C4,Enzymes,Proteases,Gamma-Secretase,gamma-secretase modulator; reduces Abeta42 levels,gamma-secretase modulator. Reduces Abeta42 levels in vitro (EC50 = 390 nM) and in vivo. Orally bioavailable.,499.54
TC-F 2,[1304778-15-1],O=C(N(CC)C6=C5C=CC=C6)N5[C@H]1CCCN(C2=NC(C3=CC(C=CC=C4)=C4O3)=CC=N2)C1,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),"Potent, reversible and selective FAAH inhibitor","Potent, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 values are 28 and 100 nM for human and rat FAAH respectively). Noncovalent inhibitor; displays selectivity for FAAH over cannabinoid-related targets (IC50 > 20 muM for CB1, CB2 and TRPV1). Active in vivo.",439.51
TC-FPR 43,[903895-98-7],CC(C)C1=C(NC(NC3=CC=C(Cl)C=C3)=O)C(N(C2=CC=CC=C2)N1C)=O,7-TM Receptors,Peptide Receptors,Formyl Peptide Receptors,Potent FPR2 agonist,Potent formyl peptide receptor 2 (FPR2) agonist (EC50 = 44 nM). Inhibits fMLP- and IL-8-induced neutrophil migration. Suppresses inflammation in a mouse model of acute inflammation. Orally bioavailable.,384.86
TC-G 1000,[245744-18-7],CC1=C2C(C(C3=CNC=N3)=CCC2)=C(C)S1.O=C(\C=C/C(O)=O)O,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,Potent and selective alpha2D agonist,"Potent and selective alpha2D-adrenoceptor agonist (Ki values are 8.6 pM and 110 nM for rat alpha2D and alpha1 receptors respectively and 25, 26 and 100 nM for human alpha2A, alpha2C and alpha2B receptors respectively. Exhibits analgesic activity in a mouse model of abdominal irritation. Orally active.",346.4
TC-G 1004,[1061747-72-5],CC1=CC(C)=NN1C2=NC(C3=CC=CC(N4CCC(OC)CC4)=N3)=CC(NC(C)=O)=N2,7-TM Receptors,Adenosine Receptors,Adenosine A2A Receptors,Potent and selective A2A antagonist,Potent antagonist of adenosine A2A receptors; displays >100-fold selectivity for A2A over A1 receptors (Ki values are 0.44 and 85 nM respectively). Potentiates L-DOPA-induced rotational behavior in 6-OHDA-lesioned rats.,421.5
TC-G 1005,[1415407-60-1],CC1=CC(OC2=CC=NC=C2C(N3C(C=CC=C4)=C4N(C5CC5)CC3)=O)=C(C)C=C1,7-TM Receptors,GPBA Receptors,,Potent and selective GPBA receptor (TGR5) agonist,Potent and selective GPBA agonist (EC50 = 0.72 nM for hTGR5). Selective for TGR5 over FXR (farnesoid X receptor). Increases plasma GLP-1 levels and reduces blood glucose in mice. Orally available.,399.48
TC-G 1006,[1324003-64-6],O=C(NC(C2=C(OC)C=CN=C2)=O)NC1=CC=C(C3=CC=CC=C3)C(C(F)(F)F)=C1,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist,"Potent and selective sphingosine-1-phosphate receptor 1 (S1P1) agonist (EC50 = 35 nM), displays >100-fold selectivity against receptor subtypes S1P2-5. Induces a dose-dependent reduction in circulating blood lymphocyte counts in rodent models. Orally bioavailable.",415.37
TC-G 1008,[1621175-65-2],CNC1=NC(NCC2=C(Cl)C=C(NS(C)(=O)=O)C=C2)=CC(C3=NC=CC=C3)=N1,7-TM Receptors,Orphan 7-TM Receptors,,Potent and selective GPR39 agonist,"Potent and selective GPR39 agonist (EC50 values are 0.4 and 0.8 nM for rat and human receptors respectively). Selective over a panel of kinases (IC50s > 10 muM) and displays minimal binding affinity for ghrelin and neurotensin-1 receptors (IC50s > 30 muM). Increases GLP-1 levels in vitro and in vivo. Reduces TNF-alpha-induced oxidative stress, mitochondrial dysfunction, cytokine expression and secretion of MMPs in fibroblast-like synoviocytes (FLS). Orally bioavailable.",418.9
TC-H 106,[937039-45-7],NC1=CC=CC=C1NC(CCCCCC(NC2=CC=C(C)C=C2)=O)=O,Enzymes,Histone Deacetylases,Class I HDACs,Class I histone deacetylase inhibitor,"Class I histone deacetylase (HDAC) inhibitor (IC50 values are 150, 370, 760 and 5000 nM for HDAC1, HDAC3, HDAC2 and HDAC8 respectively). Exhibits slow, tight-binding inhibitory activity. Displays no activity against class II HDACs. Brain penetrant.",339.43
TC-I 15,[916734-43-5],CC1(C)SCN(S(C3=CC=CC=C3)(=O)=O)[C@@H]1[C@@](N[C@H](C(O)=O)CNC(NCC2=CC=CC=C2)=O)=O,Enzyme-Linked Receptors,Integrins,,Potent alpha2beta1 inhibitor; displays antithrombotic activity in vivo,"Potent alpha2beta1 integrin inhibitor (IC50 values for the inhibition of human platelet adhesion to type I collagen are 12 and 715 nM for platelets under static conditions and under flow, respectively). Displays selectivity for alpha2beta1 over alphavbeta3, alpha5beta1, alpha6beta1 and alphaIIbbeta3 at concentrations exceeding 1000 nM. Reduces collagen IV production in mesangial cells. Active in vivo; prevents ferric chloride-induced clot formation in mice.",520.62
TC-I 2000,[1159996-20-9],O=C(NC3=CC=C(F)C=C3)N2C(C4=CC=C(C(F)(F)F)C=C4)C1=CC=CC=C1CC2,Ion Channels,Transient Receptor Potential Channels,TRPM,TRPM8 blocker,TRPM8 channel blocker. Inhibits icilin-induced TRPM8 channel activation in rTRPM8-expressing CHO cells (IC50 = 53 nM).,414.4
TC-I 2014,[1221349-53-6],FC(C(C=CC=C3)=C3C1=CC(C(F)(F)F)=C(NC(C4=NOC5(CCCCC5)C4)=N2)C2=C1)(F)F,Ion Channels,Transient Receptor Potential Channels,TRPM,Potent TRPM8 antagonist,"Potent TRPM8 antagonist (IC50 values are 0.8, 3.0 and 4.4 nM for canine, human and rat channels respectively). Exhibits antiallodynic properties in pain models in vivo.",467.41
TC-N 1752,[1211866-85-1],CC(C(NC(C)=O)=CC=C4)=C4NC1=NC=NC(N2CCC(OCC3=CC=C(OC(F)(F)F)C=C3)CC2)=N1,Ion Channels,Sodium Channels,Voltage-gated Sodium Channels,NaV channel blocker,"Human NaV channel inhibitor (IC50 values are 0.17, 0.3, 0.4, 1.1 and 1.6 muM at hNaV1.7, hNaV1.3, hNaV1.4, hNaV1.5 and hNav1.9 respectively). Also inhibits tetrodotoxin-sensitive sodium channels. Displays analgesic efficacy in the formalin pain model.",516.52
TC-O 9311,[444932-31-4],O=C(NNC(NC2=CC=CC3=C2C=CC=C3)=O)C1=CC(OC)=CC(OC)=C1,7-TM Receptors,Orphan 7-TM Receptors,,Potent and selective GPR139 agonist,Potent GPR139 agonist (EC50 = 39 nM in CHO-K1 cells expressing human GPR139). Displays no activity against a range of 90 diverse targets.,365.38
TC-S 7003,[847950-09-8],O=C3N(C4=C(C)C=CC=C4C)C1=NC7=C(C=CC=C7)N1C2=NC(NC5=CC=C(N6CCN(C)CC6)C=C5)=NC=C23,Enzymes,Kinases,Src Kinases,Potent Lck inhibitor,"Potent inhibitor of lymphocyte specific kinase (Lck). IC50 values are 0.007, 0.021, 0.042 and 0.20 muM for Lck, Lyn, Src and Syk kinases respectively. Displays >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Inhibits T cell proliferation in vitro and inhibits arthritis in two in vivo models. Orally active.",530.62
TC-S 7004,[1386979-55-0],O=C(NC3=CC(C(NCC4=CC(Cl)=CC=C4)=O)=CC=C3Cl)C2=CC1=CN=C(OC)N=C1NC2=O,Enzymes,Kinases,DYRK,Potent and selective DYRK1A/B inhibitor,Potent and selective DYRK1A/B inhibitor (IC50 values are 22 and 68 nM respectively). Selective for DYRK1A/B over a panel of other kinases. Reduces accumulation of quiescent Panc1 pancreatic cancer cells in G0 under serum free conditions. Also induces DNA damage and apoptosis in quiescent Panc1 cells.,498.32
TC-S 7006,[871307-18-5],FC(C(Cl)=C4)=CC=C4NC1=C2C(C=NC(NCC3=CN=CC=C3)=C2)=NC=C1C#N,Enzymes,Kinases,Other Kinases,Potent and selective Tpl2 (Cot; MAP3K8) inhibitor,"Potent and selective Tpl2 (Cot; MAP3K8) inhibitor (IC50 = 50 nM). Selective for Tpl2 over MEK, p38, Src, MK2, PKC and EGFR. Inhibits LPS-induced TNF-alpha secretion from monocytes and attenuates acute myeloid leukemia (AML) cell proliferation in vitro. Also reduces cytolytic activity of human CD8+ cytotoxic T lymphocytes. Cell permeable.",404.83
TC-S 7009,[1422955-31-4],ClC1=CC(F)=CC(NC3=C([N+]([O-])=O)C2=NON=C2C=C3)=C1,Signal Transduction,Transcription Factors,Hypoxia Inducible Factors,High affinity and selective HIF-2alpha inhibitor,High affinity and selective HIF-2alpha inhibitor (Kd = 81 nM). Binds to the HIF-2alpha PAS-B domain; disrupts HIF-2alpha-ARNT heterodimerization. Exhibits >60-fold selectivity for HIF-2alpha over HIF-1alpha. Decreases HIF-2alpha DNA-binding and attenuates expression of HIF-2alpha target genes in vitro.,308.65
TC-S 7010,[1158838-45-9],O=C(NC3=CC=CC=C3Cl)C(C=C2)=CC=C2NC1=C(F)C=NC(NC4=CC=C(CC(N5CCN(CC)CC5)=O)C=C4)=N1,Enzymes,Kinases,Aurora Kinases,Potent and selective Aurora kinase A inhibitor,Potent and selective inhibitor of Aurora kinase A (IC50 = 3.4 nM); exhibits 1000-fold selectivity for Aurora kinase A over Aurora kinase B. Displays antiproliferative activity in HCT116 and HT29 cells (IC50 values are 0.19 and 2.9 muM respectively).,588.07
TC-SP 14,[1257093-40-5],FC(C=C(CN4CC(C(O)=O)C4)C=C3)=C3C2=NC1=CC(CC5=CC=CC=C5F)=CC=C1S2,7-TM Receptors,Sphingosine-1-phosphate Receptors,,Potent S1P1 receptor agonist,Potent and selective S1P1 agonist (EC50 values are 0.042 and 3.47 muM for human S1P1 and S1P3 respectively). Attenuates immune response to antigen challenge and reduces circulating blood lymphocyte counts in a rodent model of delayed-type hypersensitivity. Orally bioavailable.,450.5
TCB-2,[912342-28-0],Br.COC1=C2C(CN)CC2=C(OC)C(Br)=C1,7-TM Receptors,5-HT Receptors,5-HT2 Receptors,High affinity and potent 5-HT2A agonist,High affinity 5-HT2A receptor agonist (Ki values are 0.73 and 0.75 nM for rat and human receptors respectively). Potently stimulates IP3 accumulation in NIH3T3 cells stably expressing rat 5-HT2A receptors (EC50 = 36 nM). Induces head twitches and hypothermia in mice following i.p. administration.,353.05
TCN 201,[852918-02-6],ClC1=C(F)C=CC(S(NCC2=CC=C(C(NNC(C3=CC=CC=C3)=O)=O)C=C2)(=O)=O)=C1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,GluN1/GluN2A-selective NMDA antagonist,"NMDA receptor antagonist selective for GluN1/GluN2A (formally NR1/NR2A) over GluN1/GluN2B (formally NR1/NR2B) containing receptors (pIC50 values are 6.8 and <4.3, respectively, in human recombinant GluN1/GluN2A (formally NR1/NR2A) and GluN1/GluN2B (formally NR1/NR2B) FLIPR/Ca2+ assays). Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.",461.89
TCN 238,[125404-04-8],NC1=NC(/C=C/C2=CC=CC=C2)=CC=N1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group III Receptors,Positive allosteric modulator of mGlu4 receptors,Positive allosteric modulator of mGlu4 receptors (EC50 = 1.0 muM for human and rat mGlu4 receptors). Orally available and brain penetrant.,197.24
TCS 2002,[1005201-24-0],O=S(C)C(C=C3)=CC=C3C2=COC1=CC=C(C4=NN=C(C)O4)C=C12,Enzymes,Kinases,Glycogen Synthase Kinase 3,Potent GSK-3beta inhibitor,Potent inhibitor of GSK-3beta (IC50 = 35 nM). Oral adminstration inhibits cold water stress-induced tau hyperphosphorylation in the mouse brain.,338.38
TCS 21311,[1260181-14-3],O=C(N1)C(C3=CNC4=C3C=CC=C4)=C(C2=C(C(F)(F)F)C=CC(N5CCN(C(C(O)(C)C)=O)CC5)=C2)C1=O,Enzymes,Kinases,JAK Kinase,Potent JAK3 inhibitor. Also inhibits GSK-3beta and PKC,"Potent JAK3 inhibitor (IC50 = 8 nM). Selective for JAK3 over JAK1, JAK2 and TYK2 (IC50 values are 1017, 2550 and 8055 nM respectively). Also inhibits GSK-3beta, PKCalpha and PKCtheta (IC50 values are 3, 13 and 68 nM respectively).",526.51
TCS 2210,[1201916-31-5],O=C(NO)C3=CC1=C(C=C3)NC(C(CCCC2=CC=CC=C2)=N1)=O,Stem Cells,Stem Cell Differentiation,Neural Stem Cells,Inducer of neuronal differentiation in MSCs,Inducer of neuronal differentiation in mesenchymal stem cells (MSCs) with specific phenotype change. Increases expression of neuronal markers beta-III tubulin and NSE without cytotoxicity.,323.35
TCS 2314,[317353-73-4],O=C(N2CCOC[C@H]2[C@@](N3CCC(CC(O)=O)CC3)=O)CC1=CC=C(NC(NC4=C(C)C=CC=C4)=O)C=C1,Enzyme-Linked Receptors,Integrins,,alpha4beta1 (VLA-4) antagonist,Integrin very late antigen-4 (VLA-4; alpha4beta1) antagonist (IC50 = 4.4 nM). Blocks the activation of inflammatory cells.,522.59
TCS 3035,[871085-49-3],O=C(/C(S2)=C/C1=CC=C(OCC(O)=O)C=C1)NC2=O,7-TM Receptors,GPR35,,GPR35 agonist,"GPR35 agonist (pEC50 values are 5.13 and 5.86 for rat and human GPR35 orthologs, respectively).",279.27
TCS 359,[301305-73-7],COC1=CC=C(C=C1OC)C(=O)NC1=C(C(N)=O)C2=C(CCCC2)S1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),FLT3,Potent FLT3 inhibitor,"Potent inhibitor of FLT3 receptor tyrosine kinase (IC50 = 42 nM) that displays selectivity over a range of other kinases. Exhibits antiproliferative effects on MV4-11 cells, a human acute myelogenous leukemia cell line expressing a constitutively active mutant FLT3 (IC50 = 340 nM).",360.43
TCS 5861528,[332117-28-9],O=C1C2=C(N=CN2CC(NC3=CC=C(C(C)CC)C=C3)=O)N(C)C(N1C)=O,Ion Channels,Transient Receptor Potential Channels,TRPA1,TRPA1 blocker,TRPA1 channel blocker that antagonizes AITC- and 4-HNE-evoked calcium influx (IC50 values are 14.3 and 18.7muM respectively). Attenuates diabetic hypersensitivity in an in vivo rat model.,369.42
TCS HDAC6 20b,[956154-63-5],O=C([C@@H](NC(OC(C)(C)C)=O)CCCCCSC(C(C)C)=O)NC1(CC3C2)CC(C3)CC2C1,Enzymes,Histone Deacetylases,Class II HDACs,Selective HDAC6 inhibitor,Selective inhibitor of histone deacetylase 6 (HDAC6). Inhibits HCT116 growth in combination with taxol (Cat. No. 1097). Also inhibits growth of MCF-7 cells stimulated by estrogen.,480.7
TCS OX2 29,[1610882-30-8],C[C@@](C)(C)[C@H](NCC3=CC=NC=C3)C(N(C2)CCC1=C2C=C(OC)C(OC)=C1)=O.Cl,7-TM Receptors,Peptide Receptors,Orexin Receptors,Potent and selective OX2 antagonist,"Potent and selective OX2 receptor antagonist (IC50 = 40 nM). Displays >250-fold selectivity for OX2 over OX1 and a range of receptors, ion channels and transporters. Inhibits orexin A induced IP3 accumulation and ERK1/2 phosphorylation in CHO cells transfected with the OX2 receptor.",433.97
TCS PIM-1 1,[491871-58-0],OC1=C(C2=CC(C3=CC=CC=C3)=C(C#N)C(N2)=O)C=C(Br)C=C1,Enzymes,Kinases,Pim Kinase,"Selective, ATP-competitive Pim-1 kinase inhibitor","ATP-competitive Pim-1 kinase inhibitor that displays selectivity over Pim-2 and MEK1/2 (IC50 values are 50, > 20000 and > 20000 nM for Pim-1, Pim-2 and MEK1/2 respectively).",367.2
Tegaserod maleate,[189188-57-6],O=C(/C=C\C(O)=O)O.CCCCCNC(N/N=C/C1=CNC2=C1C=C(OC)C=C2)=N,7-TM Receptors,5-HT Receptors,5-HT4 Receptors,5-HT4 partial agonist,Partial agonist of 5-HT4 (Ki = 12 nM).,417.46
Teijin compound 1,[1313730-14-1],O=C(CNC(C3=CC=CC(C(F)(F)F)=C3)=O)N[C@@H]1CCN(CC2=CC=C(Cl)C=C2)C1.Cl,7-TM Receptors,Chemokine Receptors,Chemokine CC Receptors,Potent CCR2b antagonist,Potent chemokine CCR2b receptor antagonist (IC50 = 180 nM). Potently inhibits cell chemotaxis induced by MCP-1 (EC50 = 24 nM).,476.32
Telmisartan,[144701-48-4],CCCC4=NC(C(C)=C3)=C(N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5)C=C3C2=NC1=CC=CC=C1N2C,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,AT1 antagonist; PPARgamma partial agonist,Antagonist of the angiotensin II type 1 receptor (AT1) (Ki = 3.7 nM). Exhibits antihypertensive activity in a renin-dependent model of hypertension. Partial agonist of PPARgamma receptors; shown to improve insulin sensitivity in rodents receiving high fat diets.,514.62
Temozolomide,[85622-93-1],CN1N=NC2=C(N=CN2C1=O)C(N)=O,Regulated Cell Death,Apoptosis,Apoptosis Inducers,DNA-methylating antitumor agent,"DNA methylating, chemotherapeutic agent. Displays antitumor activity against a board spectrum of tumors, including leukemias, lymphomas and solid tumors (IC50 = 5.0 muM for cytotoxicity against mouse TLX5 lymphoma cells). Induces autophagy in malignant glioma cells. Exhibits enhanced activity when used in combination with CHC (Cat No. 5029).",194.15
Tenidap,[120210-48-2],O=C1N(C(N)=O)C2=CC=C(Cl)C=C2/C1=C(O)\C3=CC=CS3,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,"NSAID, cyclooxygenase (COX-1) inhibitor. Also opener of KIR2.3","NSAID that preferentially inhibits COX-1 (IC50 values are < 0.03, 1.2 and > 30 muM for COX-1, COX-2 and 5-lipoxygenase respectively). Inhibits formation of pro-inflammatory arachidonic acid metabolites in isolated human peripheral polymorphonuclear leukocytes. Opener of inward rectifying hKir2.3 channel (EC50 = 402 nM).",320.75
Tenovin-1,[380315-80-0],CC(C)(C)C1=CC=C(C(NC(NC2=CC=C(NC(C)=O)C=C2)=S)=O)C=C1,Enzymes,Ligases,Ubiquitin E3 Ligases,Protects against MDM2-mediated p53 degradation,p53 activator that protects against MDM2-mediated p53 degradation. Elevates levels of p53 and p21CIP/WAF1 and induces expression from an endogenous p53-dependent promoter. Exhibits potent antiproliferative activity in vitro.,369.48
Terfenadine,[50679-08-8],OC(C3=CC=CC=C3)(C4=CC=CC=C4)C1CCN(CCCC(O)C2=CC=C(C(C)(C)C)C=C2)CC1,7-TM Receptors,Histamine Receptors,Histamine H1 Receptors,H1 antagonist. Also KV11.1 (hERG) and Kir6 (KATP) channel blocker,Histamine H1 receptor antagonist. Also blocks KV11.1 (hERG) and Kir6 (KATP) channels (IC50 values are 204 nM and 1.2 muM respectively). Inhibits the delayed rectifier K+ current (IKr) in guinea pig ventricular myocytes (IC50 = 50 nM). Activity prolongs QT and induces Torsades de pointes (TdP); cardiotoxic in vivo.,471.67
Teriflunomide,[108605-62-5],O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1,Enzymes,Dehydrogenases,Dihyroorotate Dehydrogenase,Inhibitor of DHODH; active metabolite of Leflunomide,Inhibitor of dihydroorotate dehydrogenase (Kd = 12 nM; Ki = 179 nM). Inhibits proliferation of mitogen- or cytokine-stimulated lymphoid cells in vitro by inhibiting cell cycle progression from G1 to S. Imunosuppressive agent. Active metabolite of leflunomide (Cat. No. 2228).,270.21
Tesaglitazar,[251565-85-2],CS(OC1=CC=C(CCOC2=CC=C(C[C@H](OCC)C(O)=O)C=C2)C=C1)(=O)=O,Nuclear Receptors,PPARs,Non-selective PPAR,PPARalpha/gamma agonist,Dual-specificity PPARalpha/gamma agonist (IC50 values are 0.35 and 3.8 muM for PPARgamma and PPARalpha respectively). Prevents atherosclerosis progression in E3L.CETP transgenic mice. Also reduces insulin resistance in obese Zucker rats. Orally active.,408.47
Tetrabenazine,[58-46-8],O=C3[C@@H](CC(C)C)CN2CCC1=CC(OC)=C(OC)C=C1[C@@]([H])2C3,Transporters,Neurotransmitter Transporters,Vesicular Monoamine Transporters,Potent inhibitor of vesicular monoamine transport,"Potent inhibitor of vesicular monoamine uptake; depletes stores of dopamine, serotonin and noradrenalin. Binds with high affinity (IC50= 3.2 nM) to vesicular monoamine transporter (VMAT) in chromaffin granule membranes and displays higher affinity for VMAT2 than VMAT1. Also reported to block dopamine receptors. Causes behavioral depression; inhibits locomotor activity and produces hypothermia upon systemic administration in rats and mice. Deuterated analog also available.",317.2
Tetrindole mesylate,[170964-68-8],CS(O)(=O)=O.C1CCC(CC1)C1=CC=C2N3CCNC4CCCC(=C34)C2=C1,Enzymes,Oxygenases/Oxidases,Monoamine Oxidase,MAO-A inhibitor,"Novel antidepressant, a selective inhibitor of MAO-A.",390.54
TFC 007,[927878-49-7],O=C(C2CCN(C3=CC=C(NC(C4=CN=C(OC5=CC=CC=C5)N=C4)=O)C=C3)CC2)N1CCOCC1,Enzymes,Synthases/Synthetases,Other Synthases/Synthetases,Potent hematopoietic prostaglandin D synthase (H-PGDS) inhibitor,"Potent hematopoietic prostaglandin D synthase (H-PGDS) inhibitor (IC50 = 83 nM). Inhibits PGD2 production and late phase nasal blockage in an animal model of allergic rhinitis. Exhibits negligible effects on COX-1, COX-2, 5-LOX, LTC4 synthase, TXA2 synthase and microsomal prostaglandin E2 synthase.",487.55
Thioperamide,[106243-16-7],S=C(NC3CCCCC3)N(CC2)CCC2C1=CNC=N1,7-TM Receptors,Histamine Receptors,Histamine H3 Receptors,H3 antagonist; also H4 inverse agonist,Potent histamine H3 and H4 antagonist/inverse agonist. Ki values are 25 and 27 nM for human recombinant H3 and H4 receptors respectively. Blocks eosinophil shape change (IC50 = 1.4 muM) and chemotaxis (IC50 = 519 nM) induced by histamine. Freely crosses the blood-brain barrier. Also available as part of the Histamine H3 Receptor Tocriset™.,292.44
THIP hydrochloride,[85118-33-8],Cl.OC1=NOC2=C1CCNC2,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,GABAA agonist,"Systemically active GABAA receptor agonist and GABAA-rho receptor antagonist. Displays antinociceptive, anticonvulsant and sedative effects. Hypnotic agent that enhances delta activity within non-REM sleep in rats.",176.6
Tiagabine hydrochloride,[145821-59-6],CC3=C(SC=C3)/C(C2=C(C)C=CS2)=C\CCN1C[C@H](C(O)=O)CCC1.Cl,Transporters,Neurotransmitter Transporters,GABA Transporters,Selective GAT-1 inhibitor; anticonvulsant,GABA uptake inhibitor (IC50 = 67 nM in vivo). Exhibits high affinity and selectivity for the GAT-1 GABA transporter. Anticonvulsant; also attenuates established dynorphin-induced allodynia in a mouse model after systemic administration.,412.01
Tiotidine,[69014-14-8],CN\C(NCCSCC1=CSC(\N=C(/N)N)=N1)=N/C#N,7-TM Receptors,Histamine Receptors,Histamine H2 Receptors,Potent and selective H2 antagonist,Potent histamine H2-receptor antagonist with negligible activity against H1- and H3- receptors.,312.41
Tiplaxtinin,[393105-53-8],O=C(C(O)=O)C2=CN(CC3=CC=CC=C3)C1=CC=C(C4=CC=C(OC(F)(F)F)C=C4)C=C12,Enzymes,Proteases,Plasminogen Activator Inhibitor 1,Plasminogen activator inhibitor-1 (PAI-1) inhibitor,Plasminogen activator inhibitor-1 (PAI-1) inhibitor (IC50 = 2.7 muM). Induces vascular smooth muscle cell apoptosis in vitro and reduces carotid artery neointimal formation in a rat vascular injury model. Promotes thrombolysis in rat and dog models of acute arterial thrombosis. Orally available.,439.38
Tizanidine hydrochloride,[64461-82-1],ClC2=C(NC3=NCCN3)C1=NSN=C1C=C2.Cl,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,alpha2 agonist,alpha2-adrenergic receptor agonist. Antinociceptive upon epidural administration in rats (IC50 = 48 nM). Also binds to imidazoline receptor.,290.17
TMN 355,[1186372-20-2],ClC1=C(C(NC(NC2C(C=CC=C4)=C4C3=C2C=CC=C3)=O)=O)C(F)=CC=C1,Other Pharmacology,Miscellaneous Compounds,,Cyclophilin A inhibitor,Potent cyclophilin A inhibitor (IC50 = 1.52 nM). Approximately 27 times more potent than cyclosporin A (Cat. No. 1101).,380.8
TMPH hydrochloride,[849461-91-2],CC1(C)NC(C)(C)CC(OC(CCCCCC)=O)C1.Cl,Ion Channels,Ligand-gated Ion Channels,Acetylcholine (Nicotinic) Receptors,Neuronal nAChR antagonist,"Potent non-competitive antagonist of neuronal nicotinic ACh receptors (nAChRs). Produces long-lasting inhibition of neuronal nAChRs formed by the combination of the most abundant alpha and beta subunits (i.e. alpha3, alpha4 and beta2, beta4 respectively). Displays little inhibition of muscle-type (alpha1beta1gammadelta) or alpha7 receptors.",305.88
TMS,[24144-92-1],COC1=CC(OC)=C(\C=C\C2=CC(OC)=CC(OC)=C2)C=C1,Enzymes,Cytochrome P450,,Cytochrome P450 1B1 inhibitor,"Potent, selective and competitive inhibitor of cytochrome P450 1B1, an enzyme overexpressed in certain tumors (IC50 = 6 nM). 50- and 520-fold selective over P450 1A1 and 1A2 respectively. Inhibits cancer cell growth in vitro.",300.35
Tolterodine L-tartrate,[124937-52-6 ],OC1=C([C@@H]([C@]2=CC=CC=C2)CCN(C(C)C)C(C)C)C=C(C)C=C1.OC([C@H](O)[C@@H](O)C(O)=O)=O,7-TM Receptors,Acetylcholine Muscarinic Receptors,Non-selective Muscarinics,"Potent, non-selective muscarinic receptor antagonist",High affinity muscarinic receptor antagonist (Ki = 3.3 nM). Active at all muscarinic receptor subtypes (M1 - M5); exhibits a greater effect on the bladder than salivary glands in vivo.,475.57
Tolvaptan,[150683-30-0],OC1C2=C(C=CC(Cl)=C2)N(C(C3=C(C)C=C(NC(C4=CC=CC=C4C)=O)C=C3)=O)CCC1,7-TM Receptors,Peptide Receptors,Vasopressin Receptors,Potent and selective vasopressin V2 receptor antagonist; renoprotective and orally active,Potent and selective competitive vasopressin V2 receptor antagonist (Ki values are 0.06 and 12.3 nM for V2 and V1a receptors respectively). Decreases urine osmolality and increases serum sodium concentrations. Delays the onset of end-stage renal disease in a mouse model of polycystic kidney disease. Exhibits myocardial and renal protective effects in hypertensive heart failure rats. Orally active.,448.94
Topiramate,[97240-79-4],CC(O2)(C)O[C@H]1[C@@H]2[C@H](OC(C)(C)O3)[C@@]3(COS(N)(=O)=O)OC1,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,GluK1 antagonist; inhibits carbonic anhydrase (CA) II and IV; also positive allosteric modulator of GABAA receptors,"Anticonvulsant. Antagonizes GluK1 (formerly GluR5) kainate receptors (IC50 = 0.46 muM), acts as a positive allosteric modulator of GABAA receptor-mediated currents, inhibits Nav channels (IC50 = 48.9 muM) and inhibits L-type Ca2+ channels. Also inhibits carbonic anhydrase (CA) (Ki values are 0.1 and 0.2 muM at rat CA II and CA IV respectively), which lowers intracellular neuronal pH. Deuterated analog also available. Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.",339.36
Torcetrapib,[262352-17-0],CC[C@H]2N(C(OCC)=O)C1=CC=C(C(F)(F)F)C=C1[C@@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C(OC)=O)C2,Enzymes,Transferases,Other Transferases,Inhibitor of cholesteryl ester transfer protein (CETP),Inhibitor of cholesteryl ester transfer protein (CETP). Also impairs endothelial function in vivo; induces hypertension and inhibits acetylcholine-induced vasodilation in rabbit central ear artery.,600.47
Torin 2,[1223001-51-1],O=C(C=C3)N(C5=CC=CC(C(F)(F)F)=C5)C2=C3C=NC1=CC=C(C4=CC=C(N)N=C4)C=C12,Enzymes,Kinases,mTOR,Potent and selective mTOR inhibitor,Potent and selective mTOR inhibitor (IC50 = 2.1 nM). Displays 800-fold cellular selectivity for mTOR over PI3K (cellular EC50 values are 0.25 and 200 nM for mTOR and PI3K respectively). Activates autophagy. Orally available.,432.4
TP 003,[628690-75-5],FC1=C(C(C)(O)C)C=CN2C1=NC=C2C3=CC=C(F)C(C4=CC=C(F)C=C4C#N)=C3,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,GABAA partial agonist; acts at benzodiazepine site,GABAA receptor partial agonist that demonstrates affinity for the benzodiazepine site. Potentiates GABAA alpha3 response with high efficacy. Produces anxiolytic-like effects in rodent elevated plus maze via action at GABAA alpha2 subtype receptors. Also evokes GABAA alpha1 mediated sedation and GABAA alpha3 mediated muscle relaxation in mice.,407.39
TPCA-1,[507475-17-4],NC(=O)NC1=C(C=C(S1)C1=CC=C(F)C=C1)C(N)=O,Enzymes,Kinases,IkB Kinase,"Potent, selective inhibitor of IKKbeta","Potent, selective inhibitor of IkappaB kinase (IKK) beta (IC50 = 17.9 nM) that displays > 22-fold selectivity over IKKalpha and > 550-fold selectivity over other kinases and enzymes. Inhibits production of pro-inflammatory cytokines in vitro and in vivo and inhibits NF-kappaB nuclear localization. Reduces the severity and onset of collagen-induced arthritis; anti-inflammatory.",279.29
TRAM 39,[197525-99-8],ClC(C=CC=C3)=C3C(C2=CC=CC=C2)(C#N)C1=CC=CC=C1,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Potent KCa3.1 blocker,Potent intermediate conductance Ca2+-activated K+ channel (KCa3.1) blocker (Kd = 60 nM). Has no effect on cytochrome p450 activity. Inhibits I-EBIO-stimulated increases in rat artery membrane potential ex vivo. Also diminishes LPS-induced cryptidin (mammalian alpha-defensin) release from paneth cells in vitro.,303.78
Tranilast,[53902-12-8],COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC,Other Pharmacology,Miscellaneous Compounds,,Antiallergic; inhibits inflammatory mediator release from mast cells,"Antiallergic via inhibition of chemical mediator release from mast cells. Shown to be an effective inhibitor of angiogenesis. Demonstrated to antagonize the effects of angiotensin II on human arteries, possibly by an interaction at the level of the AT1 receptor. Inhibits TRPV2-mediated responses; binds to Abeta40 monomers and increases Abeta40 fibrillation.",327.34
Tranylcypromine hydrochloride,[1986-47-6],N[C@H]1[C@H]([C@]2=CC=CC=C2)C1.Cl,Enzymes,Demethylases,Histone Demethylases,Irreversible inhibitor of LSD1; also inhibits MAO,"Irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Inhibits histone demethylation. In combination with CHIR 99021 (Cat. No. 4423), enables reprogramming of mouse embryonic fibroblasts transduced by only two factors, Oct4 and Klf4, into induced pluripotent stem (iPS) cells.",169.65
Trap 101,[1216621-00-9],Cl.CCN1C(=O)N(C2=CC=CC=C12)C1=C(CO)CN(CC2CCCCCCC2)CC1,7-TM Receptors,Opioid Receptors,NOP Receptors,Potent and selective NOP antagonist; active in vivo,"Potent and selective nociceptin/orphanin FQ (NOP) receptor antagonist (pA2 = 7.75). Displays selectivity for NOP receptors over classical opioid receptors (pKi values are 8.65, 6.60, 6.14 and < 5 for NOP, mu-, kappa-, and delta-opioid receptors respectively). Attenuates motor deficits in a rat model of Parkinson's Disease. Active in vivo.",434.02
Trequinsin hydrochloride,[78416-81-6],Cl.COC1=C(OC)C=C2C(CCN3C(=O)N(C)C(\C=C23)=N\C2=C(C)C=C(C)C=C2C)=C1,Enzymes,Phosphodiesterases,,Highly potent PDE3 inhibitor,"Highly potent inhibitor of cGMP-inhibited phosphodiesterase (PDE3; IC50 = 250 pM). Potently inhibits arachidonic acid-induced aggregation of human platelets (IC50 = 50 pM). Orally active antihypertensive agent; reduces systemic blood pressure in both normotensive and hypertensive animal models. Also activates CatSper channels, increases intracellular Ca2+ and cGMP levels, and decreases potassium channel activity in sperm.",441.95
Trifluorothymidine,[70-00-8],O=C1C(C(F)(F)F)=CN(C2O[C@H](CO)[C@@H](O)C2)C(N1)=O,Enzymes,Synthases/Synthetases,Thymidylate Synthetase,Thymidylate synthetase inhibitor,Nucleoside analog; inhibitor of thymidylate synthase. Incorporation of the triphosphate form into DNA induces DNA fragmentation. Exhibits antitumor activity.,296.2
Triptolide,[38748-32-2],O=C1C2=C([C@@](C[C@H]5[C@]4(O5)[C@](O6)3[C@@H]6[C@H]7[C@](C(C)C)(O7)[C@H]4O)([H])[C@]3(C)CC2)CO1,Enzymes,Polymerases,RNA/DNA Polymerase,"Inhibits RNAPII-mediated transcription; antitumor, anti-inflammatory and immunosuppressive",Inhibits DNA-dependent ATPase activity of XBP and induces inhibition of RNA polymerase II (RNAPII)-mediated transcription (IC50 = 200 nM). Selective for RNAPII over RNAPI and RNAPIII. Blocks RNA synthesis in HeLa cells (IC50 = 62 nM); exhibits potent antiproliferative activity in 60 cancer cell lines (average IC50 = 12 nM) and induces apoptosis by blocking TNF-alpha-mediated c-IAP1 and c-IAP2 induction. Also displays immunosuppressive and anti-inflammatory activity.,360.4
Troglitazone,[97322-87-7],CC1=C2C(CCC(COC3=CC=C(CC4C(NC(S4)=O)=O)C=C3)(C)O2)=C(C)C(O)=C1C,Nuclear Receptors,PPARs,PPARgamma Receptors,Selective PPARgamma agonist; antidiabetic agent,"Selective PPARgamma receptor agonist (EC50 values are 780 and 555 nM at murine and human PPARgamma receptors respectively). Displays no activity at PPARalpha or PPARdelta receptors. Antidiabetic agent; exerts potent glucose-lowering effects in insulin-resistant diabetic mice. Displays anti-invasive effect on human breast cancer cells; reduces migration, adhesion and spreading on fibronectin-coated plates. Also inhibits cell growth of hematopoietic cell lines. Inhibits lamellipodia formation and actin polymerization.",441.54
Tropicamide,[1508-75-4],CCN(CC1=CC=NC=C1)C(=O)C(CO)C1=CC=CC=C1,7-TM Receptors,Acetylcholine Muscarinic Receptors,M4 Receptors,Selective M4 antagonist,M4 selective muscarinic receptor antagonist.,284.36
Trovafloxacin mesylate,[147059-75-4],O=C2C1=CC(F)=C(N4C[C@@]([C@H]5N)([H])[C@@]5([H])C4)N=C1N(C3=C(F)C=C(F)C=C3)C=C2C(O)=O.CS(=O)(O)=O,Cell Metabolism,"DNA, RNA and Protein Synthesis",,Antibiotic; inhibits bacterial DNA synthesis,Fluoroquinolone antibiotic. Inhibits bacterial DNA topoisomerase IV and DNA gyrase and forms a stable quinolone-DNA complex with these enzymes which reversibly inhibits DNA synthesis. Displays potent activity against gram-positive and gram-negative bacteria. Increases the production of mitochondrial NO in immortalized hepatocytes; also increases mitochondrial Ca2+. Inhibits Panx-1 (IC50 ~ 4muM).,512.46
TTP 22,[329907-28-0],CC(C=C3)=CC=C3C1=CSC2=C1C(SCCC(O)=O)=NC=N2,Enzymes,Kinases,Casein Kinase 2,"High affinity, selective CK2 inhibitor","High affinity, ATP-competitive casein kinase 2 (CK2) inhibitor (IC50 = 0.1 muM, Ki = 40 nM). Displays selectivity for CK2 over JNK3, ROCK1 and MET (no inhibitory effects at 10 muM).",330.42
TUG 891,[1374516-07-0],FC1=CC(COC2=CC=C(CCC(O)=O)C=C2)=C(C3=CC=C(C)C=C3)C=C1,7-TM Receptors,Free Fatty Acid Receptors,,Potent and selective FFA4 (GPR120) agonist,Potent FFA4 (GPR120) agonist (pEC50 values are 7.36 and 7.77 for human and mouse GPR120 respectively). Selective for GPR120 over free fatty acid receptors (pEC50 = 4.19 for FFA1; displays no activity at FFA2 or FFA3). Cell permeable.,364.41
TWS 119,[1507095-58-0],FC(F)(F)C(O)=O.OC1=CC=CC(OC2=C3C(NC(C4=CC=CC(N)=C4)=C3)=NC=N2)=C1.FC(F)(F)C(O)=O,Enzymes,Kinases,Glycogen Synthase Kinase 3,GSK-3beta inhibitor; induces neuronal differentiation in ESCs,Inhibitor of glycogen synthase kinase-3beta (IC50 = 30 nM). Induces neuronal differentiation in pluripotent murine embryonal carcinoma cells and embryonic stem cells (ESCs).,546.38
TY 52156,[934369-14-9],ClC1=CC=C(/N=C(NNC2=CC=C(Cl)C=C2)/C(C(C)(C)C)=O)C=C1,7-TM Receptors,Sphingosine-1-phosphate Receptors,,S1P3 receptor antagonist,S1P3 receptor antagonist (Ki = 110 nM); inhibits S1P-induced Ca2+ release in HUVEC cells. Suppresses FTY-720-induced S1P3 receptor-mediated bradycardia in vivo. Also inhibits S1P-induced breast cancer stem cell expansion in vitro. Orally bioavailable.,364.27
U 104,[178606-66-1],FC1=CC=C(NC(NC2=CC=C(S(=O)(N)=O)C=C2)=O)C=C1,Enzymes,Lyases,Carbonic anhydrases,Potent carbonic anhydrase (CA) IX and XII inhibitor,"Potent carbonic anhydrase (CA) inhibitor (Ki values are 4.5, 45.1, 5080 and 9640 nM for CA XII, CA IX, CA I and CA II respectively in MDA-MB-231 cells). Inhibits tumor metastasis in the rat 4T1 metastasis model.",309.32
UAMC 00039 dihydrochloride,[697797-51-6],O=C([C@@H](N)CCNCC2=CC=C(Cl)C=C2)N1CCCCC1.Cl.Cl,Enzymes,Proteases,Other Proteases,Dipeptidyl peptidase II (DPP-II) inhibitor,"Potent inhibitor of dipeptidyl peptidase II (DPP-II) (IC50 = 0.48 nM). Exhibits selectivity for DPP-II against DPP-9, DPP-8 and DPP-IV (IC50 values are 78.6, 142 and 165 muM, respectively). Orally available.",382.76
UBP 302,[745055-91-8],O=C(C=CN(C[C@H](N)C(O)=O)C2=O)N2CC1=CC=CC=C1C(O)=O,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,Potent and selective kainate antagonist; active enantiomer of UBP 296 (Cat. No. 2078),"Potent and selective GluK1 (formally GluR5)-subunit containing kainate receptor antagonist (apparent KD = 402 nM); active enantiomer of UBP 296 (Cat. No. 2078). Displays ~ 260-fold selectivity over AMPA receptors, ~ 90-fold selectivity over recombinant human GluK2 (formally GluR6) and GluK5 (formally KA2)-containing kainate receptors and has little or no action at NMDA or group I mGlu receptors. Selectively blocks kainate receptor-mediated LTP induction in rat hippocampal mossy fibers. Also protects against soman-induced seizures and neuronal degeneration for up to 30 days when administered one hour after soman exposure.",333.3
UBP 310,[902464-46-4],CC1=CN(C[C@@H](C(O)=O)N)C(N(CC2=C(C(O)=O)SC=C2)C1=O)=O,Ion Channels,Ligand-gated Ion Channels,Glutamate (Ionotropic) Receptors,GluK1-selective kainate antagonist,"GluK1 (formerly GLUK5) kainate receptor antagonist (IC50 = 130 nM); also blocks recombinant homomeric GluK3 (forrmerly GLUK7) receptors. Displays 12,700-fold selectivity for GluK1 (formerly GLUK5) over GluK2 (formerly GLUK6). Exhibits no activity at mGlu group I or NMDA receptors at concentrations of up to 10 muM. Apparent KD value is 18 +/- 4 nM for depression of kainate responses on the dorsal root. Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.",353.35
UC 112,[383392-66-3],OC1=C3C(C=CC=N3)=C(COCC4=CC=CC=C4)C=C1CN2CCCC2,Regulated Cell Death,Apoptosis,Inhibitor of Apoptosis (IAP),IAP and XIAP inhibitor; antitumor,IAP inhibitor (IC50 values from 0.7 - 3.4 muM); inhibits cell growth in multiple cancer cell lines and in a melanoma xenograft model in vivo. Also suppresses X-linked inhibitor of apoptosis protein (XIAP) and survivin levels. Inhibits the growth of P-glycoproteins and activates caspase-3/7 and caspase-9.,348.44
UCL 2077,[918311-87-2],C(NC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C1=CN=CC=C1,Ion Channels,Potassium Channels,Ca2+-Activated Potassium Channels,Slow afterhyperpolarization (sAHP) channel blocker; sub-type selective Kv channel effects,"Slow afterhyperpolarization (sAHP) channel blocker; reduces sAHP in hippocampal slice preparations. Displays no effect on Ca2+ currents or the time course of sAHP/sIAHP. Exhibits potent inhibition of KCNQ1 and KCNQ2, but differential effects at other KCNQs. Rescues memory retrieval in dopamine beta-hydroxylase knockout mice.",350.46
UF 010,[537672-41-6],BrC1=CC=C(C(NNCCCC)=O)C=C1,Enzymes,Histone Deacetylases,Class I HDACs,Class I HDAC inhibitor,"Class I HDAC inhibitor (IC50 values are 0.06, 0.1, 0.5 and 1.5 muM for HDACs 3, 2, 1 and 8, respectively). Exhibits >6-fold selectivity over other HDACs. Induces accumulation of acetylated histones in HCT116 cells in vitro. Inhibits proliferation of a range of cancer cell lines. Arrests cells at G1/S transition.",271.15
"UK 14,304",[59803-98-4],BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12,7-TM Receptors,Adrenergic Receptors,Adrenergic Alpha-2 Receptors,alpha2 agonist,Full alpha2 adrenergic agonist. Centrally active following systemic administration in vivo. Available as part of the alpha2-Adrenoceptor Tocriset™ and Mixed Adrenergic Tocriset™. Water-soluble Salt also available.,292.14
UK 356618,[230961-08-7],CC1=C(C2=CC=CC=C2)C=CC(CCC[C@H](CC(NO)=O)C(N[C@H]([C@@](N[C@H](C)C3=CC=CC=C3)=O)C(C)(C)C)=O)=C1,Enzymes,Proteases,Matrix Metalloprotease,Potent and selective MMP-3 inhibitor,"Potent and selective inhibitor of MMP-3 (IC50 = 5.9 nM). Displays selectivity over a range of MMPs (IC50 values are 73, 840, 1790, 1900 and 51000 for MMP-13, MMP-9, MMP-2, MMP-14 and MMP-1 respectively).",557.72
UK 383367,[348622-88-8],ONC(C[C@H](C2=NC(C(N)=O)=NO2)CCCC1CCCCC1)=O,Enzymes,Proteases,Matrix Metalloprotease,Potent and selective BMP-1 (PCP) inhibitor,"Potent and selective inhibitor of BMP-1 (procollagen C-proteinase; PCP) (IC50 = 44 nM). Selective for BMP-1 over MMPs 1, 2, 3, 9 and 14 (IC50 values are >10,000 nM for listed MMPs).",324.38
UK 5099,[56396-35-1],O=C(/C(C#N)=C/C2=CN(C3=CC=CC=C3)C1=CC=CC=C12)O,Transporters,Ion Pumps/Transporters,Monocarboxylate Transporters,MCT inhibitor; also inhibits of pyruvate transport,Inhibitor of plasma membrane monocarboxylate transporters (MCTs) and the mitochondrial pyruvate carrier (MPC).,288.3
UNC 0224,[1197196-48-7],CN(CC4)CCC4NC1=C2C(C=C(OCCCN(C)C)C(OC)=C2)=NC(N3CCCN(C)CC3)=N1,Enzymes,Transferases,Lysine Methyltransferases,Potent G9a and GLP inhibitor,"Potent G9a and GLP inhibitor (IC50 values are 15 and 20 nM in a ThioGlo assay, respectively). Exhibits >1000-fold selectivity for G9a over SET7, SET8 and SET9.",485.67
UNC 0638,[1255580-76-7],CC(C)N(CC5)CCC5NC1=C2C(C=C(OCCCN4CCCC4)C(OC)=C2)=NC(C3CCCCC3)=N1,Enzymes,Transferases,Lysine Methyltransferases,Selective G9a and GLP inhibitor,"Selective inhibitor of G9a and GLP histone lysine methyltransferases (IC50 values are < 15 nM and 19 nM for G9a and GLP respectively, and > 10000 nM for a range of other histone methyltransferases). Potently inhibits dimethylation of H3K9 in MCF-7 cells (IC50 = 70 nM). Cell permeable.",509.73
UNC 0642,[1481677-78-4],CC(C)N(CC4)CCC4NC1=C2C(C=C(OCCCN3CCCC3)C(OC)=C2)=NC(N5CCC(F)(F)CC5)=N1,Enzymes,Transferases,Lysine Methyltransferases,Potent and selective G9a and GLP inhibitor,"Potent and selective G9a and GLP histone lysine methyltransferase inhibitor (IC50 < 2.5 nM). Exhibits >2,000-fold selectivity for G9a and GLP over PRC2-EZH2 and >20,000-fold selectivity over other methyltransferases. Reduces H3K9 dimethylation levels in MDA-MB-231 cells (IC50 = 110 nM). Displays modest brain penetration in vivo.",546.7
UNC 0646,[1320288-17-2],CC(C)N(CC6)CCCN6C1=NC(NC3CCN(C5CCCCC5)CC3)=C2C(C=C(OCCCN4CCCCC4)C(OC)=C2)=N1,Enzymes,Transferases,Lysine Methyltransferases,Potent and selective G9a and GLP inhibitor,"Potent and selective inhibitor of the homologous protein lysine methyltransferases, G9a and GLP (IC50 values are 6 nM and 15 nM for G9a and GLP, respectively). Potently blocks G9a/GLP methyltransferase activity in cells (IC50 = 10 nM in MCF7 cells); exhibits low cellular toxicity (EC50 = 4.7 muM in MCF7 cells). Selective for G9a/GLP over a range of other protein lysine methyltransferases and protein arginine methyltransferases.",621.9
UNC 1999,[1431612-23-5],CC(C)N1CCN(C2=NC=C(C3=CC(N(C(C)C)N=C4)=C4C(C(NCC5=C(CCC)C=C(C)NC5=O)=O)=C3)C=C2)CC1,Enzymes,Transferases,Lysine Methyltransferases,Potent and selective EZH2/EZH1 inhibitor,"Potent and SAM-competitive EZH2/EZH1 lysine methyltransferase inhibitor (IC50 values are 10 and 45 nM, respectively). Selective for EZH2/EZH1 over a panel of other methyltransferases and non-epigenetic targets. Reduces H3K27me3 levels in vitro. Prolongs survival of MLL-AF9 bearing mice. Orally bioavailable. Negative Control also available.",569.74
UNC 2327,[1426152-53-5],O=C(NCC(N3CCCCC3)=O)NC1=CC=C(N=NS2)C2=C1,Enzymes,Transferases,Protein Arginine Methyltransferases,Allosteric inhibitor of PRMT3,Allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) (IC50 = 230 nM). Noncompetitive with both the peptide substrate and cofactor.,319.38
UNC 3230,[1031602-63-7],O=C(N)C1=C(NC(C2CCCCC2)=O)SC(NC3=CC=CC=C3)=N1,Enzymes,Kinases,Other Kinases,Potent and selective PIP5K1C inhibitor; antinociceptive,"Potent and selective PIP5K1C inhibitor (IC50 = 41 nM). Exhibits selectivity for PIP5K1C over PIP5K1A, the PI 3-kinase family and a panel of other kinases. Reduces PIP2 levels and LPA-induced calcium signaling in dorsal root ganglia (DRG) neurons in vitro. Reduces nociception in mouse models of chronic pain.",344.43
UNC 926 hydrochloride,[1782573-49-2],BrC1=CC=CC(C(N2CCC(N3CCCC3)CC2)=O)=C1.Cl,Epigenetics,MBT Domains,,L3MBTL1 domain inhibitor,Methyl-lysine (Kme) reader domain inhibitor; binds to the MBT domain of the L3MBTL1 protein (Kd = 3.9 muM). Selectively inhibits the L3MBTL13XMBT-H4K20me1 interaction in a peptide pull down assay.,373.72
UPF 1069,[1048371-03-4],O=C2NC=CC1=C(OCC(C3=CC=CC=C3)=O)C=CC=C12,Enzymes,Polymerases,Poly(ADP-ribose) Polymerase,PARP-2 inhibitor,Selective poly(ADP-ribose) polymerase (PARP) 2 inhibitor (IC50 values are 0.3 and 8.0 muM for PARP-2 and PARP-1 respectively).,279.29
URB 597,[546141-08-6],NC(C1=CC(C2=CC=CC(OC(NC3CCCCC3)=O)=C2)=CC=C1)=O,Enzymes,Hydrolases,Fatty Acid Amide Hydrolase (FAAH),Potent and selective FAAH inhibitor,"Potent and selective fatty acid amide hydrolase (FAAH) inhibitor (IC50 values are 3 and 5 nM in human liver and rat brain, respectively). Exhibits no significant inhibitory activity against a variety of receptors, ion channels and enzymes, including human cannabinoid receptors and rat monoacylglycerol lipase. Displays antiallodynic and antihyperalgesic activity in an inflammatory pain model.",338.4
Valdecoxib,[181695-72-7],CC1=C(C3=CC=C(S(=O)(N)=O)C=C3)C(C2=CC=CC=C2)=NO1,Enzymes,Oxygenases/Oxidases,Cyclooxygenase,Selective and potent COX-2 inhibitor,Selective and potent COX-2 inhibitor (in vitro IC50 values are 0.005 and 140 muM for human recombinant COX-2 and COX-1 respectively). Displays potent anti-inflammatory activity in vivo.,314.36
"Valproic acid, sodium salt",[1069-66-5],[Na+].CCCC(CCC)C([O-])=O,Enzymes,Histone Deacetylases,Non-selective HDACs,Histone deacetylase inhibitor,"Histone deacetylase inhibitor (IC50 = 400 muM) that exhibits anticancer, anti-inflammatory and neuroprotective effects. Displays anticonvulsive activity via an increase in GABA levels and decreases Abeta production in animal models of Alzheimer's disease. Also attenuates NMDA-mediated excitation, blocks voltage-gated Na+ channels and modulates firing of neurons. Enables induction of pluripotent stem cells from somatic cells by Oct4 and Sox2. Can induce autophagy by inhibiting inositol synthesis.",166.19
Valsartan,[137862-53-4],CC(C)[C@@H]([C@@](O)=O)N(C(CCCC)=O)CC(C=C3)=CC=C3C1=CC=CC=C1C2=NN=NN2,7-TM Receptors,Peptide Receptors,Angiotensin Receptors,"High affinity, selective AT1 antagonist","High affinity AT1 receptor antagonist (Ki = 2.38 nM). Displays 30,000-fold selectivity over AT2 receptors. Inhibits angiotensin II-induced release of aldosterone in vitro. Orally active.",435.52
Vatalanib succinate,[212142-18-2],ClC(C=C1)=CC=C1NC2=NN=C(CC3=CC=NC=C3)C4=CC=CC=C42.OC(CCC(O)=O)=O,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,Potent VEGFR inhibitor; also aromatase inhibitor,"Potent VEGFR inhibitor (IC50 values are 37 and 77 nM for VEGFR-2 and -1, respectively). Inhibits proliferation, migration and survival of HUVECs in vitro and inhibits growth, vascularization and metastasis of tumors expressing VEGFR in mouse models. Also inhibits PDGFR-beta, c-Kit and c-Fms. Potent aromatase inhibitor (IC50 = 50 nM). Orally available.",464.9
Venlafaxine hydrochloride,[99300-78-4],OC2(CCCCC2)C(CN(C)C)C1=CC=C(OC)C=C1.Cl,Transporters,Neurotransmitter Transporters,5-HT Transporters,5-HT and NA reuptake inhibitor (SNRI),Dual serotonin/noradrenalin re-uptake inhibitor that displays ~ 30-fold higher affinity for SERT than NET (Ki values are 82 and 2480 nM respectively). Antidepressant; increases swimming and climbing behavior in the forced-swim test in rats.,313.86
VER 155008,[1134156-31-2],NC1=NC=NC2=C1N=C(NCC5=CC=C(Cl)C(Cl)=C5)N2[C@@H]3O[C@H](COCC4=CC=C(C#N)C=C4)[C@@H](O)[C@H]3O,Signal Transduction,Heat Shock Proteins,Hsp70,Hsp70 inhibitor,Novel adenosine-derived inhibitor of Heat Shock Protein 70 (Hsp70) (IC50 = 0.5 muM). Inhibits cell proliferation of multiple human tumor cell lines in vitro. Also binds Hsc70 and Grp78; displays selectivity against Hsp90beta (IC50 >200 muM for Hsp90beta).,556.4
Voglibose,[83480-29-9],O[C@@H]1[C@](CO)(O)C[C@H](NC(CO)CO)[C@H](O)[C@H]1O,Enzymes,Glycosylases,,Orally active alpha-glucosidase inhibitor,"Orally active alpha-glucosidase inhibitor (IC50 values are 3.9 and 6.4 nM at sucrase and maltase respectively). Increases glucagon-like peptide 1 (GLP-1) secretion and decreases food consumption in ob/ob mice, and reduces plasma concentrations of glucose, triglycerides and insulin in Wistar fatty rats. Exhibits antidiabetic and antiobesity activity in vivo.",267.28
VU 0155069,[1781834-89-6],O=C(N[C@@H](C)CN3CCC(N5C4=C(NC5=O)C=C(Cl)C=C4)CC3)C(C=C2)=CC1=C2C=CC=C1.Cl,Enzymes,Esterases,Phospholipases,Potent and selective PLD1 inhibitor,Potent and selective phospholipase D1 (PLD1) inhibitor (IC50 values are 46 and 933 nM for PLD1 and PLD2 respectively). Inhibits migration of human and mouse breast cancer cell lines in transwell assays.,499.43
VU 0238429,[1160247-92-6],O=C(C1=CC(OC(F)(F)F)=CC=C1N2CC3=CC=C(OC)C=C3)C2=O,7-TM Receptors,Acetylcholine Muscarinic Receptors,M5 Receptors,Selective positive allosteric modulator of M5 receptors,"Selective positive allosteric modulator of M5 receptors (EC50 values are 1.16, >30 and >30 muM at M5, M1 and M3 receptors respectively). Displays no activity at M2 and M4 receptors.",351.28
VU 0360172 hydrochloride,[1309976-62-2],FC1=CC=CC(C#CC2=CC=C(C(NC3CCC3)=O)C=N2)=C1.Cl,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Positive allosteric modulator of mGlu5 receptors,"Positive allosteric modulator of mGlu5 receptors (EC50 = 16 nM; Ki = 195 nM). Selective for mGlu5; displays no significant activity at mGlu1, mGlu2 or mGlu4 receptors. Exhibits antipsychotic-like activity in a rodent model. Also reduces spontaneous spike and wave discharges without affecting motor behaviour in a rat model of absence epilepsy.",330.78
VU 0361737,[1161205-04-4],ClC1=C(OC)C=C(NC(C2=NC=CC=C2)=O)C=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group III Receptors,Selective positive allosteric modulator of mGlu4 receptors,"Selective positive allosteric modulator at mGlu4 receptors (EC50 values are 240 and 110 nM at human and rat receptors respectively). Inactive at mGlu1, mGlu2, mGlu3, mGlu6 and mGlu7 receptors and displays weak activity at mGlu5 and mGlu8 receptors. Brain penetrant.",262.69
VU 0364439,[1246086-78-1],O=C(NC2=CC(Cl)=C(S(NC3=C(Cl)C=CC=C3)(=O)=O)C=C2)C1=NC=CC=C1,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group III Receptors,Positive allosteric modulator of mGlu4 receptors,Positive allosteric modulator (PAM) of mGlu4 receptors (EC50 = 19.8 nM in vitro for human mGlu4).,422.29
VU 0364739 hydrochloride,[1244640-48-9],O=C(NCCN3CCC(C(NCN4C5=CC(F)=CC=C5)=O)4CC3)C2=CC1=CC=CC=C1C=C2.Cl,Enzymes,Esterases,Phospholipases,Potent and selective PLD2 inhibitor,Potent and selective phospholipase D2 (PLD2) inhibitor (IC50 = 20 nM); displays 75-fold selectivity against PLD1 (IC50 = 1500 nM).,482.98
VU 0422288,[1630936-95-6],ClC1=CC(NC(C3=CC=CC=N3)=O)=CC=C1OC2=CC=C(Cl)C=N2,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group III Receptors,Selective positive allosteric modulator of group III mGlu receptors,"Group III mGlu receptor positive allosteric modulator (EC50 values are 108, 125 and 146 nM for mGlu4, mGlu8 and mGlu7 respectively). Exhibits selectivity over a panel of 68 other GPCRs, ion channels and transporters. Potentiates mGlu7-mediated reductions in excitatory post synaptic potentials in hippocampal slices.",360.19
VU 10010,[633283-39-3],CC1=C2C(SC(C(NCC3=CC=C(Cl)C=C3)=O)=C2N)=NC(C)=C1,7-TM Receptors,Acetylcholine Muscarinic Receptors,M4 Receptors,Selective allosteric potentiator of M4 receptors,Selective allosteric potentiator of M4 acetylcholine receptors (EC50 values are 33 and 0.7 nM for ACh in the absence and presence of VU10010 respectively). Binds to an allosteric site on the receptor increasing affinity for ACh and coupling to G-proteins.,345.85
VU 152100,[409351-28-6],CC1=C2C(SC(C(NCC3=CC=C(OC)C=C3)=O)=C2N)=NC(C)=C1,7-TM Receptors,Acetylcholine Muscarinic Receptors,M4 Receptors,Positive allosteric modulator of M4 receptors,Selective positive allosteric modulator of M4 muscarinic acetylcholine receptors (mAChRs) (EC50 = 380 nM). Induces 21-fold shift in ACh potency at M4 receptor. Displays no activity at other mAChR subtypes.,341.43
VU 1545,[890764-63-3],O=C(C4=CC=C([N+]([O-])=O)C=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2F,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Positive allosteric modulator of mGlu5 receptors,"Metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator (EC50 = 9.6 nM, Ki = 156 nM at rat mGlu5).",402.38
VU 29,[890764-36-0],O=C(C4=CC=C([N+]([O-])=O)C=C4)NC1=CC(C3=CC=CC=C3)=NN1C2=CC=CC=C2,7-TM Receptors,Glutamate (Metabotropic) Receptors,Glutamate (Metabotropic) Group I Receptors,Potent positive allosteric modulator of mGlu5 receptors,Potent allosteric potentiator at the rat mGlu5 receptor (EC50 = 9 nM); binds to the MPEP (Cat. No. 1212) allosteric site (Ki app = 244 nM). Selective for mGlu5 over mGlu1 and mGlu2 receptors (EC50 values are 557 nM and 1.51 muM for mGlu1 and mGlu2 respectively). Potentiates both DHPG-induced LTP and threshold theta-burst stimulation (TBS)-induced LTP in rat hippocampal slices. Analog of CDPPB (Cat. No. 3235).,384.39
VU 591 hydrochloride,[1315380-70-1],O=[N+]([O-])C(C=C4)=CC2=C4N=C(N2)COCC1=NC(C=CC([N+]([O-])=O)=C3)=C3N1.Cl,Ion Channels,Potassium Channels,Inward rectifier Potassium Channels,Selective Kir1.1 (ROMK) inhibitor,"Selective renal outer medullary potassium channel (Kir1.1, ROMK) antagonist (IC50 = 300 nM). Thought to block the intracellular pore of the Kir1.1 channel. Exhibits no effect on Kir7.1 at concentrations up to 10 muM; does not inhibit Kir2.1, Kir2.3 or Kir4.1. Displays similar potency to VU 590 (Cat. No. 3891).",404.76
VUF 10460,[1028327-66-3],NC1=NC(C2=CC=CC=C2)=CC(N3CCN(C)CC3)=N1,7-TM Receptors,Histamine Receptors,Histamine H4 Receptors,Selective H4 agonist,Selective histamine H4 receptor agonist; displays 50-fold selectivity for the rat H4 receptor over the H3 subtype (pKi values are 5.75 and 7.46 for rat H3 and H4 receptors respectively). Also exhibits affinity for the human H4 receptor (pKi = 8.22).,269.34
VUF 11207 fumarate,[1785665-61-3],C\C(CN(CCC2N(C)CCC2)C(C3=CC(OC)=C(OC)C(OC)=C3)=O)=C/C1=C(F)C=CC=C1.OC(/C=C/C(O)=O)=O,7-TM Receptors,Chemokine Receptors,Chemokine CXC Receptors,Potent ACKR3 (CXCR7) agonist,Potent ACKR3 (CXCR7) chemokine receptor agonist (EC50 = 1.6 nM). Induces recruitment of beta-arrestin to CXCR7 in HEK293-CXCR7 cells.,586.65
W 54011,[405098-33-1],CC(C)C1=CC=C(N(CC2=CC=C(N(C)C)C=C2)C(C3C(C=C(OC)C=C4)=C4CCC3)=O)C=C1.Cl,Signal Transduction,Complement,,High affinity C5a receptor antagonist,"High affinity C5a receptor antagonist (Ki = 2.2 nM). Inhibits C5a-induced generation of reactive superoxide species, chemotaxis and intracellular Ca2+ mobilization in human neutrophils (IC50 values are 1.6, 2.7 and 3.1 nM, respectively).",493.08
WAY 170523,[307002-73-9],CC1=CC(C(=O)NO)=C(N(CC2=CC=CC=C2)S(=O)(=O)C2=CC=C(OCCNC(=O)C3=CC4=CC=CC=C4O3)C=C2)C(C)=C1,Enzymes,Proteases,Matrix Metalloprotease,Potent and selective inhibitor of MMP-13,"Potent and selective inhibitor of MMP-13 (IC50 values are 17, 945, > 1000 and > 10000 nM for MMP-13, MMP-9, TACE and MMP-1 respectively).",613.68
WAY 200070,[440122-66-7],BrC1=C2C(N=C(C3=CC=C(O)C=C3)O2)=CC(O)=C1,Nuclear Receptors,Estrogen and Related Receptors,,Selective ERbeta agonist,Selective ERbeta receptor agonist that displays 68-fold selectivity over ERalpha (EC50 values are 2 and 155 nM for ERbeta and ERalpha respectively). Displays antianxiolytic and antidepressive effects in vivo.,306.11
WAY 207024 dihydrochloride,[872002-73-8],CC(C)(C)C(C=C6)=CC=C6C(N5)=NC1=C5C(N(CC4)CCN4CC2=CC=C(N=CC=N3)C3=C2)=CC=C1.Cl.Cl,7-TM Receptors,Peptide Receptors,Gonadotrophin-Releasing Hormone Receptors,GnRH receptor antagonist,Gonadotropin releasing hormone receptor (GnRH-R) antagonist. Exhibits potent affinity (IC50 values are 12 and 71 nM for human and rat GnRH receptors respectively). Lowers plasma leuteinizing hormone levels in the rat. Orally active.,549.54
WAY 208466 dihydrochloride,[1207064-61-6],O=S(C2=CN(CCN(C)C)C1=NC=CC=C12)(C3=CC=CC(F)=C3)=O.Cl.Cl,7-TM Receptors,5-HT Receptors,5-HT6 Receptors,Selective 5-HT6 agonist,"High affinity, selective 5-HT6 agonist (EC50 = 7.3 nM at the human 5-HT6 receptor). Elevates cortical GABA levels in vivo in rat frontal cortex. Exhibits antidepressant and anxiolytic-like effects.",420.33
WAY 213613,[868359-05-1],FC1=C(F)C=C(OC2=CC=C(NC(C[C@H](N)C(O)=O)=O)C=C2)C(Br)=C1,Transporters,Neurotransmitter Transporters,Glutamate Transporters,"Potent, non-substrate EAAT2 inhibitor","Potent, non-substrate inhibitor of EAAT2 (GLT-1) that displays > 44-fold selectivity over EAAT1 and EAAT3 (IC50 values are 85, 3787 and 5004 nM for EAAT2, EAAT3 and EAAT1 respectively). Exhibits no activity towards ionotropic and metabotropic glutamate receptors.",415.19
WAY 316606 hydrochloride,[1781835-02-6],O=S(C1=CC=C(C(F)(F)F)C(S(NC3CCNCC3)(=O)=O)=C1)(C2=CC=CC=C2)=O.Cl,Signal Transduction,Wnt Signaling,Beta-catenin,Secreted Frizzled-related protein-1 (sFRP-1) inhibitor; increases Wnt signaling,"Secreted Frizzled-Related Protein-1 (sFRP-1) inhibitor (IC50 = 0.65 muM); prevents sFRP-1 from interacting with Wnt and thus increases Wnt signaling. Increases total bone area in a murine calvarial organ culture assay. We are aware of a study in PLOS Biology where WAY-316606 was found to stimulate hair follicle growth. Please note that WAY-316606 from Tocris is for laboratory research use only, and that we will only sell to established scientific businesses and institutes.",484.94
WDR5 0103,[890190-22-4],O=C(OC)C1=CC(NC(C3=CC=CC(OC)=C3)=O)=C(N2CCN(C)CC2)C=C1,Enzymes,Transferases,Lysine Methyltransferases,WDR5 antagonist,"WD repeat-containing protein 5 (WDR5) antagonist (Kd = 450 nM). Disrupts WDR5 interaction with MLL and inhibits MLL core complex methyltransferase activity in vitro. Has no effect on a panel of seven other methyltransferases, including SETD7.",383.44
WEB 2086,[105219-56-5],CC1=NN=C2CN=C(C3=C(SC(CCC(=O)N4CCOCC4)=C3)N12)C1=CC=CC=C1Cl,7-TM Receptors,Platelet-activating Factor (PAF) Receptors,,Potent PAF receptor antagonist,"Potent, selective platelet-activating factor (PAF) receptor antagonist (Ki = 16.3 nM). Displays anti-inflammatory, antiangiogenic and anticancer activity. Inhibits growth and proliferation of MCF-7 breast cancer cells.",455.96
WH-4-023,[837422-57-8],O=C(OC5=C(C)C=CC=C5C)N(C4=CC=C(OC)C=C4OC)C1=NC(NC(C=C3)=CC=C3N2CCN(C)CC2)=NC=C1,Enzymes,Kinases,Src Kinases,Potent and selective Lck and Src inhibitor; also inhibits SIK,"Potent and selective Lck and Src inhibitor (IC50 values are 2 and 6 nM respectively). Exhibits >300-fold selectivity against p38alpha and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases. Supports self-renewal of naive hESCs in combination with PD 0325901, CHIR 99021 and SB 590885.",568.67
WHI-P 154,[211555-04-3],OC(C=C3)=C(Br)C=C3NC2=NC=NC1=CC(OC)=C(OC)C=C12,Enzymes,Kinases,JAK Kinase,JAK3 kinase inhibitor. Also inhibits EGFR,"JAK3 inhibitor (IC50 = 1.8 muM) that displays no activity at JAK1 or JAK2. Inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. Also inhibits other common kinases including EGFR (IC50 = 4 nM), Src, Abl, VEGFR, MAPK and PI 3-K and induces apoptosis in human glioblastoma cell lines (IC50 = 158 muM). Induces differentiation of neural progenitor cells.",376.2
WIN 64338 hydrochloride,[163727-74-0],O=C(NC5=CC=C(C[P+](CCCC)(CCCC)CCCC)C=C5)[C@H](CC3=CC=C(C=CC=C4)C4=C3)NC(NC2CCCCC2)=NC1CCCCC1.Cl.[Cl-],7-TM Receptors,Peptide Receptors,Bradykinin Receptors,Bradykinin B2 antagonist,"The first potent, non-peptide, competitive bradykinin B2 receptor antagonist. In organ bath studies, WIN 64338 inhibits [3H]-bradykinin binding on guinea pig trachea with nanomolar affinity but is not active in the rabbit aorta (the classical bradykinin B1 preparation).",783.95
Wiskostatin,[253449-04-6],BrC(C=C3)=CC1=C3N(CC(O)CN(C)C)C2=C1C=C(Br)C=C2,Cytoskeleton and Motor Proteins,Actin,,N-WASP inhibitor; inhibits Arp2/3 activation,Inhibitor of neural Wiskott-Aldrich syndrome protein (N-WASP) activity. Interacts with the regulatory GTPase-binding domain of N-WASP; inhibits activation of Arp2/3 complex by maintaining N-WASP in an inactive conformation. Also inhibits PIP2-induced actin polymerization (EC50 ~ 4muM).,426.15
WWL 113,[947669-86-5],CN(C(OC3=CC=C(C4=CC=C(C(OCC)=O)C=C4)C=C3)=O)CC1=CC=CC(C2=CC=NC=C2)=C1,Cell Metabolism,Lipid Metabolism,Other Lipid Metabolism,Ces3 and Ces1f inhibitor,Carboxylesterase Ces3 and Ces1f inhibitor (IC50 values are ~100 nM). Also inhibits ABHD6. Exhibits minimal activity against a panel of other serine hydrolases. Promotes lipid storage in adipocytes. Reduces weight gain in diet-induced obese mice and enhances glucose tolerance in diabetic mice. Orally active.,466.53
WWL 123,[1338574-83-6],NC(C1=CC=C(C2=CC=C(OC(N(C)CC3=CC(C4=CC=CC=C4)=CC=C3)=O)C=C2)C=C1)=O,Enzymes,Hydrolases,Other Hydrolases,alpha/beta-hydrolase domain 6 (ABHD6) inhibitor; antiepileptic,"alpha/beta-hydrolase domain 6 (ABHD6) inhibitor (IC50 = 0.43 muM). Blocks PTZ-induced seizures in healthy mice and spontaneous seizures in R6/2 mice. Antiepileptic activity is independent of CB1 and CB2 receptors, but is GABAA receptor dependent. Brain penetrant.",436.5
WY 14643,[50892-23-4],CC1=C(C)C(NC2=CC(Cl)=NC(SCC(O)=O)=N2)=CC=C1,Nuclear Receptors,PPARs,PPARalpha Receptors,Selective PPARalpha agonist,"Selective PPARalpha agonist (EC50 values are 0.63, 32 and > 100 muM at PPARalpha, PPARgamma and PPARdelta respectively). Negatively inhibits NF-kappaB transcriptional activity and decreases the inflammatory response in vitro and in vivo.",323.8
WY 45233 succinate,[448904-47-0],OC1(C(CN(C)C)C2=CC=C(O)C=C2)CCCCC1.O=C(CCC(O)=O)O,Transporters,Neurotransmitter Transporters,5-HT Transporters,5-HT and NA reuptake inhibitor (SNRI),Serotonin and noradrenalin reuptake inhibitor (SNRI); selective for human serotonin (SERT) and noradrenalin (NET) transporters against 96 other targets (Ki values are 40.2 and 558.4 nM for SERT and NET respectively). Inhibits [3H]5-HT and [3H]NE uptake (IC50 values are 47.3 and 531.3 nM). Salt form of the major active metabolite of venlafaxine (Cat. No. 2917).,381.46
WYE 687 dihydrochloride,[1702364-87-1],O=C(OC)NC(C=C4)=CC=C4C1=NC(N3CCOCC3)=C2C(N(C5CCN(CC6=CN=CC=C6)CC5)N=C2)=N1.Cl.Cl,Enzymes,Kinases,mTOR,Potent and selective mTOR inhibitor,"Potent, ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) (IC50 = 7 nM). Displays selectivity for mTOR over PI 3-Kalpha (~100-fold) and PI 3-Kgamma (~500-fold). Inhibits phosphorylation of mTORC1 and mTORC2 substrates including S6K, SGK and Akt; blocks VEGF secretion and HIF-1alpha expression. Exhibits antiproliferative effects in cancer cell lines through G1 cell cycle arrest and selective apoptosis.",601.53
Xaliproden hydrochloride,[90494-79-4],Cl.FC(F)(F)C1=CC(=CC=C1)C1=CCN(CCC2=CC=C3C=CC=CC3=C2)CC1,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,High affinity 5-HT1A agonist; orally active,"Orally active, full agonist at 5-HT1A receptors. Binds rat 5-HT1A with high affinity (Ki = 2.0 nM) and is > 300-fold selective over other 5-HT receptor subtypes (IC50 > 650 nM). Increases motoneuron survival and promotes effects of NGF on neurite outgrowth in vitro. Displays neurotrophic activity in several neurodegenerative models in vivo. .",417.9
Xamoterol hemifumarate,[73210-73-8],[H]OC(=O)\C=C\C(=O)O[H].OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1.OC(CNCCNC(=O)N1CCOCC1)COC1=CC=C(O)C=C1,7-TM Receptors,Adrenergic Receptors,Adrenergic Beta-1 Receptors,Selective beta1 partial agonist,beta1-adrenoceptor-selective partial agonist (pA2 values are 7.4 - 7.8 and 5.2 - 6.2 at beta1- and beta2-adrenoceptors respectively).,397.43
Xanomeline oxalate,[141064-23-5],CCCCCCOC1=NSN=C1C2=CCCN(C)C2.OC(C(O)=O)=O,7-TM Receptors,Acetylcholine Muscarinic Receptors,M1 Receptors,Functionally selective M1 agonist,"Functionally selective muscarinic M1 receptor agonist (EC50 values are 0.3, 5, 42, 52 and 92.5 nM at M1, M3, M5, M4 and M2 receptors respectively). Displays a complex pharmacological profile: reversible and wash-resistant binding, resulting in full agonist activity at M1; delayed wash-resistant partial agonist activity at M2; and delayed wash-resistant full agonist activity at M4. Exhibits antipsychotic activity, and improves cognitive deficits and behavioral disturbances in Alzheimer's disease and schizophrenia.",371.46
XAV 939,[284028-89-3],OC1=C(CSCC2)C2=NC(C3=CC=C(C(F)(F)F)C=C3)=N1,Enzymes,Polymerases,Tankyrase,Potent tankyrase inhibitor,Potent tankyrase (TNKS) inhibitor (IC50 values are 4 and 11 nM for TNKS2 and TNKS1 respectively). Antagonizes Wnt signaling via stimulation of beta-catenin degradation and stabilization of axin. Inhibits proliferation of the beta-catenin-dependent colon carcinoma cell line DLD-1. Promotes cardiomyogenic development in mesoderm progenitor cells.,312.31
XD 14,[1370888-71-3],CC1=C(C(C)=O)C(CC)=C(C(NC2=CC(S(N(CC)CC)(=O)=O)=CC=C2O)=O)N1,Epigenetics,Bromodomains,,BET bromodomain inhibitor,"BET bromodomain inhibitor (Kd values are 160, 170, 380, 490, 830 and 850 nM for BRD4(1), BRD2(1), BRD3(1), BRD3(2), BRD2(2) and BRD4(2) respectively). Also inhibits BRDT(1), CBP, p300 and BRDT(2) (Kd values are 1.2, 1.6, 2.6 and 3.7 muM respectively). Attenuates proliferation of HL-60 leukemia cells in vitro.",421.51
XMD 8-87,[1234480-46-6],COC1=C(C=CC(N2CCN(CC2)C)=C1)NC3=NC=C4NC(C5=CC=CC=C5N(C4=N3)C)=O,Enzymes,Kinases,Ack1,Potent Ack1/TNK2 inhibitor,Potent Ack1/TNK2 inhibitor (IC50 = 38 and 113 nM in Ba/F3 cell lines containing leukemia-associated D163E and R806Q mutations respectively). Blocks phosphorylation of TNK2 receptors containing solid-tumor type truncation mutations.,445.52
XMD 8-92,[1234480-50-2],O=C2C3=C(C=CC=C3)N(C)C1=NC(NC4=C(OCC)C=C(N5CCC(O)CC5)C=C4)=NC=C1N2C,Enzymes,Kinases,MAPK Family,ERK5/BMK1 inhibitor; also BRD4 inhibitor,"ERK5 (BMK1) and BRD4 inhibitor (Kd values are 80 and 190 nM, respectively). Also inhibits DCAMKL2, PLK4 and TNK1 (Kd values are 190, 600 and 890 nM). Blocks growth factor-induced activation of cellular BMK1 and reduces BMK1 activity in in vitro kinase assays. Also reduces BMK1-dependent transactivating activity of MEF2C. Inhibits proliferation in a variety of cancer cell lines; blocks tumor cell proliferation and tumor-associated angiogenesis.",474.55
Y 11,[1086639-59-9],OCC[N+]1(CN3C2)CN(C3)CN2C1.[Br-],Enzymes,Kinases,Focal Adhesion Kinase,Potent and selective FAK inhibitor,Potent inhibitor of focal adhesion kinase (FAK); prevents FAK autophosphorylation at the Y397 site (IC50 ~ 50 nM in an in vitro kinase assay). Displays selectivity for FAK over a panel of other kinases (concentration used in assay = 1 muM). Decreases cell viability in a number of cancer cell lines; blocks colony formation in SW620 and BT474 cell lines.,265.15
Y 134,[849662-80-2],CC(C)N1CCN(CC1)C1=CC=C(C=C1)C(=O)C1=C(SC2=CC(O)=CC=C12)C1=CC=C(O)C=C1,Nuclear Receptors,Estrogen and Related Receptors,,"Selective estrogen receptor modulator (SERM), selective for ERalpha","Selective estrogen receptor modulator (SERM) that displays selectivity for ERalpha over ERbeta (Ki values are 0.09 and 11.31 nM respectively) and no cross-reactivity with mineralocorticoid, glucocorticoid, androgen and progesterone receptors. Acts as an agonist in the bone and antagonist in reproductive tissue. Suppresses estrogen-stimulated proliferation of ER-positive human breast cancer MCF-7 and T47D cells.",472.6
YC 1,[170632-47-0],OCC4=CC=C(O4)C2=NN(CC3=CC=CC=C3)C1=CC=CC=C12,Enzymes,Cyclases,Guanylyl Cyclase,Soluble guanylyl cyclase (sGC) activator; induces G1 cell cycle arrest,"Nitric oxide-independent activator of soluble guanylyl cyclase (sGC). Significantly elevates cGMP levels and inhibits collagen-stimulated aggregation of washed rabbit platelets (IC50 = 14.6 muM); induces relaxation in denuded phenylephrine-contracted rabbit aortic rings (EC50 = 1.9 muM). Also displays antiproliferative activity in vitro and in vivo by inducing G1 cell cycle arrest in two human hepatocellular carcinoma (HCC) cell lines, and in HCC xenografts in athymic SCID mice. Exhibits low cytotoxicity in non-malignant cells.",304.34
YIL 781,[1640226-17-0],O=C2C1=CC(OC4=CC=C(F)C=C4)=CC=C1N=C(C)N2C[C@@H]3CN(C(C)C)CCC3.Cl,7-TM Receptors,Peptide Receptors,Ghrelin Receptors,Ghrelin receptor (GHS-R1a) antagonist,Ghrelin receptor antagonist (GHS-R1a) (Ki = 17 nM). Displays no significant affinity for the motilin receptor (Ki = 6 muM). Blocks the effects of ghrelin on insulin secretion both in vivo and in vitro. Improves glucose homeostasis in vivo.,445.96
YK 4-279,[1037184-44-3],O=C2NC1=C(Cl)C=CC(Cl)=C1C(CC(C3=CC=C(OC)C=C3)=O)2O,Cell Metabolism,"DNA, RNA and Protein Synthesis",,Inhibitor of RNA helicase A (RHA),Inhibitor of RNA Helicase A (RHA) binding to the oncogenic transciption factor EWS-FLI1. Inhibits Ewing's sarcoma family tumor (ESFT) cell growth; induces apoptosis.,366.2
YM 244769,[1780390-65-9],NC1=CC=CC(CNC(C2=CN=C(OC3=CC=C(OCC4=CC=CC(F)=C4)C=C3)C=C2)=O)=C1.Cl.Cl,Transporters,Ion Pumps/Transporters,Na+/Ca2+ Exchanger,Na+/Ca2+ exchange inhibitor (reverse mode); neuroprotective,"Inhibitor of the reverse mode of Na+/Ca2+ exchange (NCX). Potently inhibits Na+-dependent 45Ca2+ uptake (IC50 values are 18, 68 and 96 nM for CCL39 cells transfected with NCX3, NCX1 and NCX2 respectively). Displays selectivity for NCX over other Na+ and Ca2+ transporters. Protects against hypoxia/reoxygenation-induced cell damage in neuronal SH-SY5Y cells expressing NCX1 and NCX3.",516.39
YM 58483,[223499-30-7],O=C(C3=C(C)N=NS3)NC1=CC=C(N2N=C(C(F)(F)F)C=C2C(F)(F)F)C=C1,Ion Channels,Calcium Channels,Other Calcium Channels,Inhibitor of SOCE in non-excitable cells,"Blocker of store-operated Ca2+ entry (SOCE), which mediates the activation of non-excitable cells (e.g. lymphocytes). Inhibits calcium release-activated calcium (CRAC) channels; suppresses thapsigargin-induced sustained Ca2+ influx (IC50 = 100 nM). Displays immuno-modulatory and anti-inflammatory effects; suppresses cytokine production and proliferation of T cells in vitro.",421.32
YM 976,[191219-80-4],CCN1C(=O)N=C(C2=CC=CC(Cl)=C2)C2=C1N=C(CC)C=C2,Enzymes,Phosphodiesterases,,PDE4 inhibitor,"Orally active PDE4 inhibitor (IC50 = 2.2 nM). Low emetogenic activity, suggested to be due to poor brain penetration.",313.79
Yoda 1,[448947-81-7],ClC1=C(CSC2=NN=C(C3=NC=CN=C3)S2)C(Cl)=CC=C1,Ion Channels,Piezo Channels,,Piezo1 channel activator,"Piezo1 channel activator. Slows the inactivation phase of transient currents, sensitizes Piezo1 to activation by pressure, and partially activates channels in the absence of external pressure, in HEK cells expressing Piezo1 channels.",355.27
YZ9,[6093-71-6],O=C2C(C(OCC)=O)=CC1=CC=C(O)C=C1O2,Enzymes,Kinases,PFKFB3,PFKFB3 inhibitor,"PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor (IC50 = 0.183 muM). Also competitively inhibits F-6-P (Ki = 0.094 muM). Inhibits cell growth (GI50 = 2.7 muM) in a XTT-based in vitro toxicology assay.",234.2
Zacopride hydrochloride,[101303-98-4],Cl.COC1=C(C=C(Cl)C(N)=C1)C(=O)NC1CN2CCC1CC2,Ion Channels,Ligand-gated Ion Channels,5-HT3 Receptors,Highly potent 5-HT3 antagonist; also 5-HT4 agonist,Highly potent 5-HT3 receptor antagonist (Ki = 0.38 nM) and 5-HT4 receptor agonist (Ki = 373 nM). Antiemetic and anxiolytic following systemic administration in vivo.,346.26
Zamifenacin fumarate,[127308-98-9],C1(CCN3C[C@H](OC(C5=CC=CC=C5)C4=CC=CC=C4)CCC3)=CC=C(OCO2)C2=C1.C(\C=C\C(O[H])=O)(O[H])=O,7-TM Receptors,Acetylcholine Muscarinic Receptors,M3 Receptors,Selective M3 antagonist,"Selective M3 muscarinic receptor antagonist (pKi values are 8.52, 7.93, 7.90 and 7.78 for M3, M2, M1 and M4 receptors respectively). Displays higher affinity at ileal M3 receptors (pKi = 9.3) compared to oesophageal and tracheal M3 receptors (pKi values are 8.8 and 8.2 respectively). Inhibits gastrointestinal motility in vivo in the absence of cardiovascular effects.",531.6
Zaprinast,[37762-06-4],CCCOC1=C(C=CC=C1)C1=NC2=C(NN=N2)C(=O)N1,7-TM Receptors,GPR35,,GPR35 agonist,"Phosphodiesterase inhibitor, selective for PDE6, 5, 11 and 9 (IC50 values are 0.15, 0.76, 12.0 and 29.0 muM respectively). Putative GPR35 agonist.",271.28
Zardaverine,[101975-10-4],COC1=C(OC(F)F)C=CC(=C1)C1=NNC(=O)C=C1,Enzymes,Phosphodiesterases,,PDE3/4 inhibitor,"Phosphodiesterase inhibitor, selective for PDE3 and 4 (IC50 values are 0.5 and 0.8 muM respectively). Also available as part of the Phosphodiesterase Inhibitor Tocriset™.",268.22
ZCL 278,[587841-73-4],ClC1=C(OCC(NC(NC2=CC=C(S(NC3=NC(C)=CC(C)=N3)(=O)=O)C=C2)=S)=O)C=CC(Br)=C1,Enzymes,GTPases,Small Monomeric GTPases,Cdc42 inhibitor,"Selective inhibitor of Cdc42. Targets the binding site of the Cdc42 guanine nucleotide exchange factor, intersectin (ITSN). Inhibits Cdc42-mediated cellular effects, including microspike formation in 3T3 fibroblasts and neuronal branching in primary neonatal cortical neurons. Also suppresses cell motility and migration in PC3 cells, without cytotoxic effects.",584.89
ZD 7288,[133059-99-1],[Cl-].CCN(C1=CC=CC=C1)C1=CC(NC)=[N+](C)C(C)=N1,Ion Channels,Ligand-gated Ion Channels,HCN Channels,Inhibits pacemaker (If) current,Sino-atrial node function modulator; blocks the hyperpolarization activated cation current If (HCN channel). Blocks Ih in central neurons. Increases NMDA-evoked noradrenalin release in rat brain in vitro.,292.81
Zileuton,[111406-87-2],CC(N(O)C(N)=O)C2=CC1=CC=CC=C1S2,Enzymes,Oxygenases/Oxidases,Lipoxygenase,5-LOX inhibitor; orally bioavailable,"Orally active 5-lipoxygenase (5-LOX) inhibitor that inhibits LTB4 synthesis (IC50 values are 0.56, 2.3 and 2.6 muM in dog, rat and human blood respectively). Inhibits antigen-induced contraction of tracheal strips in vitro (IC50 = 6 muM) and exhibits antiasthmatic activity in vivo. Also weakly inhibits CYP1A2 (Ki = 66 - 98 muM).",236.29
ZK 164015,[177583-70-9],CCCCCS(=O)(=O)CCCCCCCCCCN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1,Nuclear Receptors,Estrogen and Related Receptors,,Potent estrogen receptor antagonist,Potent estrogen receptor silent antagonist. Inhibits 17beta-estradiol stimulation of luciferase activity (IC50 = 0.025 muM); potently inhibits the growth of estrogen-sensitive human MCF-7 breast cancer cells in vitro (IC50 ~ 1 nM).,513.73
ZK 93423 hydrochloride,[1216574-52-5],Cl.CCOC(=O)C1=C(COC)C2=C(NC3=C2C=C(OCC2=CC=CC=C2)C=C3)C=N1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Potent benzodiazepine agonist,"Potent benzodiazepine receptor agonist (IC50 = 1 nM). Non-selective between alpha1-, alpha2-, alpha3- and alpha5-subunit containing GABAA receptors (Ki values are 4.1, 4.2, 6 and 4.5 nM for inhibition of [3H]Ro15-1788 binding to human recombinant alpha1beta3gamma2, alpha2beta3gamma2, alpha3beta3gamma2 and alpha5beta3gamma2 receptors respectively). Anxiolytic following systemic administration in vivo.",426.9
ZK 93426 hydrochloride,[1216792-30-1],Cl.CCOC(=O)C1=C(C)C2=C(NC3=C2C(OC(C)C)=CC=C3)C=N1,Ion Channels,Ligand-gated Ion Channels,GABAA and A-rho Receptors,Potent and competitive benzodiazepine antagonist,"Potent, selective and competitive benzodiazepine receptor antagonist (IC50 values are 0.4 and 0.7 nM for inhibition of [3H]-flunitrazepam binding to rat cerebellum and hippocampus respectively). Similar in vivo profile to flumazenil (Ro 15-1788, Cat No. 1328); produces anxiogenic effects in some behavioral tests and anxiolytic effects in others. Orally active.",348.82
ZLN 024 hydrochloride,,BrC1=C(OCCSC2=NC=CC=N2)C=CC(C)=C1.Cl,Enzymes,Kinases,AMPK,Allosteric AMPK activator,"Allosteric AMP-activated protein kinase (AMPK) activator; allosterically stimulates active AMPK heterotrimers, increasing the activity of alpha1beta1gamma1 by 1.5-fold and alpha2beta1gamma1 by 1.7-fold (EC50 values are 0.42 and 0.95 muM, respectively). Inhibits dephosphorylation of AMPK Thr-172 by PP2Calpha. Stimulates glucose uptake and fatty acid oxidation without increasing the ADP/ATP ratio. Also decreases fatty acid synthesis and glucose output in primary hepatocytes. Improves glucose tolerance and decreases cholesterol content in db/db mice.",361.69
ZM 241385,[139180-30-6],NC1=NC(NCCC2=CC=C(O)C=C2)=NC2=NC(=NN12)C1=CC=CO1,7-TM Receptors,Adenosine Receptors,Adenosine A2A Receptors,Potent and highly selective A2A antagonist,"Potent and highly selective A2A adenosine antagonist, with a pA2 of 9.02 for A2A receptors in guinea pig cardiac vasculature and fold selectivities of 1000, 91 and 500,000 over A1, A2B and A3 sites respectively. Active in vivo.",337.34
ZM 323881 hydrochloride,[193000-39-4],Cl.CC1=C(O)C=C(NC2=C3C=CC(OCC4=CC=CC=C4)=CC3=NC=N2)C(F)=C1,Enzyme-Linked Receptors,Receptor Tyrosine Kinases (RTKs),VEGFR,"Potent, selective inhibitor of VEGFR-2","Potent and selective inhibitor of human vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) activity. Selectively inhibits VEGFR-2 (IC50 = 2 nM) over VEGFR-1 and a range of other receptor tyrosine kinases such as PDGFRbeta, FGFR1, EGFR and erbB2 (IC50 > 50 muM). Inhibits VEGF-A-induced endothelial cell proliferation in vitro (IC50 = 8 nM).",411.86
ZM 336372,[208260-29-1],CN(C)C1=CC(=CC=C1)C(=O)NC1=CC=C(C)C(NC(=O)C2=CC=C(O)C=C2)=C1,Enzymes,Kinases,Raf Kinase,"Potent, selective c-Raf inhibitor","Potent, selective inhibitor of c-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf). Shows 10-fold selectivity over B-Raf. Also inhibits SAPK2/p38 (IC50 = 2 muM). Selective over 17 other protein kinases including PKA, PKC, p42 MAPK, CDK1 and SAPK1/JNK (up to 50 muM). Also available as part of the MAPK Cascade Inhibitor Tocriset™.",389.45
ZM 39923 hydrochloride,,Cl.CC(C)N(CCC(=O)C1=CC=C2C=CC=CC2=C1)CC1=CC=CC=C1,Enzymes,Kinases,JAK Kinase,"Potent, selective JAK3 inhibitor","Potent, selective inhibitor of Janus tyrosine kinase 3 (JAK3). pIC50 values are 7.1, 5.6, 4.4, and < 5.0 for JAK3, EGFR, JAK1 and CDK4 respectively. Breaks down in neutral buffer (t½ = 36 mins, pH 7.43, 25°C) to form ZM 449829 (Cat. No. 1366).",367.92
ZM 447439,[331771-20-1],COC1=CC2=C(NC3=CC=C(NC(=O)C4=CC=CC=C4)C=C3)N=CN=C2C=C1OCCCN1CCOCC1,Enzymes,Kinases,Aurora Kinases,Inhibits Aurora kinase B,"Novel, selective ATP-competitive inhibitor of Aurora B kinase in vitro (IC50 values are 50, 250 and 1000 nM for Aurora B, C and A kinases respectively). Selective over a range of other kinases including cdk1 and PLK1 (IC50 > 10 muM). Inhibits cell division and displays selective toxicity towards proliferating tumor cells versus non-dividing cells.",513.59
Zolmitriptan,[139264-17-8],CN(C)CCC2=CNC1=CC=C(C[C@H](N3)COC3=O)C=C12,7-TM Receptors,5-HT Receptors,5-HT1 Receptors,Potent 5-HT1B/1D/1F agonist,"Potent 5-HT1B/1D/1F agonist (Ki values are 0.63, 5.01 and 63.09 nM for h5-HT1D, h5-HT1B and h5-HT1F receptors respectively). Inhibits trigeminal nerve stimulation-mediated neurogenic plasma protein extravasation in guinea pigs; blocks long excitatory postsynaptic potentials (EPSPs) in a rat model of spinal cord injury.",287.36
Zoniporide dihydrochloride,[241799-10-0],O=C(/N=C(N)/N)C(C=N3)=C(C4CC4)N3C1=C2C(N=CC=C2)=CC=C1.Cl.Cl,Transporters,Ion Pumps/Transporters,Na+/H+ Exchanger,Selective NHE1 inhibitor,"Sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor that displays selectivity over other NHE isoforms (Ki values are 14, 2200 and 220000 nM for human NHE1, human NHE2 and rat NHE3 respectively). Inhibits NHE1 dependent 22Na+ uptake in vitro (IC50 = 14 nM) and provides cardioprotection from myocardial ischemic injury in vivo (EC50 = 0.25 nM). Also inhibits MMP2/9 activity and invasion in breast cancer cells.",393.27
Zonisamide,[68291-97-4],NS(=O)(=O)CC1=NOC2=CC=CC=C12,Ion Channels,Other Channel Modulators,,Blocks voltage-sensitive Na+ and Ca2+ channels (T-type),"Antiepileptic that possesses a broad spectrum anticonvulsant and mechanistic profile. Blocks voltage-sensitive Na+ and T-type Ca2+ channels, stimulates BKCa channels, modulates GABA, glutamate and monoamine neurotransmission, inhibits lipid peroxidation and scavenges hydroxyl and nitric oxide free radicals. Displays neuroprotective and antiParkinsonian activity.",212.22
Zosuquidar trihydrochloride,[167465-36-3],F[C@@]2(F)[C@H]1C3=C(C=CC=C3)[C@H](N5CCN(C[C@H](COC6=CC=CC7=C6C=CC=N7)O)CC5)C4=C(C=CC=C4)[C@H]12.Cl.Cl.Cl,Transporters,Multidrug Transporters,,High affinity P-gp inhibitor,High affinity P-glycoprotein (P-gp) inhibitor (Kd = 79 nM). Restores doxorubicin (Cat. No. 2252) sensitivity in P-gp-expressing multidrug (MDR) resistant cancer cell lines. Also potentiates antitumor efficacy of taxol (Cat. No. 1097) in a MDR human non-small cell lung carcinoma xenograft mouse model.,636.99